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2. Abbreviations and definitions
A260/280 absorption at 260 and 280 nm
aa amino acids
AB human serum type AB
Ab(s) antibody(ies)
ACAD activated cell-autonomous
death
ACK ammonium chloride 
potassium phosphate
ADI adoptive immunotherapy
AEC 3-amino-9-ethylcarbazole
AICD activation-induced cell death
AJCC American Joint Committee on
Cancer
ANCA anti-neutrophilic cytoplasmic
auto-Abs
ANA anti-nuclear auto-Abs
APC Allophycocyanin
Arg arginine, amino acid
ATCC American Type Culture
Collection
aT cell(s) activated T cell(s)
BCIP 5-bromo-4-chloro-3-indoyl
phosphate
BD Becton Dickinson
bp(s) base pair(s)
BSA bovine serum albumine
C constant part of TCR
Ca2+ calcium
CAM cell adhesion molecule
cAMP cyclic adenosine
monophosphate
CCR chemokine receptor
CD cluster of differentiation
cDNA complementary DNA
CEACAM carcinoembryonic antigen-
related cell adhesion molecule
cf. Latin “confer”, - „bring 
together“
Chim chimeric
cm centimeter
cm2 square centimeter
CMV cytomegalovirus
CO2 carbon dioxide
cpm count per minute
CTC circulating tumor cells
cTECs cortical thymic epithelial cells
CTL(s) cytotoxic T cell(s)
CTLA-4 cytotoxic T lymphocyte
associated antigen 4
Cy cyanine
d day(s)
DAPI 4', 6-diamidino-2-phenylindole
dc double chain
DC dendritic cells
ddH2O double distilled water
DKFZ German Cancer Research
Center
DMEM d?????????? ??????????????
medium
DMSO dimethyl sulfoxide
DN double negative
DNA deoxyribonucleic acid
dNTP deoxyribonucleoside
triphosphate
DP double positive
DPN dysplastic nevus/nevi
DTT dithiothreitol
E:T effector to target ratio
ECL enhanced chemiluminescence
ECM extracellular matrix
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic
acid
e.g. Latin “exempli gratia”, -
“for example”
EGFP enhanced green fluorescent
protein
ELISPOT enzyme-linked immunospot
assay
EMT epithelial-to-mesenchymal
transition
env amphotropic virus envelope
et al. Latin “et alii”, - “and others”
F protein fusion protein of NDV
F(ab´)2 2 coupled variable Ab 
fragment regions
FACS fluorescence activated cell
sorting/flow cytometry
Fc constant Ab fragment region
FCS fetal calf serum
FDA Food and Drug Administration
Fig(s). figure(s)
FITC fluorescein isothiocyanate
Foxp3 forkhead box P3
g gram
gag retroviral group-specific
antigen
GAGE-1 G antigen 1
GALV Gibbon ape leukemia virus
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GITR glucocorticoid-induced TNFR
Gly glycine, amino acid
GM-CSF granulocyte macrophage
colony-stimulating factor
GnT-V N-acetyl glucosaminyl-
transferase V gene
gp100 glycoprotein 100
Gy gray
G-418 geneticin sulfate
h hour(s)
HD healthy donor
HLA-A2 human leukocyte antigen A2
HRP horseradish peroxidase
HU hemagglutination unit
Hygro hygromycin
i.e. Latin “id est”, - “that is;
in other words”
i.d. intradermal
IDO indoleamine 2,3-dioxygenase
IFN interferon
Ig(A/G/M) immunoglobulin (A/G/M)
IHC immunohistochemistry
IL interleukin
IL-2/IL-??? ?????????????-2/IL-7 receptor
i.p. intraperitoneal
IRES internal ribosomal entry site
iTreg inducible Treg
i.v. intraveneous
kb kilobase
kDa kilodalton
kV kilovolt
L1CAM L1 cell adhesion molecule
l liter
LAG3 lymphocyte-activation gene 3
LB Luria Bertani
luc luciferase
Lys lysine, amino acid
m mouse
M molar
M. mycoplasma
mA milliampere
mAb(s) monoclonal antibody(ies)
MAGE melanoma antigen family
Maxi Prep Maxi DNA preparation
MBq megabecquerel
McCT multiplex cell contamination
test
mCi millicurie
MDSC myeloid-derived suppressor
cells
MDM2 murine double minute 2
Melan-A/ tumor-associated
MART-1 melanocytic differentiation
antigen
mg milligram
Mg2+ magnesium
M gene matrix gene of NDV
MHC major histocompatibility
complex
MIF macrophage migration
inhibitory factor
min minute(s)
ml milliliter
mm millimeter
mM millimolar
MM malignant melanoma
MoMuLV moloney murine leukemia
virus
mol/l molar/liter
MPO myeloperoxidase
mRNA messanger RNA
Mt mutated
mTECs medullary thymic epithelial
cells
Mu murine
MW molecular weight
n number
NA17-A melanoma antigen from
patient NA17
NBT nitroblue tetrazolium
NC negative control
NCT National Center for Tumor
Diseases
nd not detectable
n.d. not determined
NDV Newcastle disease virus
NEAA non-essential amino acid
NEB New England Biolabs
NK natural killer
nm nanometer
NOD non-obese diabetic
NSG NOD-SCID gamma
nTreg naturally occurring Treg
NY-Eso-1 cancer/testis antigen
OD optical density
p53 protein 53
p/sec/cm2/sr photons/second/square
centimeter/steradian
PAGE polyacrylamide gel
electrophoresis
p-ANCA perinuclear anti-neutrophilic
cytoplasmic auto-Abs
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PB peripheral blood
PBMC PB mononuclear cells
PBS phosphate buffered saline
PC positive control 
PCR polymerase chain reaction
PD-1 programmed cell death-1
PE phycoerythrin
Pen/Strep Penicillin/Streptomycin
PerCP-Cy5.5 peridinin-chlorophyll-protein-
complex-cyanine 5.5
pH Latin “potentia hydrogenii”
PI propidium iodide
pmel17 melanocyte-specific
glycoprotein 17
pmol picomol
pol retroviral reverse
transcriptase polymerase
PVDF polyvinylidene difluoride
r recombinant
RAB38/ melanocyte differentiation
NY-Mel-1 antigen
rb rabbit
rIL recombinant interleukin
RLU relative light units
RNA ribonucleic acid
rpm rounds per minute
RPMI roswell park memorial institute
ROI region of interest
ROS reactive oxygen species
RT room temperature
sc single chain
s.c. subcutaneous
SCID severe combined immune-
deficient
SD standard deviation
SDS sodium dodecyl sulfate
SEB staphylococcal enterotoxin B
sec second
SEM standard error of the mean
S.O.C. super optimal broth medium
with catabolite repression
SP single positive
TAAs tumor-associated antigens
Tab(s). table(s)
TAE Tris-Acetate-EDTA
TAP transporter associated with
antigen processing
TC T cell
TCR T cell receptor
TE Tris-EDTA
???? ????????????????????????????
Th/TH T helper cells
TILs tumor-infiltrating lymphocytes
TNA tumor neutralization assay
TNF(R) tumor necrosis factor
(receptor)
TNM tumor-node-metastases
TRAIL TNF-related apoptosis-
inducing ligand
Treg regulatory T cells
Tris tris(hydroxymethyl)
aminomethane
TRP2 tyrosinase related protein 2
U unit
UICC International Union against
Cancer
UV ultraviolet
V volt
VEGF vascular endothelial growth
factor
VLA very late antigen
V? variable part of TCR ? chain
W watt
WHO World Health Organization
Wt/WT wild type
x times
X x-fold
3H tritium, hydrogen-3
7-AAD 7-aminoactinomycin D
51Cr radioactive chromium
isotope 51
? alpha or anti
? beta
?2m ?2 microglobulin
? gamma
? delta
? epsilon
? zeta
? lambda
? pi
μCi microcurie
μg microgram
μl microliter
μm micrometer
μM micromolar
~ approximately
°C degree celsius
Ø diameter
% percentage
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3. Summary
One of the leading human malignancies is cancer, a disease characterized by mostly uncontrolled 
growth of abnormal cells in the body, often forming metastases. It´s interaction with the immune 
system, that can influence the disease progression, has repeatedly been reported and gained 
increasing importance over the last decades. However, most of the current immunotherapeutic 
approaches for cancer treatment are limited, partly due to the immune controlling capacities of 
tumors. The development of novel experimental approaches and therapeutic strategies, that 
support and complement the tumor-directed pre-existing abilities of the immune system, will be 
critical for the success of future cancer immunotherapies. Therefore, and because of the general 
need of novel treatment strategies, the presented thesis focused on four different approaches to 
optimize cancer immune therapeutic interventions.
Functionally competent tumor-specific memory T cells have been reported to efficiently control 
tumor growth and be required for a durable prevention of tumor recurrence and metastasis 
formation. Therefore, the first project dealed with spontaneously induced tumor antigen-reactive 
memory T cell responses in the peripheral blood (PB) of melanoma and dysplastic nevi patients. 
Thereby, using a short-????? ????? ???????? ?????? high frequencies of pre-existing T cell 
responses were detected in both cohorts ex vivo. As antigen-presenting cells, I have used 
autologous dendritic cells, generated from monocytes which were pulsed with 13 different 50 amino 
acid long synthetic melanoma polypeptides, derived from immunodominant regions of tumor-
associated antigens (TAAs). Thereby, the nature of the identified T cell responses revealed to be 
polyvalent and HLA-unrestricted. Moreover, the designed polypeptide sequences, that covered 
MHC class I- and II-restricted epitopes, are optimal for presentation on a wide range of HLA types 
and therefore, were recognized by CD4+ and CD8+ T cells. I have shown that the long peptide 
sequence of the NA17-A antigen induce high frequencies of NA17-A-reactive memory T cells, but 
not NA17-A-specific regulatory T cell (Treg) responses. Thus, particular importance for future 
vaccination approaches might therefore have to be considered. Furthermore, the demonstration 
that the TAA-reactive T cell frequencies increased after resection of the non-metastasized tumors 
or dysplastic nevi indicates that the presence of the lesions controls pre-existing T cell responses. 
Additionally, these investigations also showed antigen-specific Treg in the PB and revealed that, in 
some patients, Treg have an immunosuppressive potential. In general, however, an essential role 
of Treg in controlling spontaneous T cell responses in non-metastasized melanoma and dysplastic 
nevi patients could not be detected. Based on these findings, besides Treg, the tumor- or lesion-
mediated TAA-reactive memory T cell suppression might also be facilitated through other potential 
effectors of immunosuppression, including combinations of soluble and cellular mediators. 
Summarized, the investigated polypeptides efficiently elucidated pre-existing T cell responses in 
melanoma and dysplastic nevi patients and thus indicate that those polyvalent responses could be
therapeutically reactivated in consequence of an appropriate peptide vaccination treatment.
For the second optimization approach a human melanoma murine xenotransplantation model 
has been established. Thereby, the in vivo efficiency and biologic relevance of human T cells, 
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which were transduced with functionally expressed, in vitro optimized, T cell receptor (TCR) 
constructs, specific for the antigens MDM2 or gp100 were investigated. For the first time in vivo,
two novel strategies that aimed to avoid hybrid mispaired TCR chain formation and thereby 
potential autoimmune disease-causing “off-target” reactions were tested. These approaches 
comprised the molecular design of the TCR ?? interphase and a single chain TCR framework. 
Thereby, optimized MDM2 as well as gp100 transgenic T cells revealed the ability to significantly 
control human melanoma tumor growth. Moreover, the engineered T cells persisted in vivo and 
controlled in the same animals even a secondary tumor growth in a memory T cell-like manner.
I could also demonstrate that a combinational treatment of adoptive T cell therapy using TCR gene-
modified human T cells with local low dose tumor irradiation (2 Gy), led to an improved T cell 
targeting into the tumor and additionally further increased the tumor growth control. Consequently,
in order to improve adoptive cancer immunotherapeutic approaches the in vivo experiments 
confirmed the feasibility and efficiency of the applied TCR design.
In the third project presented in this thesis, a novel tumor cell-mediated immunosuppressive 
mechanism, facilitated by the cell adhesion molecules CEACAM6 and L1CAM, was addressed. 
Thereby, these molecules were detected in various tumor cell lines and using short-????? ?????
ELISPOT and 51Cr release cytotoxicity assays it could be shown that their specific blockade 
resulted in increased, functional effector T cell responses. Therefore, in order to modulate the 
strength of T cell responses against malignant edited tumor cells that escaped immune recognition, 
CEACAM6 and L1CAM may consequently be attractive targets for novel immunotherapeutic 
interventions.
Finally, to increase the capacity of oncolytic virotherapies, in a fourth project, I optimized the 
viral transport of the Newcastle disease virus (NDV) to human tumor cells. In this approach, the 
loading of human T cells with NDV was specified for the first time in an in vitro co-culture system. 
Moreover, in a “hitchhiking”-like mechanism T cells have shown to be capable to transfer cell 
surface-attached NDV to MCF-7 tumor cells. In addition, monolayers of tumor cells were efficiently 
destroyed through oncolytic NDV-modified activated T cells. Based on this combinational therapy, it 
can be proposed that effector T cells can facilitate as potent carrier vehicles to transport NDV to 
tumor sites, resulting in focused tumor cell destruction.
In summary, the findings of the four different approaches, presented in this thesis, indicate 
novel perspectives for the optimization of future immunotherapeutic interventions in order to elicit 
and support protective T cell responses against clinically apparent malignant tumors.
Zusammenfassung
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4. Zusammenfassung
Krebs stellt eine der führenden malignen Erkrankungen beim Menschen dar und ist durch 
unkontrolliertes Wachstum von entarteten Körperzellen und die Bildung von Metastasen 
gekennzeichnet. Die Wechselwirkung von Krebs mit dem Immunsystem, welche die Krankheits-
entwicklung beeinflussen kann, wurde wiederholt beschrieben und hat in den letzten Jahrzehnten
an zunehmender Bedeutung gewonnen. Dennoch zeigen gegenwärtig die meisten immun-
therapeutischen Ansätze zur Krebsbehandlung nur eine begrenzte Wirksamkeit, teilweise 
hervorgerufen durch immunkontrollierende Eigenschaften von Tumoren. Die Entwicklung von 
neuen experimentellen Ansätzen und therapeutischen Strategien, welche die vorhandenen,
tumorgerichteten Fähigkeiten des Immunsystems unterstützen und zusätzlich ergänzen, wird für
den Erfolg zukünftiger Krebsimmuntherapien von entscheidender Bedeutung sein. Aus diesem 
Grund und wegen des generellen Bedarfs an neuen Strategien, beschäftigte sich die vorliegende 
Doktorarbeit mit vier verschiedenen Ansätzen zur Optimierung von immuntherapeutischen 
Interventionen für die Behandlung von Krebserkrankungen.
Es wurde gezeigt, dass funktionell kompetente tumorspezifische Gedächtnis-T-Zellen das 
Tumorwachstum effizient kontrollieren können und für einen anhaltenden Schutz vor einem 
erneuten Auftreten von Tumoren und einsetzender Metastasierung benötigt werden. Das erste
Projekt befasste sich daher mit spontan induzierten, Tumorantigen-reaktiven Gedächtnis-T-
Zellantworten im peripheren Blut (PB) von Melanom- und dysplastischen Nävipatienten. Unter 
Verwendung von ???? ELISPOT-Kurzzeituntersuchungen wurden ex vivo in beiden 
Patientengruppen hohe Frequenzen von präexistierenden, tumor-spezifischen T-Zellantworten 
nachgewiesen. Als antigenpräsentierende Zellen habe ich autologe dendritische Zellen verwendet,
welche aus Monozyten generiert wurden. Diese wurden mit 13 verschiedenen 50 Aminosäure-
langen synthetischen Melanompolypeptiden beladen, welche von immundominanten Regionen von
Tumor-assoziierten Antigenen (TAAs) abgeleitet wurden. Die resultierenden T-Zellantworten waren 
polyvalent und HLA-unrestringiert. Darüber hinaus umfassten die generierten Polypeptidsequenzen 
MHC-Klasse I und II-restringierte Epitope, welche effizient von einer Vielzahl von HLA-Molekülen 
präsentiert werden können und daher von CD4+ und CD8+ T-Zellen erkannt wurden. Weiterhin 
konnte ich zeigen, dass die lange NA17-A Peptidsequenz zur Induktion von erhöhten, NA17-A
reaktiven Gedächtnis-T-Zellfrequenzen führte, wohingegen keine NA17-A spezifischen Antworten 
durch regulatorische T-Zellen (Treg) hervorgerufen wurden. Diese Erkenntnis könnte für zukünftige 
Vakzinierungsansätze von entscheidender Bedeutung sein. Nach Entfernung des nicht-
metastasierten Tumors oder dysplastischen Nävus sind die TAA-reaktiven T-Zellfrequenzen stark 
angestiegen, wodurch gezeigt werden konnte, dass präexistierende T-Zellantworten durch das 
Vorhandensein der Läsionen kontrolliert werden. Des Weiteren wurden Antigen-spezifische Treg 
im PB nachgewiesen und bei einigen Patienten ein immunsuppressives Potenzial dieser Zellen 
aufgezeigt. Im Allgemeinen konnte jedoch keine wesentliche Rolle von Treg bei der Kontrolle von 
spontanen T-Zellantworten bei Patienten mit nicht-metastasierten Melanomen oder dysplastischen 
Nävi nachgewiesen werden. Basierend auf diesen Ergebnissen, ist eine tumor- oder 
läsionsabhängige Suppression von TAA-reaktiven Gedächtnis-T-Zellantworten, neben Treg,
vermutlich auch durch andere potentielle immunsuppressive Effektoren vermittelt. Dabei spielen 
voraussichtlich Kombinationen von löslichen und zellulären Mediatoren eine entscheidende Rolle.
Zusammenfassend zeigen diese Untersuchungen, dass die generierten langen Peptide effizient 
dazu verwendet werden können, um präexistierende Gedächtnis-T-Zellantworten bei Melanom-
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und dysplastischen Nävipatienten nachzuweisen. Darüber hinaus könnten diese polyvalenten       
T-Zellantworten infolge einer geeigneten Peptidvakzinierung therapeutisch reaktiviert werden.
Für einen zweiten Optimierungsansatz, wurde ein humanes Melanom-Maus-Xenotrans-
plantationsmodell etabliert, um die Wirksamkeit und biologische Relevanz von humanen T-Zell-
Rezeptor-(TCR) transduzierten T-Zellen, welche spezifisch für die Antigene MDM2 oder gp100
sind, in vivo zu untersuchen. Die in T-Zellen funktionell-exprimierten TCR-Konstrukte wurden zuvor 
in vitro optimiert. In diesem Zusammenhang wurden zum ersten Mal zwei neuartige Strategien 
in vivo verfolgt, welche beabsichtigten eine Fehlpaarung von TCR-Ketten zu vermeiden, um somit 
möglichen Autoimmunkrankheit-verursachenden, vom zielabweichenden, „off-target“ Reaktionen
vorzubeugen. Bei diesen Ansätzen handelte es sich um eine molekular veränderte TCR-??-
Struktur und ein Einzelketten-TCR-Konstrukt. Unter deren Verwendung konnte das Wachstum von 
humanen Melanomzellen sowohl durch die optimierten MDM2 als auch gp100 TCR-transgenen    
T-Zellen signifikant kontrolliert werden. Darüber hinaus überdauerten die optimierten T-Zellen       
in vivo und konnten in den gleichen Tieren in einer Gedächtnis-T-zellvermittelten Art und Weise
das Wachstum eines sekundären Tumors kontrollieren. Weiterhin war es mir möglich zu zeigen, 
dass eine Kombinationsbehandlung aus adoptiven T-Zelltransfer mit TCR-genmodifizierten
humanen T-Zellen und einer lokalen, niedrig dosierten Tumorbestrahlung (2 Gy) zu einer 
verbesserten T-Zelleinwanderung in den Tumor und einer verstärkten Tumorwachstumskontrolle 
führte. Diese in vivo Experimente bestätigten die Realisierbarkeit und Effizienz des angewandten
TCR-Designs in Hinblick auf die Optimierung von adoptiven Krebsimmuntherapien.
Im dritten Projekt der vorliegenden Arbeit, wurde ein neuer Tumorzell-vermittelter 
immunsuppressiver Mechanismus, welcher auf den Zelladhäsionsmolekülen CEACAM6 und
L1CAM basierte, untersucht. Zunächst konnten diese Moleküle auf verschiedenen Tumorzelllinien 
nachgewiesen werden. Unter Verwendung von Kurzzeit ???? ELISPOT- und 51Cr Zytotoxizitäts-
experimenten konnte anschließend gezeigt werden, dass ihre spezifische Blockade in erhöhten
funktionellen Effektor-T-Zellantworten resultierte. Infolgedessen, um die Intensität von T-Zell-
antworten gegen maligne Tumorzellen, welche sich einer Immunerkennung entzogen haben, zu 
stärken, könnten CEACAM6 und L1CAM attraktive Ziele für neue immuntherapeutische
Interventionen darstellen.
Um die Kapazität von onkolytischen Virustherapien zu erhöhen, optimierte ich in einem vierten
Projekt den viralen Transport des Newcastle Disease Virus (NDV) zu humanen Tumorzellen. In
diesem Ansatz wurde zum ersten Mal in einer in vitro Kokultur die Beladung von humanen T-Zellen
mit NDV untersucht. Nachfolgend konnte in einem als „hitchhiking“ definierten Transport-
mechanismus gezeigt werden, dass T-Zellen in der Lage sind zelloberflächengebundenes NDV an 
MCF-7 Tumorzellen zu übertragen. Darüber hinaus wurden Tumorzellmonolayer effizient durch 
aktivierte T-Zellen, welche mit einem onkolytischen NDV Stamm modifiziert wurden, zerstört. 
Basierend auf dieser Kombinationstherapie könnten Effektor-T-Zellen als effiziente 
„Transportsysteme“ eingesetzt werden, um NDV zu Tumorzellen zu transportieren, um so eine 
gezielte Zerstörung von Tumoren einzuleiten.
Zusammenfassend zeigen die Untersuchungen der vier unterschiedlichen Ansätze, die in dieser 
Arbeit vorgestellt wurden, neue Perspektiven für die Optimierung zukünftiger immun-
therapeutischer Interventionen, um protektive T-Zellantworten gegen klinisch-erkennbare maligne 
Tumore auszulösen und zusätzlich zu unterstützen.
Introduction 
 
page | 13 
 
5. Introduction 
The human immune system represents a complex, dynamic communication network and protects 
against diseases caused by bacterial, parasitic, fungal and viral infections. Moreover, it protects the 
organism from tumor cell growth. Thereby, it has to distinguish transformed cells from healthy cells 
and tissues (Murphy et al., 2008). The functions of the immune system are facilitated through 
diverse mechanisms of innate and adaptive immune responses (Fig. 1.). Cells of the innate 
immune system including mast cells, macrophages, dendritic cells, granulocytes and natural killer 
(NK) cells defend infections in a non-specific manner, and do not confer long-lasting or protective 
immunity. In contrast, the adaptive immunity is based on the characteristics of specificity, diversity, 
memory and the ability to discriminate between foreign and self antigens. Thereby, mainly T and B 
lymphocytes conduct the specialized responses, while B cells mediate the antibody (Ab)-driven 
humoral and T cells the cellular immunity. T cell-mediated immunity is characterized by a highly 
specific antigen-mediated clonal selection and proliferation of T cells, including the development of 
immunological memory, which shows enhanced responses on subsequent encounters with the 
antigen (Abbas and Lichtman, 2005; Murphy et al., 2008). 
 
 
 
Figure 1. The innate and adaptive immune response. The innate immune response represents 
the first line of defense against infection. It consists of soluble factors (e.g., complement proteins) 
and cellular components (e.g., mast cells, macrophages, dendritic cells, granulocytes, natural killer 
cells). In contrast, the adaptive immune response develops slower, but manifests as increased 
antigenic specificity and memory. It consists of, e.g., antibodies, B cells, and T cells. The figure is 
taken from Dranoff, 2004. 
 
During the last years, T cells have been described to mount anti-tumor responses that can 
efficiently destroy tumor cells (e.g., Boon et al., 2006). Therefore, in the course of the presented 
thesis, tumor-reactive T cells were investigated, and utilized as central mediators of cancer-
directed immune interventions. The next paragraphs will describe how T cells mature, recognize 
their specific antigen, get activated and gain specific effector and memory cell functions, which are 
required to influence cancer progression. 
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5.1. T cell maturation and selection
T cells carry a highly diverse repertoire of T cell receptors (TCR), which they use to recognize 
foreign or self-antigens as peptide fragments bound to proteins of the major histocompatibility 
complex (MHC). The MHC is located on antigen-presenting cells including dendritic cells, 
macrophages and B cells. 
In the bone marrow, lymphoid progenitor cells arise from pluripotent hematopoietic stem cells, 
followed by the migration to the thymus, where the generation and maturation of the T cell 
repertoire occurs (Abbas and Lichtman, 2005; Murphy et al., 2008). The thymus supports T cell 
differentiation, T cell repertoire selection and central tolerance induction to tissue-specific antigens 
(e.g., Miller, 1961; Zinkernagel et al., 1978; Kyewski and Derbinski, 2004). The lymphocytes in the 
thymus, the thymocytes, represent immature T cells at various stages of maturation. They perform 
a complex and highly ordered chemokine receptor-dependent, dynamic relocation through defined 
thymic regions (Plotkin et al., 2003; Benz et al., 2004; Misslitz et al., 2004). Thereby, they make 
intercellular contacts with cells of epithelial and mesenchymal origin including cortical and 
medullary thymic epithelial cells (cTECs, mTECs) as well as dendritic cells (cf., Fig. 2). The somatic
recombination of TCR gene cassettes (TCR gene rearrangement) occurs in the subcapsular zone 
of the thymic cortex, followed by the assembly of a functional pre-TCR complex (von Boehmer and 
Fehling, 1997). 
During the initial development, thymocytes are double negative (DN) for the cluster of 
differentiation 4 and 8 (CD4-CD8-), then become CD4+CD8+ double positive (DP) and undergo a 
positive and negative selection. This step ensures the deletion of thymocytes from the repertoire 
that bind peptide/MHC with insufficient avidity as well as the deletion of self-reactive thymocytes 
(Bousso et al., 2002). If low-avidity TCR-mediated interactions occur, DP thymocytes receive 
signals for survival, downregulate one of their co-receptors and become single positive (SP) CD4+
or CD8+ thymocytes (cf., Fig. 2; see also Ueno et al., 2004; Kurobe et al., 2006). The positive 
selection process leads to the maturation of thymocytes which carry a TCR with sufficient avidity to 
bind peptide/MHC. The majority of thymocytes cannot bind with sufficient avidity, and therefore 
undergo death by neglect (Kisielow et al., 1988; Jameson et al., 1995). Furthermore, self-reactive 
thymocytes undergo apoptosis, a non-inflammatory form of programmed cell death, in response to 
signals generated by high-avidity binding. This process, called “negative selection” or “clonal 
deletion”, is important for the induction of central T cell tolerance (von Boehmer et al., 1989; Robey 
and Fowlkes, 1994). Positively selected SP thymocytes mature to naive T cells with functional 
TCRs on their surface while undergoing further clonal deletion of self-reactive thymocytes. This 
additional elimination process is important to establish central T cell tolerance to peripheral tissue-
specific antigens. Thereby, diverse tissues are presented by “promiscuous gene expression”
(Zyklys et al., 2000; Kyewski and Derbinski, 2004; Derbinski et al., 2005). Moreover, the induction 
of naturally occurring regulatory T cells (nTreg) takes place in the thymus (Kyewski and Klein, 
2006). Finally, naive CD4+ T cells, CD8+ T cells and nTreg, ??????????????????????????????????????
~2x107 TCRs, leave the thymus (Arstila et al., 1999).
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Figure 2. Migration of thymocytes for T cell maturation and selection. The circulation of 
thymocytes is indicated (a-g). Lymphoid progenitor cells enter the thymus at the cortico-medullary 
junction. CD4–CD8– double-negative (DN) thymocytes migrate to the subcapsular zone. CD4+CD8+ 
double-positive (DP) thymocytes are generated in the outer cortex, and interact with cortical thymic 
epithelial cells (cTEC) and dendritic cells (DC) for positive and negative selection. Positively 
selected DP thymocytes differentiate into CD4+ or CD8+ single positive (SP) thymocytes, and 
migrate to the medulla were they undergo further negative selection through interaction with 
medullary thymic epithelial cells (mTEC) and DC. Finally, mature naive T cells leave the thymus 
through blood vessels. Chemokine receptors: CXCR4, CCR7 and CCR9. The figure is adapted 
from Takahama, 2006. 
 
 
5.2. T cell antigen recognition and T cell activation 
Naive T cells continuously migrate between secondary lymphatic organs (e.g., lymph nodes, 
spleen), the bone marrow, peripheral blood (PB) and the lymph in a blood-to-lymph recirculation. 
They get activated upon encounter of specific foreign peptide/MHC, which is presented on antigen-
presenting cells, followed by the proliferation and differentiation into effector T cells (Butcher and 
Picker, 1996; Feuerer et al., 2003; Schirrmacher et al., 2003).  
The recognition of antigens by T cells is conducted through an intercellular contact with antigen-
presenting cells, mediated by cell adhesion molecules. This highly organized and dynamic cellular 
structure, formed at the T cell-antigen-presenting cell interface, is termed as the “immunological 
synapse” (for overview see Fig. 3; see also Monks et al., 1998; Bromley et al., 2001). This structure 
plays an important role in T cell activation and delivery of effector functions. 
The TCR complex consists of two separate αβ heterodimeric peptide chains, bearing constant 
and variable regions. The chains are noncovalently associated with the cluster of differentiation 3 
(CD3) proteins that consist of the two heterodimers γε and δε as well as the homodimer ζζ (Acuto 
et al., 2008). For antigen recognition, T cells need a MHC-restricted presentation of peptide 
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fragments. Moreover, the TCR/CD3-peptide/MHC complex has to be ligated to the co-receptors, 
either CD4 or CD8. CD4+ T cells specifically respond to peptides presented by MHC class II 
molecules, while CD8+ T cells need MHC class I for peptide presentation. In general, peptides 
loaded to MHC class I molecules derive from defective ribosomal products or normal turnover of 
endogenous intracellular proteins (Yewdell et al., 2003). In contrast, peptides loaded to MHC class 
II molecules mainly originate from endocytosed extracellular proteins or autophagy (Jensen, 2007). 
Nonetheless, some potent antigen-presenting cells are capable of presenting fragments of 
internalized extracellular proteins, on MHC class I, to CD8+ T cells. This process has been 
introduced as “cross-presentation” (Carbone et al., 1998; Knutson and Disis, 2005).
Figure 3. The overview of an immunological synapse. A selection of the key ligand pairs and 
signaling molecules, involved in T cell antigen recognition, followed by T cell activation are shown.
APC, antigen-presenting cell; CD, cluster of differentiation; CTLA-4, cytotoxic T lymphocyte antigen 
4; ICAM1, intercellular adhesion molecule 1; LFA1, leukocyte function-associated antigen 1; PI3K, 
phosphatidylinositol 3-kinase; SHP2, SRC homology 2-domain-containing protein tyrosine 
?????????????????????????????????????????????-chain-associated protein 70. The figure, exemplarily 
presented, is taken from Huppa and Davis, 2003.
In order to activate T cells, upon antigen recognition through TCR engagement, co-stimulatory 
signals from B7 molecules (CD80, CD86), presented by antigen-presenting cells are needed. 
These molecules bind to the CD28 surface receptor on T cells (Frauwirth et al., 2002). Besides 
CD28, the inhibitory molecule cytotoxic T lymphocyte antigen 4 (CTLA-4) can also bind B7 
molecules, but with a higher avidity. CTLA-4 delivers inhibitory signals that make the T cell less 
sensitive to stimulation by antigen-presenting cells and lead to a decreased T cell-dependent 
production of the cytokine interleukin 2 (IL-2). The cytokine IL-2 is crucial for T cell proliferation 
(Robb et al., 1981; Smith, 1984; Teft et al., 2006). Furthermore, a comparable inhibitory function 
was also shown for the interaction of the CD28-related co-stimulatory molecule programmed death-
1 (PD-1) on T cells with PD-ligand 1 (PD-L1) or PD-L2. These ligands, presented by antigen-
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presenting cells, also belong to the B7 molecule family (Okazaki and Honjo, 2007). The here 
described mechanisms are critical for T cell proliferation control and self-tolerance maintenance. 
To functional activate T cells, besides a specific cytokine milieu (including IL-2 and IL-15), 
further co-stimulatory/adhesion molecules on T cells are needed that bind to complementary 
molecules on antigen-presenting cells including CD2, CD27, CD40L, ICOS, LFA-1, OX40 and 4-
1BB. Some of these molecules act as essential signals for T cell activation, while other stabilize the 
immunological synapse formation or enhance TCR signaling (Chambers and Allison, 1999; Watts
and DeBenedette, 1999; Coyle and Gutierrez-Ramos, 2001; Croft, 2009). The signaling via the 
TCR complex is not a linear event from the receptor to the nucleus; it rather presents a complex 
feedback and feed forward regulation at each step of the signal transduction pathways (Smith-
Garvin et al., 2009). Consequently, activated T cells that receive all the required signals start to 
proliferate and differentiate into effector T cells. Thereby, the context in which the T cells recognize 
their antigen, the abundance of antigen and the duration of antigen exposure are critical 
parameters that can affect the magnitude and nature of the T cell response. In contrast, T cells that 
do not receive the required signals become anergic, which results in a functional inactivation or 
clonal deletion. 
5.3. Effector and memory T cells 
Naive T cells have to pass three different stages until they differentiate into memory T cells (Ahmed 
and Gray, 1996; Kaech et al., 2002; Murphy et al., 2008). During the first, the “T cell expansion 
phase”, naive T cells that have encountered antigens, in course of a primary infection, clonally 
expand and differentiate into short-lived effector T cells. These are the CD4+ T helper (Th) or the 
CD8+ cytotoxic T cells (CTLs). Effector T cells are able to efficiently secrete inflammatory cytokines 
and kill infected cells. They migrate in a tissue-homing molecule-dependent way to sites of antigen 
exposure to deliver the appropriate effector and regulatory functions. After pathogen clearance, the 
majority of effector T cells rapidly die. These second phase is termed “T cell death” or “contraction 
phase”. Only a minority of T cells survives and enters the “memory phase” that characterizes the 
third stage of T cell response. The number of long-lived functional memory T cells stabilizes, and 
maintain for long periods of time. They represent the immunological memory, and provide ongoing 
protection against recurrent antigen stimuli (Sprent and Miller, 1976a, b; Kaech et al., 2002; for 
recent review see Taylor and Jenkins, 2011).
5.3.1. CD4+ effector T cells
Th cells exert their function mainly through the secretion of cytokines and chemokines. They help 
other immune cells including B cells, macrophages and CTLs to express their functional activities 
at full strength (for review see Kaufmann, 2007). At the side of antigen recognition, different 
subsets of CD4+ effector T cells, with unique functions, are generated in response to cytokines. 
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Peripheral CD4+ T cells can differentiate into three main Th cell lineages: Th1, Th2 and Th17 or 
into inducible Treg (iTreg; for overview see Fig. 4; see also Zhou et al., 2009; Zou and Restifo, 
2010).  
Interferon γ (IFNγ) and IL-12 trigger the differentiation of Th1 cells. Th1 cells produce IFNγ, IL-2, 
tumor necrosis factor (TNF) and granulocyte macrophage colony-stimulating factor (GM-CSF) and 
stimulate for instance the activation of CD8+ T cells. In contrast, Th2 cells are differentiated by the 
help of IL-4. They secrete IL-4, IL-5 and IL-13 and help for example B cells in Ab production and 
downregulate pro-inflammatory responses, induced by Th1 cells. Transforming growth factor β 
(TGFβ), IL-1, IL-6, IL-21 and IL-23 trigger the differentiation of Th17 cells. They produce IL-17 and 
IL-6, and, e.g., promote inflammation and activate neutrophiles. Besides different cytokine 
requirements, all three Th cell subsets are characterized by unique transcription factors (Th1: T-
bet, Th2: GATA3, Th17: RORγt; for further details see also Weaver et al., 2006; Zhu and Paul, 
2008; Zou and Restifo, 2010). Moreover, CD4+ T cells differentiate into iTreg in the absence of 
proinflammatory cytokines but high concentrations of TGFβ. These cells secrete TGFβ and IL-10, 
and are characterized by the transcription factor forkhead box p3 (Foxp3). They control and 
counteract immune responses by other effector T cells, and are involved in the prevention of 
autoimmunity (cf., Fig.4; Kaufmann, 2007).  
 
 
 
 
Figure 4. Subpopulations of CD4+ T cells. The main populations of CD4+ T cells are T helper 1 
(Th1 or TH1), Th2 and Th17 cells as well as inducible Treg (iTreg). Treg control the responses of 
immune effector cells. Th1 cells are responsible for cell-mediated immunity, and Th2 cells for 
humoral immunity and defense against parasites. Th17 cells are involved in the defense against 
bacteria. DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, 
interferon; IL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor. The figure, 
exemplarily presented, is taken from Kaufmann, 2007. 
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5.3.2. CD8+ effector T cells
Naive peripheral CD8+ T cells differentiate into CTLs upon antigen recognition and additional 
factors produced through CD4 T cell help, especially by Th1 cells. The main effector function of 
CTLs is the direct destruction and elimination through lysis of target cells that express the specific 
peptide/MHC class I complex, against which the CD8 T cell response was generated. Through 
exocytosis, they release cytolytic effector molecules including perforin and granzyme, stored in 
cytoplasmic g???????????????????????????????????????????????????????????????????????????????????
TNF (Abbas and Lichtman, 2005; Murphy et al., 2008). 
Perforin is a calcium-sensitive, membanolytic, pore-forming protein and granzymes are serine 
proteinases. Granzymes enter target cells either through perforin pores or by receptor-mediated 
endocytosis. They get activated intracellularly, then cleave and activate caspases, and induce 
target cell apoptosis (Barry and Bleackley, 2002; Kaufmann, 2007). Target cell apoptosis is further 
induced through various pathways that display complex networks. For example, besides the 
granule-exocytosis-mediated pathway, CTLs also induce, e.g., FAS ligand (FASL, CD95L), TNF 
and TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in target cells through 
binding of FAS (CD95, APO-1), TNF or TRAIL cell death receptors, respectively (Barry and 
Bleackley, 2002).
To maintain immune homeostasis and not to compromise the response of naive T cells to new 
pathogen stimuli, after clonal T cell expansion and antigen clearance, most of the activated effector 
T cells must be rapidly deleted (Krueger et al., 2003; Strasser and Pellegrini, 2004). To induce the 
death of peripheral T cells, several extrinsic and intrinsic apoptotic pathways have been described,
including extrinsic cell-death-receptor- and caspases-dependent apoptosis (Kroemer and Jaattela, 
2005; Arnold et al., 2006; Krammer et al., 2007). Furthermore, autonomous cell death occurs in the 
absence of appropriate survival signals, termed “death by neglect” or “activated cell-autonomous 
death” (ACAD; for details see Hildeman et al., 2002). Moreover, “activation-induced cell death”
(AICD) has been described, a process mainly mediated by IL-2. Thereby, activated and expanded 
TCR restimulated T cells, without appropriate co-stimulation, undergo cell death after engagement 
of cell-death receptors including CD95 or after exposure to reactive oxygen species (ROS; Schmitz 
et al., 2003; Krammer et al., 2007).
5.3.3. Memory T cells
After pathogen elimination, only a small proportion of effector T cells that is resistant to apoptosis 
induced cell death remain and survive, called “memory T cells” (for reviews see, e.g., Krueger et 
al., 2003; Strasser and Pellegrini, 2004; Pepper and Jenkins, 2011). These long-lived antigen-
specific T cells are more responsive and sensitive to antigens, less dependent on co-stimulatory 
signals and able to functionally respond rapidly to a subsequent encounter with the same antigen. 
Thereby, memory T cells mount a more effective immune recall response than naive antigen-
specific T cells (Beckhove et al., 2004; Ahmed et al., 2009). Moreover, in contrast to effector 
Introduction
page | 20
T cells, they are capable of producing multiple cytokines (Kaufmann, 2007; Zielinski et al., 2011). In 
addition, the precursor frequency of memory T cells is much greater compared to naive T cells 
(Becker et al., 2005). Once memory T cells are differentiated, they can persist without antigen 
stimulation while undergoing homeostatic proliferation (Lau et al., 1994; Swain et al., 1999).
Two different main subpopulations, the effector and the central memory T cell, exist. They have 
different biological functions with distinct homing potentials and can, based on homing receptors, 
phenotypically be characterized. On the one hand, effector memory T cells are negative for           
L-selectin (CD62L-), chemokine receptor 7 (CCR7-) and positive for CD45RO (CD45RO+). They 
migrate to inflamed nonlymphoid tissues, replicate less efficiently but can exert immediate rapid 
effector functions without further differentiation. Moreover, they can give rise to central memory T 
cells (Sallusto et al., 2004; Schwendemann et al., 2005; Ahmed et al., 2009). Furthermore, effector 
?????????????????????????????????????????????????????????????????????????????????????????????????????
central memory T cells circulate from the PB to secondary lymphoid organs and are CD62L+,
CCR7+ and CD45RO+. They lack immediate effector functions, but, after restimulation with 
antigens, can efficiently proliferate and mediate rapid recall responses while developing the 
phenotype and function of terminally differentiated effector T cells (Sallusto et al., 1999, 2004; 
Ahmed et al., 2009). Besides a balanced cytokine milieu, especially the cytokines IL-7 and IL-15 
are important factors for T cell memory maintenance (Marrack and Kappler, 2004; Becker et al., 
2005; Zielinski et al., 2011). However, the regulation of memory T cell differentiation, maintenance 
and the lineage relationship represent complex processes that are still under scientific debate (for 
discussion see, e.g., Kaech et al., 2002; Ahmed et al., 2009; Prlic and Bevan, 2011).
5.4. Regulatory T cells
CD4+ Treg constitutively express the IL-??????????????????????-??????????????????????????-induced 
TNFR (GITR), CTLA-4 and are positive for Foxp3. They have the ability to control and suppress 
adaptive immune responses against self or foreign antigens and maintain peripheral self tolerance 
(Hori et al., 2003; Sakaguchi, 2004; Chai et al., 2005). 
Two main populations of CD4+CD25+Foxp3+ Treg have been described, the nTreg and the 
iTreg, that both strongly depend on IL-2. The nTreg develop in the thymus, and display a diverse 
TCR repertoire that is specific for self antigens. In contrast, iTreg are generated in an extrathymic 
development in the periphery from the naive CD4+ ??????? ????? ??? ????????????????????????? ????
absence of proinflammatory cytokines (cf., Fig 4, see also, e.g., Chen et al., 2003; Fontenot et al., 
2003; Hori et al., 2003). However, the biological importance of the different Treg subtypes for the 
revealed suppressive mechanisms, responsible for the physiological and the pathological role of 
Treg in humans, is still under discussion (Zhu and Paul, 2008). The transmembrane glycoprotein 
CD127 can be used to distinguish Treg from activated CD4+ effector T cells that also upregulate 
CD25 (Liu et al., 2006)????????????????????????????????-7 receptor (IL-?????????????????????????????
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majority of mature T cells, but is absent on Treg. Moreover, CD127 is inversely correlated with the 
occurrence of Foxp3 (Liu et al., 2006; Seddiki et al., 2006).  
The induction of Treg activation and function depends on antigen-specific TCR stimulation. In 
contrast, the subsequent suppressive activity, exerted by Treg, is antigen unspecific, and 
characterized by local bystander suppression of target cells (Thornton and Shevach, 2000; von 
Herrath and Harrison, 2003; Kretschmer et al., 2006; Josefowicz and Rudensky, 2009). Treg 
mediate their suppressive function through inhibitory mechanisms that depend on direct cell 
contact and soluble molecules including inhibitory cytokines, cytolysis, metabolic disruption and 
targeting of dendritic cells (Fig. 5; Vignali et al., 2008). Thereby, preferentially inhibitory cytokines 
including IL-10, TGFβ and IL-35, cytolysis through secretion of granzymes, perforin, galectins and 
induction of death-receptor pathway-mediated apoptosis in effector T cells are used (Collison et al., 
2007; Ren et al., 2007; Vignali et al., 2008). Furthermore, Treg functions are mediated by metabolic 
disruption of the effector T cell target while consuming IL-2 through binding to CD25 on Treg. IL-2 
is needed for T cells to survive, to proliferate and to maintain effector functions. Moreover, Treg can 
release adenosine nucleosides, which suppress effector T cell functions by activating the 
adenosine receptor and by transferring the inhibitory second messenger cyclic adenosine 
monophosphate (cAMP; cf., Fig. 5; see also Bopp et al., 2007; Deaglio et al., 2007; Vignali et al., 
2008; Ring et al., 2009).  
 
 
 
Figure 5. Treg-mediated immunosuppression. The basic mechanisms of Treg functions are: 
inhibitory cytokines (a), cytolysis (b), metabolic disruption of effector T cells (c) and dendritic cell 
(DC) targeting (d). A2AR, adenosine receptor 2A; cAMP, cyclic adenosine monophosphate; CTLA4, 
cytotoxic T lymphocyte antigen 4; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; ; LAG3, 
lymphocyte-activation gene 3; TGFβ, transforming growth factor β. The figure is taken from Vignali 
et al., 2008.  
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In addition, Treg can modulate dendritic cell maturation and function. Thereby, they can 
condition dendritic cells in a CTLA-4-dependent manner, leading to the expression of indoleamine 
2,3-dioxygenase (IDO), a potent immunosuppressive regulatory molecule. Besides CTLA-4, Treg 
also express further negative co-stimulatory molecules like PD-L1. Furthermore, Treg are able to 
downregulate molecules, presented by dendritic cells, including CD80, CD86 and CD40. In 
addition, dendritic cell maturation can be blocked through Treg-mediated expression of 
lymphocyte-activation gene 3 (LAG3) while binding to MHC class II on dendritic cells (cf., Fig. 5;
see also Cederbom et al., 2000; Fallarino et al., 2003; Liang et al., 2008; Vignali et al., 2008). 
Moreover, Treg have the ability to influence immune responses by recruiting other immune cells 
such as mast cells (Lu et al., 2006).
5.5. Cancer development and immunoediting
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide 
and accounted for 7.6 million deaths (~13 % of all deaths) in 2008. The worldwide cancer deaths 
are expected to rise to more than 11 million by the year 2030 (WHO, 2011) and therefore, cancer 
represents a major public health problem (Jemal et al., 2011). The development of cancer is a 
complex multi-stage process that leads to the transformation of normal cells into invasive malignant 
tumors via pre-malignant stages. A tumor is characterized to be a benign or malign neoplasm of a
tissue, generated through dysregulation of cell growth. Thereby, the term “cancer” is used 
synonymously to “malignant tumor” that can become invasive and metastatic. In general, 
metastases indicate the major cause for cancer death. The cancer development can be initiated by 
external agents including physical, chemical and biological carcinogens (e.g., ultraviolet radiation, 
components of tobacco smoke, chronic viral infections) as well as inherited genetic factors. 
Moreover, many types of cancer show an age-dependent incidence (cf., WHO, 2011).
More than ten years ago, Hanahan and Weinberg (2000) defined the concept of “the hallmarks 
of cancer” that can collectively cause malignant cell growth. This indicates that carcinogenesis 
requires crucial events that are most likely shared by all types of human tumors. They highlighted
the six essential alterations in cell physiology and mechanistic strategies, i.e., “sustaining 
proliferative signaling”, “evading growth suppressors”, “resisting cell death”, “enabling replicative 
immortality”, “inducing angiogenesis” and “activating invasion and metastasis formation” (Hanahan 
and Weinberg, 2000). Recently, further emerging hallmarks were added that are acquired during 
the multistep cancer development. They are defined as “the reprogramming of cellular energy 
metabolism” and “the avoiding of immune destruction” in particular by T cells and B cells, 
macrophages and NK cells. Additionally, two enabling characteristics that support the multiple 
hallmark capabilities were specified, defined as “genome instability and mutation” as well as 
“tumor-promoting inflammation” caused by cells such as macrophages, mast cells and neutrophiles 
(cf., Fig. 6; see also Hanahan and Weinberg, 2011).
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The course of the multi-stage carcinogenesis is strongly dependent on the tumor 
microenvironment which contributes to the biology of many tumors and to the acquisition of the 
cancer hallmarks (Hanahan and Weinberg, 2011). To understand the biology of tumor growth, one 
has to realize the tumor not as an isolated structure consisting only of cancer cells, rather as an 
independent organ comprising a variety of different cell types that interact with each other and with 
the entire organism (Egeblad et al., 2010; Pietras and Ostman, 2010; see therein for further 
informations). Besides cancer cells and neoplastic cancer stem cells, the microenvironment 
consists of cell types that form the tumor-associated stroma including endothelial cells, cancer-
associated fibroblasts, pericytes and immune inflammatory cells (Pietras and Ostman, 2010). 
Cancer stem cells have been described to be more resistant to radio- and chemotherapies than 
conventional cancer cells. They can invasively disseminate from primary tumors, form micro-
metastases and can clonally expand, caused by their self-renewal and tumor-initiating capability. 
This process can then lead to the formation of macro-metastases (Hanahan and Weinberg, 2011). 
Moreover, cancer stem cells can persist in a latent state before they start to give rise for 
metastases formation by activating the cellular program of “epithelial-to-mesenchymal transition” 
(EMT). This process is characterized by a loss of cell-cell adhesion and a gain of cell mobility that 
involves invasion (Hanahan and Weinberg, 2011). 
 
 
 
Figure 6. The concept of the hallmarks of cancer. Overview of the essential alterations, 
acquired during the multistep cancer development. The tumor growth and progression depends on 
defined capabilities that are acquired by cancer cells and shared by most malignant tumors. The 
figure is adapted from Hanahan and Weinberg, 2011. 
 
Furthermore, Cavallo et al. (2011) focused on the “immune hallmarks of cancer”, and defined 
three major immune capabilities that are important for cancer progression, i.e., “the ability of cancer 
to develop in a chronically inflamed microenvironment”, “escape immune recognition control” and 
“suppress immune reactivity” (see also Schreiber et al., 2011). This highlights that the immune 
system, importantly participates in the development and growth of tumors, summarized as the 
“cancer immunoediting” hypothesis. Thereby, in terms of tumor cell growth, the immune system 
plays a dual extrinsic role in cancer development. It can suppress the tumor growth, but also 
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promotes the tumor progression (Schreiber et al., 2011). In general, tumor immunology is based on 
a balance between immune mediators that promote tumor progression (e.g., Treg, Th2, type 2 NK 
T cells, myeloid-derived suppressor cells (MDSC), M2/tumor-associated macrophages, mast cells),
and mediators that promote tumor rejection (e.g., CTLs, Th1, NK cells, type 1 NK T cells, M1 
macrophages; for review see Ostrand-Rosenberg, 2008). The cancer immunoediting process is 
characterized by three distinct phases, i.e., “elimination” (cancer immunosurveillance), “equilibrium”
(cancer persistence/dormancy) and “escape” (cancer progression; Fig. 7; see also Smyth et al., 
2006; Vesely et al., 2011).
Figure 7. The concept of cancer immunoediting. The cancer immunoediting, an extrinsic tumor 
suppressor mechanism, consist of three phases (elimination, equilibrium, escape), and occurs
when intrinsic mechanisms have failed. In the elimination phase, innate and adaptive immunity 
work together, to destroy developing tumors. When tumor cells survive, they will enter the
equilibrium, in which their growth is prevented by adaptive immune cells that maintain tumor cells in 
a state of functional dormancy. In this phase, editing of tumor immunogenicity occurs. Tumor cells 
that enter the escape phase are no longer recognized by the adaptive immunity, and become 
insensitive to immune effector mechanisms. Moreover, within the tumor microenvironment, the 
tumor cells induce an immunosuppressive state, and start an aggressive uncontrolled tumor 
growth, which results in cancer formation. The figure is taken from Schreiber et al., 2011.
Thereby, the elimination phase is characterized by a “cancer immunosurveillance”, mediated by 
innate and adaptive immune cells. These cells fight against the developing tumor in response to 
danger signals, directly released by dying tumor cells including type I IFN cytokines, heat-shock 
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proteins and mitochondrial products (Matzinger, 1994, 2002; Schirrmacher et al., 2003). Moreover, 
effector T cells get activated by tumor antigens, proliferate and protect the host against the 
developing tumor. If tumor cells survive the elimination phase, they enter the equilibrium were they 
survive in a functional stage of “tumor dormancy”. Controlled by adaptive immunity, this state can 
last for decades (Aguirre-Ghiso, 2007). During the escape phase, tumor cells that have acquired 
the ability to circumvent immune recognition (tumor editing) start to aggressively grow, resulting in 
cancer formation. Thereby, the tumor cell escape of poorly immunogenic tumor cell variants is 
achieved by reduced immune recognition, driven by genetic instabilities (e.g., loss of antigen, MHC 
or antigen processing function and co-stimulation). Additionally, the escape phase is mediated by 
increased resistance to cytotoxic effects of immunity, through induction of anti-apoptotic 
mechanisms or defective death receptor signaling and cancer-induced immunosuppression (Khong 
and Restifo, 2002; Zitvogel et al., 2006; Schreiber et al., 2011; Vesely et al., 2011). Moreover, in 
this stage, tumor cells are able to control and suppress anti-tumor T cell responses. They produce 
? ???????????????? ?????????? ?????????? ????????? ???????????? ??????? ??????? ???????? ??????
galectins, IDO, and can recruit regulatory immune cells such as Treg and MDSC (Schreiber et al., 
2011; Vesely et al., 2011).
In the course of the last years, human anti-tumor-directed T cell responses have been detected in 
many tumor entities (e.g., Schmitz-Winnenthal et al., 2005; Boon et al., 2006; Bonertz et al., 2009). 
Their reactivation through peptide-based vaccination approaches or utilization through adoptive 
immunotherapeutic therapies has successfully been performed, but still with clinically limited 
efficiency (cf., Yee, 2005; Caspi, 2008; Rosenberg et al., 2008; Eggermont, 2009). The next 
paragraphs will highlight important strategies, used for cancer immunotherapy, and in addition will 
illustrate their limitations in terms of tumor targeting and treatment. Thereby, the main focus will 
recline on immune therapies for melanoma. Because melanoma, as one of the most immunogenic 
solid tumors, indicate a model entity for cancer immunotherapy, and has extensively been studied
(cf., Eggermont, 2009). Moreover, the optimization of immune therapeutic approaches for 
melanoma is still be crucial and therefore will be addressed during this thesis.
5.6. Cancer immunotherapy
In addition to conventional cancer therapies including surgery, radiation- and chemotherapy, also 
immunotherapy can be used for cancer treatment. To obtain optimized treatment results, often 
different approaches are used in combination. Thereby, cancer immunotherapy attempts to 
harness and direct immune mechanisms to eradicate malignant tumors. Various 
immunotherapeutic approaches for cancer treatment exist, including triggering of inflammation, 
anti-angiogenic therapy, cytokine therapy, monoclonal Ab (mAb) therapy, cellular immunotherapy 
and anti-tumor vaccination (for reviews see, e.g., Mahabeleshwar and Byzova, 2007; Caspi, 2008).
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5.6.1. Adoptive immunotherapy 
The adoptive T cell transfer approach belongs to the cellular immunotherapies of cancer. Thereby, 
patient-derived T cells with anti-tumor activity are expanded ex vivo, followed by a T cell re-infusion 
into the lymphodepleted cancer patients. The strategy of adoptive T cell therapy is shown in Fig. 8. 
Thereby, tumor antigen-specific T cells, defined by in vitro specificity tests, have to be obtained 
from tumor tissue (tumor-infiltrating lymphocytes, TILs) or patient-derived PB and expanded to 
large numbers ex vivo. Lymphodepletion before adoptive cell therapy provides an optimal 
environment for the transferred cells. It leads to the elimination of the remaining lymphoid 
compartment such as immunosuppressive Treg and lymphocytes, which would compete with the 
transferred antigen-specific T cells for homeostatic cytokines. Preferentially, the non-myeloablative 
lymphodepletion is conducted through total body irradiation or cytotoxic drugs that suppress the 
immune system for a short period of time. Besides patient-derived tumor antigen-specific T cells, 
genetically modified human T cells can also be used as effector cells for adoptive immunotherapy. 
Thereby, TCR transgenic T cells have to be generated with defined cancer-antigen specificities, 
mainly by the help of viral particles. The approach of adoptive T cell therapy has proven to be 
functional for the treatment of cancer in experimental animal models and in cancer patients, but so 
far, only low response rates have been revealed (cf., Caspi, 2008; Rosenberg et al., 2008).  
 
 
Figure 8. The generation of anti-tumor T cells used for adoptive immunotherapy. Tumor cell 
cultures have to be established ex vivo and assayed for specific tumor recognition. Cultures with 
high anti-tumor reactivity were then expanded and reinfused into cancer patients. The figure is 
taken from Rosenberg et al., 2008. 
 
5.6.2. Tumor antigen-reactive TCR transgenic T cells 
Genetically engineered TCR transgenic T cells are used for cancer treatment. Thereby, the TCR 
gene therapy is a method to produce antigen-specific T cells for adoptive T cell transfer 
immunotherapy by introducing high affine tumor-antigen reactive TCRs into human T cells. 
Different approaches have been used for TCR gene therapies that mainly depend on vector 
systems including retroviral vectors that facilitate a stable gene transfer (Schumacher, 2002; 
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Kieback and Uckert, 2010). Thereby, most TCR-transfer studies used Moloney murine leukemia 
virus (MoMuLV)-based retroviral vector systems (Schumacher, 2002). Recent work has provided 
first evidence for the clinical potential of TCR gene therapy (Morgan et al., 2006; Johnson et al., 
2009). For example, a phase I clinical trial with metastatic melanoma patients showed a successful 
tumor rejection in the patient cohort, treated with autologous T cells engineered to express a TCR 
specific for the melanocyte differentiation antigen MART-1 (Morgan et al., 2006; de Witte et al., 
2008). 
Nevertheless, a current challenge of TCR gene therapy is a potential hybrid/mixed dimer 
?????????????????? ???? ????????????????????????????????????????????? ??????????????????????-
derived chains (Fig. 9). This formation can occur during the transfer of double chain (dc) TCRs into 
human T cells (Schumacher, 2002). The resulting hybrid or mispaired TCRs will have unpredictable 
specificities that may cause “off-target” reactivities, potentially leading to autoimmune reactions 
Schumacher, 2002; Bendle et al., 2009). To avoid misspairing and promote preferential pairing of 
introduced chains, currently different strategies are investigated for TCR optimization including
???????????????????????????????????????????????????????????????????????????????????????????????????
(e.g., additional cysteine bonds or inverse exchange of amino acids) and the generation of TCR-
like molecules as single chain (sc) TCR constructs (Kieback and Uckert, 2010).
Figure 9. The formation of hybrid/mixed TCR dimers. Hybrid TCR formation can occur between 
exogenous and endogenous TCR chains. Thereby, mixed TCR dimers with unpredictable and 
potentially self-reactive specificities can result. The figure is adapted from Schumacher, 2002.
5.6.3. Peptide-based immunotherapy
The peptide-based immunotherapy belongs to the anti-tumor vaccination treatment, indicating an 
active immunization process of cancer patients against their autologous cancers using specifically 
designed peptides derived from tumor-associated antigens (TAAs). In the context of MHC 
molecules, those TAA peptides are recognized by T cells (Parmiani et al., 2002). Using peptide-
based immunotherapy, in some studies, expansions of circulating antigen-specific CD8+ T cells 
could be induced (Jandus et al., 2009). Thereby, a first evidence of a clinical benefit has recently 
been reported in a melanoma trial using glycoprotein 100 (gp100) peptide vaccinations together 
with IL-2 (Schwarzentruber et al., 2009). Besides these promising results, most of the other 
peptide-based vaccination trials failed so far, or showed only limited overall success (Lienard et al., 
2004; Rosenberg et al., 2004; Eggermont, 2009). 
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Several reasons for this lack of response have been assumed, and will subsequently be 
discussed. Up to now, mainly human leukocyte antigen A2 (HLA-A2)-restricted peptide vaccines 
were tested in late stage cancer patients (Kirkwood et al., 2008; Jandus et al., 2009). Therefore, 
patients have to be selected accordingly to their expression of defined HLA molecules, and only 
HLA-A2+ patients can receive the vaccinations. A further limitation using HLA-A2-restricted peptide 
vaccines is that only CD8+, but not CD4+ T cell responses are induced (Melief and van der Burg, 
2008). The structure of the MHC class I molecule HLA-A2, discovered by Bjorkman and co-workers 
in the late 1980s, allowed to explain how MHC restricts the recognition of foreign antigens            
by T cells (Bjorkman et al., 1987a, b). In this context, HLA-A2 presents peptides specifically to 
CD8+ T cells. CD4+ T cells are not able to recognize peptides presented by MHC class I, they 
rather need for presentation MHC class II molecules. Historically, cancer-directed immune-based 
therapies have focused on eliciting a cytotoxic CTL response, primarily due to the fact that those 
cells can directly kill tumors (Knutson and Disis, 2005). Recently, increasing importance in cancer 
immunotherapy has been given to the stimulation of CD4+ Th cells (Bos and Sherman, 2010). 
Th cells are central for the development of an immune response by activating antigen-specific 
effector cells as macrophages, mast cells and support CTLs (Kaufmann, 2007). Moreover, Th1 can 
also directly kill tumors, via release of cytokines that activate death receptors on tumor cells 
(Knutson and Disis, 2005; Haabeth et al., 2011). Based on these informations, a combined 
induction of CD4+ and CD8+ T cell stimulation will be essential for a successful immune response 
against cancer.
In addition, recently, large interests and efforts have been given to detect tumor-reactive 
memory T cells in cancer patients. After the surgical removal of the primary tumor, these cell
responses might be required for a durable prevention of tumor recurrence and metastasis 
formation (Côté et al., 2008). Memory T cells, that can persist for decades, are particularly sensitive 
to antigens while exhibiting a faster activation and proliferation rate that is less dependent on 
co-stimulatory signals (Beckhove et al., 2004). Galon et al. (2006) showed that the infiltration of 
memory T cells into tumors can predict the clinical outcome of patients. Moreover, it could be 
revealed that the blockade of CTLA-4 by anti-CTLA-4 Abs enhance anti-tumor T cell responses in 
tumor-bearing mice, and led to the rejection of already well established tumors (Peggs et al., 2009). 
These findings demonstrate the clinical efficiency of pre-existing T cell responses. 
Moreover, it has been shown that ex vivo reactivated pre-existing memory T cells of breast 
cancer patients selectively home to autologous human breast tumors in xenotransplanted mice,
followed by an efficient tumor rejection (Beckhove et al., 2004). This observation indicated that 
memory T cells can be reactivated ex vivo and revealed a therapeutic potential upon reactivation.
In this context, spontaneously induced tumor-reactive memory T cells have been detected in 
several human tumors including breast, pancreatic and colon carcinomas as well as multiple 
myeloma and melanoma (Choi et al., 2005; Schmitz-Winnenthal et al., 2005; Mueller-Berghaus et 
al., 2006; Bonertz et al., 2009; Schuetz et al., 2009). Thereby, the tumor-reactive patient-derived 
memory T cell repertoire was polyvalent and accordingly demonstrated a highly therapeutic 
repertoire that diminishes immune evasion phenomena (Sommerfeldt et al., 2006). Thus, in 
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summary, spontaneously induced tumor-reactive memory T cells provide a repertoire of functional 
and potentially protective immune cells that can therapeutically be reactivated. Thereby, for further 
optimization of cancer immunotherapies, in particular peptide-based immunotherapies, it will be 
essential to understand the regulation of those spontaneous T cell responses and to identify 
relevant antigens for reactivation.
Further limitations for an effective cancer immunotherapy are for example immunosuppressive 
mechanisms, facilitated through, e.g., a Treg blockade of immune reactions (Andrews et al., 2008).
Treg can inhibit the development and effector functions of tumor-specific T cells (e.g., Nicholaou et 
al., 2009; Nishikawa and Sakaguchi, 2010). Moreover, in murine models of cancer it could be 
shown that the depletion of Treg permits immune-mediated tumor rejection (e.g., Kline et al., 2008). 
Since the role of Treg for controlling spontaneous T cell responses in melanoma is rather unclear in 
particular the presence and role of antigen-specific Treg, these should be addressed in future 
approaches in more detail.
Moreover, in general, the interactions between cancer and immune cells are very complex and 
can affect the success of immunotherapeutic interventions. In most experimental model systems 
the growth of tumors is accompanied by the induction of T cell tolerance towards the tumor (e.g., 
Kammertoens and Blankenstein, 2009). In this context, the inefficient T cell homing to the tumor 
area might be responsible for the limited success of immune therapeutic approaches (Mora and 
von Adrian, 2006). In addition, in order to gain clinical efficacy, T cells used for adoptive therapy 
should be equipped with the ability to persist for prolonged periods of time in vivo (Berger et al., 
2008). Therefore, a main focus of current research is how tolerance to tumors is induced and how 
tolerance and various immunosuppressive conditions at the tumor side can be broken by cancer 
immunotherapy as well as to optimize methods that increase T cell targeting to the tumor area.
5.7. Malignant melanoma
Malignant melanoma, also termed as “melanoma”, a malignancy of melanocytes, the neural crest-
derived melanin pigment-producing cells, is the most aggressive form of skin cancer and belongs 
to the most treatment-resistant human cancers (Ernfors, 2010; Ko and Fisher, 2011). Melanoma is 
less frequent than non-melanoma skin cancers, but cause the majority (more than 75 %) of skin 
cancer-related deaths (Jerant et al., 2000). The incidence of melanoma in the white population has 
more than tripled during the last two decades, posing a major threat to public health (Jemal et al., 
2010). Melanocytes are preferentially located in the basal layer of the epidermis, hair bulb, eye, ear 
and meninges (Nordlund and Boissy, 2001; Bandarchi et al., 2010). Depending on the presence of 
melanocytes, melanoma can arise on different anatomic sides including cutaneous or uveal 
melanoma. Distinct melanoma subtypes have currently been summarized (Whitman et al., 2011).
To define the stages of melanoma, different classification systems and scales are used 
including the “Breslow scale” and the “tumor-node-metastases (TNM) staging”. The Breslow scale 
comprises the thickness of the melanoma in the skin. The TNM melanoma staging is based on 
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guidance of the American Joint Committee on Cancer (AJCC) and the International Union against 
Cancer (UICC), and describes the size and the nature of the primary tumor. It furthermore, 
provides informations whether tumor cells have spread to the lymph nodes or distant parts of the 
body, while forming metastases. Using the TNM classification, melanoma can be grouped into 
different stages: “stage 0” (melanoma in situ), “stage I/II” (invasive melanoma), “stage II” (high risk 
melanoma), “stage III” (regional metastases formation in lymph nodes) and “stage IV” (distant 
metastases formation). In the non-metastasized stages (stages 0, I and II) the melanoma cells are 
only in the epidermis or dermis, possibly reaching a tumor size of up to 5 mm. Thereby, they can 
be ulcerated, but do not spread to lymph nodes or other body parts. In contrast, in the 
metastasized stages III and IV, the melanoma is invasive and has formed metastases in lymph 
nodes or other organs (Balch et al., 2009).
The carcinogenesis of melanoma is a stepwise progression of mutations that drive the 
transformation of normal melanocytes or nevus cells into a non-metastasized primary tumor, 
followed by a metastatic melanoma (Miller and Mihm, 2006). Recent studies have identified 
melanoma-initiating cells, with self-renewal potential, termed as “melanoma stem cells” (Schatton 
et al., 2008; Boiko et al., 2010; Girouard and Murphy, 2011). However, their presence has 
controversially been discussed and still is a matter of scientific debate (see, e.g., Ko and Fisher, 
2011). The oncogenic transformation of melanocytes can depend on genetic factors, germline 
predisposition and environmental factors including UV exposure (Ko et al., 2010). For the initiation 
of the pathogenesis of melanoma, multiple tumor-promoting events in key oncogenic pathways 
have been described, which are driven by the activation of oncogenes and inactivation of tumor 
suppressor genes (Ko and Fisher, 2011). Thereby, the “MAPK/ERK” and “PI3K/AKT/mTOR” 
pathways, which are connected via RAS signaling, have been shown to be centrally involved in 
melanoma survival, proliferation and tumor progression. In particular, mutations in NRAS, BRAF,
c-KIT and PTEN have been identified to play important roles in melanoma development          
(Tsao et al., 1998; Hocker and Tsao, 2007; Beadling et al., 2008). 
Nowadays, the first treatment choice for melanoma is surgery. While non-metastasized 
melanoma is mainly cured by the removal of the primary tumor, the 5-year survival rate of patients 
with metastasized melanoma is less than 10 %, due to the aggressiveness of advanced melanoma 
and existing deficiencies of therapeutic approaches (Kuphal and Bosserhoff, 2009). After surgery, 
for advanced stages, adjuvant therapies (chemotherapies, radiation and biological therapies 
including immunotherapy) are mainly used.
To specifically target the underlying melanoma pathways, in the concept of targeted inhibition of 
mutated kinase oncogenes, several therapeutic agents have been investigated including imatinib, 
farnesyl transferase inhibitors, RAF and MEK inhibitors and rapamycin (for review see, e.g., Ko and 
Fisher, 2011). Thereby, targeting only one pathway seems not likely to be clinically efficient. In 
order to avoid the escape of resistant melanoma cell clones, combinational approaches that target 
several pathways or a combination with conventional chemotherapies have been performed (see, 
e.g., McDermott et al., 2008; Kudchadkar, 2010). Since it is known that angiogenesis is crucial for 
tumor and metastasis growth, also anti-angiogenic therapies (e.g., VEGF ligand-targeting mAb 
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bevacizumab) have been used for melanoma treatment, however, preferentially in combinational 
approaches (Hanahan and Folkman, 1996). 
In the search for novel treatments, during the last decades, melanoma immunotherapies gained 
increasing importance. Melanoma is considered as one of the most immunogenic solid tumors, and 
an ideal candidate to develop immunotherapeutic approaches (Eggermont, 2009). Therefore, 
numerous early phase immunotherapy clinical trials have been reported, however, so far most of 
them failed or revealed only low clinical benefit (cf., Jandus et al., 2009; Eggermont, 2009).         
In advanced metastasized melanoma patients recombinant biologicals have widely been used, 
?????????? ????? ????? ????? ???? ??-2. Thereby, the IFN treatment demonstrated a 10-20 % 
improvement in relapse-free survival, and the IL-2 treatment revealed durable responses in          
10-20 % of the patients (Agarwala and Kirkwood, 1996; Atkins et al., 1999; Tarhini and Agarwala, 
2006). Besides the use of cytokine therapies, adoptive T cell transfer approaches have been 
performed. Thereby, ex vivo expanded autologous antigen-specific tumor-reactive T cells, isolated 
from TILs or patient-derived PB and engineered TCR transgenic human T cells were utilized. As 
immunologically active effector cells, the antigen-specific T cells were then reinfused into 
lymphodepleted patients. Thereby, mainly combination therapies are performed with non-
myeloablative but lymphodepleting chemotherapy or irradiation with concomitant administration of 
high dose IL-2, resulting in clinical response rates of 50-70 % (Dudley et al., 2005, 2008; Jandus et 
al., 2009). Moreover, for melanoma immunotherapy immune checkpoint antagonists were used 
including CTLA-4 or PD1 blocking mAbs (Jandus et al., 2009; Peggs et al., 2009; Quezada et al., 
2010; Ko and Fisher, 2011). In the case of CTLA-4 Ab blockade with ipilimumab, a recent phase III 
clinical trial with metastatic melanoma patients reported a significant survival benefit in ~1/3 of all 
patients, indicating a promising treatment option for melanoma (Hodi et al., 2010). Besides the 
chemotherapeutic drug dacarbazine, aldesleukin (recombinant IL-2), IFN-???? ???? ??????-????
recently also ipilimumab has been approved by the Food and Drug Administration (FDA) for 
melanoma treatment (CenterWatch, 2011; NCI, 2011). Furthermore, different types of anti-
melanoma antigen-defined vaccines have been described including dendritic cell-based vaccines, 
whole cell allogenic tumor vaccines, viral vectors as antigen delivery vehicles, DNA vaccines and 
peptide-based immunotherapy approaches (Jandus et al., 2009). Nowadays, for melanoma 
peptide-based vaccines, simultaneous injections of multiple tumor-associated peptides, mainly 
HLA-A2-restricted, together with immunostimulatory adjuvants (e.g., GM-CSF, IL-2, IL-12) are 
used. In the last years, numerous melanoma TAAs have been identified. The first evidence of a 
promising clinical benefit using peptide-based vaccination against melanoma has been shown in a 
prospective randomized multicentric phase III clinical trial. Thereby, a survival advantage has been 
shown for peptide vaccine-treated stage IV melanoma patients using gp100209-217 peptide 
vaccination together with high dose IL-2 (Schwartzentruber et al., 2009). These positive 
encouraging observations indicate that optimized peptide-based immunotherapy might be a
promising future melanoma treatment, to achieve clinically relevant results.
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5.8. Melanoma tumor-associated antigens
The first melanoma TAAs, specifically expressed by tumor cells, were identified and cloned in the 
1990s (van der Bruggen et al., 1991; Rosenberg, 1999). Until today, a large number of 
characterized MHC class I- and II-restricted epitopes of immunogenic melanoma TAAs have been 
added (cf., Cancer Immunity, peptide database, last update of January 2011; www.cancer 
immunity.org). As many antigens presented by tumors can also be expressed by normal tissues, 
problems can occur during targeting approaches of immunotherapy. For example, side effects such 
as vitiligo through off-target T cell responses were detected in melanoma trials using melanocyte 
differentiation antigens as target. Thereby, vitiligo, a depigmentation disorder, is an autoimmune 
disease of the skin and hair, caused by the destruction of melanocytes (Caspi, 2008).
Summarized, T cell-defined melanoma antigens can be classified on the basis of their expression 
pattern, and include melanocyte linage/differentiation antigens (e.g., Melan-A/MART-1, 
gp100/pmel17, TRP2, Tyrosinase, RAB38/NY-Mel-1), oncofetal/cancer-testis antigens that are 
expressed in germ cells of testis and ovary but silent in normal somatic cells (e.g., Mage-A1, 
MAGE-C2, GAGE-1, NY-Eso-1), mutational or atypical antigens (e.g., NA17-A) and antigens that 
are over-expressed in melanoma (e.g., MDM2, MIF, p53).
5.9. Dysplastic nevi
Dysplastic nevi are benign melanocytic dysplasias with architectural disorders and cytological 
atypia (Peter et al., 1992; Elder, 2010). A stepwise transformation of melanocytes to melanoma has 
been described by the traditional “Clark model of melanoma progression” (Fig. 10; Clark et 
al., 1984). This model emphasizes the proliferation of melanocytes, followed by the formation of 
nevi and the subsequent development of dysplasia, hyperplasia, invasion and metastasis 
(Clark et al., 1984; Miller and Mihm, 2006). Based on the described model, a dysplastic nevus has 
a malignant potential, and is characterized as an asymmetric pre-malignant lesion with irregular 
borders that give rise to a melanoma. Currently, most dermatologists emphasize that a dysplastic 
nevus is not a direct precursor that in every case, unrestricted develop into melanoma. It could be 
shown that ~26 % of all melanoma arise from nevi, of which 43 % arose from dysplastic nevi. Thus 
indicates that most cutaneous melanoma arise from normal-appearing skin, mainly in response to 
molecular events in oncogenic pathways (Bevona et al., 2003; Ko et al., 2010). Therefore, 
nowadays, dysplastic nevi are realized as lesions that can give rise to melanoma. Since melanoma 
often can only be clearly distinguished from dysplastic, but benign, lesions through pathological 
investigations, dysplastic nevi are carefully controlled and often removed by surgery.
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Figure 10. An overview of the Clark model of melanoma progression. Aberrant proliferation of 
normal melanocytes leads to the formation of a benign nevus, followed by the formation of a 
dysplastic nevus (asymmetric with irregular borders). A dysplastic nevus than enters a radial 
growth phase, followed by a vertical growth through the basement membrane and can become 
invasive, resulting in a metastasis formation. The figure is taken from Miller and Mihm, 2006.
5.10. Cell adhesion molecules 
Cell adhesion molecules (CAMs) are predominantly transmembrane glycoproteins, involved in 
intercellular binding of adjacent cells to each other or to the extracellular matrix (ECM). They play a 
crucial role in a number of biological processes including homeostasis, embryogenesis, 
development of neural tissue, inflammation, immune cell transmigration and immune response. 
Four major groups of CAMs have been described, defined as “cadherins”, “integrins”, “selectins” 
and the “immunoglobulin (Ig) superfamily” (Pignatelli and Vessey, 1994; for detailed overviews see 
Behrens and Nelson, 2004; LaFlamme and Kowalczyk, 2008; Nelson and Fuchs, 2010).
The carcinoembryonic antigen-related cell adhesion molecules (CEACAMs, CD66) are highly 
glycosylated transmembrane proteins of the Ig superfamily and have first been described in 1972 
(von Kleist et al., 1972; Mach and Pusztaszeri, 1972; see also Horst and Wagener, 2004). They are 
involved in cell-cell recognition and modulate cellular processes such as shaping of tissue 
architecture, neovascularization, angiogenesis, regulation of insulin action, T cell proliferation and 
have also been described as bacterial and viral pathogen receptors. Moreover, CEACAMs play an 
important role in tumor-associated mechanisms (see, e.g., Hammarstrom, 1999; Kuespert et al., 
2006). Thereby, the expression of CEACAM1 on melanoma cells has shown to be responsible for 
the inhibition of melanoma-specific T cell responses, leading to impaired T cell functions (Markel et 
al., 2006). 
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The L1 cell adhesion molecule (L1CAM, CD171), also a member of the Ig superfamily, was 
discovered in 1984 (Rathjen and Schachner, 1984), and has an important role in the function of the 
nervous system and the development of human malignancies. In cancer, L1CAM has been 
revealed to enhance cell proliferation, invasion, motility, tumor metastasis formation and resistance 
to chemotherapy (Schaefer and Altevogt, 2010). 
Besides CEACAM1, a potential immunosuppressive role of further tumor-expressed CAMs 
including CEACAM6 and L1CAM might be possible, and has to be addressed in future 
investigations.
5.11. Newcastle disease virus
Moreover, oncolytic virotherapy, for example mediated by Newcastle disease virus (NDV), can be 
used for cancer treatment. NDV, a paramyxovirus, is in general not infectious for humans (only mild 
flu-like symptoms, conjunctivitis or laryngitis), but able to cause the highly contagious “Newcastle 
disease” in birds (Schirrmacher and Fournier, 2009). NDV is enveloped and contains a single-
stranded negative-sense RNA genome, coding for six major proteins, i.e., “nucleocapsid protein” 
(NP), “phosphoprotein” (P), “matrix protein” (M), “fusion protein” (F), “hemagglutinin-neuraminidase 
protein” (HN) and the “polymerase large protein” (L).
Cassel and Sinkovics introduced NDV into the clinic as an experimental therapeutic oncolytic 
agent. There, it now is used for more than 50 years (e.g., Cassel and Garrett, 1965; Sinkovics and 
Horvath, 2000). Thereby, NDV has been used for cancer therapy, because of its safety, cancer-
selective replication and oncolytic and immune stimulatory properties (Pecora et al., 2002; 
Schirrmacher, 2005). The clinical anti-cancer potential of NDV oncolytic virotherapy has been 
evaluated for oncolysates and whole cell vaccines including the “autologous tumor vaccine 
modified by infection with NDV” (ATV-NDV) that stimulate the immune system. Additionally, 
patients have also been infected with lytic NDV (cf., Schirrmacher and von Hoegen, 1993; 
Schirrmacher and Fournier, 2009). For example, NDV oncolysates were used for the treatment of 
melanoma in phase I and II clinical trials, and revealed an improved overall survival (Murray et al.,
1977; Cassel and Murray, 1992).
After the systemic application, in general, only a fraction of the virus reach the tumor tissue 
(Bian et al., 2005), therefore, a major problem for oncolytic viral applications is the efficient viral 
tumor targeting. In this context, the viral transport through “hitchhiking” on blood circulating cells 
has been shown for retrovirus and vesicular stromatitis virus (Cole et al., 2005; Rooney, 2005; Qiao 
et al., 2008). If this kind of viral transfer will also be possible for NDV, has to be investigated.
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5.12. Objectives of the thesis 
Besides conventional therapies, immunotherapies are used as a promising and potent option for 
cancer treatment. Thus, for malignant melanoma various different immunotherapeutic strategies 
have been investigated, and revealed promising results. In this context, the improved 
understanding of the regulation of spontaneous tumor-associated antigen (TAA)-reactive 
autologous T cell responses in cancer patients and the identification of relevant antigens for a 
therapeutic induction of those responses appears to be crucial for the optimization of future 
immunotherapies. Moreover, using gene therapy, currently various approaches follow the 
generation of optimized T cell receptor (TCR) transgenic T cells to prevent the potential generation 
of hybrid dimer self-reactive TCRs. Therefore, pre-clinical studies, that utilize animal models, have 
to be conducted to reveal the functionality and safety of the TCR constructs. In order to optimize 
immune-based cancer treatments, the identification of further mechanisms, responsible for the 
induction of cancer-directed functional-loss of impaired effector T cells, will also be important. In 
addition, to increase the treatment efficiency of oncolytic NDV virotherapy, the viral transport to the 
tumor is needed to be optimized. Therefore, while focusing on four different approaches, the major 
aim of the presented thesis is to address mechanisms, crucial for the optimization of cancer 
immune therapeutic interventions.
The first approach will characterize spontaneously induced endogenous TAA-reactive memory      
T cell responses, and analyze their regulation after tumor or lesion resection in the peripheral blood 
of melanoma and dysplastic nevi patients. Therefore, various polypeptides specific for melanoma 
TAAs that contain epitopes for CD4+ and CD8+ T cell recognition will be designed. Thereby, in non-
metastasized melanoma patients the spontaneously induced T cell responses will be investigated 
after tumor resection over time and compared to responses revealed in healthy donors. 
Additionally, the Treg contribution to the activation status of the pre-existing TAA-reactive T cells 
will be addressed.
In a second project, the in vivo efficiency of human T cells, transduced with previously optimized 
and functional-expressed TCR constructs, specific for the antigens MDM2 and gp100 will be 
investigated in a murine xenotransplantation model. Thereby, the TCR constructs were optimized 
in order to avoid “off-target” reactions, caused by hybrid mispaired TCR chain formation.
The third approach will aim the immunosuppressive importance of the cell adhesion molecules 
CEACAM6 and L1CAM. In this context, the tumor cell-mediated impact on human TAA-reactive     
T cell responses and T cell-dependent tumor recognition will be addressed.
In the fourth project, the viral transport of the Newcastle disease virus (NDV) to tumor cells will be 
optimized. Thereby, human T cells will be investigated for their potential to deliver NDV particles.
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6. Material
All brand and product names used are registered trademarks of the manufacturers.
6.1. Laboratory equipment
Product Supplier
Autoclip wound clip applier / remover Becton Dickinson (BD), Heidelberg, Germany
Axioplan 2 imaging microscope Carl Zeiss, Jena, Germany
Axiophot 2 microscope / AxioCam HR Carl Zeiss
Axiovert 25 microscope Carl Zeiss
Binocular microscope Carl Zeiss
Biological safety cabinet Integra Biosciences, Fernwald, Germany
Biological safety cabinet The Baker Company, Sanford, ME, USA
Caliper Bauhaus, Heidelberg
Cell culture incubator Sanyo, Bad Nenndorf, Germany
Centrifuge Biofuge fresco Heraeus, Hanau, Germany
Centrifuge Megafuge 2.0R Heraeus
CTL ImmunoSpot S5 UV analyzer CTL, Bonn, Germany
Digital analytical balance Mettler Toledo, Giessen, Germany
Dissecting cutlery Fine Science Tools, Heidelberg
Electroblotting chamber CTI, Idstein-Taunus, Germany
Electrophoresis power supply Biotec-Fischer, Reiskirchen, Germany
Flow cytometer FACS Calibur BD
Flow cytometer FACScan BD
Flow cytometer FACS Canto II BD
Flow sorter Aria 2 BD
Freezer (-20°C) Liebherr, Ochsenhausen, Germany
Freezer (-80°C) Thermo Fisher Scientific, Karlsruhe, Germany
Freezing container Mr. Frosty Nalgene, Thermo Fisher Scientific
Freezing container Carl Roth, Karlsruhe
Fridge (4°C) Liebherr
Gammacell 1000 Atomic Energy of Canada, Ottawa, ON, Canada
Gammatron Cobalt 60 therapy unit Siemens, Munich, Germany
Glass cuvettes Thermo Fisher Scientific
Heatable magnetic stirrer Heidolph Instruments, Schwabach, Germany
Heat block, thermo mixer Grant Instruments, Cambridgeshire, UK
Heat sealer Perkin-Elmer
Ice machine Hoshizaki, Willich-Muenchheide, Germany
Innova 44 incubator / shaker New Brunswick, Wesseling-Berzdorf, Germany
Inoculation loop holder neoLab, Heidelberg
IVIS100 in vivo imaging system Xenogen, Caliper, Mainz, Germany
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Leica CM3050 S cryo-microtome Leica Microsystems, Wetzlar, Germany
Leica DM LB2 microscope / DC480 camera Leica Microsystems
Liquid scintillation counter Perkin-Elmer, Ueberlingen, Germany
MicroBeta Trilux 1450
Lumat LB 9507 luminometer Berthold Technologies, Bad Wildbad, Germany
Magnetic particle concentrator Dynal, Invitrogen, Darmstadt, Germany
Micropipettes (2-???????? Gilson, Middleton, WI, USA
Microwave Bosch, Heidelberg
Milli-Q water purification device Millipore, Eschborn, Germany
Multichannel pipettes Rainin, Mettler Toledo
Neubauer hemocytometer Brand, Wertheim, Germany
Novex mini-cell gel chamber Invitrogen
OctoMACS separator Miltenyi Biotec, Bergisch Gladbach, Germany
Owl EasyCast gel electrophoresis system Nunc, Thermo Fisher Scientific
???????????????-counter Perkin-Elmer
PCR thermal cycler PTC-100 MJ Research, Waltham, MA, USA
pH meter WTW, Weilheim, Germany
Photometer GeneQuant pro Amersham Biosciences, Freiburg, Germany
Pipetboy Brand
Plate reader Perkin-Elmer
Precision balance (PB602-S/FACT) Mettler Toledo
Quartz cuvettes Hellma Analytics, Muellheim, Germany
Rollers synchronous mixer RM5 Karl Hecht GmbH, Sondheim, Germany
Shandon cytospin 2 cytocentrifuge Thermo Fisher Scientific
Shaver for mice (type 1556) Moser, Berlin, Germany
Table top centrifuge Heraeus
Tomtec Harvester Mach 3 Perkin-Elmer
Ultracentrifuge Beckman Coulter, Krefeld, Germany
UV gel documentation system Konrad Benda, Wiesloch, Germany
Video graphic printer UP-890 CE Sony, Berlin
Vaccu-Pette/96, multiwell pipetter Bel-Art, Sigma-Aldrich, Munich
Vortexer (Reax 2000) Heidolph Instruments
Vacuum pump neoLab
Water bath Julabo, Seelbach, Germany
X-ray film-processor Optimax Typ TR MS Laborgeraete, Heidelberg
Material
page | 38
6.2. Consumables
Product Supplier
Black 96 microwell plate Nunc
Blood lancets B. Braun, Melsungen, Germany
Capillaries, heparinized (32 mm / 9 μl) Hirschmann Laborgeraete, Eberstadt, Germany
Cell culture dishes TPP, Trasadingen, Switzerland
(Ø 60 x 16, 96 x 21, 146 x 21 mm)
Cell scraper Sarstedt, Nuembrecht, Germany
Cell strainer (40, 70, 100 μm) Falcon, BD
Conical centrifuge tubes (15, 50 ml) TPP
Cryogenic vials (2 ml) Corning, VWR, Darmstadt
Cryomold adapters, Tissue-Tek Sakura Finetek, Staufen, Germany
Dako Pen Dako, Hamburg, Germany
Disposable needles BD
Disposable scalpel, Feather PfM, Cologne, Germany
Disposable syringes (1, 5, 10, 20 ml) BD
Disposable syringes (50 ml) Terumo, Eschborn
ELISPOT 96 well plate (MAHA S45, clear) Millipore
Erlenmeyer glass flasks Thermo Fisher Scientific
Ficoll tubes - Leucosep (50 ml) Greiner Bio-one, Frickenhausen, Germany
Filter cards/sample chambers for cytospin Thermo Fisher Scientific
Flat-bottom plates (6, 12, 24, 48, 96 well) Falcon
Flat-bottom plates (6, 12, 24, 48, 96 well) TPP
Glass cover slips R. Langenbrinck, Teningen, Germany
Konica-Minolta medical film Konica-Minolta, Langenhagen, Germany
Luminometer tubes (5 ml, 75 x 12 mm) Sarstedt
MACS columns Miltenyi Biotec
Menzel Super Frost Plus object slides Thermo Fisher Scientific
Micro-fine insulin syringe/needle (1 ml) BD
Microtome blades Leica 819 Leica Microsystems
Needles (0.4 mm x 19 mm) BD
Optilux petri dishes (Ø 100 x 20 mm) Falcon
Parafilm Pechiney Plastic Packaging, Chicago, IL, USA
Petri-Seal, adhesive sealing film Sigma-Aldrich
Pipette filter tips Starlab, Ahrensburg, Germany
???????????????????????????
??????????????????????????????? Starlab
????????????????????? Rainin
Plastic membrane bag for 1450 MicroBeta Perkin-Elmer
Plastic serum pipettes, sterile Greiner Bio-One
Poly-prep slides, poly-L-lysine coated Sigma-Aldrich
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Polypropylene tubes (1.3 ml) Greiner Bio-one
Polypropylene round bottom tubes (5 ml) Falcon
Polypropylene round bottom tubes with Falcon
cap (14 ml)
Polystyrene tubes (0.6 ml) Greiner Bio-one
Polystyrene round bottom tubes with Falcon
cap (5 ml)
Polystyrene round bottom tubes with Falcon
35 μm cell strainer cap (5 ml)
Polyvinylidene difluoride (PVDF) membrane Millipore
Printed Filtermate A for MicroBeta Perkin-Elmer
(90 x 120 mm)
Reagent reservoirs, sterile (50 ml) Corning
Round-bottom plate (96 well) TPP
Round-bottom plate (96 well) Falcon
Safe-lock tubes (0.5, 1.5, 2 ml) Eppendorf, Wesseling-Berzdorf
Safe-lock tubes, Biopur (1.5, 2 ml) Eppendorf
Serological pipettes, 5, 10, 25 ml Falcon
S-Monovette 10ml 9NC, trisodium citrate Sarstedt
Soft Ject tuberkulin syringe (1 ml) Henke Sass Wolf, Tuttlingen, Germany
??????????????????????????????????? Millipore
Tissue culture flask/filter cap TPP
(25, 75, 150 cm2)
Whatman 3MM gel blot paper Sigma-Aldrich
6.3. Assay kits
Product Supplier
Alkaline phosphatase conjugate substrate kit Bio-Rad, Munich
CD4+CD25+ regulatory T cell isolation kit, human Miltenyi Biotec
DakoCytomation EnVision+ system-HRP (AEC) kit Dako
Dual-luciferase reporter assay system Promega, Mannheim, Germany
Dynal CD4+ isolation kit Dynal
Dynal CD8+ isolation kit Dynal
Dynal T cell negative isolation kit Dynal
Dynabeads untouched human T cell kit Dynal
Endofree plasmid Maxi kit Qiagen, Hilden, Germany
Enhanced chemiluminescence (ECL) detection system Amersham-Buchler, GE
Healthcare, Freiburg
QIAprep spin Miniprep kit Qiagen
Venor GeM mycoplasma detection kit Minerva Biolabs, Berlin
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6.4. Chemicals, biological reagents, media, supplements and buffers
All chemicals used for media, buffers and other solutions were obtained from Merck (Darmstadt), 
Sigma-Aldrich, Roche Diagnostics (Mannheim), Serva (Heidelberg) or Carl Roth. Further reagents 
are indicated respectively. Double distilled water (ddH2O) was received using a Milli-Q water 
purification device and autoclaved before use.
6.4.1. Chemicals and biological reagents
Product Supplier
4',6-diamidino-2-phenylindole (DAPI) Serva
7-AAD BD
100 bp DNA Ladder Invitrogen
100 bp DNA Ladder New England Biolabs (NEB),
Frankfurt, Germany
1 kb DNA Ladder NEB
Acetic acid Fluka, Sigma-Aldrich
Acetone Sigma-Aldrich
Agarose Invitrogen
Ammonium chloride (NH4Cl) Fluka
Ammonium hydroxide solution (NH4OH; 1 M) Fluka
Ampicillin Sigma-Aldrich
Antibody (Ab) diluent Dako
Aqua ad iniectabilia B. Braun
BamHI methyltransferase reaction buffer NEB
Benzonase Merck
Bouin’s solution Sigma-Aldrich
Bovine serum albumin (BSA), fraction V Sigma-Aldrich
Bromphenol blue Merck
BSA (100X) NEB
CD4 MicroBeads, human Miltenyi Biotec
Coomassie brilliant blue R-250 Sigma-Aldrich
Deoxyribonuclease I from bovine pancreas (DNase I) Sigma-Aldrich
Dimethyl sulphoxide (DMSO) Sigma-Aldrich
Dithiothreitol (DTT) Serva
Diphteria toxin Calbiochem, Merck
D-luciferin potassium salt Synchem, Felsberg, Germany
Dulbecco`s PBS powder without Ca2+, Mg2+ (for 10 l) Biochrom
Dynabeads pan mouse IgG Dynal
Dynabeads CD3/CD28 T cell expander, human Dynal
EDTA (1 % in PBS without Ca2+, Mg2+) Biochrom
Endobulin (human IgG) Baxter, Unterschleißheim,
Germany
Ethanol absolute Sigma-Aldrich
Ethidium bromide Sigma-Aldrich
Fixation/permeabilization concentrate eBioscience, Frankfurt
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Fixation/permeabilization diluent eBioscience
Fluoromount-G Southern Biotech, Biozol, Eching,
Germany
GeneRuler DNA ladder mix Fermentas, Thermo Fisher
Scientific
Geneticin sulfate (G-418) Gibco, Invitrogen
Glacial acetic acid Sigma-Aldrich
Glycerol Carl Roth
Glycine Gerbu, Gaiberg, Germany
Heparin-Natrium (25 000 I.E./5 ml) B. Braun
Hyaluronidase from sheep testes, type V Sigma-Aldrich
Hygromycin B Invitrogen
Isofluran Baxter
Isopentane Carl Roth
Isopentanol Sigma-Aldrich
Isopropanol Fluka
JetPEI transfection reagent Polyplus-transfection, Peqlab,
Erlangen, Germany
Ketanest S Pfizer, Karlsruhe
Loading dye solution (6X) Fermentas
Low molecular weight DNA Ladder NEB
Lympholyte-M cell separation centrifugation medium, mouse Cedarlane, Biozol
Matrigel basement membrane matrix, phenol-red free BD
Mayer´s Hematoxylin (Lillie´s modification) Dako
MB Taq DNA polymerase (hot-start) Minerva Biolabs
Methanol VWR
[methyl-3H]-Thymidine (5 mCi, 185 MBq) Perkin-Elmer
Milk powder Carl Roth
MTS cell titer 96 aqueous solution Promega
NaCl (sodium chloride) Sigma-Aldrich
Na251CrO4 (5 mCi, 185 MBq) Perkin-Elmer
NEB reaction buffer 1 and 3 NEB
Norleucine-DL Sigma-Aldrich
Normal serum (chicken, goat, mouse) Santa Cruz Biotechnology,
Heidelberg
Normal serum (rat) eBioscience
Paraffin wax pellets BDH Prolabo, VWR
Paraformaldehyde Merck
Permeabilization buffer (10X) eBioscience
Plasmocin Invivogen, Toulouse, France
Polybrene (Hexadimethrine bromide) Sigma-Aldrich
Poly-L-lysine hydrobromide Sigma-Aldrich
Potassium hydrogen carbonate (KHCO3) Sigma-Aldrich
Propidium iodide (PI) Sigma-Aldrich
Protein assay dye reagent concentrate Bio-Rad
Protein marker, broad range (2-212 kDa) NEB
Puromycin PAA, Pasching, Austria
Restriction enzymes (BamHI, HindIII, KpnI, NcoI, PstI) NEB
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Retronectin Takara Bio, Mobitec, Goettingen,
Germany
Rompun 2 % Bayer-Schering Pharma,
Leverkusen, Germany
SDS Carl Roth
Sodiumhydroxide pellets Sigma-Aldrich
Spitacid Ecolab, Duesseldorf, Germany
Staphylococcal enterotoxin B (SEB) Sigma-Aldrich
Streptavidin-alkaline phosphatase Mabtech, Hamburg
Tissue-Tek Sakura Finetek
TransIT-LT1 transfection reagent Mirus Bio, MoBiTec, Goettingen
Tris(hydroxymethyl)aminomethane Sigma-Aldrich
Tris-glycine 4-20 % gradient gels Anamed, Gross-Bieberau,
Germany
Triton X-100 Fluka
Trypan blue solution (0.4 %) Fluka
Trypsin-EDTA (10X) PAA
Tween 20 Sigma-Aldrich
6.4.2. Media and supplements
Product Supplier
AB serum, human PAN Biotech, Aidenbach, Germany
Agar Fluka
Biocoll separating solution (density 1.077 g/ml) Biochrom
DMEM high glucose (4.5 g/l), L-Glutamine, Sigma-Aldrich
sodium pyruvate, sodium bicarbonate (D6429)
DMEM high glucose (4.5 g/l), without L-Glutamine (E15-009) PAA
DMEM/F-12 (1:1) high glucose (3.2 g/l) Gibco
without L-Glutamine (21331020)
D-PBS without Ca2+, MgCl2 (D8537; 1X) Sigma-Aldrich
Fetal calf serum (FCS) Biochrom
Hepes (1 M) PAA
L-Glutamine (200 mM) BioWhittaker, Lonza, Cologne
Non-essential amino acids (NEAA; 100X) BioWhittaker
Penicillin/Streptomycin (Pen/Strep; 100X) PAA
RPMI 1640 with L-Glutamine, sodium bicarbonate (R8758) Sigma-Aldrich
RPMI 1640 with Hepes, without L-Glutamine and phosphate PAN-Biotech
S.O.C. medium Invitrogen
Tryptone Applichem, Darmstadt
X-VIVO 20 serum-free medium with L-Glutamine, gentamicin Lonza
Yeast extract Gerbu
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FCS and AB serum were generally inactivated at 56°C for 30 min and filtered (0.22 μm) sterile 
before used as media supplements.
? Dendritic cell medium
X-VIVO 20 50 ml
Human rGM-CSF 560 U/ml
Human rIL-4 50 U/ml
? DMEM, 10 % FCS
DMEM with L-Glutamine 500 ml
10 % FCS 50 ml
Pen/Step 5 ml
Hepes 5 ml
? DMEM, 20 % FCS
DMEM with L-Glutamine 500 ml
20 % FCS 100 ml
Pen/Step 5 ml
Hepes 5 ml
? DMEM/F-12, 10 % FCS
DMEM/F-12 500 ml
10 % FCS 50 ml
Pen/Step 5 ml
Hepes 5 ml
200 mM L-Glutamine 5 ml
? Freezing medium
80 % FCS 40 ml
20 % DMSO 10 ml
Freezing medium was routinely filtered (0.22 μm) sterile and 5 ml aliquots in 15 ml tubes were 
prepared and stored at -20°C until use.
? LB medium
Tryptone 10 g
Yeast extract 5 g
NaCl 10 g
add ddH2O to 1 l, pH 7.0, autoclaved 
? LB Agar medium for bacterial plates (LB Agar plates)
Tryptone 10 g
Yeast extract 5 g
NaCl 10 g
Agar 15 g
add ddH2O to 1 l, pH 7.0, autoclaved
The homogeneous solution was cooled to ~50°C, ampicillin was added and the Agar medium 
spilled to Optilux petri dishes and allowed to solidify under sterile conditions. The plates were 
stored upside down at 4°C for up to 2 weeks until use.
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? Phoenix medium
DMEM with L-Glutamine 500 ml
10 % FCS 50 ml
NEAA 5 ml
Pen/Step 5 ml
Hepes 5 ml
? Phosphate-free T cell TCR medium
RPMI without L-Glutamine and phosphate 500 ml
10 % AB Serum 50 ml
Pen/Step 5 ml
200 mM L-Glutamine 5 ml 
? Phosphate-free T cell TCR medium with cytokines
Phosphate-free T cell TCR medium 50 ml
Human rIL-2 100 U/ml
Human rIL-4 3 U/ml
Human rIL-7 20 ng/ml 
Human rIL-15 20 ng/ml 
? RPMI medium 10 % FCS
RPMI with L-Glutamine 500 ml
10 % FCS 50 ml
Pen/Step 5 ml
Hepes 5 ml
? RPMI medium without serum
RPMI with L-Glutamine 500 ml
Pen/Step 5 ml
Hepes 5 ml
? T cell medium
RPMI with L-Glutamine 500 ml
10 % AB serum 50 ml
Pen/Step 5 ml
Hepes 5 ml
? T cell medium with cytokines
T cell medium 50 ml
Human rIL-2 100 U/ml
Human rIL-4 3 U/ml
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6.4.3. Buffers
The following buffers used, were generally freshly prepared and stored at 4°C.
? ACK lysis buffer for red blood cell lysis
NH4Cl 8.29 g
KHCO3 1 g
EDTA 0.0372 g (0.1 mM)
add ddH2O to 1 l, pH 7.2 - 7.4
? Bluing reagent for IHC staining 
1 M NH4OH solution 18.5 ml
add ddH2O to 500 ml
? BSA blocking buffer for retronectin plate coating (2 % in PBS)
PBS 50 ml
BSA (fraction V) 1 g
Solution was filtered (0.22 μm) sterile.
? Coomassie brilliant blue staining solution
Coomassie brilliant blue R-250 0.2 g
Isopropanol 400 ml
Acetic acid 70 ml
add ddH2O to 1 l, pH 7.2
? Dulbecco`s PBS without Ca2+, Mg2+ (10X)
Dulbecco`s PBS powder (for 10 l)
add ddH2O to 1 l, pH 7.2 - 7.4
? ELISPOT washing buffer (0.25 % Tween in PBS)
PBS 500 ml
Tween 20 1.25 ml
? ELISPOT 6 % AB serum blocking buffer
RPMI with L-Glutamine 46 ml
6 % AB serum 3 ml
Pen/Step 0.5 ml
Hepes 0.5 ml
? ELISPOT 10 % AB serum blocking buffer
RPMI with L-Glutamine 44 ml
10 % AB serum 5 ml
Pen/Step 0.5 ml
Hepes 0.5 ml
? FACS buffer
PBS 49 ml
FCS 1 ml
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? Formaldehyde fixation buffer
Paraformaldehyde 1 g
PBS 100 ml
? Laemmli sample buffer (2X)
Tris 3.6 g (10 mM)
DTT 0.6 g
Glycerol 20 ml
SDS 10 g
Bromophenol blue 0.2 g
add ddH2O to 100 ml, pH 6.8
? MACS buffer
PBS 46.827 ml
EDTA 2.923 ml (2 mM)
AB serum 250 μl
? Permeabilization buffer for microscopy
PBS 100 ml
Triton X-100 0.2 g
? PVDF membrane blocking milk buffer
PBS (10X) 100 ml
Milk powder 50 g
Tween 20 0.5 g
add ddH2O to 1 l, pH 7.2 - 7.4
? PVDF membrane destaining buffer
Isopropanol 400 ml
Acetic acid 70 ml
add ddH2O to 1 l, pH <7.2
? PVDF membrane washing buffer (PBS-Tween)
PBS (10X) 100 ml
Tween 20 0.5 g
add ddH2O to 1 l, pH 7.2 - 7.4
? SDS-PAGE electrophoresis running buffer (10X)
Tris 28 g (231 mM)
SDS 20 g
Glycine 144 g
add ddH2O to 1 l, pH 8.8
? Semi-dry transfer buffer 1
Tris 36.3 g (300 mM)
Isopropanol 200 ml
add ddH2O to 1 l, pH 10.4
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? Semi-dry transfer buffer 2 
Tris 3.025 g (25 mM)
Isopropanol 200 ml
add ddH2O to 1 l, pH 10.4
? Semi-dry transfer buffer 3 
Tris 3.025 g (25 mM)
Norleucine-DL 5.24 g 
add ddH2O to 1 l, pH 9.4
? Tris-acetate-EDTA (TAE) buffer (50X)
Tris 242 g (2 M)
Glacial acetic acid 57.1 ml
0.5 M EDTA 100 ml
add ddH2O to 1 l, pH 8.5
? Tumor digestion buffer
PBS 10 ml
Hyaluronidase type V 0.5 mg/ml
DNase I 0.5 mg/ml
6.5. Antibodies
If not further indicated, the listed Abs react against human epitopes.
6.5.1. Flow cytometry
Specificity Species Isotype Conjugate Clone Supplier
CCR7 rat IgG2a PE 3D12 BD
CD3 mouse IgG2a FITC HIT3a BD
CD3 mouse IgG1 PE UCHT1 BD
CD3 mouse IgG2a PE-Cy5 HIT3a BD
CD4 mouse IgG1 FITC RPA-T4 BD
CD4 mouse IgG1 PerCP-Cy5.5 RPA-T4 BD
CD4 mouse IgG1 APC RPA-T4 BD
CD8 mouse IgG1 FITC HIT8a BD
CD8 mouse IgG1 APC-Cy7 SK1 BD
CD11c mouse IgG1 PE B-ly6 BD
CD14 mouse IgG2a PE M5E2 BD
CD25 mouse IgG1 FITC M-A251 BD
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CD25 mouse IgG1 APC-Cy7 M-A251 BD
CD27 mouse IgG1 PerCP-Cy5.5 M-T271 BD
CD45 mouse IgG1 APC HI30 BD
CD45RO mouse IgG2a PE UCHL1 BD
CD45RO mouse IgG2a APC UCHL1 BD
CD62L mouse IgG1 FITC DREG-56 BD
CD69 mouse IgG1 PE FN50 BD
CD127 mouse IgG1 PE HIL-7R-M21 BD
CEACAM1 mouse IgG1 - GM8G5 Axxora,
Loerrach,
Germany
CEACAM6 mouse IgG1 - 9A6 Axxora
CEACAM6 mouse IgG1 FITC 9A6 Santa Cruz
Biotechnology
Fusion (F) mouse IgG1 - Icii Prof. Dr. V.
protein anti NDV Schirrmacher,
of NDV DKFZ
Foxp3 mouse IgG1 APC 236A/E7 eBioscience
HLA-A2 mouse IgG2b - BB7.2 Dr. G. Molden-
hauer, DKFZ
HLA-ABC mouse IgG1 FITC G46-2.6 BD
HLA-DR mouse IgG2a PE G46-6 BD
IgG/IgM goat Ig FITC polyclonal BD
anti mouse
IgG goat Ig, F(ab´)2 FITC polyclonal Jackson Immuno
anti mouse Research,
Dianova,
Hamburg
IgM/IgG/ goat Ig, F(ab´)2 PE polyclonal Southern Biotech
IgA anti mouse
Isotype mouse IgG1 FITC MOPC-21 BD
control
Isotype mouse IgG1 PE MOPC-21 BD
control
Isotype mouse IgG1 APC MOPC-21 BD
control
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L1CAM mouse IgG1 - L1-9.3 Dr. G. Molden-
hauer
V? 6 TCR rat anti IgG2b PE RR4-7 BD
(MDM2 TCR) mouse
V? 14 TCR mouse IgG1 PE CAS1.1.3 Beckman Coulter
(gp100 TCR)
6.5.2. Cell culture and ELISPOT
Specificity Species Isotype Conjugate Clone Supplier
CD3 mouse IgG2a - Okt3 Dr. G. Molden-
hauer
CD19 mouse IgG1 - HD37 Dr. G. Molden-
hauer
CD28 mouse IgG2a - 9.3 Dr. G. Molden-
hauer
CD56 mouse IgG1 - C218 Beckman Coulter
CEACAM6 mouse IgG1 - 9A6 Axxora
???? mouse IgG1 - 1-D1K Mabtech
???? mouse IgG1 biotin 7-B6-1 Mabtech
Isotype mouse IgG1 - DAK-GO1 Dako
control
L1CAM mouse IgG1 - L1-9.3 Dr. G. Molden-
hauer
ELISPOT analyses were performed using streptavidin-alkaline phosphatase.
6.5.3. Immunohistochemistry, immunofluorescence and immunoblot
Specificity Species Isotype Conjugate Clone Supplier
actin mouse IgG1 - C4 MP Biomedicals,
Illkirch Cedex,
France
CD45 mouse IgG1 - HI30 BD
gp100 mouse IgG1 - HMB45 Enzo, Loerrach
Isotype mouse IgG1 - DAK-GO1 Dako
control
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Keratin 8 mouse IgG1 - Ks8-17.2 Progen,
Heidelberg
Keratin 18 mouse IgG1 - Ks18.174 Progen
L1CAM mouse IgG1 - L1-9.3 Dr. G. Molden-
hauer
MDM2 mouse IgG2b - IF2 Invitrogen
MDM2 mouse IgG2b - IF2 Calbiochem
Melan-A/ mouse IgG2b - M2-7C10 + Thermo Fisher
MART-1 M2-9E3 Scientific
Melan-A/ mouse IgG1 - A103 Dako
MART-1
NDV rabbit anti Ig - polyclonal Prof. Dr. V.
NDV Schirrmacher
Pan- mouse IgG1 - C11 Santa Cruz 
cytokeratin Biotechnology
p53 mouse IgG2a - Bp53-11 Progen
Tyrosinase mouse IgG2a - T311 Invitrogen
Vimentin mouse IgG2a - VIM 3B4 Progen
Secondary Abs conjugated with fluorochromes used for immunofluorescence microscopy were
directed against species-specific IgGs and had been generated in goat or chicken. Cy3- (Jackson 
Immuno Research) and Alexa Fluor 488- or Alexa Fluor 594-conjugated (Invitrogen) secondary 
Abs against mouse and rabbit IgGs were used. Immunoblot analyses were performed using 
horseradish peroxidase (HRP)-conjugated secondary goat anti mouse IgG/IgM Abs (Jackson 
Immuno Research).
6.6. Multimers/tetramers (HLA-A*0201)
Product Supplier
gp100 (280-288, YLEPGPVTA)-PE-Cy5 [0.43 mg/ml] Prof. Dr. P. Romero, Ludwig
Institute for Cancer Research,
Lausanne, Switzerland
MDM2 (81-88, LLGDLFGV)-PE [0.38 mg/ml] Prof. Dr. P. Romero
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6.7. Primers
The primers used for sequencing were produced by Eurofins MWG Operon, Ebersberg, Germany.
Product Primer sequence
pBullet-IRES forward 5'- tcg ctg gaa agg acc tta c -3' (19 mer)
pBullet-IRES reverse 5'- cgg gcc agg tga ata tca aat c -3' (22 mer)
6.8. Peptides
The following peptides were produced by the Peptide Synthesis Facility of the DKFZ (Dr. R. 
Pipkorn).
Protein Amino acid sequence Peptide
GAGE-1 MSWRGRSTYR  PRPRRYVEPP  EMIGPMRPEQ  FSDEVEPATP  EEGEPATQRQ (1-50)
gp100/pmel17 SITGSLGPLL  DGTATLRLVK  RQVPLDCVLY  RYGSFSVTLD  IVQGIESAEI (449-498)
MAGE-A1 PARYEFLWGP  RALAETSYVK VLEYVIKVSA  RVRFFFPSLR  EAALREEEEG (259-308)
MAGE-C2 WGPRAHSESI  KKKVLEFLAK  LNNTVPSSFP  SWYKDALKDV  EERVQATIDT (301-350)
MDM2 KEVLFYLGQY  IMTKRLYDEK  QQHIVYCSND  LLGDLFGVPS  FSVKEHRKIY (51-100)
Melan-A/MART-1 GHGHSYTTAE  EAAGIGILTV  ILGVLLLIGC  WYCRRRNGYR  ALMDKSLHVG (16-65)
MIF LMAFGGSSEP  CALCSLHSIG  KIGGAQNRSY  SKLLCGLLAE  RLRISPDRVY (47-96)
NA17-A MVLPDVFIRC  VVFCLTVVCW  TWVPLRGPSS  PGSYRKWMCF  SESQVQPTQK (1-50)
NY-Eso-1 FTVSGNILTI  RLTAADHRQL  QLSISSCLQQ  LSLLMWITQC  FLPVFLAQPP (126-175)
p53 TAKSVTCTYS  PALNKMFCQL  AKTCPVQLWV  DSTPPPGTRV  RAMAIYKQSQ (118-167)
RAB38/NY-Mel-1 ATIGVDFALK  VLHWDPETVV  RLQLWDIAGQ  ERFGNMTRVY  YREAM GAFIV (40-89)
TRP2 ALPHSAANDP  IFVVISNRLL  YNATTNILEH  VRKEKATKEL  PSLHVLVLHS (381-430)
Tyrosinase MLLAVLYCLL  WSFQTSAGHF  PRACVSSKNL  MEKECCPPWS  GDRSPCGQLS (1-50)
gp100 YLEPGPVTA (280-288)
HIV-pol ILKEPVHGV (476-484)
MDM2 LLGDLFGV (81-88)
p53 LLGRNSFEV (264-272)
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6.9. Cytokines
Product Supplier
Human rGM-CSF (Leukine, Sargramostim) Berlex, Bayer-Schering Pharma
Human rIL-2 (Proleukin) Chiron, Ratingen, Germany
Human rIL-4 Promokine, PromoCell, Heidelberg
Human rIL-7 Promokine
Human rIL-15 Promokine
6.10. Plasmids
pBullet ??????? ??????????? ??????? ????? ?????????? ????? ?????? ??? ?? ??? ??
chain), cytomegalovirus (CMV) promoter
pCOLT-GALV packaging helper plasmid for retroviral production, expression of 
GALV envelope (env) proteins, CMV promoter
pHIT60 packaging helper plasmid for retroviral production, expression of 
MuLV gag/pol proteins of retroviral capsid and reverse 
transcriptase polymerase, CMV promoter
pcDNA3.1-luc-hygro coding for firefly luciferase, CMV promoter
All different pBullet plasmid constructs as well as the packaging helper plasmids pCOLT-GALV and 
pHIT60 were kindly provided by Dr. R.-H. Voss (Department of Hematology and Oncology, 
University of Mainz, Mainz). The individual TCR transduction settings using different pBullet 
plasmid combinations are indicated in the table below (bold letters). The original retroviral pBullet 
vector was developed and first described by Willemsen et al., 2003. The pcDNA3.1-luc-hygro 
plasmid was kindly provided by Dr. J. Ni (DKFZ).
Product Plasmid maps / informations
pBullet_IRESpuro-[NcoI] Appendix 13.1.
pBullet_IRESneo-[NcoI] Appendix 13.2.
? Mock
pBullet_Mu Wta TCR MDM2_IRESpuro Appendix 13.3.
pBullet_Mu Wtb TCR MDM2_IRESneo Appendix 13.4.
? Mu Wt TCR MDM2
pBullet_Mu Mta TCR MDM2 G85.1caR_IRESpuro Appendix 13.5.
pBullet_Mu Mtb TCR MDM2 R88cbG_IRESneo Appendix 13.6.
? Mu Mt Arg/Gly TCR MDM2
pBullet_Hu Wta TCR gp100_IRESpuro Appendix 13.7.
pBullet_Hu Wtb TCR gp100_IRESneo Appendix 13.8.
? Hu Wt TCR gp100
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pBullet_Mu Ca T84caC_IRESpuro Appendix 13.9.
pBullet_Hu Chim scTCR gp100 Mu Cb S79cbC_IRESneo Appendix 13.10.
? Hu Chim scTCR gp100 MuC? S79C + MuC? T84C
pBullet_IRESpuro-[NcoI] Appendix 13.1.
pBullet_eGFP_IRESneo Appendix 13.11
? EGFP
pCOLT-GALV Weijtens et al., 1998
pHIT60 Soneoka et al., 1995
pcDNA3.1-luc-hygro firefly luciferase fragment of vector
pGL3-Basic (Promega) was integrated
into pcDNA3.1/Hygro pasmid
(Invitrogen)
6.11. Viruses
Strains of the Newcastle disease virus (NDV), a negative-sense single stranded RNA virus, 
belonging to the viral family of paramyxoviridae (Avulavirus) can be differentiated on the basis of 
their avian (chicken) pathogenicity into strains of high (velogenic), intermediate (mesogenic) and 
low-to-no (lentogenic) virulence.
Product information
NDV-Ulster lentogenic strain, nonlytic, avirulent
NDFL-EGFP lentogenic strain, nonlytic, avirulent; recombinant strain expressing 
the jellyfish EGFP protein, based on the NDV strain LaSota
NDFLtagEGFP mesogenic strain, lytic, virulent; recombinant strain expressing the 
jellyfish EGFP protein, based on the NDV strain LaSota
MTH-68 mesogenic strain, lytic, virulent
All different viruses were propagated in embryonated chicken eggs, harvested from the allantoic 
fluid, purified by ultracentrifugation, resuspended in a PBS/0.1 % EDTA solution and cryopreserved 
in aliquots at -80°C. The virus amount was quantified by a hemagglutination assay, while                
1 hemagglutination unit (HU) was defined as the smallest virus concentration leading to visible 
sheep erythrocyte agglutination (see also Schirrmacher et al., 1999). The different NDV strains 
were produced and kindly provided by Prof. Dr. V. Schirrmacher.
6.12. Bacteria
Product Supplier
?????????????????????????ompetent cells Invitrogen
One Shot TOP10 competent cells Invitrogen
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6.13. Cell lines
Most cell lines were obtained from the American Type Culture Collection (ATCC; supplier LGC 
Standards, Luckenwalde, Germany). Further cell line contributors are indicated.
Cell line Origin Supplier Medium
BT-474 human adenocarcinoma, ATCC (HTB-20) DMEM/F-12, 10 % FCS
breast
C32 human melanoma, ATCC (CRL-1585) DMEM, 10 % FCS
primary, skin
Capan-1 human adenocarcinoma, ATCC (HTB-79) RPMI, 10 % FCS
pancreas
HCT-15 human adenocarcinoma, ATCC (CCL-225) DMEM, 10 % FCS
colorectal
HT-29 human adenocarcinoma, ATCC (HTB-38) DMEM/F-12, 10 % FCS
colorectal
IM-9 human multiple myeloma ATCC (CCL-159) RPMI, 10 % FCS
Jurkat human T cell leukemia Tumor bank, DKFZ RPMI, 10 % FCS
(JCD28)
KPL-4 human adenocarcinoma, Dr. D. Zopf, Bayer RPMI, 10 % FCS
breast Schering Pharma
KS 22.24 human adenocarcinoma, Dr. B. Gueckel RPMI, 10 % FCS
breast University of 
Tuebingen,
Tuebingen, Germany
KS WT human adenocarcinoma, Dr. B. Gueckel RPMI, 10 % FCS
breast
LoVo human adenocarcinoma, ATCC (CCL-229) RPMI, 10 % FCS
colorectal
Malme-3M human melanoma, ATCC (HTB-64) DMEM, 20 % FCS
metastasis, lung
MCF-7 human adenocarcinoma, ATCC (HTB-22) DMEM, 10 % FCS
breast
MCF-7 human adenocarcinoma, C. Pfirschke, DMEM, 10 % FCS
CEACAM6 breast personal thesis
high contribution
MeWo human melanoma, ATCC (HTB-65) DMEM, 10 % FCS
metastasis, lymph node
MeWo-luc human melanoma, C. Pfirschke, DMEM, 10 % FCS +
metastasis, lymph node personal thesis 100 μg/ml Hygromycin
contribution
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Phoenix human embryonic ATCC (SD-3443) Phoenix medium
ampho kidney
RPMI 8226 human multiple myeloma ATCC (CCL-155) RPMI, 10 % FCS
SK-Mel-2 human melanoma, ATCC (HTB-68) DMEM, 10 % FCS
metastasis, skin
SK-Mel-23 human melanoma, Prof. Dr. L. Old, RPMI, 10 % FCS
metastasis, skin Memorial Sloan-Ketter-
ing Cancer Center,
New York, NY, USA
SKMM2 human multiple myeloma Prof. Dr. H. Gold- RPMI, 10 % FCS
schmidt, University
Hospital Heidelberg,
Heidelberg
T2 human lymphoblast ATCC (CRL-1992) RPMI, 10 % FCS
U266 human multiple myeloma ATCC (TIB-196) RPMI, 10 % FCS
U2OS human osteosarcoma ATCC (HTB-96) DMEM, 10 % FCS
WM-115 human melanoma, ATCC (CRL-1675) DMEM, 10 % FCS
primary, skin
WM-266-4 human melanoma, ATCC (CRL-1676) DMEM, 10 % FCS
metastasis, skin
6.14. Mice
The non-obese diabetic (NOD)-severe combined immune-deficient [(SCID); NOD-SCID] mice have 
impaired T and B lymphocyte development, whereas NOD scid gamma (NSG) mice bear a 
targeted mutation in the gene encoding the IL-2 receptor gamma chain gene (IL2rgnull) and lack 
mature T cells, B cells, functional natural killer (NK) cells and are deficient in cytokine signaling. For 
animal experiments 7-9 week old female mice of the two immunodeficient mice strains NOD-SCID 
(NOD.CB17-Prkdcscid/NcrCrl) and NSG (NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ) were used. The NOD-
SCID mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and the NSG 
mice from the Animal Facility of the DKFZ. All mice were kept under specific pathogen-free 
conditions in individually ventilated cages (Animal Facility, DKFZ). Food and water were 
administered “ad libitum” and a day night rhythm of 12 h was ensured. All animal experiments were 
approved and authorized by the regulatory authorities (Karlsruhe) and performed according to local
animal experimental ethics committee guidelines and permissions.
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6.15. Peripheral blood samples of healthy donors and patients
Leukocyte cell concentrates, also referred to as “Buffy coat” blood samples, of healthy donors were 
provided from the Blood Donation Center of the University of Heidelberg. Peripheral blood samples 
of melanoma and dysplastic nevi patients were obtained from the Department of Dermatology, 
University Hospital Heidelberg. The ethics application form for this study was approved by the 
ethical committee and the written consent was obtained from all analyzed patients.
6.16. Software
Product Supplier
Adobe Photoshop (CS2) Adobe Systems, Munich
AxioVision LE (4.4) Carl Zeiss
CellQuest Pro (4.02) BD
Clone Manager Professional (9) Scientific & Education Software, Cary, NC, USA
CTL ImmunoSpot Professional (4) CTL
EndNote (X4) Adept Scientific, Frankfurt
FACS Diva software (6) BD
FlowJo (8.8) Tree Star, Ashland, OR, USA
GraphPad Prism (5) GraphPad Software, LaJolla, CA, USA
KS-ELISPOT software (4) Carl Zeiss
Living Image (2.50), Igor Pro (4.09A) Xenogen
Microsoft Office 2007 Microsoft, Redmond, WA, USA
Microsoft Windows 7 Microsoft
SigmaPlot (10.0) Systat Software, Erkrath, Germany
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7. Methods
7.1. Cell culture methods
7.1.1. Thawing cryopreserved cells
For thawing of cells, growth medium (37°C) was added to frozen cells into cryogenic vials and the 
content immediately transferred into 15 ml tubes, containing 10 ml growth medium. After one 
washing and centrifugation step with respective growth medium [1200-1400 rpm, 5 min, room 
temperature (RT)], the cells were seeded in cell culture flasks in fresh medium and cultured in a 
cell culture incubator at 37°C, 5 % CO2. The medium was completely renewed after 24 h and the 
cells cultured until use.
7.1.2. Cultivation of adherent and suspension cells
All cell lines were grown in cell culture dishes or flasks and incubated at 37°C, 5 % CO2. For 
detachment of adherent cells from the culture flask surface, the growth medium was removed and
the cell layer carefully washed with warm phosphate buffered saline (PBS). Then 1X Trypsin-
ethylenediaminetetraacetic acid (Trypsin-EDTA) solution was added for ~5 min at 37°C, depending 
on the type of cells. The Trypsin-EDTA solution was inactivated using double amount of fresh 
culture medium supplemented with fetal calf serum (FCS), followed by a centrifugation step (1200 
rpm, 5 min, RT). For sub-cultivation, cells were distributed to new culture plates or flasks in a 1:5 to 
1:20 ratio, depending on the cell line. 
Suspension cells were usually maintained by the addition or replacement of the required fresh 
growth medium. In general, the cell lines were passaged 2-3x per week. Permanent cell lines were 
only used for experiments until they reached a passage number of thirty, afterwards a new vial of 
cells was thawed. All permanent cell lines were regularly tested for mycoplasma contamination 
(7.3.14.).
7.1.3. Determination of cell number and viability
Viable cells were quantified using a Neubauer hemocytometer. Since Trypan blue can only 
traverse the damaged plasma membrane of nonviable cells, it was used to distinguish between 
alive or dead cells. In order to produce a statistically significant count, all four large chamber 
squares and at least hundred living cells were counted for each sample. The cell number was 
calculated using the following formula:
x dilution factor x volume x 104
number of counted large squares
Cell number  =
total cell count
Methods
page | 58
7.1.4. Irradiation of cells
For antigen-specific stimulation of T cell receptor (TCR) transgenic T cells, peptid-loaded 
transporter associated with antigen processing (TAP)-deficient T2 cells were used and autologous 
peripheral blood mononuclear cells (PBMC) as feeder cells. Peptide-pulsed T2 cells were irradiated 
with 70 gray (Gy) and PBMC with 35 Gy using the Gamma cell 1000 irradiation device. The cells 
were irradiated at a concentration of 1x106 cells/ml medium in 15 or 50 ml tubes. To get a 
homogenous cell suspension, cells were carefully shacked shortly before irradiation.
7.1.5. Blockade of cell adhesion molecules on tumor cells
To block carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) or L1 cell 
adhesion molecule (L1CAM), human tumor cells of lines, e.g., MeWo, KS WT, MCF-7, MCF-7
CEACAM6 high or Capan-1 (1x106 - 2x106) were incubated with monoclonal antibodies (mAbs)
specific for CEACAM6, L1CAM or the isotype control at 37°C for 30 min. Thereby, the cells were 
resuspended in 200 μl X-VIVO medium and an Ab concentration of 30 μg/ml was used. Afterwards,
the cells were centrifuged and the medium discarded, followed by a washing step with X-VIVO 
medium. The Ab-blocked cells were immediately used for ELISPOT (7.2.10.) or radioactive
chromium isotope 51 (51Cr) release cytotoxicity (7.2.12.) assays.
7.1.6. Fixation of cultured cells
For fixation, on the one hand, the cells were grown on sterile glass cover slips, which had been 
pre-coated with 0.01 % poly-L-lysine in double distilled water (ddH2O) for 30 min at RT, and
washed 2x with PBS (37°C). On the other hand, cells were instead harvested with Trypsin-EDTA 
(7.1.2.) and single cell suspensions were dispersed to poly-prep slides using a cytospin
cytocentrifuge at 500 rpm for 3 min. The cells were then fixed in methanol at -20°C for 5 min 
followed by incubation in acetone at -20°C for 30 sec. Cover slips and slides were air-dried at RT 
and immediately used for histological stainings (7.3.15.).
7.1.7. Freezing cells
For freezing of cells, PBMC and T cells were resuspended in 500 μl FCS and permanent cell lines 
in 500 μl growth medium and transferred into cryogenic vials. After addition of 500 μl freezing 
medium [final dimethyl sulfoxide (DMSO) concentration of 10 %], the vials were placed into a 
freezing container with isopentanol or a Styrofoam box and transferred immediately to -80°C. After 
24 h, the cells were transferred to liquid nitrogen (-196°C), for long time storage.
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7.2. Immunological methods
7.2.1. Peptide synthesis and storage 
Lyophilized 50aa synthetic long peptides were solved in Aqua ad iniectabilia containing 10 % 
DMSO. The lyophilized human leukocyte antigen A2 (HLA-A2)-restricted short peptides were 
instead solved in pure DMSO. After dissolving, the peptide concentration was controlled via 
Bradford protein assay (7.3.1.) and optical density (OD) measurement at 280 nm using a 
photometer (7.3.5.). Aliquots of the peptides were stored at -80°C.
7.2.2. Isolation of human PBMC from melanoma and dysplastic nevi patients
For the PBMC isolation, a Ficoll density gradient centrifugation was performed. Therefore, ~40 ml 
peripheral blood (PB) was removed from each patient using sodium citrate vacutainers (green 
blood sample tubes). Biocoll separating solution (15.5 ml) was added into Leucosep 50 ml tubes 
(carrying a porous barrier) and centrifuged for 2 min at 1400 rpm, to allow the separating solution to 
pass the porous barrier. Beforehand, 20 ml of gently mixed PB was added, each Ficoll tube was 
loaded with 15 ml Roswell Park Memorial Institute (RPMI) medium supplemented with Hepes and 
Penicillin/Streptomycin (Pen/Strep). The tubes were then centrifuged at 2000 rpm for 20 min at RT 
without the centrifuge break, allowing the gradients not to mix. The resulting plasma/separating 
solution interphase contained the mononuclear cells as shown in Fig. 11.
The cells with a higher density, like granulocytes or erythrocytes were sedimented at the bottom 
of the Ficoll tube, below the porous barrier. Above the interphase, the plasma was removed and
stored at -20°C for further analyses (7.3.17.). The interphase of each patient was collected with 
plastic serum pipettes and combined in a 50 ml tube. The cells were washed with RPMI,
performing a centrifugation step (1400 rpm, 10 min, RT). The cell pellet was then resuspended in 
20 ml X-VIVO medium and transferred into tissue treated cell culture dishes (Ø 96 x 21 mm).
Figure 11. Ficoll centrifugation using Leucosep 50 ml tubes with a porous barrier. After Ficoll 
density gradient centrifugation, the sequence of layers occurred as indicated from a) - f). PBMC (b)
were used for isolation of autologous T cells and dendritic cells. The plasma (a) was stored at         
-20°C for further investigations. The figure is modified from the Greiner Bio-one Leucosep 
information sheet.
a) plasma
b) interphase of PBMC
c) Biocoll separating solution
d) porous barrier
e) Biocoll separating solution
f) pellet of erythrocytes and
granulocytes
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To allow the adherence of mononuclear cells to the plastic surfaces of the cell culture dishes, an
adherence phase was performed at 37°C for 2 h. Since lymphocytes remain in the supernatant, the
non-adherent mononuclear cells were carefully removed, centrifuged and resuspended in 20 ml 
T cell medium supplemented with human recombinant cytokines of interleukin 2 (rIL-2) and rIL-4.
Finally, the cells were cultured in non-tissue treated cell culture plates (Optilux, Falcon). In parallel, 
20 ml dendritic cell medium supplemented with human recombinant granulocyte macrophage 
colony-stimulating factor (rGM-CSF) and rIL-4 was added to the adherent cells. In general, in order 
to mature dendritic cells out of mononuclear cells, autologous dendritic cells and T cells of the 
same donor were separately cultivated for 7 d. Every 2-3 d half of the medium was replaced with 
new cytokine-supplemented medium.
7.2.3. Isolation of human PBMC from healthy donors
PBMC of healthy donors were isolated performing a Ficoll density gradient centrifugation from 
leukocyte cell concentrates (Buffy coat). The blood was diluted 1:1 in PBS and added to the Ficoll 
tubes that contained 15.5 ml Biocoll separating solution below a porous barrier. The tubes were 
centrifuged at 2000 rpm for 20 min at RT without the centrifuge break. The plasma/separating 
solution interface was collected with plastic serum pipettes, combined in a 50 ml tube and washed 
with PBS. The PBMC were counted using Trypan blue and either stored frozen (5x107 cells / 
cryogenic vial) for later retroviral TCR transductions (7.3.9.) or directly used as healthy donor 
controls for ELISPOT (7.2.10.) and flow cytometry (7.2.13.) assays. In the latter case, cells were 
equally treated as described above (7.2.2.).
7.2.4. Generation and enrichment of dendritic cells from human PBMC
GM-CSF and IL-4 promote the differentiation and maturation of monocytes into dendritic cells. After 
a human rGM-CSF and human rIL-4 cytokine-dependent cultivation phase in X-VIVO medium for
7 d, dendritic cells were enriched via negative magnetic separation using mAb-pre-coupled 
Dynabeads. Thereby, T cells [cluster of differentiation 3 (CD3)], B cells (CD19) and NK cells 
(CD56) were depleted. After enrichment, the dendritic cells were bead- and Ab-free.
Prior to dendritic cell isolation, 100 μl X-VIVO medium washed pan mouse IgG Dynabeads per 
patient were coupled with 4 μg of CD3, CD19 or CD56 mAbs, respectively while incubating on a 
rotator at 4°C for 30 min. All three fractions were pooled in a 15 ml tube and washed 2x with        
X-VIVO medium. Thereby, the resuspended beads were placed into the magnetic field of a 
magnetic particle concentrator for 2 min. The washed beads were then resuspended in 300 μl
X-VIVO medium and stored on ice until the cells were prepared for further purification.
Matured dendritic cells that have a plastic cell shape with cellular processes can be removed 
from the plate by rinsing with X-VIVO medium. After a centrifugation step (1400 rpm, 10 min, RT),
the pellet was resuspended in 1 ml X-VIVO medium and transferred to a 15 ml tube. In a next step, 
300 μl of the CD3/CD19/CD56 Ab pre-coupled Dynabeads were added to the cells and incubated 
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on a rotator at 4°C for 30 min. Afterwards, X-VIVO medium was added up to 7 ml and the tube 
placed into a magnetic particle concentrator for 2 min. The supernatant without beads, that 
contained the purified dendritic cells, was carefully removed, transferred into a 15 ml tube, 
centrifuged, counted and immediately used for ELISPOT (7.2.10.) and regulatory T cell (Treg) 
specificity (7.2.11.) assays.
7.2.5. Pulsing of dendritic cells with peptides
Purified dendritic cells were used as antigen-presenting cells in ELISPOT (7.2.10.) and Treg 
specificity (7.2.11.) assays. For the ELISPOT assay, 1x104 dendritic cells per well were used. They 
were resuspended in 30 μl X-VIVO medium and directly added to the pre-treated ELISPOT plate.
To avoid drying of the plate, already 20 μl X-VIVO medium were provided. To reach a final peptide 
concentration of 20 μg per 1x104 dendritic cells in 100 μl medium (0.2 μg/μl) per well, polypeptides 
in a concentration of 20 μg in 50 μl X-VIVO medium were added. To guarantee the functionality of 
the assay, as positive control, staphylococcal enterotoxin B (SEB) as super antigen, was used in a 
concentration of 10 μg per 1x104 dendritic cells in 100 μl X-VIVO medium (0.1 μg/μl). Dendritic 
cells in the presence of peptides were pulsed at 37°C for 18 h, before the T cells were added.
For the Treg specificity assay, 5x103 dendritic cells in 50 μl X-VIVO medium were used per well
(96 well round-bottom plate, TPP). Polypeptides in a concentration of 20 μg in 50 μl X-VIVO 
medium were added (final peptide concentration per well 0.2 μg/μl). The dendritic cells were pulsed 
with peptides at 37°C for 18 h, before the Treg were added.
7.2.6. Pulsing of T2 cells with peptides
To receive a peptide-dependent antigen-specific activation of T cells, TAP-deficient T2 cells were 
used as antigen-presenting cells, to present HLA-A2-restricted short peptides to TCR transgenic
T cells. T2 cells (1x106) were resuspended in 90 μl growth medium and transferred to a 96 well 
round-bottom plate (Falcon). To gain a final peptide concentration of 100 μM, 10 μl diluted peptides 
were added to the cells and incubated at 37°C for 2 h. The peptide-loaded T2 cells were used as 
target cells in a 51Cr release cytotoxicity assay (7.2.12.) and as irradiated antigen-presenting cells 
(7.1.4.) for the antigen-specific expansion of TCR transgenic T cells (7.3.9.).
7.2.7. Isolation of CD3+ T cells from human PBMC
Human CD3+ T cells were purified from PBMC using the “Dynal T cell negative isolation kit” or the 
“Dynabeads untouched human T cell kit”, according to the manufacturer´s recommendations. 
These kits deplete B cells, NK cells, monocytes, platelets, dendritic cells, granulocytes and 
erythrocytes. The purified T cells are bead- and Ab-free. Finally, the negatively isolated T cells 
were centrifuged, counted and used for ELISPOT (7.2.10.), Treg specificity (7.2.11.) or 51Cr release 
cytotoxicity (7.2.12.) assays.
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7.2.8. Isolation of CD4+CD25+ Treg
CD4+CD25+ Treg were purified from CD3+ T cells using the “CD4+CD25+ regulatory T cell isolation 
kit” according to the manufacturer`s protocols. The protocol is a two-step procedure, thereby, in the 
first step CD4+ T cells were negatively isolated using a T cell Biotin-Ab cocktail and anti-biotin 
??????????? ????? ????? ????? ?????? ?????? ?????? ?????? ?????? ??????? ??????? ???? ???????
positive cells. In the second step, CD4+CD25+ Treg were positively selected from CD4+ pre-
enriched cells using CD25 MicroBeads. The CD4+CD25+ Treg were used for Treg specificity 
assays (7.2.11.) and flow cytometry analyses (7.2.13.). The Treg-depleted remaining cells were 
also used for further investigations including ELISPOT (7.2.10.) and Treg specificity (7.2.11.) 
assays. Therefore, the eluted magnetic labeled CD4- cell fraction (mainly CD8+ cells), received 
during the first protocol step, were recombined with the “flow-through fraction” (cell fraction, not 
retained in the magnetic field) of CD4+CD25- cells from the second protocol step. The CD8+ and
CD4+CD25- T cells were termed “T cells without Treg”.
7.2.9. Isolation of CD4+ and CD8+ T cells
CD4+ T cells were purified from CD3+ T cells using “CD4 MicroBeads” according to the 
manufacturer`s recommendations. The unlabeled cells obtained from the flow-through fraction (for 
definition see 7.2.8.) were CD8+. CD4+ and CD8+ T cells were used for ELISPOT assay (7.2.10.). 
For NDV modification experiments (7.3.12.), CD4+ and CD8+ T cell populations were directly 
isolated from PBMC using the “Dynal CD4+ and CD8+ isolation kits”, respectively.
7.2.10. Enzyme-linked immunospot assay
The enzyme-linked immunospot also referred as ELISPOT assay is a sensitive single cell assay 
that allows the analysis of immune responses by counting the number of cytokine-producing,
activated antigen-specific T cells in cell material, like PB. Moreover, it provides informations about 
the frequency of the ex vivo analyzed antigen-specific T cell immunity. During the T cell activation
cytokines, ????????????????????????, are secreted that can be detected in the ELISPOT assay using
mAbs. Each spot that develops during the assay represents a single reactive cell. The principle of 
the ?????ELISPOT assay is shown in Fig. 12.
To remove all added cytokines from the medium, 1 d before the purification of dendritic cells 
and T cells, the medium of both parallel cell cultures was completely removed, centrifuged and the 
cells resuspended in X-VIVO medium (without cytokines). MultiScreen-HA 96-well ELISPOT plates 
with a 0.45 μm pore size mixed cellulose esters membrane (mixture of cellulose acetate and 
cellulose nitrate), were coated with mouse anti-????????????????? ??????????????????????) and 
incubated overnight at 4°C. The supernatant was discarded and the plate washed 3x with 200 μl 
ELISPOT washing buffer followed by 2 washes with 200 μl PBS per well using a multichannel 
pipette. To block unspecific binding, the plate was incubated with ELISPOT 10 % AB serum 
blocking buffer at 37°C for 2 h. Afterwards, the plate was washed 2x with ELISPOT washing buffer 
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and 2x with PBS, followed by an incubation with ELISPOT 6 % AB serum blocking buffer at 37°C 
for 30 min. The blocking solution was removed and the plate washed 3x using X-VIVO medium. 
Then 100 μl X-VIVO medium was added per well to the freshly prepared, Ab coated, washed and 
blocked ELISPOT plate. The plate was placed to 37°C and prior addition of dendritic cells, the 
medium was discarded and immediately 20 μl X-VIVO medium added per well to avoid drying of 
the membrane. 
Purified dendritic cells (1x104 in 30 μl X-VIVO medium; 7.2.4.) were transferred to the prepared 
ELISPOT plate. During the next step, dendritic cells were pulsed with polypeptides (final peptide 
concentration per well: 20 μg peptide / 1x104 dendritic cells / 100 μl medium) in the ELISPOT plate 
(7.2.10.) and incubated at 37°C for 18 h. To assess the background T cell reactivity against 
endogenous human proteins, human IgG (Endobulin) was used as a control for the tumor-
associated antigens (TAAs). To guarantee the functionality of the ELISPOT assay, as positive 
control, the super antigen SEB was used. Additionally, mono-cultures of unpulsed dendritic 
cells and T cells served as negative controls. Moreover, each individual setting was tested in 
triplicates. After peptide-pulsing of dendritic cells overnight, T cells (5x104 T cells / 100 μl X-VIVO 
medium / well) were added to the ELISPOT assay at a dendritic cell:T cell ratio of 1:5. Following 
different T cell subsets were used for the assay: 
? CD3+ T cells, termed as “T cells with Treg” (7.2.7.)
? CD8+ and CD4+CD25- T cells, termed as “T cells without Treg” (7.2.8.)
? CD4+ T cells (7.2.9.)
? CD8+ T cells (7.2.9.)
The total volume of the ELISPOT assay after dendritic cell, peptide and T cell application was 
200 μl / well and assay was incubated at 37°C and 5 % CO2 for 40 h. Afterwards, the plate was 
washed 4x with 200 μl ELISPOT washing buffer. Remaining cells were lysed, adding 200 μl ddH2O
to each well, followed by further 3 washing steps with ELISPOT washing buffer and 3x with PBS.
A biotin-conjugated mouse anti-?????? ????????? ???? ??????? ??? ???? ???? ????) was added and 
?????????? ??? ????? ???? ?? ??? ????? ???? ?????????? ??? ????? ???????? ????? ???????? ????? ???? ???????,
recognized by the coating ?????Ab. During the next steps, the plate was washed 4x with ELISPOT 
washing buffer and 3x with PBS before 100 μl streptavidin-alkaline phosphatase (1:1000 dilution in 
PBS) was added and incubated at 37°C for 1.5 h. Afterwards, the plate was washed 5x with
ELISPOT washing buffer and 3x with PBS. The membrane-????????????????????????????????????????
the “alkaline phosphatase conjugate substrate kit”. A color development reagent containing           
5-bromo-4-chloro-3-indoyl phosphate (BCIP) and nitroblue tetrazolium (NBT) yields purple spots at 
the sides of the antigen-Ab-complexes on the white background. The color reaction was stopped 
by washing the plate 3x with ddH2O, followed by an incubation with ddH2O at RT for 10 min. 
Finally, the supernatant was completely discarded, the bottom of the ELISPOT plate removed and 
the membrane wrapped in tissue papers and dried for 3 d in the dark. ????? ?????? ?????
automatically quantified using the Axioplan 2 imaging microscope (KS-ELISPOT software) or the 
CTL ImmunoSpot analyzer (CTL ImmunoSpot software).
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???????????????????????????????????????????? Autologous dendritic cells (DC) were pulsed with 
specific 50aa polypeptides or human IgG as control. Autologous TAA-reactive T cells (TC) that 
were able to respond to the specific presented peptides got stimulated (1) and secreted cytokines 
???????????2?????????????????????????????s ??????????????????????????????????????????????????
(3). The cytokine-Ab ?????????? ????? ????????? ???????? ?? ????????????? ????? ??, followed by the 
incubation with alkaline-phosphatase conjugated streptavidin (4). After the addition of substrate (5), 
a colored precipitate formed and appeared as purple spots at the sites of antigen-Ab-complexes on 
the ELISPOT membrane (6). For the generation of the figure, illustrations of cells were used from 
the Nature Reviews journal.
7.2.11. Treg specificity assay - [3H] -Thymidine uptake assay
The Treg specificity assay analyzes the suppression of polyclonally activated T cell proliferation 
by antigen-specific Treg that had been stimulated via antigen-pulsed autologous dendritic cells. 
The T cell proliferation was detected by an incorporation of [3H]-Thymidine into the nucleic acid of 
proliferating cells. The more proliferation had occurred in an investigated well, the more [3H]-
Thymidine had been incorporated into nucleic acid and could be detected using a liquid scintillation 
counter. The principle of the Treg specificity assay is shown in Fig. 13.
The enriched dendritic cells (5x103 in 50 μl X-VIVO medium; 7.2.4.) were transferred into         
96 well round-bottom plates (TPP) and polypeptides in a concentration of 20 μg in 50 μl X-VIVO 
medium were added (final peptide concentration: 20 μg peptide / 5x103 dendritic cells / 100 μl 
medium) and incubated at 37°C for 18 h. As a control for the TAAs, human IgG was used. 
Afterwards, 2.5x104 Treg in 50 μl X-VIVO medium (7.2.8.) were added to peptide-pulsed dendritic 
cells and incubated overnight. Finally, 2.5x104 polyclonally activated CD8+ and CD4+CD25- T cells 
(“T cells without Treg”; 7.2.8.) were transferred in 50 μl X-VIVO medium to the peptide-pulsed 
dendritic cells and Treg and incubated at 37°C for another 72 h.
Beforehand, CD8+ and CD4+CD25- T cells (1x106 cells / 2 ml X-VIVO medium per well) had
been polyclonally activated using a mouse anti-human CD3 mAb ?????? ???????????????????-coated 
12 well plate (Falcon) at 37°C for 14 h. The plate was pre-coated with the Ab overnight at 4°C. 
Afterwards, the Ab was removed and the plate carefully washed 3x with PBS, to remove the 
unbound Ab, before the T cells were added. After activation, the T cells were removed from the 
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coated plate, centrifuged (14000 rpm, 10 min, RT), washed 1x with PBS, resuspended in X-VIVO 
medium, counted and finally applied to the Treg specificity assay (described above). The final 
volume was 200 µl per well and for each setting a triplicate was analyzed. As controls, unpulsed 
dendritic cells were cultured with Treg and polyclonally activated T cells. Furthermore, a co-culture 
of dendritic cells and polyclonally activated T cells in the absence of Treg and a dendritic cells 
mono-culture was investigated. After cultivation for 72 h, 1 µCi [3H]-Thymidine was added per well 
and incubated at 37°C for further 24 h. Afterwards, in order to promote complete cell lysis, the plate 
was frozen at -20°C and thawed 2x at 37°C. Following, the cells were harvested and nucleic acid 
was captured on a filter membrane. The membrane displayed spots of bound nucleic acids, 
comprising distinct quantities of incorporated [3H]-Thymidine. Then, the membrane was dried in a 
microwave at 600 W for 2 min and transferred into a plastic membrane bag. Scintillation fluid (5 ml) 
was added and the plastic bag sealed. The extent of cell proliferation was measured with a liquid 
scintillation counter, quantifying the amount of β-radiation on the filter membrane. 
 
 
Figure 13. The principle of the Treg specificity assay. 1) For the determination of Treg 
specificity, dendritic cells (DC) were pulsed with 50aa TAA polypeptides or human IgG. As control 
unpulsed DC were investigated (no peptide). Autologous Treg were added. Treg specific for an 
antigen, presented by DC, were selectively activated (black compared to yellow Treg cells). 2) 
Polyclonally (αCD3 mAb) activated effector T cells without Treg (TC) were transferred to the Treg 
and peptide-pulsed DC co-culture. 3) Specifically activated Treg, suppressed the proliferation of 
effector T cells, measured by [3H]-Thymidin incorporation (turquoise compared to red effector T 
cells). As control, the proliferation of polyclonally activated effector T cells, without Treg addition 
was investigated. For the generation of the figure, illustrations of cells were used from the Nature 
Reviews journal. 
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7.2.12. 51Cr release cytotoxicity assay
The method to analyze cell-dependent cytotoxicity is based on the release of radioactive 51Cr from 
dead cells. As target cells, peptide-loaded T2 cells (7.2.6.) or cells from cancer lines including
MeWo and KS WT were used. Therefore, dependent on the experiment, 1-5x106 cells were 
resuspended in 100 μl growth medium in 5 ml tubes and labeled with 100 μCi radioactive 51Cr at 
37°C for 1.5 h. Thereby, the 51Cr enters the membrane of the cells, and binds covalently to proteins 
and accumulates within the cytoplasm of the cells. The used volume of 51Cr per 5 ml tube depends 
on the age of the 51Cr, as indicated below:
? 1st week: 100 μl 51Cr
? 2nd week: 125 μl 51Cr
? 3rd week: 150 μl 51Cr
After 45 min of incubation, the cells were gently shacked. The labeled target cells were washed 3x 
with the appropriate growth medium to remove the unbound 51Cr. Then, the cells were counted, 
resuspended to a final concentration of 3x104 cells/ml and 100 μl of 51Cr labeled target cells were 
co-cultured with cytotoxic effector T cells at 37°C for 4 h.
Beforehand, in parallel, effector T cells had to be transferred to 96 well round-bottom plates 
(Falcon). Serial T cell dilutions (100:1, 50:1, 25:1, 12.5:1, 6.25:1, 3.125:1, 1.56:1, 0.78:1, 0.39:1)
were analyzed in triplicates with a maximum T cell concentration of 3x105 cells in 100 μl medium 
(100 effector T cells:1 target cell). The total volume of the assay was 200 μl. As negative control,
the spontaneous release of the 51Cr by the target cells was analyzed using 51Cr-labeled target cells 
without effector cells. Moreover, the maximum release of the 51Cr by the target cells was achieved 
using 51Cr-labeled target cells together with 100 μl of 10 % Triton X-100, as detergent, in the 
appropriate growth medium. The plates were centrifuged (500 rpm, 3 min, RT) and incubated at 
37°C for 4 h. Afterwards, the plates were centrifuged again (1000 rpm, 3 min, RT) without the 
centrifuge brake and 100 μl of the supernatants carefully removed and transferred to polystyrene 
tubes (0.6 ml). The tubes were sealed with melted paraffin wax pellets and the radioactivity 
measured in the culture supernatant using the Packar?????????-counter. The higher the amount 
of 51Cr released into the culture supernatant (% specific lysis) was, the more target cells have 
specifically been killed by the effector T cells. The following formula was used to calculate the 
specific cytotoxicity:
7.2.13. Flow cytometry
Flow cytometry or fluorescence activated cell sorting (FACS) is a method that can be used to 
discriminate cells based to their size, structure, cell surface properties and cellular internal 
composition. To analyze cells via FACS, they must be labeled with Abs specific for certain cellular 
x 100percent specific lysis  
(cpm, counts per min) (maximum release cpm - spontaneous release cpm)
(experimental cpm - spontaneous release cpm)
=
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structures. The staining can either be a “direct labeling” using primary Abs linked to fluorescent 
dyes or an “indirect labeling” using an unlabeled primary Ab followed by a fluorescent-dye labeled 
secondary Ab. For the investigation of the phenotype of primary cells and cells of permanent 
culture lines, surface/extracellular and intracellular/intranuclear stainings were performed. In 
general, all staining procedures were conducted on ice, while protecting the cells from light.
7.2.13.1. Surface/extracellular staining
The immunophenotype and activation status of different cell populations were investigated. Thus, 
single cell suspensions were produced, counted and defined cell numbers (1-5x105 cells)
transferred into polypropylene tubes (1.3 ml). The cells were then washed with 600 μl FACS buffer
using a table centrifuge and the supernatants discarded. Subsequently, cell surface Fc-receptors 
were blocked, performing an incubation step in 5 % Endobulin in a volume of 50 μl on ice for 
15 min. The cells were again washed in FACS buffer and the pellet resuspended in 50 μl of the 
primary Ab and incubated for 30 min. Unbound Abs were removed, by a washing step with FACS 
buffer and the pellet was either resuspended in 200 μl FACS buffer (if the primary Ab was direct-
fluorochrome labeled) or in 50 μl of a secondary fluorescent-dye labeled Ab. In the latter case, to 
allow the Ab binding, again incubated for further 30 min, followed by a washing step in FACS buffer 
and finally also resuspended in 200 μl FACS buffer. Subsequently, the cells were analyzed on a 
FACScan, FACS Calibur or FACS Canto II flow cytometer using CellQuest Pro and FACS Diva 
software, respectively. In general, at least 20 000 events were recorded. As control stainings,
single stainings of each Ab and unstained cells were investigated.
7.2.13.2. Intracellular/intranuclear staining
In order to stain for regulatory T cells, after a surface/extracellular staining, an intranuclear staining 
for Foxp3 was added. Therefore, the cells were fixed in 200 μl fixation/permeabilization buffer 
(eBioscience) on ice for 30 min, centrifuged and permeabilized with 500 μl permeabilization buffer 
(eBioscience) for 20 min. Afterwards, the cells were centrifuged and blocked in 2 % normal rat 
serum in a volume of 50 μl for 15 min, followed by the addition of 50 μl Foxp3 Ab, diluted in 
permeabilization buffer (1:5 dilution). Finally, a washing step with permeabilization buffer was 
performed, the cells resuspended in 100 μl FACS buffer and analyzed on a FACS Canto II flow 
cytometer (in general, 50 000 events were recorded).
7.2.13.3. Multimer/tetramer staining
Multimers, of peptide/major histocompatibility complex (MHC) linked with fluorescent dyes, were 
used as TCR ligands to directly identify and quantify antigen-specific T cells that express a specific 
TCR on their surface. Based on the receptor specificity, fluorochrome-labeled MHC-peptide 
tetramers are bound by TCRs on T cells and can be detected and counted using the FACS 
method. T cells, transduced with TCRs for glycoprotein 100 (gp100) or murine double minute 2 
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(MDM2; 7.3.9.) were phenotypically analyzed for their antigen-specific TCR expression using 
gp100 (280-288) and MDM2 (81-88) HLA-A2-restricted tetramers.
In general, a tetramer staining was combined with a staining of T cell surface markers. TCR 
transgenic T cells (1x105 cells) were washed with FACS buffer and blocked with 5 % Endobulin for 
15 min (see also 7.2.13.1.). Following, the cells were washed and incubated with 0.5 μl tetramer in 
50 μl FACS buffer (~4 μg/ml), protected from light at 4°C for 45 min. Then, the cells were washed, 
incubated with anti-CD8 or anti-CD4 fluorochrome-labeled Abs on ice for 30 min, washed again, 
centrifuged and the pellet was resuspended in 200 μl FACS buffer. Finally, the stained cells were
analyzed on a FACS Calibur flow cytometer (at least 20 000 events were recorded).
7.2.13.4. Detection of nonviable cells in the flow cytometry assay
In general, propidium iodide (PI), a fluorescent molecule that intercalates into double-stranded 
nucleic acids, is excluded from viable cells but can penetrate cell membranes of dying or dead cells 
and bind to deoxyribonucleic acid (DNA), resulting in a red fluorescent signal. Therefore, PI was 
used to exclude dead cells from FACS stained, non-fixed cell populations. The FACS staining was 
performed as described above (7.2.13.1.). Before starting the measurement on a flow cytometer, 
50 μl PI (working stock 5 μg/ml diluted in PBS) were added to the stained cells, resuspended in 
???????????????????????????????????????? ??????????????????????????????????????????? ??
For the exclusion of nonviable cells from the FACS assays, besides PI, a further nucleic acid 
dye, 7-aminoactinomycin D (7-AAD) was used. The advantage of 7-AAD is the ability to be used in 
conjunction with phycoerythrin (PE)- and fluorescein isothiocyanate (FITC)-labeled Abs, with 
minimal spectral overlap between the 7-AAD, PE and FITC fluorescence emissions. Therefore, 
before starting the FACS measurement, 5 μl 7-AAD (stock 50 μg/ml) were added to the stained 
cells, resuspended in 200 μl FACS buffer (final 7-?????????????????????????? ?????????????????????
10 min.
7.2.13.5. Cell separation by flow cytometry
In order to receive MCF-7 cells that express to a higher percentage CEACAM6, compared to MCF-
7 parental cells, a FACS sort for CEACAM6-positive MCF-7 cells was performed. Therefore, single 
cell suspensions of MCF-7 cells were resuspended at 3x105 cells / per tube. The staining was 
conducted as described for the surface/extracellular staining (7.2.13.1.), with the exception that the 
whole procedure was performed in 15 ml centrifuge tubes under sterile conditions in a cell culture
hood. The cells were centrifuged (1200 rpm) at 4°C for 5 min. All solutions used, were sterile 
[FACS buffer, Endobulin, Abs, PI]. As primary Ab, mouse anti-human CEACAM6 Ab and as 
secondary fluorescent-dye labeled Ab, goat anti-mouse IgG-FITC were used. After the staining, the 
cells were filtered through a sterile 35 μm cell strainer cap into a 5 ml polystyrene round bottom 
tube. To label dead cells, prior to sorting, 50 μl PI solution was added to the 200 μl cell suspension.
Using the Flow sorter Aria 2, PI-CEACAM6+ MCF-7 single cells were sorted into FCS-precoated 
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polystyrene tubes (5 ml) that contained 1 ml growth medium. The sterile cell sort was thankfully 
performed by Dr. S. Schmitt (Flow Cytometry Unit, DKFZ).
7.2.13.6. Identification of HLA-A2+ blood donors
PB cells of each donor were stained for their surface expression of HLA-A2 using flow cytometry 
(7.2.13.1.). Therefore, 70 μl of mouse anti-human HLA-A2 Abs and as secondary fluorochrome-
labeled Abs, goat anti-mouse IgG-FITC were used. As a positive control, cells of HLA-A2+ lines 
including T2, MeWo or MCF-7, were stained in parallel.
7.3. Molecular biological methods
7.3.1. Bradford protein assay
The Bradford protein assay is a method to determine the total protein concentration in a sample 
solution. Thereby, the absorbance maximum of the dye Coomassie brilliant blue shifts from 465 nm 
to 595 nm, as bindings to proteins occurs. The increase of absorbance at 595 nm can be used to
measure the protein concentration in the solution. For the generation of a standard curve, 
standardized samples with known BSA concentrations (0.1-1.2 mg/ml) were used. Into a 96 well 
flat-??????? ??????? ???? ??? ??? ???? ????????? and the test samples were transferred in duplicates. 
???????????? ???? ??? protein assay dye reagent concentrate (1:5 diluted in ddH2O; Bio-Rad) was 
added to each well and the absorbance measured after 6 min using a plate reader. The protein 
concentration within the samples was calculated using the linear scale of the resulting standard 
curve.
7.3.2. Transformation of bacteria
Bacterial transformation is a method that enables bacteria to absorb exogenous DNA. Thereby, 
competent bacteria are used as bacteria that can be transformed naturally or via artificial 
modification (i.e., chemical methods or electroporation). As competent bacteria, the Escherichia 
????? ???? ?????? ???????? ????????? ???????????????? ?????????? ??????? ???? ?????????? ????0 competent 
cells” were use and stored in aliquots at -80°C.
Plasmid DNA (10 ng) was transferred into sterile 14 ml polypropylene tubes with caps and 
placed on ice. As negative transformation control, a tube without plasmid DNA was used. 
Competent bacteria aliquots were thawed on ice and 100 μl bacteria were added to the plasmid 
DNA, immediately mixed and incubated on ice for 30 min, to allow the attachment of the DNA to 
the bacteria. For DNA uptake, a heat shock step at 42°C for 45 sec was performed, followed by 
incubation on ice for further 2 min. To recover from the heat shock, 900 μl sterile antibiotic-free 
super optimal broth medium with catabolite repression (S.O.C. medium) was added per tube and
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then placed to 37°C in a bacteria incubator for 1 h. During this time the plasmid-encoded antibiotic 
resistance was accomplished.
Due to the low number of bacteria which contain the plasmid DNA, it was necessary to select 
for plasmid-containing bacteria, performing an antibiotic selection with ampicillin. In general, E. coli 
strains are sensitive to antibiotics like ampicillin. However, the plasmids used for transformation 
comprised ampicillin resistance genes. Thus, when the bacterial transformation is plated to 
medium containing ampicillin, only bacteria with plasmid DNA have the ability to metabolize 
ampicillin and form bacterial colonies. Therefore, during the next step, the bacteria transformation 
approach was plated to Luria Bertani (LB) Agarplates (pre-warmed at 37°C), containing ampicillin 
(final concentration 100 μg/ml). Different quantities (10 μl, 50 μl, 100 μl, 200 μl) were transferred to 
individual plates and the bacteria solution was streaked using an inoculation loop. The inoculation 
loop was sterilized in a flame between the individual plates and allowed to cool down. To absorb 
the inoculums, the plates were incubated for 5 min, then inverted and further incubated at 37°C 
overnight. In a final step, individual colonies were picked with a sterile pipette tip to inoculate 
“bacteria start cultures” for plasmid amplification (7.3.4.). The selection plates with transformed 
colonies of bacteria were finally closed with Petri-Seal and stored at 4°C.
7.3.3. Storage and recovery of bacteria strains
Frozen stocks of all transformed bacteria were produced. Therefore, 150 μl sterile glycerol was 
transferred to a cryogenic vial (2 ml) and 850 μl bacteria suspension was added, mixed, stored on 
ice for 30 min and finally transferred to -80°C for long term storage. For recovery, bacteria from 
frozen stocks were scraped using a sterile pipette tip and transferred to Erlenmeyer flasks 
containing LB medium and ampicillin. In order to prevent loss in cell viability, during this procedure 
the frozen stocks were not thawed.
7.3.4. Preparation of plasmid DNA from bacteria
“Bacteria start cultures” [5 ml LB medium containing ampicillin (100 μg/ml)] were inoculated with a
single colony from a streaked selective bacterial LB plate or material from a frozen bacterial 
glycerol stock (7.3.3.). The cultures were incubated in 50 ml Erlenmeyer flasks and vigorously 
shaken at 37°C overnight. The next day, 1 ml of the culture was utilized to isolate plasmid DNA 
using the “QIAprep spin Miniprep kit” according to the manufacturer´s instructions. Before the Maxi 
DNA preparation (Maxi Prep) was performed, the accuracy of the plasmid Miniprep DNA was 
investigated via enzymatic digestion (7.3.7.). 
For Maxi DNA preparation, 250 ml LB medium containing ampicillin (100 μg/ml) was inoculated 
with 500 μl of the bacteria start culture using 1000 ml Erlenmeyer flasks for incubation. The culture 
was vigorously shaken at 37°C overnight. The next day, the plasmid DNA was purified using the 
“Endofree plasmid Maxi kit” according to supplier´s instructions. Afterwards, the plasmid DNA was 
resuspended in endotoxin-free Tris-EDTA (TE) buffer (content of Qiagen kits), diluted 1:10 in 
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endotoxin-free Aqua ad iniectabilia. A photometer was used to measure the plasmid DNA 
concentration (7.3.5.). For the retroviral plasmids, the plasmid DNA was adjusted to a final 
concentration of 0.5 μg/μl. The firefly-luciferase plasmid DNA had a concentration of 1 μg/μl. Before 
the plasmid DNA was used for experiments, the accuracy of the DNA was analyzed by enzymatic 
digestion (7.3.7.) and sequencing (7.3.8.).
7.3.5. Determination of nucleic acid and protein concentration
The nucleic acid [DNA, total ribonucleic acid (RNA)] and the protein concentration were determined 
photometrically via measuring the absorbance. Nucleic acids absorb ultraviolet (UV) light with a 
wave length of 260 nm. Thereby, the optical density at 260 nm (OD260) of 1.0 is equivalent with a 
DNA concentration of 50 μg/ml. In contrast, proteins absorb UV light with an absorption maximum 
at 280 nm. The optical density at 280 nm (OD280) of 1.4 is equivalent with a protein concentration 
of 1 mg/ml. The ratio of the absorption at 260 and 280 nm (A260/280) enables the estimation of a 
protein contamination in a DNA preparation and can therefore be used as a measure of the sample 
purity. The ratio should be in a range of 1.8-2.0. The absorption of DNA or protein was normalized 
against the respective diluents, i.e., Aqua ad iniectabilia, TE buffer or DMSO.
7.3.6. Agarose gel electrophoresis
Agarose gel electrophoresis is a method to determine the size of nucleic acid fragments. As DNA is 
negatively charged, it is forced to migrate through an agarose matrix in response to an electric 
current and runs from the negatively charged cathode towards the positively charged anode. 
Thereby, small fragments run faster than larger ones, at a rate proportional to their size. For
electophoretic separation of DNA, 1 % agarose gels that can resolve DNA from 0.2-10 kilobase 
(kb) in length have been used. In some cases, 1.5 % agarose gels were used to separate smaller 
fragments more precisely.
The agarose was dissolved in 1X Tris-acetate-EDTA (TAE) buffer using a microwave and 
allowed to cool. Ethidium bromide (stock concentration 10 mg/ml), an UV-fluorescent dye was 
used for DNA visualization. It was directly added to the melted agarose solution (final concentration 
0.2 μg/ml) and gently poured into a gel tray. The gel was allowed to harden and the combs were 
removed. As running buffer, 1X TAE was added to the electrophoresis chamber and the gel 
covered with buffer. The gel was then loaded with sample volumes of 5-10 μl resuspended in 6X 
loading dye solution (10 μl restriction digest, 5 μl polymerase chain reaction (PCR) product, 0.5 μl 
pure DNA; mixed with 1-2 μl loading dye solution, if required adjusted with Aqua ad iniectabilia).
Following DNA molecular weight standard ladders were used: “Low molecular weight ladder”:
25-766 base pairs (bps), “100 bp ladder”: 0.1-1.5 kb, “1 kb ladder”: 0.5-10 kb and “GeneRuler”:
0.1-10 kb. The gel chamber was attached to the electrodes and constant voltages were applied 
(~80-110 volts for 30-50 min, depending on the gel size). Finally, the gels were examined using an 
UV gel documentation system.
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7.3.7. Enzymatic restriction digest of plasmid DNA
The enzymatic digestion of plasmid DNA using restriction enzymes, the restriction endonucleases,
is a process of cutting DNA into smaller pieces. Restriction endonucleases recognize specific 
palindromic sequences and cleave a phosphodiester bond on each strand at the appropriate 
specific DNA sequence. After digestion with restriction endonucleases, the resulting DNA 
fragments can be separated by agarose gel electrophoresis (7.3.6.) and their size can be 
estimated. For optimum activity, each restriction enzyme required specific reaction conditions.
The following procedure of a restriction digestion was generally performed. Thereby, the
plasmid DNA (0.5-1 μg) was transferred to safe-look tubes (1.5 ml) and a mixture, containing 
restriction enzymes and buffers was added (Tab. 1), carefully mixed and incubated at 37°C for 1 h., 
To prevent nonspecific degradation of the DNA, the tubes were afterwards placed on ice. Finally, to 
separate the digested fragments, an agarose gel electrophoresis (7.3.6.) was performed. In Fig. 14 
a representative gel of an enzymatic restriction digest is shown.
Constituents Volume per single reaction
plasmid DNA 0.5 - 1 μg
10X NEB reaction buffer 2 μl
100X BSA* 0.2 μl
Restriction enzyme 1 μl
Aqua ad iniectabilia add to 20 μl 
Table 1. Solutions for the restriction digestion of plasmid DNA. * BSA was used if required.
Figure 14. Representative 1 % agarose gel of an enzymatic restriction digest. Using the 
enzymes NcoI, BamHI, KpnI and PstI, a restriction digest of plasmid DNA (1) pBullet_IRESpuro-
[NcoI] and (2) pBullet_IRESneo-[NcoI] was performed and evaluated on an agarose gel. Instead of 
plasmid DNA, Aqua ad iniectabilia was used for the digest as negative control (NC). Since the 
expected fragments sizes were detected, the plasmids had the correct structure [NcoI + BamHI:
7073 bps (1) / 7168 bps (2); KpnI: 3342, 1530, 1013, 1200 bps (1) / 3341, 1633, 1006, 1200 bps 
(2); PstI: 5881, 1022 bps (1) / 5151, 1015, 635 bps (2)]. As size markers 100 bp and 1 kb DNA 
ladders were used. 
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7.3.8. Sequencing
Before the plasmid DNA (7.3.4.) was used for experiments, the sequence accuracy was analyzed 
by sequencing. Thereby, the nucleotide order of a DNA fragment was analyzed. “Single read 
sequencing” was performed by GATC Biotech (Konstanz, Germany) using a DNA concentration of 
30-70 ng/μl. All sequence specific primers were used at a concentration of 10 pmol/μl.
7.3.9. Production of TCR transgenic human T cells
To obtain high affine mono-specific tumor antigen-reactive TCR transgenic T cells, recognizing 
specific melanoma antigens, human T cells were genetically modified by TCR gene transfer. TCR
transgenic T cells could be received, while performing a retroviral transduction of T cells using 
retrovirus-containing supernatants of transfected Phoenix ampho cells.
7.3.9.1. Transfection of the packaging cell line Phoenix ampho
The cell line Phoenix ampho is an amphotropic system that allows the delivery of genes to dividing 
cells of most mammalian species, including human cells. Thereby, it can be used for moloney 
murine leukemia virus (MoMuLV)-derived retrovirus production. The cell line is based on the 
human embryonic kidney line 293T and has stable integrated expression vectors for retroviral 
group-specific antigen (gag), retroviral reverse transcriptase polymerase (pol) and amphotropic 
virus envelope (env) proteins (see also Pear et al., 1997; Swift et al., 2001).
In order to receive Phoenix cells that produce high virus titers, a drug selection of the cells had 
to be performed before they were used for transfection. The selection was achieved with plasmocin 
(25 μg/ml) and hygromycin B (312.5 μg/ml) for 6 d. Moreover, plasmocin (25 μg/ml) and diphteria 
toxin (1 μg/ml) were added from d7 until d14. To maintain and not to reduce the transfection 
efficiency, during the whole cultivation process, the cells did never reach a higher confluence than
~70 % before they were passaged. Afterwards, the cells were cultured in normal growth medium 
for one week and multiple aliquots of drug-selected Phoenix ampho cells (3x106 cells/cryogenic 
vial) were frozen until used for following transfection experiments.
For starting a retroviral transfection, the drug-selected Phoenix ampho cells were thawed and 
cultured in growth medium in T75 flasks for 3 d. Subsequently, 1.5x106 cells per flask were plated 
in 15 ml medium and cultured at 37°C, 5 % CO2. Thereby, one flask for each individual transfection 
approach was prepared. The medium was completely removed 1 d later, 10 ml fresh growth 
medium added, and the cells incubated at 37°C for at least 4 h before the transfection was 
performed. In general, Phoenix cells were transfected with two retroviral pBullet plasmids at the 
same time. One vector that carried the genes for the TCR ???????????????????????????????????????
vector containing genes for the TCR ????????(neomycin resistance). In addition, the Phoenix cells 
were co-transfected with the helper plasmids pHIT60 (coding for viral gag and pol proteins) and 
pCOLT-GALV (coding for viral env proteins). As control, cells were transfected with empty retroviral 
plasmids (mock) without genes for TCR ? or TCR ????????????????an enhanced green fluorescent 
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protein (EGFP) transfection was conducted using the pBullet_eGFP_IRESneo vector together with 
the empty pBullet_IRESpuro vector. The solutions, used for the transfection (indicated in Tabs. 2 
and 3) were prepared in safe-lock tubes (1.5 ml, Biopur) and the final transfection mixture 
incubated at RT for 20 min. Thereafter, the content of one reaction tube was dropwise added to 
each Phoenix cell culture flask and placed back into the incubator. The next day, the medium of the 
transfected Phoenix cells was removed and fresh phosphate- and cytokine-free T cell TCR medium 
(8.5 ml) added and the cells again incubated at 37°C overnight. On the following day, the 
transduction of T cells was performed using the retroviral-containing Phoenix cells supernatant 
(7.3.9.3.). The transfection efficiency of Phoenix cells, transfected with the pBullet-eGFP plasmid, 
was analyzed via flow cytometry for EGFP staining. Before analysis, the EGFP transfected Phoenix 
cells were fixed in 1 % formaldehyde fixation buffer at RT for 20 min. Thereby, the revealed EGFP 
transfection efficiency was always ~99%.
Constituents Volume per single reaction
pCOLT-GALV (0.5 μg/μl) 4 μl (2 μg)
pHIT60 (0.5 μg/μl) 13 μl (6.5 μg)
Table 2. pCOLT-GALV/pHIT60 plasmid mixture. The plasmids were purified using the “Endofree 
plasmid Maxi kit”. The plasmid mixture was used for transfection of Phoenix ampho cells (Tab. 3).
Constituents Volume per single reaction
DMEM without supplements 900 μl
TransIT-LT1 transfection reagent 60 μl
pCOLT-GALV/pHIT60 mixture (Tab. 2) 17 μl
pBullet_IRESpuro - TCR ????????(0.5 μg/μl) 11.5 μl (5.75 μg)
pBullet_IRESneo - TCR ????????(0.5 μg/μl) 11.5 μl (5.75 μg)
Table 3. Solutions for the transfection of Phoenix ampho cells. The transfection of Phoenix 
cells was performed using the TransIT-LT1 transfection reagent in ??????????? ???????? ????????
medium (DMEM) without supplements (PAA). 
7.3.9.2. Coating of cell culture plates with Retronectin
Retronectin is the recombinant human fibronectin fragment CH-296 that was pre-coated to culture 
plates (12 well, Falcon). It enhances retroviral mediated gene transduction by co-localizing integrin 
receptor [very late antigen 4 and 5 (VLA-4, VLA-5)]-positive target cells and virions on the 
fibronectin fragments. The plates were coated with 1 ml retronectin per well (final concentration    
50 μg/ml in PBS) and incubated at 4°C overnight. The Retronectin solution was removed, the wells 
blocked with 1 ml 2 % BSA (fraction V) in PBS at RT for 30 min followed by a washing step with 
PBS. Human T cells that should be transduced with retroviral vectors can now be added to the 
Retronection pre-coated plate (7.3.9.3.).
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7.3.9.3. Retroviral transduction of human T cells
Human PBMC from healthy donors (7.2.3.) were thawed, resuspended in phosphate-free T cell 
TCR medium with cytokines at a concentration of 2x106 cells/ml and transferred to 24 well plates 
(Falcon). Thereby, a volume of 2 ml/well was used and the medium supplemented with the human 
cytokines rIL-2, rIL-4, rIL-7 and rIL-15. For T cell activation, the mouse anti-human CD3 mAb (clone 
Okt3; 20 ng/ml) was added to the medium, and the cells incubated at 37°C for 2 d. Afterwards, pre-
activated T cells were centrifuged, counted in Trypan blue, resuspended in phosphate- and 
cytokine-free T cell TCR medium (5x106 T cells/500 μl) and transferred to Retronectin pre-coated 
12 well plates (7.3.9.2.).
In order to transduce human T cells, supernatants of Phoenix cells, transfected 2 d before with 
retroviral pBullet plasmids (7.3.9.1.), were used. Therefore, the Phoenix cell supernatants, of each 
individual transfection approach, were removed and transferred to 15 ml tubes. Immediately, 8.5 ml 
phosphate- and cytokine-free T cell TCR medium was carefully added to the Phoenix cells and the 
flasks placed back to 37°C and incubated again overnight. To remove Phoenix cells that may have 
been transferred to the supernatants, the virus-containing supernatants were centrifuged         
(1000 rpm, 3 min, RT). Afterwards, 8 ml were carefully removed and transferred to new 15 ml 
tubes. In the next step, the viral supernatants (4 ml/well) were added together with polybrene        
(4 μg/ml) and rIL-2 (100 U/ml) to the pre-plated T cells. The content of all wells was carefully mixed 
using a 1 ml pipette tip, the plates centrifuged (3000 rpm, 60 min, 30°C) without the centrifuge 
brake and incubated at 37°C overnight. In general, T cells of two different donors were transduced 
in parallel.
The next day, a second transduction cycle was performed. Therefore, from each well of the     
12 well plates, 3.5 ml supernatant were carefully removed and discarded. Fresh virus-containing 
supernatants of Phoenix cells were prepared (as the day before) and added in a volume of
3.5 ml/well, supplemented with polybrene and rIL-2. The plates were again centrifuged without the 
centrifuge brake and incubated at 37°C for at least 4 h. After incubation, the T cells were removed 
from the 12 well plates and the second transduction cycle was completed. Therefore, the T cells 
were centrifuged (1500 rpm, 5 min, RT) and the supernatant discarded. Afterwards, cells were 
washed with T cell TCR medium and counted. Finally, T cells were resuspended to a concentration 
of 0.5x106 cells/ml in phosphate-free T cell TCR medium supplemented with cytokines and 
Dynabeads CD3/CD28 T cell expander (12.5 μl beads/1x106 cells; 0.5 beads:1 T cell). In general,
3 d after completed transduction, TCR transgenic T cells could be selected (7.3.9.4.).
7.3.9.4. Drug selection of retrovirally transduced human T cells
In order to receive only T cells that were efficiently transduced with both exogenous TCR chains, a 
drug selection was performed ???? ???? ?????? ??? ??????? ???? ???? ???? ?? ??????? ?eneticin sulfate       
(G-418) and ????????????????????puromycin were used. The transduced T cells were adjusted to a 
concentration of 0.5x106 cells/ml in phosphate-free T cell TCR medium containing cytokines, and 
G-418 (final concentration 0.8 mg/ml) was added for 7 d. After 6 d, additionally puromycin (final 
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concentration 5 μg/ml) was added for 1 d. In order to complete the drug selection, the cells were 
centrifuged. Beforehand, the CD3/CD28 T cell expander beads were removed in the magnetic field 
of a magnetic particle concentrator. Subsequently, the cells were counted, resuspended to a 
concentration of 0.5x106 cells/ml in phosphate-free T cell TCR medium containing cytokines and 
cultured at 37°C. In order to increase the number of the genetically engineered T cells, the cells 
were expanded as described in 7.3.9.5..
7.3.9.5. Expansion of retrovirally transduced human T cells
After the G-418/puromycin drug selection (7.3.9.4.), the TCR transduced T cells were expanded 
either polyclonally using CD3/CD28 T cell expander beads or antigen-specifically using irradiated 
peptide-loaded T2 cells and irradiated PBMC feeder cells. Thereby, during the whole cultivation 
time, the medium was partially renewed if necessary and cells were expanded in volume to larger 
cell culture plates or flasks.
For polyclonal expansion, T cells adjusted to a concentration of 0.5x106 cells/ml were treated 
with CD3/CD28 T cell expander beads (12.5 μl beads / 1x106 cells; 0.5 beads:1 T cell). The beads 
were left in culture for approximately two weeks.
For antigen-specific expansion, 1 ml of T cells, adjusted to a concentration of 0.5x106 cells/ml, 
were transferred to 24 well plates (Falcon). As antigen-presenting cells, irradiated T2 cells, loaded 
with HLA-A2-restricted short peptides, were added per well (2x105 / 500 μl). In addition, irradiated 
PBMC, as feeder cells were used (2x106 / 500 μl per well). Thereby, the irradiation of the cells was 
performed as described in 7.1.4., and irradiated cells were centrifuged, counted and resuspended 
in fresh phosphate-free T cell TCR medium containing cytokines, before they were transferred to 
the pre-plated T cells. The wells were carefully mixed using a 1 ml pipette tip and incubated at 
37°C. In general, between d7-d10 a re-stimulation was carried out using the same protocol as 
described for the primary stimulation. 
7.3.9.6. Specificity of retrovirally transduced human T cells
Before TCR transduced T cells were used for animal experiments (7.4.3.), there specificity was 
???????????? ??????????? ???? ??????????? ??? ???? ????????? ???? ?? ?????? ??? ???? ???? ???? ?????????
performing a flow cytometry surface staining (7.2.13.1.). Thereby, for the gp100 V? staining (mouse 
anti-human V? 14-PE mAb, clone CAS1.1.3), the protocol was performed exceptional at RT for 
30 min. Furthermore, in order to analyze the preferential TCR chain pairing, a tetramer staining 
(7.2.13.3.) was conducted. In addition, the cytolytic function of the transduced T cells was 
examined by 51Cr release cytotoxicity assay (7.2.12.) using peptide-loaded T2 cells or cells of 
cancer lines including MeWo and KS WT, as target cells. Moreover, the functional expression of
??????????????????????????????????????????????????????????????????????????
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7.3.10. Stable transfection of MeWo cells with a luciferase expression vector
To construct stable transfected, firefly luciferase-positive cells, cells of the human melanoma line 
MeWo were transfected with plasmid DNA (pcDNA3.1-luc-hygro) using the cationic polymer 
transfection reagent jetPEI according to the manufacturer’s instructions. The transfection was 
carried out in 6 well plates (TPP) in DMEM, supplemented with 10 mM Hepes and 10 % FCS, and
was performed when the cells had a confluency of 50-60 %. After 48 h, the cells were detached 
using 1X Trysin-EDTA, distributed to two cell culture dishes (Ø 60 x 16 mm) and cultured in growth 
medium. The next day, h?????????????????????? ??? ??????????? ???????????????????????????? ????
The medium was completely renewed after 3 d and hygromycin B was added in general from now 
on in a final concentration of 100 μg/ml. Every 2 d the medium was changed, until single clones 
were detectable. 
Single clones were then transferred to flat-bottom 96 well plates (TPP), directing a sterile pipette 
tip to the cell colony followed by the transfer to fresh medium into a single separate well. These 
clones were expanded until ~90 % confluence was reached and analyzed for in vitro luciferase 
expression (7.3.11.). The luciferase-positive clones were kept in culture and grown to higher cell 
numbers. Thereby, recurrent testing for stable luciferase gene expression occurred using the 
“Dual-luciferase reporter assay system” and in vitro luciferase imaging on the IVIS100 imaging 
machine. Finally, the stable transfected cells were used for the engraftment of immunodeficient 
mice and analyzed through in vivo imaging using the IVIS100 imaging system (7.4.4.).
7.3.11. In vitro luciferase measurement
The luciferase activity of stable transfected MeWo cell clones (7.3.10.) was examined through two 
different in vitro assays. First, single clone cells were analyzed for luciferase expression using the 
“Dual-luciferase reporter assay system” according to the manufacturer’s recommendations.
Therefore, the cells (~90 % confluency in 96 well) were lysed using passive lysis buffer. Afterwards, 
luciferase assay reagent II (50 μl) was added to 5 ml luminometer tubes, followed by the addition of 
10 μl cell lysate. Finally, the firefly luciferase activity was measured at the Lumat LB 9507 
luminometer.
Second, in vitro luciferase imaging on the IVIS100 imaging machine was performed. Therefore, 
cells of the individual clones were washed in PBS, counted and resuspended in 100 μl PBS. The 
cell suspension was transferred to black 96 well plates, 100 μl D-luciferin (600 μg/ml) was added 
per well (final concentration 300 μg/ml) and immediately the luciferase activity measured.
7.3.12. Infection of cells with NDV
In order to optimize the viral transport of NDV to tumor cells, various cell types were treated with 
NDV including MCF-7 cells and human cells of healthy donors (PBMC, CD3+, CD4+, CD8+ T cells). 
Thereby, nonactivated and activated T cells were used. The activation of human T cells (adjusted 
to 1x106 cells/ml) was performed in 12 well plates (Falcon) for 20 h using anti-CD3 (clone Okt3) 
Methods
page | 78
and anti-CD28 (clone 9.3) Abs (2 μg each/4x106 cells), or CD3/CD28 T cell expander beads (25 μl 
beads/1x106 cells; 1 beads:1 T cell). The T cell activation was analyzed by flow cytometry, 
measuring CD25 and CD69 expression. The NDV strains NDV-Ulster, NDFL-EGFP, 
NDFLtagEGFP and MTH-68 were investigated.
7.3.12.1. Virus binding and modification of cells with NDV
For NDV modification, cells were washed with serum- and antibiotic-free growth medium (1200 
rpm, 5 min, RT) and counted. Afterwards, 1x107 cells were incubated with NDV (0.5 HU - 500 HU) 
in a volume of 1 ml of serum- and antibiotic-free growth medium at 37°C for 1 h. During the 
incubation, cells were homogenized with a vortexer every 15 min. The cells were then washed 2x
in their respective growth medium, counted and cultured in serum containing medium. To 
investigate the bound virus, cells were directly stained with Abs against NDV (staining of viral 
fusion (F) protein) and analyzed by flow cytometry (7.2.13.). For the study of viral replication,
through F protein staining or intracellular EGFP signal, the infected cells were seeded into cell 
culture plates and analyzed at later time points.
7.3.12.2. Co-culture of MCF-7 cells with NDV-modified human carrier cells
Human PBMC and T cells (for more information about the different cell types used, see 7.3.12.) 
were modified with NDV as described above (7.3.12.1.). Afterwards, NDV-modified carrier cells 
were added to MCF-7 target cells and co-cultured for 3, 6, 9, 20 or 30 h. Thereby, the ratio of tumor 
cells to NDV-modified carrier cells varied from 1:0.25 - 1:5, and directly infected MCF-7 tumor cells 
were used as controls. The extent of MCF-7 cell infection by NDV, either direct or indirect via        
T cell-mediated cross-infection through viral hitchhiking, was analyzed using flow cytometry 
(7.2.13.) or immunofluorescence microscopy (7.3.15.).
7.3.13. Tumor neutralization assay
To analyze the anti-tumor effect of T cell-mediated viral hitchhiking in vitro, MCF-7 cells were co-
cultured for 2 d with NDV-modified nonactivated or activated T cells. Thereby, various NDV 
amounts (0.5, 10, 50 HU) and tumor cell to T cell ratios (1:1, 1:2, 1:5) were analyzed.
Before T cells were added, 2x104 untreated MCF-7 cells were resuspended in 100 μl growth 
medium, transferred to 96 well plates and allowed to attach for at least 4 h. After modification of 
T cells with NDV (7.3.12.1.), respective T cell numbers according to the different cell ratios were 
resuspended in 100 μl medium and added to the pre-plated tumor cells. All experimental 
approaches were performed in triplicates. Moreover, as controls, directly infected MCF-7 cells and 
MCF-7 cells without NDV (positive values) were investigated. The total volume was 200 μl/well and 
the plates were incubated at 37°C for 2 d. Subsequently, the supernatants were removed, the 
plates carefully washed with PBS and 100 μl RPMI supplemented with 5 % FCS transferred to 
each well. Afterwards, 20 μl MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-
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sulfophenyl)-2H-tetrazolium] solution was added to the MCF-7 cell layer and incubated at 37°C for 
~40 min, protected from light. Thereby, viable cells were able to convert the yellow MTS-tetrazol 
component into the brown-colored formazan product. The reaction was stopped with 20 μl 10 % 
sodium dodecyl sulfate (SDS) per well, and the color alteration measured with a plate reader at 490 
nm. Control wells that only contained medium and MTS solution were used to define the 
background value. The tumor growth inhibition in percent was calculated using the following 
formula:
7.3.14. Testing of cell lines for mycoplasma infection
All cell lines used for experiments were routinely tested for mycoplasma infection using the PCR-
based “Venor GeM mycoplasma detection kit” according to the manufacturer’s instructions. 
Additionally, directly before implantation into mice, tumor cells used for animal experiments were 
tested for mycoplasma infection. Thereby, all cell lines used for investigations in the presented
thesis were proven to be mycoplasma free.
The cell supernatants were collected in safe-lock tubes (1.5 ml), heated at 96°C for 5 min and 
centrifuged (13000 rpm, 5 sec, RT). Afterwards, the supernatants were transferred into new tubes 
and stored at 4°C for up to 14 d. The mycoplasma detection kit utilizes PCR to detect most 
common mycoplasma (M.) species including Acholeplasma laidlawii, M. arginini, M. fermentans,
M. hominis, M hyorhinis, M. orale, M. pneumoniae, M. salivarium and M. synoviae. The used 
primer set is specific to the highly conserved 16S rRNA coding region in the mycoplasma genome. 
For PCR, 2 μl of the sample supernatants were incubated with 23 μl of the mixture shown in
Tab. 4. The PCR program included 1 cycle at 94°C for 2 min, followed by 39 cycles at 94°C, 55°C 
and 72°C, each step for 30 sec. Thereafter, 5 μl of the PCR product was loaded to a 1.5 % agarose 
gel (7.3.7.). A representative gel electrophoresis of a mycoplasma PCR is shown in Fig. 15.
Furthermore, besides the mycoplasma PCR, a multiplex cell contamination test (McCT) was 
performed for the cell lines. The test was carried out by the Genomics and Proteomics Core Facility 
(Dr. M. Pawlita) at the DKFZ (for further details see Schmitt and Pawlita, 2009).
Constituents Volume per single reaction
PCR grade water 15.3 μl
10X reaction buffer 2.5 μl
Primer/nucleotide mix 2.5 μl
Internal control 2.5 μl
Polymerase (5 U/μl) 0.2 μl
Table 4. Mycoplasma PCR mixture. All components were purchased from Minerva Biolabs.
x 100percent tumor
growth inhibition A490 positive well - A490 background
A490 experimental well - A490 background= 1 -
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Figure 15. Representative 1.5 % agarose gel of a mycoplasma PCR. Internal control DNA, 
indicating a successfully performed PCR, was used in each sample, resulting in a distinct 191 bp 
band in every lane. The positive control (PC) shows in addition to the internal control band at 191 
bp, a band at 266 bp. As negative control (NC), instead of sample supernatant, 2 μl PCR grade 
water was used. All tested human cell lines (1: MeWo, 2: SK-Mel-23, 3: Capan-1, 4: IM-9, 5: MCF-
7, 6: U2OS, 7: Malme-3M), investigated in the presented PCR, are mycoplasma-free, as no band 
at 265-274 bp size was detected. As size marker a 100 bp ladder (L) was used.
7.3.15. Immunohistochemistry and immunofluorescence microscopy
To investigate the presence of several antigens in cell culture and in situ, immunohistochemistry 
(IHC) and immunofluorescence microscopy were performed. Beforehand, the tumors and various 
organs were removed from mice. The samples were immediately snap-frozen in isopentane, which 
had been pre-cooled in liquid nitrogen and stored at -80°C. To achieve sections of 5 μm thickness, 
the frozen samples were placed into cryomold adapters, aligned using Tissue-Tek and sectioned 
with a Leica cryo-microtome. Afterwards, the sections were transferred to Super Frost Plus object 
slides, air-dried for a minimum of 1 h, fixed in acetone at -20°C for 10 min and immediately used for 
histological stainings or stored at -20°C until use. In general, the staining procedures were always 
performed in wet chambers, and glass cuvettes were used for the washing steps. Primarily, the 
fixed tissue sections were thawed to RT and a Dako Pen was used to encircle the staining regions.
Prior to the immunostaining procedure, all tissue sections were rehydrated in PBS and 
permeabilized with PBS containing 0.2 % Triton X-100 for 5 min, followed by 3 washing steps in 
PBS (each 5 min).
For IHC investigations, the “DakoCytomation EnVision+ system-horseradish peroxidase (HRP) -
3-amino-9-ethylcarbazole (AEC) kit” for use with mouse primary Abs was utilized according to the
manufacturer’s recommendations. This system is a two-step IHC staining technique, based on a 
HRP-labeled polymer which is conjugated with secondary Abs. After permeabilization the 
endogenous peroxidase of the sections had to be blocked, followed by rinsing with ddH2O and 2x
in PBS (each step 5 min). The primary mouse anti-human Abs, diluted in Antibody diluent, were 
added and incubated for 1 h. Afterwards, 3 washing steps in PBS (each 5 min) were carried out 
and HRP-labeled Polymer-anti-mouse were added for 35 min, followed by 2 further washing steps 
in PBS. Then, the AEC-substrate chromogen was administered, which resulted in a red-brown-
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colored precipitate at the antigen site. The sections were rinsed with ddH2O and washed 2x in PBS 
(each 5 min) and 2x in ddH2O (each 3 min). For nuclear counter stain, the sections were incubated 
with Mayer´s Hematoxylin for ~1 min, rinsed with ddH2O, placed in bluing reagent (0.037 mol/l 
ammonia water) for 30 sec and washed 2x in ddH2O (each step 5 min). Finally, the specimens 
were aqueously mounted with Fluoromount-G using glass cover slips. The IHC samples were 
recorded with a Leica DM LB2 microscope which was equipped with a DC480 Leica camera.
For immunofluorescence microscopy, tissue sections or cultured cells, grown on glass cover 
slips or cytocentrifuged to slides (7.1.6.), were used. The fixed cells or tissue sections were also 
rehydrated and permeabilized using PBS containing 0.2 % Triton X-100. Furthermore, to avoid 
unspecific staining of the secondary Ab, the specimens were blocked with PBS containing 5 % 
serum of the appropriate species for 15 min, followed by 3 washing steps in PBS. The primary Abs 
were applied at RT for 1 h. Subsequently, 4 washing steps were performed using PBS (5 min each) 
before the secondary Abs coupled to Cy3, Alexa Fluor 488 or Alexa Fluor 594 were added and 
incubated at RT for 45 min, protected from light. For staining of the nuclei, 4',6-diamidino-2-
phenylindole (DAPI) was used, and incubated together with the secondary Ab. Accordingly,           
4 washing steps with PBS (each 5 min), 3x short rinses in ddH2O and finally dehydration in 100 % 
ethanol for 1 min were performed. After air-drying, specimens were finally mounted with 
Fluoromount-G using glass cover slips. The images were recorded with a Zeiss Axiophot 2 
microscope, equipped with an AxioCam HR.
7.3.16. SDS-polyacrylamide gel electrophoresis and immunoblotting
For the identification of proteins, present in cultured cells, SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) followed by immunoblot analysis using specific Abs were performed. The SDS-PAGE 
is based on the principle that polypeptides can be separated according to their electrophoretic 
mobility (Weber and Osborn, 1969). Therefore, dithiothreitol (DTT) is used as a reducing agent to 
destroy disulfide bridges, and SDS to break up the secondary and tertiary structure of proteins and 
protein-complexes by destroying hydrogen bonds. Thereby, the resulting SDS-modified 
polypeptide-based chains dissociate and become negatively charged, resulting in the ability to 
migrate in the electric field in relation to their specific charge and mass.
In general, cells were grown to confluence in tissue culture flasks or dishes and gently washed 
2x with PBS (37°C) to remove dead cells and residual medium. Immediately, 1 ml 2X Laemmli 
sample buffer was added and the cells were scraped off using cell scrapers and transferred to 
safe-look tubes (1.5 ml). The samples were then incubated with 3 μl benzonase per ml buffer and 
homogenized by sucking up and down using a 1 ml pipette tip for several times. Thereby, 
benzonase acts as an unspecific endonuclease which decomposes all kinds of RNA and DNA. 
Then, the samples were heated at 95°C for 5 min, to denature and SDS-couple the polypeptides,
centrifuged (13000 rpm, 3 min, RT) and the supernatants used for subsequent protein separation 
or stored at -20°C until use.
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Accordingly, 10-20 μl of the samples were loaded per slot of a Tris-glycine 4-20 % gradient gel,
which had been placed into a gel chamber, filled with 1X SDS-PAGE electrophoresis running 
buffer. As reference system for the molecular weight of the polypeptides, a broad range 2-212 
kilodalton (kDa) protein marker with 13 different polypeptides of known molecular weight was used. 
The proteins were separated at 20 mA per gel for 1.5-2 h. Afterwards, the polypeptides were 
transferred from the gel to a polyvinylidene difluoride (PVDF) membrane using a special semi-dry 
transfer technique (Kyhse-Andersen, 1984). Therefore, Whatman 3MM blotting papers were 
equilibrated in transfer buffer 1, 2 and 3, respectively, and arranged in the blotting chamber with the 
PVDF-membrane sheet (rinsed in isopropanol and equilibrated in transfer buffer 2) and the SDS
gel (equilibrated in transfer buffer 3). The alignment of the semi-dry blot is shown in Tab. 5 
(beginning at the anode). Subsequently, the semi-dry blots run at 130 mA for 1.5 h.
Afterwards, to visualize the polypeptide bands, the resulting PVDF membrane was stained with 
Coomassie brilliant blue R-250 staining solution. Thereby, background staining was reduced using 
PVDF membrane destaining buffer for washing. Finally, before immunodetection, the membranes 
were air-dried. The detection of the polypeptides, bound to the PVDF membrane, was performed 
using an indirect enzyme immune assay. Background reactions, due to non-specific binding, were 
reduced through incubation in PBS-Tween buffer containing 5 % milk powder for 30 min. 
Subsequently, the membranes were incubated with the primary Abs (diluted to appropriate 
concentrations in PBS-Tween milk buffer) for at least 1 h, washed 3x in PBS-Tween buffer and 
incubated for further 30 min with HRP-conjugated secondary goat anti-mouse IgG/IgM Abs,
followed by several washing steps in PBS. All steps were performed at RT using a shaker.
Finally, for the detection of the secondary Ab, bound to the proteins, the “Enhanced chemi-
luminescence (ECL) detection system” was used. Therefore, the membranes were shortly dried 
and incubated for 1 min in the ECL solution. Thereby, the HRP catalyzed the oxidation of luminol to 
3-aminophthalate, which led to the emission of low intensity light at 428 nm, detectable on a 
Konica-Minolta medical film using a developing machine.
cathode
6 x Whatman papers in transfer buffer 3
SDS gel in transfer buffer 3
PVDF membrane in transfer buffer 2
3 x Whatman papers in transfer buffer 2
6 x Whatman papers in transfer buffer 1
anode
Table 5. Semi-dry blot alignment. Whatman 3MM blotting papers were equilibrated in transfer 
buffer 1, 2 or 3, the PVDF membrane in transfer buffer 2 and the SDS gel in transfer buffer 3.
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7.3.17. Detection of autoimmune markers in human plasma
Human plasma was obtained after Ficoll density gradient centrifugation (see also 7.2.2.) of PB from 
melanoma and dysplastic nevi patients and stored in aliquots at -20°C. The plasma was used to 
measure the following autoimmune markers: anti-nuclear auto-Abs (ANA), anti-neutrophilic 
cytoplasmic auto-Abs (ANCA), perinuclear ANCAs (p-ANCA) and the rheumatoid factor. The 
autoimmune diagnostics was performed by the central laboratory of the Analysis Center of the 
University Hospital Heidelberg (head: Prof. Dr. P. Nawroth).
7.4. Animal methods
7.4.1. Anesthesia of mice
To receive a narcosis time of ~30 min, non-obese diabetic-severe combined immune-deficient 
(NOD-SCID) and NOD scid gamma (NSG) mice were anesthetized intraperitoneally (i.p.). Thereby,
per mouse up to 30 g body weight, 100 μl Rompun/Ketanest S solution were used (0.4 mg xylazin, 
1 mg ketamin per mouse; for composition of solution see Tab. 6.). The anesthetic effect was 
controlled by checking the plantar reflexes of the mouse. During anesthesia, to avoid hypothermia, 
mice were kept on a thermal mat and PBS was placed to the eyes to avoid drying. Furthermore, 
until they woke up, the mice were monitored during the recovery phase. During the in vivo imaging, 
inhalative anesthesia with 2 l/min Isofluran-O2 mixture was performed (7.4.4.).
Constituents Volume per 10 ml solution
1X PBS 4 ml
20 mg/ml Rompun 2 % (xylazin) 2 ml
25 mg/ml Ketanest S (ketamin) 4 ml
Table 6. Preparation of injection anesthesia solution. The solution was always sterile freshly 
prepared prior to each animal experiment and stored at RT until use.
7.4.2. Inoculation of tumor cells
The cells of various tumor lines were injected into mice to observe their in vivo growth behavior,
resulting in a tumor formation. In general, cells of the different lines were collected from tissue 
culture flasks, and 1 ml of the cell culture supernatants were removed for mycoplasma PCR 
investigation (7.3.14.). 
For intradermal (i.d.) primary and secondary tumor cell inoculation, the cells were centrifuged 
(1200 rpm, 5 min, RT), washed in PBS, counted, resuspended to a concentration of 2.5x106 cells in 
50 μl matrigel basement membrane matrix and transferred to sterile safe-lock tubes (1.5 ml). Since 
matrigel is only liquid at lower temperatures and becomes solid at higher temperatures, after the 
addition of matrigel, the cell suspension was kept on ice at all times. Afterwards, the mice were 
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anesthetized with Rompun/Ketanest S (7.4.1.) and shaved before the resuspended cells (2.5x106
cells / 50 μl matrigel) were injected i.d. to the right (primary tumor) or the left (secondary tumor) 
flank using 0.4 mm x 19 mm needles connected to 1 ml syringes. In contrast for tumor irradiation 
experiments (7.4.5.), tumor cells were applied i.d. to the right hind leg. In general, the tumor growth 
was measured every 2-3 d using a caliper and the tumor diameters and the tumor volumes (e.g., 
Schatton et al., 2008) were calculated using the following formulas:
In some experiments, the primary tumor was removed and a secondary tumor administered to 
the opposite flank of the same mice. Therefore, the mice were again anesthetized and shaved 
around the primary tumor. Since the tumor has been injected i.d., it could be carefully lifted with 
sterile tweezers and subsequently be removed with sterile scissors. The wound was immediately 
closed using the autoclip wound clip applier. A second tumor was injected i.d. to the left flank of the 
same mice 2 d later. After 10 d, the wound clips were removed under anesthesia (7.4.1.).
For subcutaneous (s.c.), intraveneous (i.v.) or i.p. tumor cell inoculations, the tumor cells were 
centrifuged (1200 rpm, 5 min, RT), washed in PBS and counted. Afterwards, they were 
resuspended to a concentration of 2.5x106 cells in 100 μl PBS and transferred to sterile safe-look 
tubes (1.5 ml) and placed on ice. Subsequently, 100 μl of the cells were injected s.c. to the shaved 
right murine flank or i.p. using appropriate needles and syringes as described above. For i.v. 
application, 100 μl of the tumor cell suspension was injected into the tail vain using 1 ml Micro-Fine 
insulin syringes with 0.33 mm x 12.7 mm needles. Prior to cell application, the mouse tail was pre-
warmed with a red light lamp to allow the vessel vasodilatation.
7.4.3. Adoptive T cell transfer in vivo
To investigate whether the tumor growth was controlled by TCR transgenic T cells (7.3.9.), various 
MDM2 and gp100 TCR transduced human T cell constructs were adoptively transferred to mice,
priorily engrafted i.d. with human melanoma cells resuspended in matrigel (7.4.2.). In general, on
d7 after primary tumor cell inoculation, the transduced T cells (2x106 - 5x106 cells) were
resuspended in 100 μl PBS and injected i.v. into the tail vain (1 ml Micro-Fine Insulin syringes, 
0.33 mm x 12.7 mm needles). Before i.v. injection, a vasodilatation of the mouse tail was 
performed as described (7.4.2.). As control settings, mock transduced T cells (empty retroviral 
plasmid with??????????????????????????????????????????????????????????????????? PBS without T cells 
were injected. 
Tumor diameter
(mm) 2
(length + width)
=
x 0.5 x length x (width)2Tumor volume
(mm3) 6
?
=
? = 3.14159
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7.4.4. In vivo imaging of luciferase expression
The IVIS100 imaging system was used for bioluminescence imaging in vivo to repeatedly 
investigate the tumor growth of stably transfected firefly luciferase-positive tumor cells (7.3.10.) in 
mice. Therefore, D-luciferin was used as substrate for the firefly luciferase. This enzyme catalyzes 
the oxygenation of D-luciferin using ATP and molecular oxygen to oxyluciferin, a highly unstable 
singlet-excited compound, which emits light upon relaxation to its ground state. 
The lyophilized D-luciferin powder was solved in PBS, filtered sterile (???????????????????????????)
and stored in 1 ml aliquots at -80°C. The in vivo imaging of shaved mice was performed 5 min after 
i.p. injection of the D-luciferin solution and up to five mice could be analyzed in parallel. Thereby, 
the injected volume of D-luciferin was dependent on the body weight of the mice (cf., Tab. 7). 
During the whole imaging process, the mice received inhalative anesthesia of an Isofluran/O2
mixture (2 l/min). The bioluminescence signal was quantified in units of photons/second/square 
centimeter/steradian (p/sec/cm2/sr). In general, the mice were imaged 2x per week, investigating 
different exposure times (1, 10, 20, 30, 60, 120 and 300 sec).
Weight of mice [g] D-luciferin (30 mg/ml) [μl]
17.5 - 18.5 90
18.5 - 19.5 95
19.5 - 20.5 100
20.5 - 21.5 105
21.5 - 22.5 110
22.5 - 23.5 115
23.5 - 24.5 120
24.5 - 25.5 125
25.5 - 26.5 130
26.5 - 27.5 135
27.5 - 28.5 140
28.5 - 29.5 145
29.5 - 30.5 150
Table 7. D-luciferin volume for mice injection. D-luciferin was constituted in PBS at a stock con-
centration of 30 mg/ml. Depending on the murine body weight, respective volumes were injected.
7.4.5. Irradiation of mice
To investigate a combinational treatment approach, consisting of local low dose tumor irradiation 
and adoptive immunotherapy with TCR transgenic T cells, mice were locally irradiated at the tumor 
injection side, in general, 6 d after i.d. tumor application to the right hind leg (7.4.2.). An irradiation 
with 2 Gy was performed using the Gammatron Cobalt 60 therapy unit. Therefore, the mice were 
fixed in a special rack that only allowed the irradiation of the tumor (see also Fig. 66). The local low 
dose irradiation was kindly performed by A. Tietz-Dalfuß (Clinical Cooperation Unit Radiation 
Oncology, DKFZ). 
Methods
page | 86
7.4.6. Preparation of single cell suspensions from murine organs
To analyze the presence of previously i.v. injected TCR transgenic T cells, single cell suspensions 
were produced from PB and tumors of tumor-bearing mice.
7.4.6.1. Cell suspensions from PB 
Murine PB samples were obtained from the retro-orbital venous plexus of mice using heparinized 
capillaries or from the submandibular vein using blood lancets. Thereby, if the blood was taken 
from the venous plexus behind the eye, the mice received inhalative anesthesia with Isofluran. In 
general, ~200 μl PB were removed per mouse and immediately mixed with 100 μl heparin, to 
prevent clotting and placed on ice until treated with 10 ml ACK lysis buffer at RT for 10 min, to 
obtain red blood cell lysis. The reaction was stopped using PBS supplemented with 5 % FCS. 
Afterwards, the cells were centrifuged (1500 rpm, 5 min, 4°C), washed with FACS buffer and 
used for flow cytometry analysis to stain for human T cells, which had before been adoptively 
transferred to mice (7.3.9.; 7.4.3.). FACS staining was performed as described in 7.2.13., with the 
exception that 5 % Endobulin together with 5 % hybridoma supernatant 2.4G2 in PBS (anti-
CD16/CD32; kindly provided by Dr. J. Ni) were used for initial blocking of the surface Fc-receptors. 
7.4.6.2. Cell suspensions from tumors
The tumors applied i.d., were either surgically removed (see 7.4.2.), keeping the mice alive, or the 
mice were sacrificed by cervical dislocation before tumor removal. The weights of the individual 
tumors were measured with a digital analytical balance. Afterwards, the tumors were stored frozen 
to use for later IHC stainings (7.3.15.) or single cell suspensions were immediately prepared for 
FACS analysis. For the latter, the tumors were cut into small pieces (~8 mm), treated in 50 ml 
tubes with tumor digestion buffer (10 ml/tumor; containing hyaluronidase and DNase I) and 
incubated at 37°C for 30 min while permanent shaking. Single cell suspensions were obtained by 
mincing the digested tumors through 70 μm-pore cell strainers, followed by a washing and 
centrifugation step in PBS (1600 rpm, 10 min, 4°C). The cells were subsequently resuspended in 
7 ml PBS and filtered through 40 μm-pore cell strainers. The cell suspension was then loaded       
to 6 ml Lympholyte-M solution in 15 ml tubes, followed by a density gradient centrifugation (1500 g, 
26 min, 22°C, decelerated brake). After the centrifugation step, the PBMC layer was removed, 
washed with FACS buffer and used for flow cytometry (7.2.13.) to stain for human T cells (7.4.3.). 
The FACS protocol was used with the modification of Fc-receptor blocking (see 7.4.6.1.).
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7.4.7. Staining of lung metastases
To control metastases formation after tumor cell injection in vivo, lungs from tumor bearing mice 
were removed and stained in Bouin’s solution containing picrinic acid at RT for 72 h. In Bouin’s 
solution, normal tissues become a brown color while metastases stain yellow. Therefore, at the 
lung surface, the metastatic nodules could be analyzed.
7.5. Statistical analysis
Differences between the test groups were analyzed using the nonparametric unpaired two-tailed 
“Student t test” and differences were considered to be significant on the basis of the 95 % 
confidence interval. The calculated p values indicate, whether a statistical significant difference 
between the test groups exist. Following p values display significant difference????????????????????
** ?? ?????? ?? ????? ???? ???? ?? ?????? ?? ?????. In contrast, p values > 0.05 and < 0.1 were not 
considered to be statistically significant but indicated a trend. If not indicated differently, the 
experimental data were expressed as Mean ± standard error of the mean (SEM).
The tumor volume and diameter of various TCR transgenic T cell adoptively transferred mice,
from independent experiments, were combined and analyzed against the PBS and mock treated 
reference control groups over time using the linear regression model with mixed effects (fixed: 
baseline, treatment, day; random: individual animal, individual experiment). Thereby, the 
calculation of statistical differences of tumor growth behavior over time, between the individual 
treated murine groups, was kindly performed by A. Benner (Statistics for Translational Oncology, 
Division of Biostatistics, DKFZ).
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8. Results
8.1. Characterization of human spontaneous tumor antigen-reactive T cell 
responses 
Spontaneously induced human tumor antigen-reactive memory T cell responses of melanoma 
patients were investigated by short-term co-culture experiments of patient-derived autologous 
dendritic cells and T cells. The reactivation of T cells was performed using dendritic cells, loaded 
with synthetic 50 amino acids (aa) long polypeptides and analyzed through T cell-???????????????
secretion, measured by a short-term ELISPOT assay.
8.1.1. Generation of 50aa polypeptides of melanoma tumor-associated antigens
According to their capacity to contain different epitopes that can be presented in the context of 
MHC class I and class II molecules, synthetic polypeptides with a length of 50aa were generated. 
Thereby, polypeptides for the following 13 selected melanoma tumor-associated antigens (TAAs)
were constructed: GAGE-1, gp100/pmel17, MAGE-A1, MAGE-C2, MDM2, Melan-A/MART-1, MIF, 
NA17-A, NY-ESO-1, p53, RAB38/NY-Mel-1, TRP2 and Tyrosinase (see also, Tab. 8, NCBI 
GenBank accession numbers are indicated therein).
The polypeptide sequences were chosen to cover at least one known HLA-A2-(HLA-A*0201)
restricted epitope, which had been described in the literature (cf., Tab. 8). Besides these known 
epitopes, further putative MHC class I and class II epitopes were contained in the peptide 
sequences, presented through alleles frequently occurring in the human population. These were 
identified by the help of HLA peptide binding epitope prediction algorithms using the two databases
“Syfpeithi” (www.syfpeithi.de; Rammensee et al., 1999) and “Bimas” (www-bimas.cit.nih.gov;
Parker et al., 1994). According to the Syfpeithi database, for all 50aa polypeptides, a selection of 
possible epitopes, presented on MHC class II and class I, with exception of HLA-A2, were 
predicted and are listed in Appendix 13.12.. Only the top-scoring 2 % of all predicted peptides are 
shown, because only they should contain the naturally presented epitopes. A reliability of at least 
80 % for predicted MHC class I epitopes can be expected. In comparison, since the pocket binding 
behavior of MHC class II is more variable, the predicted MHC class II motifs have a reliability of 
~50 % (Rammensee et al., 1999). Besides the known HLA-A2-restricted epitopes, in all designed 
50aa polypeptides, further predicted HLA-A2-restricted epitopes were present (see Appendix 
13.13.). To investigate the specificity of the generated 50aa sequences of all polypeptides, a 
GenBank alignment of the protein sequences were performed using the NCBI Blast database 
(www.ncbi.nlm.nih.gov/BLAST/Blast.cgi). For all polypeptide sequences, a complete and specific 
alignment was obtained with the corresponding protein sequence of the respective antigen.
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Table 8. Melanoma TAAs and sequences of the generated 50aa polypeptides. HLA-A2-(HLA-A*0201) restricted epitopes of melanoma TAAs as
described in the literature are listed, respectively. The 50aa polypeptide sequences for the 13 individual antigens are indicated. The respective HLA-A2-
restricted epitopes, as described in the literature, are demonstrated in red letters in the context of the polypeptide sequence. * NCBI GenBank accession 
number; ** NCBI GenBank accession number, a part of an intron sequence was used; *** epitope was selected according to informations from the 
indicated research paper in combination with an epitope prediction, performed using the Syfpeithi database.
Tumor antigen HLA-A*0201 epitope Reference 50aa polypeptide
GAGE-1 YRPRPRRYV  9-17 *** van den Eynde et al., 1995 MSWRGRSTYR  PRPRRYVEPP  EMIGPMRPEQ  FSDEVEPATP  EEGEPATQRQ 1-50
(AAA82744)* and Syfpeithi prediction
gp100/pmel17 LLDGTATLRL 457-466 Kawakami et al., 1994a SITGSLGPLL  DGTATLRLVK  RQVPLDCVLY  RYGSFSVTLD  IVQGIESAEI 449-498
(AAC60634)* VLYRYGSFSV 476-485 Kawakami et al., 1995
MAGE-A1 KVLEYVIKV 278-286 Ottaviani et al., 2005 PARYEFLWGP  RALAETSYVK  VLEYVIKVSA  RVRFFFPSLR  EAALREEEEG 259-308
(NP_004979)* Pascolo et al., 2001
MAGE-C2 ALKDVEERV 336-344 Ma et al., 2004 WGPRAHSESI  KKKVLEFLAK  LNNTVPSSFP  SWYKDALKDV  EERVQATIDT 301-350
(AAF07211)*
MDM2 LLGDLFGV 81-88 Stanislawski et al., 2001 KEVLFYLGQY  IMTKRLYDEK  QQHIVYCSND  LLGDLFGVPS  FSVKEHRKIY 51-100
(AAL40178)* VLFYLGQY 53-60 Asai et al., 2002
Melan-A/MART-1 EAAGIGILTV 26-35 Kawakami et al., 1994b GHGHSYTTAE  EAAGIGILTV  ILGVLLLIGC  WYCRRRNGYR  ALMDKSLHVG 16-65
(NP_005502)* AAGIGILTV 27-35 Kawakami et al., 1994b
ILTVILGVL 32-40 Castelli et al., 1995
MIF LLCGLLAER 79-87 *** Cha et al., 2007 LMAFGGSSEP  CALCSLHSIG  KIGGAQNRSY  SKLLCGLLAE  RLRISPDRVY 47-96
(CAG30406)* LLCGLLAERL 79-88  and Syfpeithi prediction
NA17-A VLPDVFIRC  2-10 Guilloux et al., 1996 MVLPDVFIRC  VVFCLTVVCW  TWVPLRGPSS  PGSYRKWMCF  SESQVQPTQK 1-50
(X91652)** VLPDVFIRCV  2-11 Fonteneau et al., 1997
NY-ESO-1 SLLMWITQC 157-165 Jaeger et al., 1998 FTVSGNILTI  RLTAADHRQL  QLSISSCLQQ  LSLLMWITQC  FLPVFLAQPP 126-175
(CAA05908)*
p53 STPPPGTRV 149-157 Theobald et al., 1995 TAKSVTCTYS  PALNKMFCQL  AKTCPVQLWV  DSTPPPGTRV  RAMAIYKQSQ 118-167
(BAC16799)*
RAB38/NY-Mel-1 VLHWDPETV 50-58 Walton et al., 2006 ATIGVDFALK  VLHWDPETVV  RLQLWDIAGQ  ERFGNMTRVY  YREAM GAFIV 40-89
(NP_071732)*
TRP2 ATTNILEHV 403-411 Khong and Rosenberg, 2002 ALPHSAANDP  IFVVISNRLL  YNATTNILEH  VRKEKATKEL  PSLHVLVLHS 381-430
(ABI73976)* NATTNILEHV 402-411
Tyrosinase MLLAVLYCL  1-9 Woelfel et al., 1994 MLLAVLYCLL  WSFQTSAGHF  PRACVSSKNL  MEKECCPPWS  GDRSPCGQLS 1-50
(AAK00805)* CLLWSFQTSA  8-17 Riley et al., 2001
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The HLA-A2-restricted epitope for the NA17-A antigen, is a atypical peptide, encoded by an 
intron sequence of the N-acetyl glucosaminyl-transferase V gene (GnT-V). The NA17-A antigen 
was derived from a patient (NA17) with cutaneous melanoma metastases (Pandolfino et al., 1992). 
A promoter within the intron of NA17-A is specifically activated in melanoma cells, resulting in the 
production of an intron-coated mRNA (Guilloux et al., 1996). Therefore, the 50aa polypeptide for 
NA17-A was constructed, based on intron and exon sequences as shown in Fig. 16. Besides the 
described HLA-A2-restricted epitopes, the generated 50aa polypeptide contains further predicted 
MHC class I (including HLA-A2) and MHC class II epitopes (Appendix 13.12. and 13.13.).
Figure 16. Generation of the 50aa polypeptide for NA17-A. The HLA-A2-restricted epitope
VLPDVFIRC from the human GnT-V gen is encoded by an intron sequence. Specifically in 
melanoma cells, a cryptic promoter within the intron is activated. A synthetic 50aa polypeptide was
generated surrounding the HLA-A2-restricted epitope (blue underlined sequence). The figure is 
modified from Guilloux et al., 1996.
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8.1.2. Patient cohorts used for investigations
The analysis for the presence of spontaneously induced tumor antigen-reactive memory T cell 
responses was investigated using peripheral blood (PB) samples of 3 patients with dysplastic nevi 
(DPN), 38 patients with non-metastasized and 8 patients with metastasized malignant melanoma 
(MM; Tab. 9). As control group, healthy donor PB samples were examined. The main group of 
patients was diagnosed as non-metastasized melanoma stage IA (cf., Tab. 9). The tumor in these 
patients is less than 1 mm in diameter and the covering skin layer is not ulcerated. During this 
stage the melanoma is only located in the skin and there is no sign that it has spread to lymph 
nodes or other parts of the body. 
For the investigation of spontaneously induced tumor antigen-reactive memory T cell 
responses, PB was taken after resection of the primary tumor from all 38 non-metastasized 
melanoma patients (stages I and II; Tab. 9). Representative images of a dysplastic nevus and a
melanoma stage IA are shown in Fig. 17.
Table 9. Summary of the patient cohorts used. The PB of 3 patients with dysplastic nevi lesion, 
38 non-metastasized as well as 8 metastasized melanoma patients were analyzed for the presence 
of spontaneously induced tumor antigen-reactive memory T cell responses. The numbers of 
patients for the different melanoma stages are shown, respectively.
    number of patients
    dysplastic nevus 3 patients
    non-metastasized melanoma 38 patients
melanoma in situ 0  -
stage I IA 24
IB 5
IIA 5
stage II IIB 2
IIC 2
    metastasized melanoma 8 patients
IIIA 2
stage III IIIB 1
IIIC  - 
stage IV IV 5
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Figure 17. Representative images of patients, suffering from a dysplastic nevi lesion (left 
column) or a non-metastasized melanoma stage IA (right column). Survey micrographs 
present a dysplastic nevus on the back of patient # 64 (indicated by arrow) and a melanoma stage 
IA on the thigh of patient # 62. In the middle lane, higher magnifications are shown, whereas in the 
lower images, a dermatoscope was used for detailed visualization. The pictures were kindly 
provided from Dr. C. Gebhardt, Department of Dermatology, University Hospital Heidelberg. 
8.1.3. Tumor antigen-reactive T cell responses to polypeptides in melanoma patients
The presence of spontaneously induced tumor antigen-reactive memory T cells was analyzed in 
the 38 non-metastasized (stages I, II) and the 8 metastasized melanoma patients (stages III, IV; cf., 
Tab. 9), performing an ex vivo short-???????????????????????????????????????4 mature PB-derived 
dendritic cells were pulsed with the generated 50aa polypeptides of melanoma TAAs for 18 h. The 
cells were co-cultured with 5x104 autologous PB T cells for 40 h. During this short-term T cell 
???????????? ???? ????????? ?????? ????????? ??? ??activated memory T cells, is bound through plate-
coupled anti-??????????????? (Abs)?? ????? ???????? ??? ????? ?????????? ??? ???????????????? ???? ?????
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???????? ???????? ??????????? ???? ?????????? ??? ????? ???? ????? ??? ????????? ???????? ???-existing 
tumor antigen-reactive memory T cells were present in the PB of melanoma patients upon 
reactivation.
??????????????? ?????? ??? ??? ???????? ??????? ???????? ????????? ????? ????? ?????????? ???? ????
associated graph, are displayed in Fig. 18. As control settings, a co-culture of dendritic cells pulsed 
with human IgG together with autologous T cells as well as single cultures of T cells and dendritic 
cells were performed. To guarantee the functionality of the performed assay, the bacterial super 
antigen staphylococcal enterotoxin B (SEB) was used as positive control. In addition, 
??????????????? ????? ???????? ???????? ??? ??????????? ???-metastasized melanoma patients are 
indicated in Figs. 18 and 19. In the presented ELISPOT assay, which was performed with T cells 
and dendritic cells of patient # 16 significantly increased tumor antigen-reactive T cell responses 
were shown against the 50aa polypeptides p53 and TRP2, compared to the human IgG control 
(Fig. 19A). In contrast, however, patient # 5 and # 36 revealed polyvalent T cell responses against 
all tested polypeptides (Figs. 18B and 19B).
The cumulative data of 38 non-metastasized as well as 8 metastasized melanoma patients 
showed that spontaneously induced tumor antigen-reactive T cell responses were detected in 
76.3 % of all analyzed non-metastasized and in 62.5 % of all metastasized melanoma patients 
(Fig. 20). In comparison to the IgG control, in all of these samples, the T cell responses were 
significantly increased against at least one of the tested polypeptides. If patient-derived T cells 
responded to the generated polypeptides, then they mainly responded against four or more 
antigens at the same time and therefore, showed a polyvalent T cell response (Fig. 21). For this 
analysis of response rates, only assays in which at least four 50aa polypeptides of melanoma 
TAAs could be tested in parallel, were counted.
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Figure 18. ??????????????? ?????????????????????? ?????-metastasized stage IIC melanoma 
patient. Tumor antigen-reactive memory T cell responses against the polypeptides (gp100/ 
pmel17, Melan-A/MART-1, p53, Tyrosinase, MDM2, NA17-A, NY-Eso-1, TRP2, MIF, MAGE-A1, 
MAGE-C2, GAGE-1, RAB38/NY-Mel-1) were present in the PB of melanoma patient # 36. As 
endogenous negative control, a co-culture of dendritic cells loaded with human IgG peptide 
together with T cells was performed. Additionally, single cultures of dendritic cells and T cells 
were accomplished as negative controls and a co-culture of SEB pulsed dendritic cells together 
with T cells were investigated as positive control. A) An image of representative ELISPOT wells is 
shown. B) Resulting graph of the spots indicated in A. For statistical analysis, an unpaired two-
tailed t test was performed. Significant increased p values were compared to human IgG control: 
gp100/pmel17 (0.04), Melan-A/MART-1 (0.0001), p53 (0.00009), Tyrosinase (0.0002), MDM2 
(0.001), NY-Eso-1 (0.0003), TRP2 (0.001), MIF (0.00001), MAGE-A1 (0.00004), MAGE-C2 
(0.00002), GAGE-1 (0.0002), RAB38/NY-Mel-1 (0.0002). DC, dendritic cells; Mean ± SEM; TC,
??????????????????????????????????????????????
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Figure 19. ??????????????? ????? ???????? ???????? ??? ???? ???-metastasized stage IA 
melanoma patients. Spontaneously induced tumor antigen-reactive memory T cell responses 
were detected against polypeptides, derived from melanoma TAAs. A) Melanoma patient # 16 
showed significant increased spontaneous T cell responses against the polypeptides p53 and 
TRP2, compared to the human IgG control. B) Polyvalent significantly increased T cell responses 
were detected in melanoma patient # 5, against all investigated polypeptides (gp100/pmel17, 
Melan-A/MART-1, p53, Tyrosinase, MDM2, NA17-A), compared to human IgG T cell responses. 
Single cultures of T cells and dendritic cell were accomplished as controls. For statistical analysis, 
an unpaired two-tailed t test was performed. DC, dendritic cells; Mean ± SEM; TC, T cells; *** p 
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Figure 20. Proportion of melanoma patients with spontaneously induced tumor antigen-
reactive T cell responses. Tumor antigen-reactive memory T cells occurred in non-metastasized 
?????????????????????????? ??????????????????? ???????????? ?????????? ??????? ??? ????? ?????? ???
T cells, in response to at least one TAA polypeptide/dendritic cell setting compared to control 
human IgG peptide/dendritic cell approach. For non-responder, no significantly increased T cell 
responses were detected. n, number of patients
Figure 21. Number of recognized 50aa polypeptides of melanoma TAAs per responding 
melanoma patients. In the majority, when analyzed responders of non-metastasized and 
metastasized melanoma stages, TAA-reactive T cell responses were found in parallel, against four 
or more polypeptides. Only the samples, where at least four peptides could be tested have been 
analyzed. n, number of patients; nd, not detectable
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8.1.4. Tumor antigen-reactive T cell responses to polypeptides in dysplastic nevi patients
A dysplastic nevus is a lesion that can give rise to malignant melanoma. Therefore, patients with 
dysplastic nevi, as a kind of a pre-malignant cohort, were also examined for the presence of 
spontaneously induced tumor antigen-reactive memory T cell responses in the PB. After the 
?????????? ??? ???? ??????????? ????? ???????? ????????????????????????? ???????????????? ???????????
T cells and dendritic cells. For T cell reactivation, the dendritic cells were pulsed with the 50aa 
polypeptides of melanoma TAAs. Two patients were investigated and both showed significantly 
increased T cell responses against the tested polypeptides (exemplarily depicted for patient # 53 in 
Fig. 22).
Figure 22. ??????????????????????????????????????????????????????????????????????????????? In 
patient # 53, polyvalent significantly increased tumor antigen-reactive T cell responses were 
detected against all investigated polypeptides (Melan-A/MART-1, NA17-A, Tyrosinase, p53, 
MDM2), after the resection of the dysplastic nevus. In comparison, single cultures of T cells and 
dendritic cell were performed as controls. For statistical analysis, an unpaired two-tailed t test was 
performed. DC, dendritic cells; Mean ± SEM; ????????????????????????????????
8.1.5. HLA-unrestricted CD4+ and CD8+ T cell responses to polypeptides
The 50aa polypeptides were constructed to cover at least one known HLA-A2-restricted epitope 
(Tab. 8). Predicted by database analysis, other putative MHC class I and class II epitopes were 
covered in addition. In order to test, whether HLA-A2- patient-derived T cells were able to recognize 
the polypeptides, the patient samples were separated according to their expression of HLA-A2 into 
HLA-A2+ and HLA-A2- samples. The HLA-A2 expression was assessed by flow cytometry and is 
representatively shown in Fig. 23A. To guarantee the function of the cellular surface staining, a 
HLA-A2+ cell line was always co-stained in parallel as positive control. 
The cumulative data of 20 HLA-A2+ and 18 HLA-A2- non-metastasized as well as 4 HLA-A2+
and 4 HLA-A2- metastasized melanoma patients showed that HLA-A2- and HLA-A2+ patient-
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derived T cells can specifically recognize the polypeptides, in a similar manner (Fig. 23B). In 70 %
of all analyzed HLA-A2+ and in 83.3 % of all HLA-A2- non-metastasized melanoma patients, 
significantly increased tumor antigen-reactive memory T cell responses were detected against at 
least one of the tested polypeptides, in comparison to the IgG control. HLA-A2+ T cells, derived 
from metastasized patients recognized the polypeptides in 50 % and HLA-A2- T cells in 75 % of all 
performed ELISPOT assays (Fig. 23B). 
The HLA-A2 expression was also investigated in 2 dysplastic nevi patients, after the resection 
of the lesion. Both patients-derived T cells specifically recognized the polypeptides, whereas one 
patient was HLA-A2+ and the other HLA-A2-. The T cell response of the HLA-A2- dysplastic nevi 
patient # 53 is shown in Fig. 22.
In general, peptides are presented to CD8+ T cells by MHC class I molecules like HLA-A2, 
whereas CD4+ T cells need the presentation through MHC class II, for peptide recognition.          
As shown in Appendix 13.12., the generated polypeptides contained predicted MHC class II-
restricted epitopes that could theoretically be recognized by CD4+ T cells. In order to investigate, 
whether CD4+ T cells of malignant melanoma patients were able to respond to these polypeptides, 
CD4+ T cells were separated from CD8+ T cells using CD4 MicroBeads. The obtained purity of 
CD4+ ????????????????????????????????????????????????? ?????????????????????CD4+ as well as 
CD8+ T cells of the same patient significantly recognized the tested melanoma 50aa polypeptides 
(Figs. 24C and D). The cumulative data of 2 non-metastasized melanoma patients (in total 15 
individual performed tests) showed that after primary tumor resection the frequency of TAA-
reactive memory T cells among CD4+ and CD8+ T cells was comparable (Fig. 24B). In the HLA-A2+
patient # 52, strong CD8+ T cell responses against the tumor antigens Melan-A/MART-1 and p53 
were observed, indicating the presence of well defined HLA-A2-restricted epitopes, presented by 
the generated melanoma polypeptides. In addition, CD4+ T cells of the same patient also revealed 
increased responses against both polypeptides (Fig. 24C). The analysis of the HLA-A2- patient
# 58 indicated that besides HLA-A2 further MHC class I-restricted epitopes were present in the 
polypeptide sequences. This is exemplarily shown by significant increased CD8+ T cell responses 
against the polypeptide for Tyrosinase (Fig. 24D). In the same patient, spontaneously induced 
tumor antigen-reactive memory CD4+ T cell responses were present and revealed strong ?????
production in response to almost all investigated polypeptides. This observation also indicated the 
predicted presence of MHC class II-restricted epitopes that were efficiently presented to T cells. 
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Figure 23. Proportion of HLA-A2+ and HLA-A2- melanoma patients with spontaneously 
induced tumor antigen-reactive T cell responses. The 50aa polypeptides were recognized by 
HLA-A2+ and HLA-A2- T cells of non-metastasized and metastasized melanoma patients. A) HLA-
A2 flow cytometry staining was used to separate melanoma patient derived cells, concerning to 
their HLA-A2 expression into HLA-A2+ and HLA-A2- cohorts. B) T cells of HLA-A2+ and HLA-A2-
patients recognized the polypeptides to a similar extent. Responder, significantly increased number 
??????? spots by T cells, in response to at least one TAA peptide/dendritic cell setting compared to
control human IgG peptide/dendritic cell setting. n, number of patients
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Figure 24. The 50aa polypeptides are significantly recognized by CD4+ and CD8+ T cells of 
the same melanoma patients. A) The purity of CD4+ T cells, isolated with CD4 MicroBeads, was 
investigated by flow cytometry staining. Dead cells were excluded via 7AAD (left, dot plot; right, 
histogram). B) Frequency of TAA-reactive T cells among CD4+ and CD8+ T cells. C) CD4 and CD8 
T cell responses of HLA-A2+ patient # 52 (stage IA). D) CD4 and CD8 T cell responses of HLA-A2-
patient # 58 (stage IA). For statistical analysis, an unpaired two-tailed t test was performed. DC, 
dendritic cells; Mean ± SEM; n, number of tests; TC, T cells; ????????????????????????????????????
????????????????????
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8.1.6. T cell responses to the 13 individual polypeptides in non-metastasized melanoma 
patients
The T cell responses against the 13 individual 50aa melanoma polypeptides were investigated in a 
cohort of 36 non-metastasized melanoma patients after primary tumor resection (36 out of 38 
patients, since 2 were used for the CD4+ and CD8+ T cell investigation; cf., 8.1.5). In summary,
high T cell reactivities were detected against all tested polypeptides. The highest responses were 
received for Melan-A/MART-1 (63.9 %), Tyrosinase (61.5 %) and NA17-A (41.4 %), followed by 
MDM2 (39.1 %), p53 (38.2 %), MAGE-C2 (36.4 %), MAGE-A1 (31.3 %), NY-Eso-1 (31.3 %), 
RAB38/NY-Mel-1 (30.8 %) and GAGE-1 (30.8 %). Even the lowest T cell responses against 
gp100/pmel17 (23.8 %), MIF (21.4 %) and TRP2 (21.1 %) were above 20 % response rate (Figs. 
25A and B). 
For all of the examined polypeptides, frequencies of TAA-reactive T cells were analyzed in 
addition. For instance, within 5x104 CD3+ T cells, ~69 Melan-A/MART-1 and 73 Tyrosinase-reactive 
T cells as well as 51 NA17-A and 55 MDM2- reactive T cells were detected (Fig. 25C). After short-
term reactivation for 40 h using the polypeptides, the percentage of TAA-reactive memory T cells in 
the PB of non-metastasized melanoma patients, after primary tumor resection was 0.15 % for 
Tyrosinase (highest frequency) to 0.03 % for TRP2 (lowest frequency). The combined percentages 
of TAA-reactive T cell among total CD3+ T cells in response to all 13 investigated melanoma 
polypeptides was 1.09 % (Fig. 25C).
8.1.7. T cell frequencies after primary tumor resection in non-metastasized melanoma 
patients over time
To investigate how the frequencies of TAA-reactive memory T cells behave after primary tumor 
resection over time, different time points (0-15 d, 16-30 d, 31-45 d, 46-60 d, >60 d) after tumor 
resection were analyzed for the presence of spontaneously induced tumor antigen-reactive 
memory T cells (Figs. 26A and B). Thereby, the T cell reactivities were measured using short-term 
????????????????????
In summary, the general frequency of TAA-reactive T cells was strongly increased after primary 
tumor resection over time. Shortly after tumor resection (0-15 d), a mean frequency of 26 TAA-
reactive T cells per 5x104 total CD3+ TC was detected. The highest frequency (mean 132 TAA-
reactive T cells per 5x104 total CD3+ TC) was observed 46-60 d after tumor resection. This 
demonstrates a strong increase in TAA-reactive T cell frequency in the PB of non-metastasized 
melanoma patients over time (Figs. 26A and B). At later time points, the tumor antigen-reactive 
memory T cell frequency decreased to a baseline level (>60 d, mean 21 TAA-reactive T cells per 
5x104 total CD3+ T cells; Figs. 26A and B). 
Moreover, the individual frequencies of Melan-A/MART-1, Tyrosinase, NA17-A and p53 reactive 
T cells after tumor resection over time are shown in Figs. 27A-D. All four specificities of TAA-
reactive T cells (Figs. 27A-D) showed a similar pattern than the cumulative data of all T cell 
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frequencies (Fig. 26). The Melan-A/MART-1, Tyrosinase as well as NA17-A and p53 memory T cell 
frequencies were significantly increased after tumor resection over time, while the strongest 
increase was detected for Tyrosinase specific T cells (Figs. 27A-D).
Figure 25. Recognition of the 13 individual polypeptides by T cells of non-metastasized 
melanoma patients after primary tumor resection. A) Response rate of 36 melanoma patients 
to the 13 investigated polypeptides. B) Overview on the tested polypeptides, regarding the 
numbers of patients studied. Moreover, the numbers of patients are indicated, for those significant 
increased T cell responses were detected. C) Frequency of TAA-reactive T cells against individual 
polypeptides. Mean ± SEM; TC, T cells
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Figure 26. Frequency of spontaneously induced tumor antigen-reactive memory T cells in 
non-metastasized melanoma patients after primary tumor resection over time. The
cumulative data of T cell frequencies in response to the 50aa polypeptides after primary tumor 
resection over time are presented. For the analysis, only the significant increased individual T cell 
frequencies per investigated polypeptides in comparison to the human IgG control were used.     
A) The scatter plot shows the increase of TAA-reactive memory T cells investigated in 36 non-
metastasized melanoma patients after tumor resection over time, up to d60. B) The column bar 
graph indicates the same data as shown in A. For statistical analysis, an unpaired two-tailed t test 
was performed. Mean ± SEM; n, number of tests; ???????????????????????????????????????????????????
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Figure 27. Frequency of Melan-A/MART-1, Tyrosinase, NA17-A and p53 tumor antigen-
reactive T cells in non-metastasized melanoma patients after primary tumor resection over 
time. The graphs show the increase of TAA-reactive T cells, specific for A) Melan-A/MART-1, 
B) Tyrosinase, C) NA17-A and D) p53, investigated in the PB of non-metastasized melanoma 
patients after tumor resection over time. The individual T cell frequencies per analyzed 
polypeptides are indicated in response to the IgG control. For statistical analysis, an unpaired two-
tailed t test was performed. Mean ± SEM; n, number of patients; ????????????????????????????????????
??????????????????????????????001
8.1.8. Analysis of the alteration of T cell responses and plasma autoimmune markers in 
response to the surgical removal of a lesion
In the case, that a skin lesion was suspected to be a skin cancer, a total removal of the lesion 
(excisional skin biopsy) was performed by dermatologists and diagnosed by pathologists. During 
the primary surgical removal, the incision was performed elliptical or eye-shaped narrow around the 
lesion. The wound was then sutured with stitches. Representative images of a surgical removal of 
a skin lesion - dysplastic nevi - are shown in Fig. 28. In general, the intervention performed to 
remove a dysplastic nevus or a non-metastasized melanoma indicates a minimal invasive surgery. 
It is narrowly defined and has only low removal risks including scar formation and redness.
A B
Melan-A/MART-1
0-15 d (n = 8) 16-30 d (n = 10) 31-45 d (n = 7) 46-60 d (n = 4) >60 d (n = 7) 
0
50
100
150
200
250
300
* (0.04)
*** (0.0004)
TA
A
-r
ea
ct
iv
e 
TC
 / 
5x
10
4  T
C
Tyrosinase
0-15 d (n = 7) 16-30 d (n = 8) 31-45 d (n = 4) 46-60 d (n = 3) >60 d (n = 4) 
0
50
100
150
200
250
300 ** (0.004)
TA
A
-r
ea
ct
iv
e 
TC
 / 
5x
10
4  T
C
C DNA17-A
0-15 d (n = 6) 16-30 d (n = 8) 31-45 d (n = 7) 46-60 d (n = 3) >60 d (n = 5) 
0
50
100
150
200
250
300
(0.051)
** (0.0032)
TA
A
-r
ea
ct
iv
e 
TC
 / 
5x
10
4  T
C
p53
0-15 d (n = 7) 16-30 d (n = 10) 31-45 d (n = 7) 46-60 d (n = 4) >60 d (n = 6) 
0
50
100
150
200
250
300 (0.0505)
TA
A
-r
ea
ct
iv
e 
TC
 / 
5x
10
4  T
C
0-15 d
(n = 8)
16-30 d
(n = 10)
31-45 d
(n = 7)
46-60 d
(n = 4)
>60 d
(n = 7)
0-15 d
(n = 7)
16-30 d
(n = 8)
31-45 d
(n = 4)
46-60 d
(n = 3)
>60 d
(n = 4)
0-15 d
(n = 6)
16-30 d
(n = 8)
31-45 d
(n = 7)
46-60 d
(n = 3)
>60 d
(n = 5)
0-15 d
(n = 7)
16-30 d
(n = 10)
31-45 d
(n = 7)
46-60 d
(n = 4)
>60 d
(n = 6)
Results
page | 105
Figure 28. Representative images of a surgical dysplastic nevi removal. Micrographs show a 
dysplastic nevi lesion (indicated by arrow) before (A) and after (B) the surgical removal, on the 
back of a patient. Two weeks later, the stitches were taken out (C).
To analyze, whether the revealed increase of TAA-reactive memory T cell responses after 
resection over time, occurred as an unspecific response or side effect to the surgical intervention, 
blood samples of the same patients were investigated before and after the surgical removal of a 
lesion. The repeated analysis of the same patient, before and after resection, demonstrated that 
TAA-reactive T cell responses specifically increased, while unspecific responses against control 
IgG did not comparably alter over time (Figs. 29A and B). Furthermore, if an unspecific T cell 
response, caused by the surgical resection, had taken place, ??? ????????? ??? ??????????????????
would had to be ????????????????????????????????????????????????????????????????????????????????
against TAAs and unspecific against IgG) were not elevated, 13 d after resection, compared to the 
??????????????????????????????????????????????????????????????????????????
In addition, autoimmune markers were investigated in the plasma of patients before and after 
resection. Therefore, the anti-nuclear (ANA) and anti-neutrophilic cytoplasmic auto-Abs (ANCA) as 
well as the rheumatoid factor were analyzed. In the case of a positive ANCA analysis, an additional 
test for perinuclear ANCAs (p-ANCA) was performed, against myeloperoxidase (MPO) a target 
antigen of the p-ANCAs. In summary, comparing the values of autoimmune markers before and 
after tumor resection, in none of the tested dysplastic nevi as well as non-metastasized melanoma 
patients, a considerable increase of any autoimmune marker could be detected (Tab. 10).
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Figure 29. TAA- and IgG-reactive T cell responses before and after surgical resection.        
A) Significantly increased tumor antigen-reactive T cell responses developed after the resection, 
???????????????????????????????????????????????????????????????????????????????????????????????????
numbers of TAA-reactive T cells were strongly increased, 64 d but not 13 d, after resection. T cell 
responses against the endogenous control antigen (human IgG) were not comparably altered. B)
Melanoma patient # 57 showed, before and after resection, increased T cell responses against all 
tested 50aa polypeptides. Thereby, the TAA-reactive T cell frequencies strongly further increased 
after resection, while T cell responses against IgG were not altered in a comparable attitude. For 
statistical analysis, an unpaired two-tailed t test was performed. DC, dendritic cells; Mean ± SEM; 
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Table 10. Investigation of plasma autoimmune markers. The plasma of 2 dysplastic nevi 
patients (DPN) and 3 patients with non-metastasized melanoma (MM) were analyzed for the 
alteration of autoimmune markers. The auto-Abs ANA, ANCA, p-ANCA and the rheumatoid factor 
were investigated, before and after surgical resection of the respective lesion. The reference 
ranges of the respective markers are indicated in the headline of the table. Values out of the 
reference range are labeled in green bold numbers. Ab, antibody; MPO, myeloperoxidase; n.d., not 
determined
8.1.9. Analysis of a Treg-dependent control of spontaneous T cell responses 
It has been shown that tumor-directed T cell responses can be affected by regulatory T cells (Treg; 
cf., Wang et al., 2004; Bonertz et al., 2009). Therefore, in a next step, a potential role of Treg in 
controlling spontaneously induced tumor antigen-reactive memory T cell responses, in the PB of 
patients with dysplastic nevi or non-metastasized melanoma, was analyzed.
In order to detect Treg, an intracellular/intranuclear flow cytometry staining for CD3+CD4+CD25+
Foxp3+ T cells was performed. Representative dot plots thereof are shown in Fig. 30A. The 
percentage of Treg in the PB of non-metastasized melanoma patients after primary tumor resection
was comparable to the Treg percentage, in healthy donors (Fig. 30B; median: melanoma 5.0, 
healthy donor 4.6). Furthermore, to investigate a potential contribution of Treg in controlling 
spontaneously induced tumor antigen-reactive memory T cell responses, Treg were depleted from 
the CD3+CD4+ T cell fraction using ?CD25-magnetic beads. The depletion of Treg was performed 
as shown in Fig. 31. Using this protocol, revealed by flow cytometry, the percentage of 
CD25+Foxp3+Treg in the CD3+CD4+ T cell population was strongly reduced. Representative data of 
melanoma patient # 31 showed a reduction of the Treg percentage from 4.66 to 0.89 % (Fig. 31).
reference range:  1:80 titer  <1:10 titer  <9.0 U/ml   <25 IU/ml
time between anti- anti- perinuclear anti-
patient primary resection nuclear neutrophilic neutrophilic rheumatoid
(d0) and PB Ab cytoplasmic cytoplasmic Ab factor
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 d57  1:160 negative n.d.  7.7
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3 (MM) before resection
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Figure 30. Percentage of Treg in the PB of healthy donors and non-metastasized melanoma 
patients after primary tumor resection. The percentage of Treg was determined by flow 
cytometry staining. A) Representative FACS dot plots of melanoma patient # 29 are presented. 
Treg were gated on the basis of CD3+CD4+ cells (left plot, indicated by quadrant) using Abs against 
CD25 and Foxp3 (right plot, indicated by quadrant). The numbers in the dot plots, indicate the 
percentage of the respective cell populations. B) Cumulative percentage of Treg in the PB of 20 
healthy donors (HD) and 12 non-metastasized melanoma patients (MM), after tumor resection. 
Some of the Treg numbers of HD, used for cumulative calculation, were kindly provided by Dr. Y. 
Ge, Unit of Translational Immunology, DKFZ. n, number of HD or MM patients respectively; TC, T 
cells
Figure 31. Depletion of Treg. After ficoll gradient centrifugation, CD3+ T cells were negatively 
isolated. One part, was directly used (TC with Treg) and from the second part, CD4+ and CD8+       
T cells were isolated. CD25+ cells were depleted from the CD4+ fraction (CD4+CD25+ Treg). Finally, 
CD8+ T cells were recombined with CD4+CD25- T cells (TC without Treg). The T cell fractions were 
stained for the presence of CD3+CD4+CD25+Foxp3+ Treg by flow cytometry. The numbers in the 
dot plots indicate the percentage of the respective cell population. Representative data of non-
metastasized melanoma patient # 31 are shown. TC, T cells
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In some of the non-metastasized melanoma patients, the depletion of CD4+CD25+ Treg, from 
the T cell fraction, resulted in a strong increase of TAA-reactive T cell responses, compared to non-
Treg depleted cell populations. For example, in melanoma patient # 9 increased TAA-reactive 
memory T cell responses against Melan-A/MART-1, p53 and Tyrosinase were only detectable, 
after the Treg depletion (Fig. 32). This finding was observed for ~16 % of the investigated patient 
samples. Thereby, preferentially Melan-A/MART-1, p53 and Tyrosinase-reactive T cell responses 
were shown to be suppressed by Treg.
However, in regard to the cumulative data of 36 non-metastasized melanoma patients after 
primary tumor resection, the frequency of spontaneously induced tumor antigen-reactive memory
T cells was not further increased after Treg depletion (Fig. 33). The same finding was observed for 
the cumulative data of all 13 individual 50aa polypeptides (Fig. 34). Thereby, compared to the 
respective total CD3+ non-Treg depleted cell fractions, the cumulative T cell frequencies for all 
tested polypeptides were not further increased after Treg depletion (Fig. 34). In addition, Treg 
depletion did not led to a further increase of cumulative TAA-reactive T cell frequencies at any time 
point, analyzed after tumor resection (Fig. 35). Without Treg depletion, in comparison to healthy 
donors, the cumulative frequencies of TAA-reactive memory T cells were strongly elevated in the 
PB of non-metastasized melanoma patients after resection of the tumor (Fig. 33). 
Figure 32. ??????????????? ????????????? ??????? ??? ?????-metastasized stage IA melanoma 
patient analyzing T cells with and without Treg. Increased tumor antigen-reactive T cell 
responses against 50aa polypeptides could only be detected after Treg depletion from the 
investigated T cell subset of melanoma patient # 9. As controls, single cultures of dendritic cells 
(DC only) as well as T cells with Treg (TC only) and T cells without Treg (TC-Treg only) were 
investigated. For statistical analysis, an unpaired two-tailed t test was performed. DC, dendritic 
cells; ????????????????????????????????????????????????????????????
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Figure 33. Frequency of TAA-reactive T cells with and without Treg depletion in healthy 
donors and non-metastasized melanoma patients. Cumulative data of TAA-reactive memory 
T cell frequencies against the 13 individual polypeptides. The T cell frequencies were analyzed 
without depleting Treg (TC with Treg) as well as with Treg depletion (TC without Treg). The cells of 
36 non-metastasized melanoma patients (MM) as well as 10 healthy donors (HD) were 
investigated. For statistical analysis, an unpaired two-tailed t test was performed. DC, dendritic 
cells; Mean ± SEM; n, number of tests; ????????????????????????????????
In subsequent experiments, the influence of a tumor or pre-malignant lesion on the nature of 
spontaneously induced tumor antigen-reactive memory T cell responses was addressed. 
Therefore, dysplastic nevi and non-metastasized melanoma patients were analyzed for TAA-
reactive T cell responses before and after surgical resection. Before tumor resection, increased 
TAA-reactive T cell responses were present, without depletion of Treg, in melanoma patient # 57 
(Fig. 36). Treg depletion, only marginally increased the tumor-reactive T cell frequencies. After 
tumor resection, the tumor antigen-reactive T cell responses were strongly elevated and a Treg 
depletion did not led to a further increase (Fig. 36). The cumulative data of 3 dysplastic nevi as well 
as 2 non-metastasized melanoma patients showed that TAA-reactive memory T cell responses, 
against the 50aa polypeptides, were already present before resection. Moreover, at this time, a
depletion of Treg did not led to a significant increase of the T cell frequencies. Compared to healthy 
donors, the T cell frequencies of both patient cohorts were clearly elevated (Fig. 37). After surgical 
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resection, TAA-reactive memory T cell frequencies were shown to be increased, compared to the 
frequencies, measured before resection. Whereas, an additional increase of T cell frequencies in 
response to Treg depletion was not observed (Fig. 37).
Figure 34. Recognition of the 13 individual polypeptides by T cells of non-metastasized 
melanoma patients with and without Treg depletion. Autologous dendritic cells were pulsed 
with melanoma polypeptides and a co-culture with autologous T cells was performed. Thereby,     
T cell fractions with (circles) and without Treg (squares) were analyzed in parallel. The cumulative 
data of 36 non-metastasized melanoma patients is displayed and only significantly increased T cell 
responses are shown, compared to the human IgG control. The frequencies of TAA-reactive 
memory T cells for the individual polypeptides are not elevated after depletion of Treg. TC, T cells
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Figure 35. Frequency of spontaneously induced TAA-reactive T cells with and without Treg 
depletion, in non-metastasized melanoma patients after primary tumor resection, over time.
The frequency of TAA-reactive memory T cells is increased, after primary tumor resection up to 
d60, in 36 non-metastasized melanoma patients (gray columns). The depletion of Treg did not 
further increase the frequency of tumor-reactive memory T cells (black columns). The TAA-reactive 
T cell frequencies represent the cumulative data, from the T cell frequencies, against the 13 
individual 50aa melanoma polypeptides. For the cumulative analysis, the significant increased 
individual T cell frequencies per analyzed peptides in response to the human IgG control were 
used. TC, T cells
Figure 36. TAA-reactive T cell responses with and without Treg depletion before and after 
surgical resection. ?????????????????????????????????????????????????????????????????????????????
spot numbers after Treg depletion, before but not after resection of the primary tumor. As controls, 
single cultures of dendritic cells (DC only) as well as T cells with Treg (TC only) and T cells without 
Treg (TC-Treg only) were investigated. For statistical analysis, an unpaired two-tailed t test was 
performed. DC, dendritic cells; ????????????????????????????????????????????????????????????????????
????????????
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Figure 37. Frequency of TAA-reactive T cells with and without Treg depletion, in dysplastic 
nevi and non-metastasized melanoma patients, before and after surgical resection. ?????????
ELISPOT data of 3 dysplastic nevi (DPN) and 2 non-metastasized melanoma (MM) patients, before 
and after resection is shown. Moreover, the data of 10 healthy donors (HD) are depicted. Before 
the resection of the lesion, the frequency of TAA-reactive memory T cells was clearly elevated in 
DPN or MM, compared to HD. The depletion of Treg did not significantly increase the T cell 
frequency in both patient cohorts. The blood of the same patients was investigated for a second 
time on d45, d46, d57 or d64. After surgical resection, the tumor-specific T cell frequencies were 
increased, compared to the obtained responses, before resection. A depletion of Treg had no 
additional impact. The TAA-reactive memory T cell frequencies represent the cumulative data, from 
the individual T cell frequencies against the 50aa melanoma polypeptides Melan-A/MART-1, NA17-
A, Tyrosinase, p53 and MDM2. For the cumulative analysis, the significant increased individual 
T cell frequencies per analyzed peptides, compared to the human IgG control were used. For 
statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, number of tests; 
???????????????????????????????????????????????????
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8.1.10. Antigen-specific Treg in melanoma and dysplastic nevi patients
A Treg specificity assay on the basis of a [3H]-Thymidine uptake was performed to investigate 
whether CD4+CD25+ Treg, that were depleted (see, e.g., 8.1.9.) from the CD3+CD4+ T cell fraction,
contained antigen-specific Treg. The percentage of CD3+CD4+CD25+Foxp3+ Treg in the depleted 
cell fraction was determined by flow cytometry. A representative staining of melanoma patient # 43 
showed that the depleted cell population consisted of pure CD3+CD4+ T cells of which more than 
60 % revealed a CD25+Foxp3+ Treg phenotype (Fig. 38). 
Figure 38. Percentage of CD4+CD25+Foxp3+ Treg in the CD4+CD25+ depleted T cell fraction.
The percentage of Treg was determined by flow cytometry staining. Representative FACS dot plots 
of melanoma patient # 43 are presented. The left plot shows the gating strategy for CD3+CD4+       
T cells (indicated by quadrant). Treg were gated on the basis of CD3+CD4+ cells using Abs against 
CD25 and Foxp3 (right plot). The quadrant in the right plot indicates the population of 
CD4+CD25+Foxp3+ Treg among CD3+ T cells from the CD4+CD25+ depleted cell fraction (cf.,
Fig. 31). The numbers in the dot plots indicate the percentage, of the respective cell population. 
TC, T cells
To test, whether in dysplastic nevi or non-metastasized melanoma patients the depleted 
CD4+CD25+ cell fractions contained antigen-specific Treg, depleted cells were antigen-specifically 
activated. Therefore, autologous dendritic cells were pulsed with polypeptides of melanoma TAAs 
or human IgG. Afterwards, CD3 polyclonally activated autologous T cells, depleted from Treg (TC 
without Treg) were added and the T cell proliferation was examined. Thereby, the T cell 
proliferation in the context of peptide-stimulated Treg was analyzed, compared to the total T cell 
proliferation obtained from the co-culture of dendritic cells with polyclonally activated Treg-depleted 
T cells (Figs. 39A-C; DC + aTC). Before resection of the lesion, for both cohorts, the T cell 
proliferation was significantly controlled by peptide-stimulated Treg, either TAA-specific (Melan-
A/MART-1, Tyrosinase, p53, MDM2) or TAA-unspecific (human IgG, unpulsed dendritic cells). 
Moreover, compared to the unpulsed dendritic cell setting, antigen-specific Treg were detected for 
Melan-A/MART-1, Tyrosinase, p53 and human IgG (Figs. 39A-C; no polypeptide).
After resection, the T cell proliferation was no longer controlled in comparison to the unpulsed 
dendritic cell setting. Compared to the total T cell proliferation, measured in the co-culture of 
dendritic cells with polyclonally activated Treg-depleted T cells, a Treg-dependent control of T cell 
proliferation was only marginally detected for p53 and human IgG, (Fig. 39). However, in none of 
the performed Treg specificity assays, specific Treg for NA17-A were detected (Figs. 39A-C).
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Figure 39. Control of T cell proliferation by TAA or IgG-specific Treg. The detailed figure 
legend is presented on the next page.
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Figure 39. Control of T cell proliferation by TAA or IgG-specific Treg. The proliferation of 
polyclonally activated Treg-depleted T cells was analyzed in the context of CD4+CD25+ Treg in 
dysplastic nevi (DPN; A) and non-metastasized melanoma (MM; B) patients, before (left column) 
and after (right column) surgical resection. Treg were stimulated with 50aa polypeptides (dark gray 
bars) or human IgG (light gray bars), loaded to autologous dendritic cells. C) Combined T cell 
proliferations of DPN and MM patients are shown. The reduction in T cell proliferation, calculated 
compared to the total proliferation (magenta bars; DC + aTC; magenta p values) and to an
unpulsed dendritic cell approach (white bars; DC/no polypeptide + Treg + aTC; black p values). For 
statistical analysis, an unpaired two-tailed t test was performed. ????? ????-polyclonal activated     
T cells; DC, dendritic cell; Mean ± SEM; n, number of tests; ??????????????????????????????????????????
???????????????????????????
8.1.11. Analysis of T cell co-depletion during Treg depletion 
After depletion of CD4+CD25+ Treg from the CD3+ T cell fraction of non-metastasized melanoma 
patients, the cumulative data showed that frequencies of TAA-reactive T cells were not increased. 
Moreover, the depletion led to a reduction of tumor antigen-reactive T cell frequencies (see also, 
Figs. 33-35). In addition, after Treg depletion, the CD4+CD25+Foxp3- T cell fraction was reduced 
from 5.13 % to 2.59 %, as exemplarily shown for melanoma patient # 31 (Fig. 31). 
To investigate whether conventional T cells were co-depleted during Treg depletion, the 
depleted cell fractions were analyzed by flow cytometry using Abs specific for CD3, CD4, CD25, 
Foxp3 and CD127. Effector and memory T cells express CD127 whereas Foxp3+ Treg are negative 
(cf., Liu et al., 2006). The FACS staining revealed that CD4+CD127+Foxp3- cells (Fig. 40; 
exemplarily ~22 % for melanoma patient # 43) were co-depleted besides CD4+CD25+Foxp3+ Treg 
(Fig. 40; exemplarily ~64 % for melanoma patient # 43). This observation was representative for six 
individual samples, of investigated CD4+CD25+ Treg-depleted fractions of independent patients.
Figure 40. Co-depletion of CD4+CD127+Foxp3- T cells during Treg depletion. The percentage 
of Treg and T cells was determined in the depleted cell fraction by flow cytometry. Representative 
dot plots of melanoma patient # 43 are presented. The upper left plot shows the gating for 
CD3+CD4+ T cells (quadrant). Treg were gated on the basis of CD3+CD4+ cells using Abs specific 
for CD25 and Foxp3 (upper right plot). The gated Treg population is negative for CD127 (lower 
right plot). The lower left plot indicates CD127+Foxp3- conventional T cells and CD127-Foxp3+
Treg. The numbers indicate the percentage of the respective cell populations. Approximately 64 % 
Foxp3+ Treg and 22 % conventional CD127+ T cells were present in the depleted cell fraction.
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8.1.12. Summary on spontaneous human tumor antigen-reactive T cell responses 
Spontaneously induced tumor antigen-reactive T cells occur in the PB of non-metastasized and 
metastasized melanoma as well as dysplastic nevi patients. TAA-reactive T cell responses against 
the 13 generated 50aa melanoma polypeptides (GAGE-1, gp100/pmel17, MAGE-A1, MAGE-C2, 
MDM2, Melan-A/MART-1, MIF, NA17-A, NY-ESO-1, p53, RAB38/NY-Mel-1, TRP2, Tyrosinase)
were detected in the majority of non-metastasized and metastasized melanoma patients. 
Compared to healthy donors, the observed TAA-reactive memory T cell frequencies were strongly 
increased in melanoma and dysplastic nevi patients. Thereby, the responses after surgical 
resection in both cohorts were elevated. The TAA-recognition pattern of melanoma T cells was 
highly polyvalent and independent of the patients HLA-type. HLA-A2+ and HLA-A2- patients 
recognized the polypeptides, that cover MHC class I- and II-restricted epitopes, in a similar 
manner. Furthermore, CD4+ and CD8+ T cells of the same patient responded to the designed 
polypeptides. Frequencies of TAA-reactive T cells of non-metastasized melanoma patients strongly 
increased after primary tumor resection over time. The percentage of Foxp3+ Treg in the PB of non-
metastasized melanoma patients after tumor resection was comparable to the Treg percentage 
observed in healthy donors. In some patients, a depletion of Treg resulted in an increase of TAA-
reactive T cell frequencies. Moreover, antigen-specific Treg for Melan-A/MART-1, p53, Tyrosinase 
and MDM2 have been detected in the PB of melanoma and dysplastic nevi patients. Finally, the 
cumulative data of the melanoma cohort revealed that a Treg depletion did not led to an additional 
increase of tumor-reactive T cell frequencies.
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8.2. In vivo efficiency of optimized TCR transgenic human T cells in a 
xenotransplantation model
Human T cells equipped with tumor antigen-reactive T cell receptors (TCRs) for the antigens 
MDM2 or gp100 have been optimized in vitro, in order to avoid hybrid TCR formation of 
exogenously introduced and endogenous TCR ??? chains. Those hybrid TCRs have unknown 
specificities and thus could potentially result in autoimmune reactions. 
Therefore, the group of Dr. R.-H. Voss developed different strategies to avoid the formation of 
hybrid TCRs while favoring preferential pairing of introduced chains. In a cooperation project, 
during this PhD thesis, those optimized TCR transgenic T cells with specificities for MDM2 or
gp100 were investigated under in vivo conditions, concerning their ability to control tumor growth.
8.2.1. The establishment of the human melanoma murine xenotransplantation model
Since the human TCR transgenic T cells were generated to specifically recognize the antigens 
MDM2 or gp100, human MDM2+ and gp100+ cell lines, have to be used as target lines for the 
xenotransplantation model. Therefore, several human primary and metastasized melanoma-
derived cell lines were investigated beforehand, concerning their specific tumor antigen expression. 
The origins of the seven different melanoma cell lines analyzed are indicated in Tab. 11. 
To examine the presence of selected tumor antigens (gp100, Melan-A/MART-1, MDM2, p53, 
Tyrosinase and L1CAM), for all cell lines SDS-PAGE followed by immunoblot analyses were
performed. Thereby, the equal amounts of proteins of the respective cell lines were demonstrated 
by the presence of actin. Summarized, the cell lines Malme-3M, MeWo and SK-Mel-23 comprised 
all tumor markers investigated (Fig. 41). As control, the human osteosarcoma cell line U2OS and
the human breast-adenocarcinoma line MCF-7 were examined. Both cell lines revealed to be 
negative for the melanoma TAAs gp100 and Melan-A/MART-1. The developmental origin of the 
melanoma cell lines was controlled by analyzing the intermediate-sized filaments vimentin (for 
mesenchymal-derived origin) and the keratins 8 and 18 (for epithelial-derived origin). While all 
melanoma cell lines were positive for vimentin and negative for the keratins 8 and 18, the MCF-7
cells were keratin-positive and vimentin-negative. However, due to some subclones, the 
osteosarcoma line U2OS revealed both, vimentin and also minor amounts of the keratins 8 and 18-
positive cells (Fig. 41).
In addition, since the TCRs used for T cell transduction only recognize peptides presented by 
HLA-A2 molecules, the HLA-A2 expression of the melanoma cell lines was analyzed by flow 
cytometry. The cell lines Malme-3M, MeWo, SK-Mel-23 and WM-266-4 were HLA-A2+, whereas 
WM-115 revealed to be HLA-A2- (Fig. 42). Here, the presence of HLA-A2 for the cell lines C32 and 
SK-Mel-2 was not analyzed in detail. However, their HLA-A2 expression has well been described in 
the literature. C32 cells were shown to be HLA-A2+ (Butler et al., 2007) and SK-Mel-2 cells to be 
HLA-A2- (von Bergwelt-Baildon et al., 2002).
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Human melanoma Origin
cell lines
Malme-3M metastasis, lung
C32 primary melanoma, skin
WM-115 primary melanoma, skin
WM-266-4 metastasis, skin
MeWo metastasis, lymph node
SK-Mel-23 metastasis, skin
SK-Mel-2 metastasis, skin
Table 11. Origins of the human melanoma cell culture lines analyzed. The two melanoma cell 
lines C32 and WM-115 are derived from primary melanoma whereas Malme-3M, WM-266-4, 
MeWo, SK-Mel-23 and SK-Mel-2 cells are derived from melanoma metastasis (see also Bean et 
al., 1975; Carey et al., 1976; Lang et al., 2001; Schmitt et al., 2007).
In order to investigate the engraftment and tumor formation of human melanoma cell lines in 
NOD-SCID mice in vivo, the cell lines Malme-3M, MeWo and SK-Mel-23 were selected. On the one 
hand, all three cell lines were HLA-A2+, on the other hand, they expressed the complete panel of 
selected tumor antigens investigated, in particular MDM2 and gp100, the target antigens of the 
TCR transgenic T cells. Therefore, the cells of the respective lines (2.5x106 cells resuspended in 
50 μl matrigel) were administered intradermally (i.d.) to the right murine flank. The tumor growth 
was then investigated using a caliper over time up to d50. As control approach, in parallel, 50 μl 
matrigel without cells was examined. The matrigel degraded in vivo and did not increase in volume 
over time. From d20 on, no further matrigel could be measured (Fig. 43). 
However, the cell lines MeWo and SK-Mel-23 showed a strong tumor growth over time whereas 
the tumor formation of the slowly growing Malme-3M cells did not measurable increase (Fig. 43). 
SK-Mel-23 cells grew aggressively, since 2 mice from this group died ahead of time by d31 and
d44, respectively. In contrast, the tumor formation that resulted from the MeWo cells strongly 
increased over time, without premature decrease of mice (Fig. 43). On d50, all remaining mice 
were sacrificed by cervical dislocation and visually investigated for potential metastases formation.
In addition, the tumor and the lung of each mouse were removed for further investigations. The 
determined weights of the MeWo and SK-Mel-23 tumors were strongly increased compared to the 
Malme-3M tumors (insert in Fig. 43). Furthermore, no metastases formation could be visually
detected for mice that received MeWo or Malme-3M cells, whereas inguinal tumor-draining lymph 
node metastases were detected in both remaining mice that had received SK-Mel-23 cells (Fig. 
44). Using picrinic acid containing Bouin´s solution, in none of the mice in which Malme-3M, MeWo 
or SK-Mel-23 cells had been injected, lung metastases could be observed.
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Figure 41. Protein immunoblot detection of various human melanoma cell lines. Equal 
amounts of total proteins from seven melanoma lines (Malme-3M, C32, WM-115, WM-266-4, 
MeWo, SK-Mel-23, SK-Mel-2) were examined, in comparison to human osteosarcoma (U2OS) and
human breast-adenocarcinoma cells (MCF-7). PVDF-membranes were probed with Abs specific for 
tumor antigens (gp100, Melan-A/MART-1, MDM2, p53, Tyrosinase, L1CAM), intermediate-sized 
filaments (vimentin, keratins 8+18) and actin. Tumor antigen gp100 is present in Malme-3M, 
MeWo, SK-Mel-23 and SK-Mel-2, whereas Melan-A/MART-1 is additionally expressed in C32 cells.
Varying amounts of MDM2, p53, Tyrosinase and L1CAM are present in all cells. However, MDM2 
is lacking in SK-Mel-2 and L1CAM in C32 cells. Note also the positivity of vimentin in all cells, 
except of MCF-7, which are instead positive for keratins 8 and 18. Molecular weight markers in kDa 
are indicated on the left margin. For Melan-A/MART-1 two different Ab clones were used (Thermo 
Fisher Scientific: Melan-A/MART-1; Dako: Melan-A/MART-1*).
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Figure 42. Flow cytometry analysis of the HLA-A2 presence in various human melanoma cell 
lines. The cells of the lines Malme-3M (A), MeWo (B), SK-Mel-23 (C) and WM-266-4 (D) were 
analyzed using flow cytometry and revealed to be HLA-A2+ whereas WM-115 cells (E) were HLA-
A2-. As positive control cells of the line MCF-7 (F) and as negative control cells of the human T cell 
leukemia line Jurkat, over-expressing CD28, (JCD28; G) were used.
Figure 43. Engraftment and tumor formation of human melanoma cell lines in vivo after i.d. 
injection into NOD-SCID mice. Resuspended in 50 μl matrigel, 2.5x106 cells of the melanoma 
lines SK-Mel-23 (green), MeWo (orange) or Malme-3M (blue) were injected i.d. onto the right flank
of NOD-SCID mice. The tumor growth was measured over time up to d50. As control setting,
matrigel without cells (grey) was examined. In contrast to Malme-3M cells, a tumor formation over 
time was detected for MeWo and SK-Mel-23 cells. The insert, in the upper left corner, indicates the 
tumor weight, resulted from the respective melanoma cells, after tumor removal on d50. For 
statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, number of mice; 
????????????????
Malme-3M
MCF-7
MeWo SK-Mel-23
WM-115
WM-266-4
JCD28
m?h HLA-A2 + g?m IgG-FITC
PI negative cells
PI negative cells + g?m IgG-FITC 
PI negative cells + m?h HLA-A2 + g?m IgG-FITC 
A B C D
E F G
m?h HLA-A2 + g?m IgG-FITCm?h HLA-A2 + 
g?m IgG-FITC
0 3 8 15 20 23 27 31 34 38 41 44 48 50
0
100
200
300
400
500
600
MeWo (n = 4)
SK-Mel-23 (n = 4-2)
Malme-3M (n = 2)
Matrigel (n = 1)
tu
m
or
 v
ol
um
e 
(m
m
3 )
days after tumor cell inoculation
SK
-M
el-
23
Me
wo
Ma
lm
e-3
M
Ma
tri
ge
l
0
200
400
600
800
* (0.02)
* (0.02)
tu
m
or
 w
ei
gh
t o
n 
d5
0 
(m
g)
Results
page | 122
Figure 44. Lymph node metastases formation of SK-Mel-23 cells in NOD-SCID mice. SK-Mel-
23 tumor-bearing NOD-SCID mice, after i.d. tumor cell injection, were sacrificed on d50 and
showed metastases in the inguinal tumor-draining lymph nodes. The primary formed tumor and the
lymph node metastasis of one mouse are depicted before (A) and after (B) opening of the 
abdominal skin. In C), the SK-Mel-23 tumor and lymph node metastasis of a second mouse is 
shown. The primary tumors are indicated by arrows, the inguinal tumor-draining lymph node 
metastasis by arrowheads.
For subsequent experiments, as tumor target cell line for the murine xenotransplantation model, 
the MeWo cell line has been selected, since cells of this line displayed a reproducible engraftment 
and tumor formation in NOD-SCID mice in vivo over time, without leading to the death of the mice. 
Moreover, the MeWo cells were shown to be positive for MDM2, gp100 and HLA-A2. To verify the 
presence of MDM2 and gp100 on MeWo cells, as shown by immunoblot investigations              
(cf., Fig. 41), immunofluorescence microscopy was performed. These stainings also showed that 
MeWo cells were positive for MDM2 and gp100 (Fig. 45). The cell lines MCF-7 and U2OS were 
used for control stainings. Thereby, MCF-7 cells were positive for MDM2 and negative for gp100
whereas U2OS cells were generally negative for both markers. However, the U2OS cell line
revealed some distinct cell clones that were positive for MDM2 (Fig. 45).
To investigate, how the different approaches of MeWo cell administration influence the tumor 
formation in vivo, 2.5x106 MeWo cells were resuspended in PBS and injected either 
intraperitoneally (i.p.), intravenously (i.v.) or subcutaneously (s.c.). Between d35 and d42 after cell 
inoculation, the mice were sacrificed by cervical dislocation and examined for tumor metastases
formation. NOD-SCID mice that received MeWo cells i.p. developed metastases throughout the 
entire abdominal cavity, preferentially in the lymph nodes, the spleen and the intestine as well as 
showed pleural effusions, hemorrhagic ascites and organ fusions (left column in Fig. 46). 
Moreover, when MeWo cells were injected i.v., metastases could be detected particularly in the 
lung and in the intestine (right column in Fig. 46). Lung metastases, that developed after i.v. 
injection, were stained with Bouin`s solution and are exemplarily shown in Fig. 47B. Furthermore, 
the administration of tumor cells s.c., did not lead to visible metastases formation. But, compared to 
i.d. application, the tumor formation in mice that received the cells s.c. was not defined as clearly 
as in the i.d. injection setting. This would most likely complicate a reliable measurement of the 
tumor with a caliper. Therefore, for subsequent experiments of the murine xenotransplantation 
model, the MeWo cells were i.d. injected.
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Figure 45. Immunofluorescence microscopy of MDM2 and gp100 in MeWo cells. Immuno-
fluorescense microscopical images of MeWo, MCF-7 and U2OS cells are presented. MeWo cells 
show a strong nuclear staining of MDM2 and gp100 in the cytoplasm (both in red). MCF-7 cells 
revealed positive for MDM2 and negative for gp100. U2OS cells do not express MDM2 and gp100. 
However, some single cell clones were MDM2-positive. DAPI (blue) was used to show the cell 
nuclei and the phase contrast picture to present the cell morphology. Bars represent 20 µm. 
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Figure 46. Metastases formation of MeWo cells after in vivo i.p. or i.v. cell injection.
Representative pictures of mice that received 2.5x106 MeWo cells, resuspended in PBS i.p. (left 
column) or i.v. (right column). The presented i.p. treated mouse was sacrificed on d42 and the i.v. 
treated mouse on d36 after MeWo cell injection. The lower micrographs show metastasized murine 
organs of the respective mice, including intestine and lung.
Figure 47. Lung metastases staining with Bouin`s solution. A) Lung without metastases 
formation. The mouse received MeWo cells i.d. and was sacrificed on d38 after tumor cell injection,
followed by an examination of the lung for metastases. B) Lung with metastases formation. The 
used mouse received MeWo cells i.v. and was prepared on d35 after injection, before the lung was 
analyzed for metastases.
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8.2.2. The production of optimized MDM2 or gp100 TCR transgenic human T cells
TCR transgenic T cells with specificities for MDM2 or gp100 were applied for adoptive transfer 
experiments using the murine xenotransplantation model. In order to avoid hybrid TCR formation 
between exogenous and endogenous TCRs, the TCR constructs, used for T cell transduction, were
optimized by the group of Dr. R.-H. Voss.
The MDM2 (81-88)-specific TCR, is a mouse-derived TCR originally generated in a partially 
humanized HLA-A2.1 transgenic mouse model (Stanislawski et al., 2001). ??????????? genes have
been isolated from murine MDM2 specific T cell clones and were cloned into a retroviral vector 
system. Using these retroviral plasmids, human T cells can be transduced with the MDM2 TCR 
genes. To promote TCR chain pairing of the introduced MDM2 TCRs, reciprocally mutant TCRs 
have been generated. Therefore, a pair of interacting amino acid residues, located in the core 
MDM2 TCR C-domain interface, Gly-85.1C? and Arg-88C?, was reciprocally replaced in order to 
swap the steric and electrostatic relationship (reciprocal mutation C?-Arg/C?-Gly; for further details 
see Voss et al., 2008). Moreover, the molecular design of the C?? interface was further optimized 
by changing the side chain volume, charge and H-bonding. One of the most promising constructs 
revealed through functional in vitro investigations, appeared to be the reciprocal mutation            
C?-Lys/C?-Gly. Moreover, to prove antigen-specific recognition of MDM2 TCR transduced T cells 
in vivo, further constructs with ?????????? ??????????????????????????????????????were developed 
(Dr. R.-H. Voss). The mutations sustained the TCR surface expression, but abolished the avidity of 
the TCR. All MDM2 TCR constructs, investigated concerning their in vivo tumor growth control, are 
summarized in Fig. 48.
Figure 48. MDM2 TCR constructs used for retroviral transduction of human T cells. A) The 
murine dc Wt MDM2 TCR sustains in the core C-domain interface the Gly-85.1C? and Arg-88C?
pair of interacting aa residues. B) and C) In order to favor chain pairing of introduced TCRs, two 
optimized reciprocally mutated MDM2 TCR constructs were analyzed (B, Gly-85.1C?-Arg/Arg-
88C?-Gly; C, Gly-85.1C?-Lys/Arg-88C?-Gly). D) and E) Two control MDM2 TCR constructs with aa
mutations in the CDR3 region of t??? ???? ?? ??????? sustained TCR surface expression but with
abolished avidity (D, CDR3 mutation Trp-109C?-Ala; E, CDR3 mutation Gly-113C?-Val).
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Performing a different strategy, compared to the optimized MDM2 TCRs, the human A2.1-
restricted gp100 (280-288)-specific dc TCR (Schaft et al., 2003) was also modified in order to avoid 
hybrid dimer TCR formation. Therefore, a 3-domain single chain (sc) TCR was constructed 
??????????? ???? ????????? ?? ????? ??????? ??? ???? ???? ?? ????? (Voss et al., 2010). Moreover, to 
increase the stable expression on the cell surface, the sc construct was further optimized by 
?????????? ??????????????????????? ??????????????? ?????????????????????, consisting of the signal 
peptide and the C? domain was generated and co-expressed. To additionally increase the chain 
pairing, an artificial disulfide bond was introduced between C? and C?. Furthermore, since it could 
be shown that introduced murine TCR constructs are functional in human T cells and even more 
efficiently expressed (Sommermeyer et al., 2006), chimeric TCRs were generated for gp100,
replacing the human C? and C? domains by constant murine domains. 
Using the retroviral pBullet vector system, the optimized gp100 constructs were introduced into 
human T cells, as mentioned for the MDM2 TCR constructs. All gp100 TCR constructs that were 
investigated are presented in Fig. 49..
Figure 49. gp100 TCR constructs used for retroviral transduction of human T cells. The 
human dc Wt TCR gp100 (A) and 3 scTCR gp100 constructs (B-D) were analyzed. The scTCR 
was constructed by connecting the variable V? domain to the TCR ? chain (B-D). To provide the 
missing C? domain, a truncated TCR ? was co-expressed (C-D). To further increase the interchain 
binding, an artificial disulfide bond (indicated in red) was integrated between the C? and C? (D). All 
scTCR constructs are chimeric molecules, since their C domains are of murine and their V domains 
of human origin (B-D).
In order to investigate the ability to control tumor growth, the optimized MDM2 or gp100 TCR 
transduced T cells were analyzed during this thesis in the murine melanoma xenotransplantation 
model in vivo. Therefore, the utilized TCR transgenic T cells were either produced by Dr. R.-H. 
Voss or single handedly (cf., 6.10. for further informations about the used constructs and 7.3.9. 
about the TCR transgenic T cell generation procedure). Beforehand, using flow cytometry, 
ELISPOT and 51Cr release assays, all Wt and optimized MDM2 or gp100 TCR constructs were 
tested for their functional expression on the human transgenic T cells.
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The majority of the transgenic PBMCs showed a phenotype of CD3+ T cells, which were 
preferentially CD8+ (Fig. 50). During in vitro cell expansion, the CD4+ / CD8+ T cell ratio shifted 
towards CD8+ cells, however, also CD4+ transduced T cells remained in the cultures (Fig. 50).
Using a retroviral EGFP carrying reporter plasmid, the retroviral transduction efficiency was 
controlled. Shortly after transduction, only a marginal percentage of cells were EGFP-positive 
(Fig. 51A). In contrast, after drug selection and cell expansion, the EGFP positivity of the 
transduced cells was >97% (Fig. 51B). 
Figure 50. Representative FACS staining of cell subsets after TCR transduction, drug 
selection and expansion of human bulk PBMCs. To investigate the transgenic cell phenotype, 
the cells were analyzed by flow cytometry after TCR transduction, drug selection and expansion 
using direct labeled Abs (CD3-PE, CD8-FITC, CD4-FITC, CD14-PE). The transduced cells were 
mainly CD3+ T cells, whereas more CD8+ than CD4+ T cells and no CD14+ monocytes could be 
detected. Representative cumulative data of 4 PBMC transduction approaches are indicated. Mean 
± SEM
Figure 51. Retroviral transduction efficiency of EGFP transgenic T cells. EGFP transduced 
T cells, before (A) and after (B) drug selection and cell expansion, compared to Mock transgenic 
(tg) T cells. The upper dot plot panel indicates the EGFP-positive cells against the 2nd channel 
(FL2-H). The lower panel shows the same EGFP data blotted against the forward scatter (FSC-H). 
The magenta numbers in the dot plots indicate the percentage of EGFP-positive cells. Shortly after 
transduction ~2 % of the T cells were EGFP-positive, while after drug selection and expansion the 
EGFP positivity was >97 %. TC, T cells
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In addition, the expression of the transduced TCRs on the cell surface was investigated by flow 
cytometry and tetramer staining for the V? chains. Representative flow cytometry data of MDM2 
and gp100 transgenic T cells are shown in Fig. 52. Almost all human MDM2 TCR transduced T 
cells were positive for the V?? 6 subfamily domain of this receptor and bound MDM2 tetramers
(Fig. 52A). Moreover, human gp100 TCR transduced T cells were positive for the V? 14 subfamily 
domain and bound gp100 tetramers (Fig. 52B).
Analyzed by 51Cr release assays, the transduced MDM2 and gp100 transgenic T cells showed a 
cytolytic function. The transduced T cells were able to specific lyse T2 target cells, loaded with the 
associated peptides (Figs. 53A and B). Mu Wt TCR MDM2 and Mu Mt Arg/Gly TCR MDM2 
transduced T cells efficiently recognized MDM2 peptide-loaded T2 cells, showing an equivalent 
cytolytic activity, while T2 cells loaded with irrelevant gp100 peptide were not recognized          
(Fig. 53A). Furthermore, Hu Wt TCR gp100 and Hu Chim scTCR gp100 MuC? S79C + MuC? T84C 
transduced T cells efficiently and comparably recognized gp100 peptide-loaded T2 cells. In 
contrast, T2 cells loaded with irrelevant MDM2, p53 or HIV-pol peptides were not recognized by Hu 
Chim scTCR gp100 MuC? S79C + MuC? T84C transduced T cells (Fig. 53B). Compared to Wt 
TCR MDM2 or gp100 transduced T cells, optimized MDM2 and gp100 TCR transduced T cells 
showed an equivalent cytolytic activity (Figs. 53A and B). Moreover, the lysis of gp100, MDM2, p53 
or HIV-pol peptide-loaded T2 cells was not observed by Mock transduced T cells (Fig. 53B).
Figure 52. Expression and tetramer avidity of MDM2 or gp100 TCRs on human T cells.
A) Mock, Mu Wt TCR MDM2 and Mu Mt Arg/Gly TCR MDM2 transduced human T cells were 
tested for V? 6 expression and for binding of tetrameric MDM2 (81-88)-A2.1 complexes by flow 
cytometry. B) Mock, Hu Wt TCR gp100 and Hu Chim scTCR gp100 MuC? S79C + MuC? T84C 
transduced human T cells were investigated for V? 14 expression and tetramer gp100 (280-288)-
A2.1 binding. The blue numbers depict the combined percentages of positive cells, among all CD8+
and CD8- cells concerning V? staining or tetramer binding.
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Figure 53. Cytolytic effector functions of MDM2 or gp100 TCR transduced human T cells.   
A) Cytotoxicity of human T cells transduced with MDM2 TCR constructs towards MDM2 peptide-
pulsed T2 cells at the indicated T cell:target cell ratios. As control setting, T2 cells pulsed with the 
irrelevant gp100 peptide were analyzed. B) Cytotoxicity of human T cells transduced with gp100 
TCR constructs towards gp100 peptide-pulsed T2 cells at the indicated T cell:target cell ratios. As 
control settings T2 cells pulsed with the irrelevant MDM2, p53 or HIV-pol peptides were 
investigated. TC, T cells
The phenotype of Hu Chim scTCR gp100 MuC? S79C + MuC? T84C transduced T cells was 
investigated by flow cytometry, at the time point of i.v. injection. These transduced T cells revealed 
to be CCR7-CD45RO+CD62L- and thus showed an effector memory-like phenotype, whereas more 
than 35 % of the cells were CD27+ (Fig. 54). In order to investigate their potential to control tumor 
growth, various TCR transduced T cells were tested in vivo in immunodeficient mice, priorily 
engrafted with melanoma cells of line MeWo. After tumor growth onset, the transduced T cells were 
i.v. injected. The precise time schedule of the utilized murine xenotransplantation model is shown 
in Fig. 55.
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Figure 54. Representative flow cytometry staining of TCR transduced T cells used at i.v. 
injection. The phenotype of Hu Chim scTCR gp100 MuC? S79C + MuC? T84C transduced T cells 
was analyzed by flow cytometry. The upper plots show that the transduced cells are CD62L-. The 
lower left plot indicates the gated population, shown in the upper right plot and demonstrates the 
expression of CD45RO and CCR7. The transduced T cells revealed an effector memory phenotype 
(CCR7-CD45RO+CD62L-). More than 35 % of these cells were CD27+ (lower right plot), that 
indicates functional effector memory T cells. The numbers in the dot plots show the percentage of 
the respective cell populations.
Figure 55. Experimental setting of the murine xenotransplantation model. A) Application of
the primary tumor: Mice were engrafted i.d. with cells of the line MeWo (blue arrows), resuspended 
in 50 μl matrigel on d0. TCR transgenic T cells were adoptively transferred i.v. on d7 and the tumor 
growth was measured over time. B) Application of the secondary tumor: In some mice the primary 
tumor was removed and the wound closed. Two days later a secondary tumor (blue arrow) was 
injected to the left flank of the same mice and the tumor growth also analyzed over time.
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8.2.3. Human melanoma growth in mice treated with MDM2 TCR transgenic T cells
The established murine xenotransplantation model was then used, to determine the ability of 
human T cells, transduced with various MDM2 (81-88)-specific TCRs, to control tumor growth of 
HLA-A2+MDM2+ MeWo cells in NOD-SCID mice. Therefore, 2.5x106 cells of the human melanoma 
cell line were injected on the right flank. Seven days later, the mice were treated with MDM2 TCR 
transgenic T cells (mean 1.8x106 cells). Thereby, up to three independent adoptive transfer 
experiments with those T cells were performed using 40 individual mice in total.
The cumulative data of the independent approaches are shown in Fig. 56. Mice that received 
PBS or Mock transduced T cells revealed a continuous tumor growth over time, comparable to
mice that were treated with control MDM2 TCR transduced T cells. Those TCR constructs were 
expressed but showed a reduced TCR avidity, caused by mutations in the CDR3 region of the TCR
???????? Therefore, the TCRs were restricted in MDM2 epitope recognition, which resulted in an 
uncontrolled continuous tumor growth over time (Fig. 56A). In contrast, compared to the control 
approaches, mice that were treated with high avidity MDM2 TCR specific T cells, showed a 
melanoma tumor growth control over time (Fig. 56A). In summary, the control of melanoma growth 
was emerged for all specific MDM2 TCR constructs. Wt TCR MDM2 and both optimized mutant 
TCR constructs led to a comparable controlled tumor growth whereas the strongest control was 
received using optimized Mu Mt Arg/Gly TCR MDM2 transgenic T cells. Thereby, the tumor growth 
was reduced compared to Mock, PBS, Mu Mt TCR MDM2 CDR3 W109A and G113V treated mice 
(Fig. 56B). Furthermore, the tumor growth of Mu Wt TCR MDM2 processed animals was
decreased in comparison with the mice that received the TCR CDR3 W109A construct (Fig. 56B). 
Moreover, the ability of MDM2 TCR transgenic T cells to control tumor growth over time could 
be demonstrated more precisely, comparing the combined tumor growth of mice that either 
received MDM2 TCR specific T cells (Mu Wt TCR MDM2, Mu Mt Arg/Gly TCR MDM2, Mu Mt 
Lys/Gly TCR MDM2) or control approaches (Mock, Mu Mt TCR MDM2 CDR3 W109A, Mu Mt TCR 
MDM2 CDR3 G113V, PBS). Thereby, mice adoptively treated with MDM2 TCR specific T cells 
indicated a strongly reduced tumor growth over time (Fig. 57).
8.2.4. Human melanoma growth in mice treated with gp100 TCR transgenic T cells
Using the established xenotransplantation model, human T cells transduced with various gp100 
(280-288)-specific TCR constructs were investigated, concerning their ability to control tumor 
growth in vivo (cf., Voss et al., 2010). Therefore, 2.5x106 cells of the human HLA-A2+gp100+ MeWo 
line were injected on the right flank, followed by adoptive T cell transfer of gp100 TCR transgenic
T cells (mean 2.4x106 cells), 7 d later. The primary tumor growth was investigated in up to five 
independent adoptive transfer experiments, including 108 individual mice. The cumulative data of 
the independent experiments are presented in Fig. 58.
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Figure 56. Melanoma growth in NOD-SCID mice treated with MDM2 TCR transgenic T cells.
A) The MeWo growth in individual mice from up to three independent experiments is indicated over 
time. Matrigel inoculation without tumor cells was analyzed as control. The mice were treated with 
specific MDM2 TCR transduced T cells or with control approaches on d7. B) Statistical analysis of 
tumor growth on d34. Numbers of mice, investigated per group: Mock n = 5, Mu Wt TCR MDM2 
CDR3 W109A n = 3, Mu Wt TCR MDM2 CDR3 G113V n = 3, PBS n = 9, Mu Wt TCR MDM2 n = 6,
Mu Mt Arg/Gly TCR MDM2 n = 6, Mu Mt Lys/Gly TCR MDM2 n = 4). For statistical analysis, an 
unpaired two-tailed t test was performed. Mean ± SEM; n, number of individual mice; ????????????
0.05; ** p va???????????????????????????????
The tumor volumes of mice treated with Mock transduced T cells or PBS, continuously 
increased over time (Fig. 58A). Moreover, adoptive transfer of T cells bearing Hu Wt TCR gp100 
led to a moderate, but not significant reduction in primary tumor growth over time, indicating a trend 
of growth control (Fig. 58A). The Hu Chim scTCR gp100 MuC? construct did not led to a decrease 
in tumor volume, compared to PBS or Mock control groups. However, compared to mice treated 
with PBS, optimized scTCR gp100 constructs that co-expressed a C? domain showed a 
significantly reduced tumor growth over time. Thereby, the strongest control was received using the 
individual treated groups on d34
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Cys-modified Hu Chim scTCR gp100 MuC? S79C + MuC? T84C construct that sustained an 
additional disulfide bond between the C? and C? (Fig. 58B). In this context, a reduction in the tumor 
volume for individual mice at d25 could be shown for the Cys-modified Hu Chim scTCR gp100 
construct compared to PBS and unmodified scTCR (Fig. 58B).
In order to investigate, if transferred TCR transgenic T cells circulate or latently reside in 
memory niches of secondary lymphatic organs and can be provided for an antigen-specific recall 
response, mice were engrafted with a secondary tumor without additional T cell application       
(Fig. 55B). The growth of the secondary tumor was investigated in up to three independent animal 
experiments, which included in total 61 mice. Thereby, compared to Mock transduced T cell and 
PBS treated mice, both optimized scTCR gp100 transduced T cell constructs (Hu Chim scTCR 
gp100 MuC? + MuC?, Hu Chim scTCR gp100 MuC? S79C + MuC? T84C) revealed a strongly
reduced secondary tumor growth over time, indicating a memory T cell response of the optimized 
scTCR gp100 transduced T cells (Fig. 59B). Moreover, the secondary tumor sizes at d25 were 
significantly reduced in these treated murine cohorts. In contrast, the growth of the secondary 
tumors in mice originally treated with the un-optimized three domain scTCR or the dc Wt gp100 
constructs, were not controlled over time (Fig. 59). Summarized, the revealed differences in tumor 
growth control were more pronounced in the course of the secondary than the primary tumor 
immune response, although mice received the gp100 TCR transduced T cells only once, at the 
beginning (d7) of the consecutive experiments.
Figure 57. Combined melanoma growth in NOD-SCID mice treated with MDM2 TCR specific 
T cell or control approaches. The MeWo growth, from three independent experiments, in mice
that either received MDM2 TCR specific T cells (red: Mu Wt TCR MDM2, Mu Mt Arg/Gly TCR 
MDM2, Mu Mt Lys/Gly TCR MDM2) or control approaches (black: Mock, Mu Mt TCR MDM2 CDR3 
W109A, Mu Mt TCR MDM2 CDR3 G113V, PBS) are indicated. Compared to mice of control 
groups, significant tumor growth regression is shown for animals, treated with specific MDM2 TCR 
constructs. For statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, 
number of individual mice; ?????????????????01
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Figure 58. Primary melanoma growth in NOD-SCID mice treated with gp100 TCR transgenic 
T cells. NOD-SCID mice were i.d. engrafted with MeWo cells at the right flank and adoptively 
transferred i.v. with gp100 TCR transduced T cells on d7 after tumor cell injection. The effect of 
adoptive immunotherapy (ADI) on primary tumor growth over time is indicated. A) Tumor growth of 
mice treated with PBS, Mock or Hu Wt TCR gp100 transduced human T cells. As control Matrigel 
without tumor cells was i.d. inoculated. B) Tumor growth of mice treated with PBS, Hu Chim scTCR 
gp100 MuC?, Hu Chim scTCR gp100 MuC? + MuC? or Hu Chim scTCR gp100 MuC? S79C + 
MuC? T84C transduced human T cells. The cumulative Mean ± SEM of up to five independent 
animal experiments is presented. P values in brackets indicate the statistical significant differences 
in tumor progression over time, calculated by the linear regression model with mixed effects 
against [PBS; Mock]. The graphs on the right side indicate the tumor volume of individual mice 
after primary tumor cell inoculation on d25. For statistical analysis, an unpaired two-tailed t test was 
performed. Mean ± SEM; n, number of individual mice; NS, not significant; #, significant higher 
compared to PBS control; * p ???????????????????????????????
0 5 10 15 20 25
0
20
40
60
80
Mock (n = 17-16)
Hu Wt TCR gp100
(n = 17-16)
PBS (n = 16)
Matrigel (n = 11)
days after 1st tumor cell inoculation
tu
m
or
 v
ol
um
e 
(m
m
3 )
[NS; -]
[0.0687; NS]
[- ; NS]
0
20
40
60
80
100
120
140
160
tu
m
or
 v
ol
um
e 
(m
m
3 )
d25
A
0 5 10 15 20 25
0
20
40
60
80
Hu Chim scTCR gp100
MuC?  + MuC? (n = 19-18)
Hu Chim scTCR gp100
MuC?  S79C + MuC? T84C
(n = 17-16)
Hu Chim scTCR gp100
MuC?  (n = 11-10)
PBS (n = 16)
days after 1st tumor cell inoculation
tu
m
or
 v
ol
um
e 
(m
m
3 ) [* (0.0384); NS]
[** (0.0012); 0.06]
[** (0.0053)#; NS]
[- ; NS]
0
20
40
60
80
100
120
140
160
** (0.006)
* (0.042)
tu
m
or
 v
ol
um
e 
(m
m
3 )
B
d25
Results
page | 135
Figure 59. Secondary melanoma growth in NOD-SCID mice treated with gp100 TCR 
transgenic T cells. Primary i.d. applied tumors of NOD-SCID mice, previously treated with gp100 
TCR transduced T cells were removed from the right flank and a secondary MeWo tumor was 
injected to the left flank of the same mice 2 d later (reset to d0). No further adoptive immunotherapy 
(ADI) with gp100 TCR transgenic T cells was performed. The secondary tumor growth over time 
under the effect of a long-term T cell response is indicated. A) Tumor growth in mice treated with 
PBS, Mock or Hu Wt TCR gp100 transduced human T cells. As control Matrigel without tumor cells 
was inoculated. B) Tumor growth of mice treated with PBS, Hu Chim scTCR gp100 MuC?, Hu 
Chim scTCR gp100 MuC? + MuC? or Hu Chim scTCR gp100 MuC? S79C + MuC? T84C 
transduced human T cells. Curves show the cumulative Mean ± SEM of up to three independent 
animal experiments. P values in brackets indicate the statistical significant differences in tumor 
progression over time calculated by the linear regression model with mixed effects against [PBS; 
Mock]. The graphs on the right side indicate the secondary tumor volume of individual mice on d25. 
For statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, number of 
individual mice; NS, not ??????????????????????????????
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8.2.5. Generation of a stable firefly luciferase transfected MeWo cell line for optimization 
of the xenotransplantation model
To further investigate the tumor growth, a second measuring system was established. This 
approach aimed to verify the data of the melanoma growth control by TCR transgenic T cells,
described in the previous sections that were obtained using a caliper for tumor growth 
measurement. In order to confirm the received results, a bioluminescence-based in vivo imaging of 
luciferase-positive tumor cells was established.
Therefore, human melanoma cells of line MeWo were transfected with the pcDNA3.1-luc-hygro
vector that contained the firefly luciferase gene under control of a cytomegalovirus (CMV)
promoter. The stable transfection was achieved by performing a selection with hygromycin. 
Afterwards, the firefly luciferase expression on single MeWo clones was analyzed by the in vitro 
luciferase measurement using the firefly luciferase reporter assay. The resulting 34 hygromycin 
resistant single clones of MeWo-luc were analyzed for firefly luciferase expression in the period of 
28 to 41 d post transfection (Fig. 60). 
After 4 independent experimental analyzes, of in vitro luciferase activity, the 10 hygromycin 
resistant MeWo-luc clones (11, 27, 29, 34, 36, 39, 44, 45, 49, 54) that revealed the strongest 
luciferase signal were additionally analyzed for luciferase expression. Therefore, an in vitro 
luciferase imaging was performed, in the period of 52 to 77 d post transfection. In three
independent experiments, only the MeWo-luc clones 11, 34 and 36 revealed a stable and 
reproducible expression of luciferase over time (Figs. 61A-D). Thereby, different cell numbers of 
the individual clones were examined and revealed that the measured luciferase expression signals 
correlated with the cell numbers of the analyzed clones. At least 1x104 MeWo-luc cells were 
required, to receive a luciferase signal that was clearly above the background signal, obtained from 
cells of the parental MeWo line (Fig. 61). 
In order to use the luciferase-positive MeWo clones as potential tumor target cells for the 
murine xenotransplantation model for following applications, the expression of the MDM2 and
gp100 antigens were analyzed by fluorescence microscopy. In this context, all three MeWo-luc 
lines (clones 11, 34 and 36) revealed positive for MDM2 and gp100 (Fig. 62). Furthermore, to 
analyze their in vivo growth behavior and bioluminescence signal, the MeWo-luc clones 11, 34 and 
36 were applied to NOD-SCID mice. Each of the cell lines were i.d. injected in numbers of 2.5x106
cells, resuspended in 50 μl matrigel, to the right flank of NOD-SCID mice. The mice were imaged 
using the IVIS100 imaging machine. Moreover, the tumor growth was additionally measured using
a caliper. All three luciferase cell lines showed a tumor formation in vivo that was comparable to the 
tumor growth of the parental MeWo cells, with exception of cells from the line MeWo-luc 36 that 
showed a reduced growth behavior (Figs. 63A and B). 
Furthermore, only for cells of the MeWo-luc 11 line, a successful tumor formation through in vivo 
imaging was revealed. This was characterized by increased bioluminescence signals over time, in 
contrast to the other MeWo-luc clones (Figs. 63C and D). The luciferase signals of MeWo-luc 34 
and 36 increased up to d7. At this time point they were clearly above the background signal of the 
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negative controls and comparable to the signal of clone MeWo-luc 11. But in contrast to clone 11, 
they did not further increase during the following time course (Fig. 63C). Since generally, the 
tumors of the MeWo-luc 34 and 36 clones grew normally in vivo, both clones seemed to be strongly 
dependent on an ongoing selection by hygromycin, to keep a stable luciferase expression (Figs. 
63A-D). In contrast to the in vitro cell cultivation, hygromycin was not added to the mice in vivo.
Moreover, a treatment with matrigel or the application of cells from the parental MeWo line did not 
exceed the background luciferase value of an untreated mouse (Fig. 63C).
Figure 60. Generation of firefly luciferase expressing MeWo cell clones. Cells of the human 
melanoma line MeWo were transfected with the pcDNA3.1-luc-hygro vector and single clones were 
selected by hygromycin addition. Thereby, 34 hygromycin resistant single clones of MeWo-luc 
were obtained and analyzed for in vitro firefly luciferase activity, indicated by relative light units 
(RLU) using the firefly luciferase reporter assay. The 10 MeWo-luc clones, indicated by red arrows 
were further investigated by in vitro luciferase imaging using the IVIS100 imaging machine.
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Figure 61. Verification of firefly luciferase expression in stable transfected MeWo-luc clones. 
The stable transfected MeWo-luc clones 11 (A), 34 (B) and 36 (C) were investigated for firefly 
luciferase expression through in vitro luciferase imaging using the IVIS100 imaging system. To 
investigate the background signal (indicated by dashed line), cells of the parental MeWo line were 
examined (D). Various numbers of cells (1, 1x101, 1x102, 1x103, 1x104, 1x105, 1x106, 2x106, 5x106) 
of each clone or the parental line were analyzed, in three independent experiments, between d52 
to d77 after transfection. As negative control, PBS without any cells was analyzed. The 
micrographs on the right side show a representative in vitro measured plate (exposure time of 300 
sec). Thereby, the MeWo-luc clones or the parental line are highlighted by red circles, indicating 
the calculated region of interest (ROI), which is presented by the respective cumulative data in the 
graphs on the left side. The bioluminescent signal of the calculated ROI is indicated as 
p/sec/cm2/sr. 
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Figure 62. Immunofluorescence microscopy showing MDM2 and gp100 in selected human 
melanoma MeWo-luciferase expressing cell clones. Immunofluorescence microscopy images of 
MeWo-luc 11, 34 and 36 cells show a strong expression of MDM2 and gp100 (both in red). DAPI 
(blue) was used to indicate the cell nuclei and the phase contrast image to present the cell 
morphology. Bars represent 20 µm. 
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Figure 63. In vivo imaging of tumor formation of the selected MeWo-luc clones 11, 34 and 
36. Local i.d. tumor formation in NOD-SCID mice of stable transfected cells of MeWo-luc clones 11, 
34 and 36 (3 mice/group). Cells (2.5x106) were injected on d0, followed by in vivo imaging and 
tumor measurement. The growth of the luciferase transfected lines were compared to the parental 
cell line (3 mice). As negative controls, mice injected only with matrigel (2 mice) or entirely 
untreated (1 mouse) were used. The tumor size-measurement data are indicated as tumor 
diameter (A) and tumor volume (B). The bioluminescent luciferase expression (exposure time of 
120 sec) is shown in log (C) and linear scale (D). The calculated ROI is indicated as p/sec/cm2/sr. 
Since the MeWo-luc 11 line revealed a stable expression of luciferase, going along with an 
increased tumor formation over time after a continuous cultivation for more than four months, also 
in the absence of hygromycin, these cells were used as tumor target line for the murine 
xenotransplantation model (Fig. 64A). Moreover, cells of this line did not metastasize to murine 
organs when i.d. injected and only the tumor showed a specific luciferase signal. In mice that 
received the cells 52 d beforehand, no luciferase signal was detectable in the spleen, lung, liver, 
intestine, stomach or kidneys (Fig. 64B). In addition, using flow cytometry, the MeWo-luc 11 cells 
were proven to be HLA-A2+ (Fig. 64C). In summary, these cells were suitable for an i.d. in vivo
tumor formation, followed by ADI with TCR transgenic T cells.
Therefore, MeWo-luc 11 cells (2.5x106) were injected i.d. to the right flank of NSG mice and 7 d 
later, treated with gp100 TCR transgenic T cells (5x106). The tumor growth was analyzed using a 
caliper and by detection of the bioluminescence signal of MeWo-luc 11 cells. Compared to NOD-
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SCID mice, which lack endogenous T and B cells, in NSG mice also NK cells are absent. They 
additionally reveal a higher level of engraftment of human cells. The luciferase signal and the 
measured tumor volume, of PBS treated mice, increased continuously from d4 to d56 (Figs. 65A 
and B). Compared to PBS treated mice, adoptive transfer of T cells bearing Hu Wt TCR gp100 or 
Hu Chim scTCR gp100 MuC? S79C + MuC? T84C constructs led to a strongly reduced luciferase 
signal and tumor volume (Figs. 65A and B). Moreover, beforehand transferred human T cells
revealed to be CD3+ (Fig. 50) and CD45+ (data not shown), could be detected in the PB of 
adoptively treated mice on d12 (Figs. 65C and D). 
The MeWo-luc 11 cells, as target line for the xenotransplantation model, verified the treatment 
results obtained for the adoptive immunotherapy with TCR transgenic T cells. Thereby, the tumor 
growth was controlled, measured with a caliper and analyzed through luciferase bioluminescence 
imaging. In these optimized model, Hu Wt TCR gp100 transduced T cells revealed a tumor growth 
control comparable to Hu Chim scTCR gp100 MuC? S79C + MuC? T84C modified cells, 
explainable by the use of twice as high amounts of transferred T cells, compared to the previous 
setting (cf., 8.2.4) and the use of NSG mice as model organisms.
Figure 64. In vivo imaging of tumor formation and analysis of HLA-A2 expression of MeWo-
luc 11 cells. A) Stable transfected MeWo-luc 11 cells (2.5x106) were i.d. injected to three NOD-
SCID mice on d0. The tumor formation was followed over time using the IVIS100 imaging system 
(exposure time of 120 sec). B) The mice were sacrificed on d52 and the organs imaged for 
metastases (exposure time of 60 sec). Representative organs of two MeWo-luc 11 tumor-bearing 
mice are presented. C) Using flow cytometry, MeWo-luc 11 cells were HLA-A2+.
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Figure 65. In vivo imaging of MeWo-luc 11 tumor growth in NSG mice treated with gp100 
TCR transgenic T cells. NSG mice were engrafted with MeWo-luc 11 cells (2.5x106 cells) to the 
right flank on d0 and adoptively transferred with gp100 TCR transduced T cells (Hu Wt TCR gp100,
Hu Chim scTCR gp100 MuC? S79C + MuC? T84C) on d7 (5x106 cells). The effect of ADI on tumor 
growth over time is indicated, measured using a caliper (A) and by detection of the luciferase 
bioluminescence signal of MeWo-luc 11 cells (exposure time of 120 sec; calculated ROI is 
indicated as p/sec/cm2/sr; B). The statistical differences between the groups on d56 are indicated. 
C) The PB of mice (2 mice/group) was analyzed by flow cytometry for CD45+ or CD3+ human 
T cells on d12. D) Representative FACS dot plots (left column: staining with CD45-APC Ab; right 
column: Isotype-APC Ab control) of PB samples of a tumor-bearing mouse treated with scTCR 
gp100 (Hu Chim scTCR gp100 MuC? S79C + MuC? T84C) transgenic human T cells (upper panel) 
and of a tumor-bearing mouse treated with PBS (lower panel). Dead cells were excluded by 7AAD. 
The magenta numbers in the dot plots indicate the percentage of positive stained cells. For 
statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, number of 
individual mice; * p ???????????????????????????????
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8.2.6. Combinational treatment of adoptive human T cell therapy and local low dose 
tumor irradiation for optimization of the xenotransplantation model
For the RIP1-Tag5 mouse model of spontaneous insulinomas it has been shown that murine T cell 
infiltration into the tumor was increased while combining a local low dose tumor irradiation with an
adoptive T cell therapy (Ganss et al., 2002; Seibel, 2010). Therefore, to further optimize the 
xenotransplantation model, before injection of the TCR transgenic T cells, a local low dose tumor 
irradiation was performed.
In order to irradiate the tumor and not other organs of the mice, the treatment protocol of the 
animal model had to be modified (cf., Fig. 66). The MeWo cells were i.d. injected to the right murine 
hind leg of NSG mice. That allowed the irradiation of the tumor-bearing leg without hitting other 
organs at the same time. A local low dose tumor irradiation with 2 Gy was performed on d6 after 
tumor cell injection. The adoptive T cell transfer with Hu Chim scTCR gp100 MuC? S79C + MuC?
T84C modified human T cells occurred on d7 and the tumor growth was measured over time.
Figure 66. Experimental setting of the xenotransplantation model with combinational 
treatment of local low dose tumor irradiation and ADI. NSG mice were engrafted i.d. on the 
right hind leg with cells of the line MeWo on d0 (white arrows). A local low dose tumor irradiation 
(2 Gy) was performed on d6. The area of irradiation is indicated by the white-bordered circuit (right 
image). TCR transgenic T cells were transferred i.v. on d7 and the tumor growth measured over 
time.
Two independent murine experiments with combinational treatment of tumor irradiation and ADI 
were performed, including 21 individual NSG mice. Thereby, the two established tumor 
measurement methods were used. In the first experiment, MeWo cells (2.5x106 cells) were 
injected, followed by the local low dose tumor irradiation on d6 and the transfer of Hu Chim scTCR 
gp100 MuC? S79C + MuC? T84C transduced human T cells (2.5x106 cells) on d7, d8 and d9. 
Summarized, already without additional T cell transfer, the local low dose irradiation of the tumor 
influenced the tumor growth in vivo and led to a slower growth compared to the non-irradiated PBS 
d0: tumor inoculation 
(MeWo i.d.)
d7: ADI (gp100 TCR 
transgenic T cells i.v.)
Measurement of
tumor growth
d6: local low dose 
tumor irradiation (2 Gy)
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treated control mice (Figs. 67A and B). However, compared to the PBS treated groups, the 
combinational approach of local low dose irradiation and adoptive transfer was able to further 
strongly control the tumor growth over time (Figs. 67A and B). The transferred human T cells could 
be detected in the PB of adoptively treated mice on d13, after tumor cell injection (Fig. 67C). 
Compared to PBS treated mice, increased amounts of human CD45+ cells were found in the PB of 
the adoptively transferred animals. Thereby, in the PB of the tumor irradiated mice, the percentage 
of these CD45+ cells was slightly, but not significantly, increased compared to adoptively treated 
non-irradiated animals (Figs. 67C and D).
In the second combinational treatment experiment, MeWo-luc 11 cells were again injected to 
the right hind leg of NSG mice. The local low dose tumor irradiation was performed on d7, followed 
by the transfer of Hu Chim scTCR gp100 MuC? S79C + MuC? T84C transduced human T cells 
(5x106 cells) on d8. In summary, both methods for analysis of tumor growth using caliper and 
bioluminescence signal detection, revealed comparable and reproducible results. It could be shown 
that the tumor was best controlled in mice that received a combinational treatment (Figs. 68A-D). In 
addition, this experiment confirmed the observation that the local low dose tumor irradiation alone
already slowed the tumor growth (Figs. 67A and B, 68A and B). However, compared to irradiated 
tumor-bearing mice treated with PBS, it could be confirmed that a combinational treatment with 
tumor irradiation and ADI using gp100 TCR modified T cells led to an additional reduction in tumor 
growth, indicted by reduced luciferase signal and measured tumor volume (Figs. 68C and D). 
Moreover, the luciferase signal and the caliper-measured tumor volume of tumor-bearing mice 
treated with PBS increased continuously from d3 to d23 (Figs. 68A and B). As shown for the 
previous experiments, the adoptively transferred T cells were successfully detected in the PB by 
flow cytometry staining for human CD45+ cells on d14 (data not shown). 
Figure 67. Melanoma growth in NSG mice treated with local low dose tumor irradiation and 
gp100 TCR transgenic T cells. NSG mice were engrafted with MeWo cells (2.5x106 cells) at the 
right hind leg on d0. The tumor was locally irradiated with 2 Gy on d6 and the mice were adoptively 
transferred with Hu Chim scTCR gp100 MuC? S79C + MuC? T84C transduced T cells on d7, d8
and d9 (each 2.5x106 cells). The effect of ADI and local low dose tumor irradiation on the tumor 
growth is indicated and was measured by a caliper (A). The statistical differences between the 
groups on d50 (A) and d31 (B) are shown. C) Using flow cytometry, the PB of mice (3 mice/group) 
was analyzed for human CD45+ cells on d13. D) Representative FACS dot plots (left column: 
staining with CD45-APC Ab, right column: Isotype-APC Ab control) of PB samples of a tumor-
bearing mouse, locally irradiated with 2 Gy and treated with scTCR gp100 TCR transgenic human 
T cells (upper panel) and of an equally treated mouse injected with PBS (lower panel). Dead cells 
were excluded by 7AAD. The magenta numbers in the dot plots indicate the percentage of positive 
stained cells. For statistical analysis, an unpaired two-tailed t test was performed. Mean ± SEM;
n, number of individual mice; * p ???????????????????????????????
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Figure 67. Melanoma tumor growth in NSG mice treated with local low dose tumor 
irradiation and gp100 TCR transgenic T cells. The detailed figure legend is presented on the 
previous page.
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Figure 68. MeWo-luc 11 tumor growth in NSG mice treated with local low dose tumor 
irradiation and gp100 TCR transgenic T cells. NSG mice were engrafted with MeWo-luc 11 cells 
(2.5x106 cells) at the right hind leg on d0. The tumor was locally irradiated with 2 Gy on d7 and the 
mice were adoptively transferred with Hu Chim scTCR gp100 MuC? S79C + MuC? T84C 
transduced T cells on d8 (5x106 cells). The effect of ADI and local low dose tumor irradiation on the 
tumor growth is indicated and was measured using a caliper (A) and by detection of the 
bioluminescence signal of luciferase-positive MeWo-luc 11 cells using the IVIS100 imaging system
(exposure time of 60 sec; calculated ROI is indicated as p/sec/cm2/sr; B). The statistical differences 
between the groups measured by caliper (C) or in vivo luciferase imaging (D) on d23 are shown 
(black: MeWo-luc 11 / PBS n = 2, gray: MeWo-luc 11 2 Gy / PBS n = 3, red: MeWo-luc 11 2 Gy / 
Hu Chim scTCR gp100 MuC? S79C + MuC? T84C transduced T cells n = 3). For statistical 
analysis, an unpaired two-tailed t test was performed. Mean ± SEM; n, number of individual mice;
????????????????? ?????????????????
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Furthermore, the obtained tumors of the combinational treatment experiment were investigated 
for infiltrated human T cells. Using immunohistochemistry, human CD45+ cells were detected in 
locally irradiated tumors of adoptively transferred mice. Compared to mice only treated with T cells, 
were no human CD45+ cells could be detected, the number of revealed CD45+ cells was increased 
in tumors of mice that received a combinational treatment (Fig. 69). Representative stainings of 
tumor sections from a mouse that received a combinational treatment are shown in Fig. 70. To 
ensure the human CD45 Ab specificity, human spleen tissue was tested in parallel. In contrast, the 
human spleen tissue as expected was negative for gp100 stainings (data not shown).
In addition, flow cytometry analysis was performed to detect human CD45+ cells in the removed 
tumors. Thereby, no specifically stained CD45+ cells were detected, probably due to the many lost 
or dead cells caused by digestion or mechanical procedures during the single cell preparation that 
was needed to perform subsequent stainings.
Figure 69. Cumulative detection of human CD45+ cells in MeWo tumors by immuno-
histochemistry. Mice were injected with MeWo cells (2.5x106 cells), followed by combinational 
treatment with local low dose irradiation (2 Gy) and ADI using Hu Chim scTCR gp100 MuC? S79C 
+ MuC? T84C transduced T cells (5x106 cells). As control, mice were treated with PBS instead of 
T cells and without local low dose tumor irradiation (0 Gy). The tumors of the respective treated 
murine groups were removed (between d22-d24 after tumor cell injection) and immediately snap-
frozen. The cumulative data of several tumor tissue sections, stained with human CD45 Abs are 
indicated. The CD45+ stained cells were counted and calculated per tumor area using the following 
?????????????????????????????????????????????????????????????????????Compared to the other groups, 
mice treated with the combinational approach showed an increased tumor infiltration of CD45+
cells. n = number of tissue slides; TC, T cells 
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Figure 70. Immunohistochemical stainings of MeWo tumor sections of a combinational 
therapy treated mouse. The NSG mouse was injected with MeWo-luc 11 cells (2.5x106 cells),
followed by therapy with local low dose tumor irradiation (2 Gy) and ADI using Hu Chim scTCR 
gp100 MuC? S79C + MuC? T84C transduced T cells (5x106 cells). The tumor was removed on d24 
after tumor cell injection and immediately snap-frozen. Microscopically images of representative 
tumor sections are presented, showing strong expression of gp100 (red-brown (A and B) and 
human CD45+ cells (red-brown), indicated by black arrows (C-F). D) The magnification of the 
boxed area presented in C is depicted. A nuclear counter stain was performed with Hematoxylin 
(blue; C and D). To present the cell morphology, the phase contrast is indicated in image F. Bars 
represent 200 μm (A), 100 μm (B, C, E, F) and 50 μm (D).
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8.2.7. Summary on the in vivo efficiency of optimized TCR transgenic human T cells
TCRs with specificities for MDM2 or gp100, optimized to avoid hybrid dimer formation between 
exogenous and endogenous TCR chains, were analyzed. The various optimized TCR constructs 
were transduced into human T cells using retroviral pBullet vectors and shown to be stable and 
functional expressed by the T cells in vitro. In order to investigate the impact of the adoptively 
transferred, optimized TCR transgenic T cells in vivo, a murine xenotransplantation model was 
established using immunodeficient NOD-SCID or NSG mice. As tumor target line, cells of the HLA-
A2+MDM2+gp100+ human melanoma line MeWo were i.d. applied.
Human T cells equipped with specifically optimized TCRs for the antigens MDM2 or gp100 were
thereby able to strongly control the tumor growth in vivo. The tumor growth was analyzed in a large 
and statistically reliable scale, measured using a caliper and verified by bioluminescence in vivo
imaging of the stable transfected MeWo-luc 11 line. It could be shown that the effect of tumor 
growth control by TCR modified T cells was increased using higher numbers of transferred cells. 
The transduced T cells revealed an effector memory-like phenotype (CCR7-CD45RO+CD62L-),
containing cells positive for CD27, a marker that promotes long-term survival and persistence of 
functional effector memory T cells in vivo. Moreover, without further T cell injection, a secondary 
tumor growth was strongly reduced in the originally adoptively transferred animals, showing a 
memory T cell response of the transduced T cells. Finally, a combinational treatment of local low 
dose tumor irradiation of 2 Gy together with an adoptive therapy of gp100 TCR transduced T cells,
further controlled the tumor growth in vivo.
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8.3. Further strategies to influence human tumor cell growth
Besides tumor antigen-specific TCR transgenic T cells for tumor growth control, further strategies 
to target tumor cells and influence the tumor growth behavior were addressed in the presented 
thesis. On the one hand, the impact of the carcinoembryonic antigen-related cell adhesion 
molecule 6 (CEACAM6) and L1 cell adhesion molecule (L1CAM) was investigated in the context of 
T cell-mediated tumor recognition. On the other hand, the viral targeting of oncolytic Newcastle 
disease virus (NDV) to tumor cells was addressed using human T cells as transfer vehicles to 
deliver the viral particles in a “hitchhiking”-like process.
8.3.1. CEACAM6 expression and impact of CEACAM6 inhibition on human tumor cells
The presence of the cell adhesion molecule CEACAM6 on the surface of tumor cells was analyzed 
by flow cytometry using a panel of various human tumor cells of breast, colorectal and pancreatic
adenocarcinomas as well as multiple myeloma and melanoma lines. Repeated stainings revealed 
that CEACAM6 was strongly expressed by cells of the breast adenocarcinoma lines BT-474, KS 
WT, KS 22.24 and KPL-4 (Fig. 71A), cells of the colorectal lines HT-29 and LoVo (Fig. 71B) and
cells of the pancreatic adenocarcinoma line Capan-1 (Fig. 71C). Besides the carcinoma lines, in 
general, CEACAM6 was not present in the multiple myeloma (SKMM2, U266) and melanoma 
(MeWo) cell lines (Figs. 71D and E). However, compared to the staining controls, cells of the 
multiple myeloma line RPMI 8226 showed a marginal CEACAM6 presence (Fig. 71D). 
In order to test, whether an inhibition of CEACAM6 on tumor cells can influence the tumor cell 
recognition by human T cells, CEACAM6 was blocked using a CEACAM6-specific Ab. Thereby, as 
readout system, the short-??????????????????????????????????Therefore, a co-culture of Capan-1
cells (1x104 cells) and pancreatic adenocarcinoma patient-derived PB T cells (5x104 cells) was 
performed for 40 h. Compared to untreated Capan-1 cells, after Ab blockade of CEACAM6 on 
tumor cells, a ????????? ?????????? ????? ??????????? was revealed by patient-derived T cells. In 
contrast to the measured T cell responses against CEACAM6 Ab blocked tumor cells, an isotype 
Ab used for tumor cell blocking, resulted in a significantly lower T cell-????????? ???????????????
(Fig. 72).
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Figure 71. Flow cytometry analysis of CEACAM6 in various human tumor cell lines. The 
breast adenocarcinoma cell lines BT-474, KS WT, KS 22.24, KPL-4 (A), colorectal 
adenocarcinoma cell lines HT-29 and LoVo (B) as well as the pancreatic adenocarcinoma cell line 
Capan-1 (C) were positive for CEACAM6. Compared to the control stainings, the multiple myeloma 
line RPMI 8226 was marginal positive (D) and the colorectal adenocarcinoma line HCT-15 (B), the 
multiple myeloma lines SKMM2 and U266 (D) as well as the melanoma line MeWo (E) revealed to 
be CEACAM6-negative. Dead cells were excluded by PI. The blue numbers in the dot plots 
indicate the percentage of CEACAM6-positive cells.
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??????????? ????????????????????????????? ??????????????????CEACAM6-inhibited Capan-1
tumor cells. Spontaneously induced tumor antigen-reactive memory T cell responses were 
detected against cells of the human pancreatic adenocarcinoma line Capan-1. CD3+ T cells were 
negatively isolated from the PB of a patient suffering from a pancreatic adenocarcinoma (obtained 
from the Department of General, Visceral and Transplantation Surgery, University Hospital 
Heidelberg). A short-??????????????????????????????????????????????????-1 cells (1x104) to T cells 
(5x104) was performed in triplicates for 40 h. The impact of tumor-expressed CEACAM6 on T cell 
responses was investigated through CEACAM6 inhibition on Capan-1 cells using CEACAM6
specific Ab for the blockade as well as isotype Ab as control. Compared to untreated or isotype 
blocked tumor cells, the CEACAM6 blockade on Capan-1 cells led to a strong increase in ?????
allogenic T cell responses. For statistical analysis, an unpaired two-tailed t test was performed. 
??????????????????????????????????????????????????? ?????????????????????????
To prove the observation of a CEACAM6-mediated T cell inhibition, a novel cell line was 
generated. Therefore, the HLA-A2+ breast adenocarcinoma line MCF-7 was selected, since cells of 
this line revealed an intermediate CEACAM6 positivity of ~20 % (Fig. 73A). Compared to the 
parental cell line, the novel isolated line showed an elevated CEACAM6 presence. Thereby, 
CEACAM6-positive MCF-7 cells were received through flow cytometry based cell sorting. The 
gating strategy used for the cell sorting is shown in Fig. 73. After sorting, more than 90 % of the 
MCF-7 cells were positive for CEACAM6 (Fig. 73B). In order to expand these CEACAM6 high 
expressing MCF-7 cells, to obtain adequate cell numbers, they were cultured in vitro. Using flow 
cytometry, the CEACAM6 level was repeatedly analyzed and revealed that more than 50 % of the 
cultured cells expressed CEACAM6. Thus, compared to the parental MCF-7 line, the sorted cells 
indicated an increase of ~30 % in CEACAM6 expression (Fig. 74).
In order to investigate, whether a 30 % elevated CEACAM6 expression on tumor cells 
influenced the function of human T cells, CEACAM6 was blocked on the tumor cells using a 
CEACAM6-specific Ab. A short-????? ????? ???????? ?????? ???? ?????????? ?????? ?????? ??? ????
respective MCF-7 lines (1x104 cells of parental and CEACAM6 high) together with breast 
adenocarcinoma patient-derived PB T cells (5x104 cells). Spontaneously induced tumor antigen-
reactive memory T cell responses were detected against cells of both MCF-7 lines. However, 
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compared to untreated or isotype controls?????????????????????????????????????????????????-derived 
T cells could only be detected for MCF-7 CEACAM6 high cells, after CEACAM6 Ab blockade
(Fig. 75). A blockade of CEACAM6 on cells of the parental MCF-7 line did not led to an increase in 
????????????????????????????????????
Figure 73. Gating strategy to isolate CEACAM6-positive MCF-7 cells by flow cytometry 
sorting. A) As shown by flow cytometry, ~20 % of the MCF-7 cells expressed CEACAM6. B) To 
increase this percentage, a FACS-based cell sorting for CEACAM6-positive cells was performed 
and resulted in a cell population of more than 90 % CEACAM6-positive MCF-7 cells. Dead cells 
were excluded by PI. The numbers in the dot plots indicate the percentage of positive stained cells.
In addition to the cell lines Capan-1 and MCF-7, cells of the line KS WT were investigated as 
tumor target line. KS WT cells were shown to be HLA-A2+ by flow cytometry (Fig. 76A). Moreover,
using immunofluorescence microscopy, the tumor cells revealed to be positive for MDM2 (data not 
shown). Therefore, cells of this HLA-A2+MDM2+CEACAM6+ line were used as target for Mu Wt 
TCR MDM2 transgenic human T cells (cf., Fig. 48). Using a ???????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????-culture with CEACAM6 Ab-blocked 
KS WT cells (Fig. 76B). Th?????? ?????????????????????????????e transgenic cells was obtained
using T2 cells loaded with the corresponding MDM2 (81-88) peptide (Fig. 76B). Furthermore, using 
the 51Cr release cytotoxicity assay, the impact of tumor-expressed CEACAM6 on the tumor-
directed cytolytic function of MDM2 TCR transgenic T cells was addressed. Compared to the lysis 
of unmodified tumor cells, the specific lysis of CEACAM6 Ab-blocked KS WT cells by TCR MDM2 
modified T cells was significantly increased (Fig. 76C). Thereby, cells of the MDM2 peptide-loaded 
line T2, showed the maximum cytolytic potential of the TCR transduced T cells (Fig. 76C).
Summarized, these data demonstrate that MDM2 TCR transduced T cells were able to specifically 
lyse tumor target cells of line KS WT, in accordance with an increased T cell-depende??? ?????
production as long as CEACAM6 was specifically blocked on the respective tumor target cells.
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Figure 74. CEACAM6 expression on cells of the sorted MCF-7 CEACAM6 high cell line.       
A) The percentage of CEACAM6 expression on HLA-A2+ MCF-7 cells was ~20 %. B) After cell 
expansion, ~50 % of the CEACAM6-sorted HLA-A2+ MCF-7 cells expressed CEACAM6.               
C) Overlay of FACS histograms of the individual stainings. Compared to cells of the parental line, 
sorted cells showed an elevated CEACAM6 level. Dead cells were excluded by PI. The magenta 
numbers in the dot plots indicate the percentage of positive stained cells.
??????? ???? ????? ???????? ?? human T cell responses against CEACAM6-inhibited MCF-7
CEACAM6 high cells. Spontaneously induced tumor antigen-reactive memory T cell responses 
were detected against MCF-7 and MCF-7 CEACAM6 high cells. CD3+ T cells were negatively 
isolated from the PB of a patient, suffering from breast adenocarcinoma (received from the 
Gynecological Department, University Hospital Heidelberg). A short-????? ????? ???????? ??????
using a 1:5 ratio of respective MCF-7 cells (1x104) to T cells (5x104) was performed in triplicates for 
40 h. The impact of tumor-expressed CEACAM6 on T cell responses was investigated through 
CEACAM6 inhibition using specific Abs as well as isotype Ab as control. Compared to untreated or 
isotype blocked cells and MCF-7 parental cells, the blockade of CEACAM6 on MCF-7 CEACAM6 
high cells led to a strong ????????? ??? ?????????????????????? ????????????????????????????????????????
unpaired two-????????????????????????????? ????????????????????????????????????????
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Figure 76. Functional human T cell responses against KS WT tumor cells through blockade 
of tumor-expresses CEACAM6. The detailed figure legend is presented on the next page.
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Figure 76. Functional human T cell responses against KS WT tumor cells through blockade 
of tumor-expresses CEACAM6. MDM2 antigen-reactive T cell responses were detected against 
cells of the breast adenocarcinoma line KS WT. A) Using flow cytometry, the KS WT cells revealed 
to be HLA-A2+. Dead cells were excluded by PI. B) A short-term ?????????????????? using a 1:5 
ratio of KS WT cells (1x104) to Mu Wt TCR MDM2 transgenic T cells (5x104) was performed in 
triplicates for 40 h. The impact of tumor-expressed CEACAM6 on T cell responses was 
investigated through CEACAM6 inhibition on KS WT cells. Moreover, to analyze the maximum 
????? ?? ????? ?????????? ??? ?????? ??????? ????? ???? ????????? ????? ???-88) peptide, were used. 
??????????????????????????????????????????????????????????? ???????????????????????????????????
T cell responses. C) Cytotoxicity of human T cells transduced with Mu Wt TCR MDM2 towards KS 
WT cells and MDM2 peptide-pulsed T2 cells are shown. The used T cell:target cell ratios are 
indicated. The impact of tumor-expressed CEACAM6 on cytolytic effector functions of MDM2 TCR 
transgenic T cells was analyzed through CEACAM6 inhibition on KS WT cells. Thereby, in general,
CEACAM6-specific Abs for the blockade and isotype Abs were used as control. Compared to 
untreated tumor cells, the blockade of CEACAM6 on KS WT cells resulted in an increased 
percentage of specific tumor cell lysis by T cells. For statistical analysis, an unpaired two-tailed t 
???????????????????? ????????????????????????????????????????
8.3.2. Analysis of L1CAM inhibition on human melanoma cells 
Since the blockade of the molecule CEACAM6 on tumor cells revealed an increase in T cell 
function, a further cell adhesion molecule, L1CAM, was additionally investigated concerning the 
specified effect. 
Cells of the melanoma line MeWo were used as tumor target line, since these cells strongly 
expressed L1CAM, as shown by immunoblot analysis (cf., Fig. 41) and verified by FACS staining 
(Fig. 77A). Besides the intense L1CAM presence using flow cytometry, MeWo cells were shown to 
be positive for CEACAM1 (~50 % positivity, data not shown) but negative for CEACAM6 (Fig. 71E).
In order to investigate, whether a specific blockade of L1CAM on MeWo cells resulted in an 
increased cytolytic function of antigen-specific T cells against tumor cells, a 51Cr release 
cytotoxicity assay was performed. Therefore, as effector cells, Hu Chim scTCR gp100 MuC? S79C 
+ MuC? T84C transduced T cells (cf., Fig. 49) and as target cells, cells of the HLA-
A2+gp100+L1CAM+ MeWo line were used. In summary, compared to untreated or isotype Ab-
blocked MeWo target cells, the specific Ab-mediated blockade of L1CAM on MeWo cells led to a 
significant increase in T cell-mediated cytotoxicity (Fig. 77B). Moreover, using gp100 peptide-
loaded cells of the line T2, the maximum cytolytic potential of the gp100 TCR transduced T cells 
could be shown (Fig. 77B).
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Figure 77. Functional human T cell responses against MeWo cells through blockade of 
tumor-expressed L1CAM. Gp100 antigen-reactive T cell responses were detected against cells of 
the melanoma line MeWo. A) Using flow cytometry, the MeWo cells revealed to be positive for 
L1CAM. Dead cells were excluded by PI. The magenta numbers in the dot plots indicate the 
percentage of positive L1CAM MeWo cells. B) The cytotoxicity of human T cells, transduced with 
the Hu Chim scTCR gp100 MuC? S79C + MuC? T84C construct, towards MeWo cells and gp100 
(280-288) peptide-pulsed T2 cells is shown. The used T cell:target cell ratios are presented. The 
impact of L1CAM on the cytolytic effector function of gp100 TCR transduced T cell was 
investigated through L1CAM inhibition on MeWo cells using L1CAM specific Abs for the blockade
as well as isotype Ab as control. Compared to untreated tumor cells, the blockade of L1CAM on 
MeWo cells increased the percentage of specific tumor cell lysis by T cells. For statistical analysis, 
an unpaired two-????????????????????????????? ???????????????????????????????????????????
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8.3.3. Human tumor cell infection and growth inhibition by Newcastle disease virus 
transferred on human T cells
In order to test, whether human T cells can be loaded with NDV and used as transport vehicles to 
transfer the loaded viral particles to tumor cells, PB-derived T cells from healthy donors were 
modified with the virus. Therefore, T cells were incubated with increased amounts of 
hemagglutination units (HU) of the lentogenic strain NDV-Ulster or the virulent mesogenic strain 
MTH-68. Using flow cytometry-based surface staining for the viral fusion (F) protein, the binding of 
NDV to human T cells was analyzed after an adsorption step of 1 h and 20 h. For both NDV 
strains, a dose-dependent increase of viral antigens at the cell surface was detected (Figs. 78A 
and B). Thereby, the percentage of cells that sustained viral antigens was comparable at both time
points analyzed (Figs. 78A and B). Investigating the EGFP protein by flow cytometry, the 
cytoplasmic viral expression in T cells could be addressed after 20 h of infection with the 
recombinant lentogenic NDV strain NDFL-EGFP. Besides non-activated T cells, also CD3/CD28 
activated T cells and MCF-7 cells were modified with NDFL-EGFP and analyzed for EGFP 
expression. All three cell types showed an EGFP signal in more than 60 % of the cells (Fig. 78C). 
However, the mean fluorescent intensity of the individual tested groups was different. Compared to 
non-activated T cells, MCF-7 tumor cells and activated T cells showed a high mean fluorescent 
intensity (cf., Pfirschke and Schirrmacher, 2009). Moreover, using quantitative real-time PCR, the 
cytoplasmic viral RNA for the NDV matrix (M) gene was analyzed 20 h after NDFL-EGFP 
modification. Thereby, the highest amount of the viral M gene was shown for activated T cells,
while non-activated T cells expressed much lower and MCF-7 tumor cells intermediate amounts 
(cf., Pfirschke and Schirrmacher, 2009). 
To test, whether NDV can replicate in the different cell types used and produce viable progeny 
virus, the lytic mesogenic NDV strain NDFLtagEGFP was used for cell modification. After 2 d, the 
cell culture supernatants of the three infected cell types were carefully removed and tested for the 
presence of infectious progeny virus. Therefore, MCF-7 cells were used as target for viral 
modification by NDV particles contained in the supernatant. While supernatants of infected MCF-7
tumor cells contained infectious virus particles, supernatants of non-activated and activated T cells 
did not contain infectious NDV (Fig. 79).
Correspondingly to analyze whether NDV-modified human T cells can transfer NDV to human 
tumor cells, an in vitro co-incubation of both cell types was performed. Therefore, the virus (NDV 
strain NDFL-EGFP, 50 HU) was loaded to PBMCs, “non T cells” (PBMCs after removal of T cells), 
non-activated and activated T cells as well as of CD4+ and CD8+ T cell subsets. The NDV transfer 
to MCF-7 cells was investigated after a co-culture period of 20 h. Therefore, a flow cytometry-
based analysis of EGFP-positive cells was performed while gating on MCF-7 tumor cells. After co-
incubation with NDV-modified T cells, ~25 to 40 % of MCF-7 cells were EGFP-positive, depending 
on the cell ratios used (Figs. 80A-C). In contrast, after co-culture with PBMCs or non T cells only 
~12 % of the tumor cells were infected (Fig. 80A). The direct infection of MCF-7 cells revealed an 
EGFP signal in ~75 % of the cells (Figs. 80A-C).
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Figure 78. Modification of human T cells with NDV. The binding of NDV to human T cells was 
analyzed 1 h (A) and 20 h (B) after treatment with different amounts of the NDV strains, NDV-
Ulster or MTH-68. Using flow cytometry, the T cells were stained for surface expression of the viral 
F protein and the percentage of positive cells is indicated. C) T cells, activated T cells (aT cells)
and MCF-7 cells were modified with the NDV strain NDFL-EGFP using a dose of 50 HU. A flow 
cytometry analysis for cytoplasmic viral EGFP was performed after 20 h of viral treatment and the 
percentage of EGFP-positive cells is indicated. These data show an efficient modification of human 
T cells by NDV. As controls, cells without NDV modification were investigated. In each case 
representative data from one of two experiments are shown.
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Figure 79. Analysis of the formation of infectious progeny virus in T cells, activated T cells 
and MCF-7 tumor cells. T cells, activated T cells (aT cells) and MCF-7 tumor cells were 
separately modified with 10 HU of the multicyclic NDV strain, NDFLtagEGFP for 2 d. The 
supernatants of the NDFLtagEGFP-modified cells were transferred to untreated MCF-7 tumor cells 
and tested in log 10 dilutions. The MCF-7 cells were analyzed for EGFP expression by flow 
cytometry, 20 h later. Thereby, progeny virus was only revealed in the supernatants of MCF-7 cells, 
but not of NDV-modified T cells. As control, MCF-7 samples without supernatants of NDV-modified 
cells (no NDV; 0 HU) and direct infection controls of MCF-7 cells using different NDFLtagEGFP 
viral amounts, were investigated.
Since activated T cells could be more efficiently modified with NDV than non-activated T cells, 
indicated by increased viral mRNA and EGFP protein expression without production of infectious 
progeny virus (Figs. 78C, 79 and Pfirschke and Schirrmacher, 2009), viral hitchhiking mediated by 
activated T cells was analyzed. Thereby, compared to non-activated T cells, a higher transfer of 
NDV to tumor target cells was revealed (Fig. 80B). Moreover, certain subsets of T cells as CD3+
and purified CD4+ and CD8+ T cells were analyzed, concerning their capacity to transfer NDV. All 
investigated subsets were similarly active in conducting the transfer of NDV (Fig. 80C).
Furthermore, kinetic experiments were performed, to investigate whether direct infection of 
tumor cells and infection via hitchhiking of NDV-modified T cells take a different time course.
Thereby, the time course of MCF-7 cell infection through hitchhiking on NDV-modified T cells 
compared to direct virus infection of MCF-7 cells is indicated in Figs. 81A and B. By the mean 
fluorescent intensity of the EGFP signal of MCF-7-infected cells, it could be shown that the direct 
infection route took ~10 h, while the T cell-mediated hitchhiking-based infection lasted ~20 h
(Fig. 81B). 
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Figure 80. Transfer of NDV from human T cells via hitchhiking to human tumor target cells. 
Flow cytometry analysis showing PBMC, T cells, non T cells (PBMC depleted of T cells) (A) and
activated T cells (aT cells) compared to non-activated T cells (B) as well as CD3+, CD4+ and CD8+
T cells (C) which were modified with 50 HU of the NDV strain NDFL-EGFP for 1 h. Following, the 
NDV-modified cells were co-cultured with untreated MCF-7 tumor cells for 20 h using a tumor cell 
to T cell ratio of 1:4 (A), 1:2 (B) or 1:5 (C), respectively. As controls, MCF-7 cells without NDV (no 
NDV) and directly modified with NDV (grey bars), were used. The EGFP signal was analyzed by 
flow cytometry after a co-culture of 20 h. In accordance to the positive virus modification setting, 
the specific MCF-7 infection by NDV, transferred via hitchhiking on various human T cell 
populations could be shown (A-C). Representative data from one of two experiments are shown.
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Figure 81. Kinetic of the T cell-mediated NDV hitchhiking to human tumor target cells. Using 
flow cytometry, the time-course of the hitchhiking process of NDV (50 HU NDFL-EGFP) on human 
T cells was analyzed after 3, 6, 9, 20 and 30 h of co-culture with MCF-7 tumor cells using a tumor 
cell to T cell ratio of 1:5. A) Representative flow cytometry-based histograms present the respective 
EGFP signals over time. B) Graphs indicate the percentage of EGFP-positive cells (left) and the 
mean of the EGFP positivity (right). Representative data from one of two experiments are shown. 
 
In a next approach, to visualize MCF-7 tumor cell infection by NDV, transferred through 
hitchhiking on T cells, immunofluorescence microscopy stainings were performed. Therefore, NDV-
Ulster (50 HU) was loaded to T cells and co-cultured with MCF-7 cells for 20 h. After washing off 
the non-adherent cells, the remaining cells were converted to slides. Co-localizations of MCF-7 
tumor cells, positive for cytokeratin and NDV, were revealed for the direct infection setting and the 
hitchhiking approach (Figs. 82A and B). 
Moreover, the impact of the used tumor cell to T cell ratios for the hitchhiking approach was 
examined. A transfer of NDV to MCF-7 cells was clearly detectable using a 1:1 tumor cell to T cell 
ratio, however, the most effective results were obtained at a 1:5 ratio (Fig. 83A). Furthermore, the 
dependence of the hitchhiking efficiency on the used virus dose was investigated using different 
NDV doses for the T cells modification. Thereby, compared to the efficiency with 50 HU of NDV, an 
increased T cell-dependent hitchhiking of NDV to MCF-7 cells could be observed when a dose of 
500 HU was used for T cell modification (Fig. 83B). 
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Figure 82. Immunofluorescence microscopy of NDV-infected MCF-7 cells. Immuno-
fluorescence microscopical images are presented of direct NDV-infected MCF-7 cells (A)           
and MCF-7 cells infected via hitchhiking of NDV, through NDV-modified T cells using a tumor cell 
to T cell ratio of 1:5 (B). The NDV-Ulster strain (50 HU) was used for investigation. After 20 h 
cultivation, the MCF-7 cells were dispersed to slides using a cytospin cytocentrifuge and analyzed 
for virus presence by immunofluorescence microscopy. Cytokeratin stainings were used to 
visualize the MCF-7 tumor cells (green) and NDV stainings to indicate the virus (red). Indicated by 
white arrows, the merged pictures exemplarily present NDV-positive MCF-7 tumor cells, resulted 
from direct NDV infection (A) or through hitchhiking-mediated NDV infection (B). DAPI (blue) was 
used to show the cell nuclei. Bars represent 20 µm. 
 
 
To analyze the tumor growth control by T cell-mediated hitchhiking of NDV in vitro, a tumor 
neutralization assay (TNA) was performed. Therefore, tumor cell monolayers were co-cultured with 
NDV-loaded T cells for 2 d and the anti-tumor activity, indicated as tumor growth inhibition of NDV, 
was measured by uptake of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium solution (MTS) through the remaining viable tumor cells. Thus, non-
activated T cells and activated T cells were loaded with different doses of NDV-Ulster or MTH-68. 
Different tumor cell to T cell ratios were investigated and a tumor growth inhibition of 50 % was 
observed at a 1:5 ratio, when non-activated T cells were loaded with 10 HU of MTH-68 (Fig. 84A). 
A similar effect was seen, when 10 HU MTH-68 were directly used for infection. The less virulent 
strain NDV-Ulster, as expected, revealed less anti-tumor activity after both, direct and hitchhiking-
mediated viral infection (Fig. 84A).  
Furthermore, elevated anti-tumor activities were observed when activated T cells, instead of 
non-activated T cells, were used as NDV transfer vehicles. A tumor growth inhibition of 50 % could 
be shown when activated T cells, without NDV modification, were co-cultures with MCF-7 cells in a 
tumor cell to T cell ratio of 1:5 (Fig. 84B). Only slightly higher anti-tumor effects were measurable, if 
activated T cells were loaded with NDV-Ulster, while much stronger anti-tumor activity was 
examined with MTH-68 modified activated T cells (Fig. 84B). Finally, using this combination of 
activated T cells and virulent NDV strain MTH-68, the measured tumor growth inhibition was higher 
than observed for the direct infection of MCF-7 tumor cells with respective amounts of MTH-68 
(Fig. 84B).  
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Figure 83. Flow cytometry analysis of MCF-7 to T cell ratios and impact of NDV doses for 
optimization of hitchhiking. A) Hitchhiking of NDV strain NDFL-EGFP (50 HU) on T cells co-
cultured with MCF-7 cells was investigated, analyzing different tumor cell to T cell ratios (1:0.25, 
1:0.5, 1:1, 1:2, 1:5). The EGFP signal of MCF-7 cells was measured by flow cytometry after 20 h of 
incubation and the percentage of EGFP-positive cells (left) and the mean of the EGFP positivity 
(right) are presented and indicate a NDV transfer to tumor cells at all investigated ratios. Thereby, 
the most efficient transport was revealed at a ratio of 1:5. B) Hitchhiking of NDV strain NDV-Ulster 
on T cells, co-cultured with MCF-7 cells (tumor cell to T cell ratio 1:2) was examined, analyzing 
different NDV doses (50 HU, 500 HU). The NDV-positive cells (staining for F protein) were then 
analyzed after a co-culture of 20 h and showed a maximum transport rate using 500 HU of NDV. 
As controls, MCF-7 cells without NDV (no NDV) and directly modified by NDV (grey bars) were 
used. Representative data from one of two experiments are shown.
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Figure 84. Tumor cell growth control in vitro through T cell-mediated NDV hitchhiking. Using 
the tumor neutralization assay, the inhibition of tumor cell growth was determined after 2 d co-
culture of MCF-7 cells with virus-modified T cells using the NDV strains NDV-Ulster or MTH-68. For 
NDV hitchhiking, non-activated T cells (A) and activated T cells (aT cells; B) were used. Different 
tumor cell to T cell ratios (1:1, 1:2, 1:5) and NDV doses (0.5 HU, 10 HU, 50 HU) were tested and 
revealed the most efficient tumor growth control using MTH-68-modified aT cells as NDV carriers.
As controls, MCF-7 cells directly infected with the respective NDV strains and MCF-7 cells co-
cultured with T cells or aT cells without NDV modification were used. For each individual setting, 
triplicates were performed. Representative data from one of two experiments are shown. Mean ± 
SEM
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8.3.4. Summary on further strategies to influence human tumor cell growth
The presence of the cell adhesion molecule CEACAM6 was shown for different human tumor cell 
lines derived from breast, colorectal and pancreatic adenocarcinomas and multiple myeloma. 
Thereby, compared to respective untreated control cells, the inhibition of CEACAM6 on cells of 
these tumor lines revealed strongly increased functional human T cell responses, indicated through
elevated ??????????????????????????-directed cytolytic T cell functions. Moreover, in comparison to 
the parental MCF-7 cell line, a CEACAM6 blockade on flow cytometry-sorted CEACAM6 high 
MCF-????????????????????????????????????????????????????-cultured patient-derived T cells. 
Besides the immunosuppressive role of tumor-expressed CEACAM6, a comparable function 
was shown for the cell adhesion molecule L1CAM. The inhibition of L1CAM on human MeWo 
melanoma cells also revealed an increased cytolytic T cell function against the investigated tumor 
cells. Summarized, these data show that human T cell responses against human tumor cells were 
functionally suppressed by the molecules CEACAM6 and L1CAM, expressed by tumor cells.
Furthermore, to influence human tumor cell growth in vitro, a human T cell-mediated oncolytic 
viral tumor cell targeting was examined for NDV. Human PB-derived T cells were modified with 
NDV, while activated T cells were most efficiently loaded with the virus. Thereby, in T cells NDV 
was not able to replicate and to form infectious progeny virus. Using an in vitro co-culture system, 
the virus-modified T cells were used to transfer NDV in a “hitchhiking”-like process to tumor target 
cells. The efficiency of NDV transfer via T cells to tumor cells was dependent on the co-culture ratio 
and the viral dose. Finally, while investigating the tumor growth inhibition, the T cell-mediated 
transport of NDV could be used to control the tumor growth in vitro.
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9. Discussion
Cancer causes high mortality in terms of several million deaths per year for both men and women 
and represents therefore a major public health problem all over the world (Jemal et al., 2010). In 
order to efficiently fight cancer, existing therapeutic strategies have to be optimized and novel 
approaches will need to be established. To overcome tumor escape, malignant tumors have to be 
attacked from different angles. Moreover, to achieve a successful intervention, the fact that cancer 
represents a multifunctional disease that requires the combination of various therapeutic 
approaches is of central importance. In addition to conventional cancer therapies including surgery, 
radiation- and chemotherapy, a number of other approaches for cancer treatment exist, such as 
immunotherapy. Different immunotherapeutic approaches have been performed for cancer 
treatment. All of them aim to harness and direct immune mechanisms against transformed 
malignant tumor cells. 
Nevertheless, the clinical efficiency of current tumor immunotherapies remains low, in part due 
to the capacity of tumors to interfere and control immune responses. The identification of 
mechanisms, that help to down-regulate those tumor-mediated anti-immune responses, and 
strategies, that efficiently reactivate pre-existing cancer-directed immune cells, are of great 
importance. In addition, the optimization of specific gene-modified tumor-reactive cells and 
combinational treatment approaches are of central clinical importance for tumor targeting. 
Therefore, this thesis focused on different aspects of cancer immune therapeutic interventions, 
which are separately discussed in the following paragraphs. 
9.1. Spontaneously induced tumor antigen-reactive T cell responses in melanoma 
and dysplastic nevi patients
Tumor-reactive memory T cell responses have been discussed to be required for a durable 
prevention of tumor recurrence and metastasis formation, especially after surgical tumor removal 
(Côté et al., 2008). They provide a repertoire of functional and potentially protective immune cells 
that can be therapeutically reactivated (Beckhove et al., 2004). Although, spontaneously induced 
pre-existing tumor antigen-reactive memory T cells have been extensively studied and shown to be 
present in patients suffering from various types of cancer including breast, pancreatic and 
colon carcinomas as well as multiple myeloma and melanoma (Choi et al., 2005; Schmitz-
Winnenthal et al., 2005; Mueller-Berghaus et al., 2006; Bonertz et al., 2009; Schuetz et al., 2009), 
little is known about the regulation of their spontaneous responses. Moreover, the identification of 
relevant antigens to reactivate pre-existing memory T cell responses is still of central importance 
for the optimization of cancer treatment, especially for peptide-based immunotherapy.
In the presented thesis the presence and kinetic of spontaneously induced memory T cells was 
characterized in the peripheral blood (PB) of non-metastasized melanoma patients after primary 
tumor resection over time. Thereby, T cell responses against a broad variety of different melanoma 
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TAAs were examined. Spontaneously induced tumor antigen-reactive memory T cell responses 
can be identified using a 40 h short-????? ????????????????????????????????????????????????? ???
could be shown that the measured T cell reactivity via ????? secretion resulted mainly from the 
CD45RO+ and not the CD45RO- T cell population (Bonertz et al., 2009). Therefore, spontaneously 
induced pre-existing memory T cells but not recently primed CD45RO- naive/effector T cell fractions 
??????? ?????????????? ?????????????? ????????????????????????-culture of peptide-pulsed autologous 
dendritic cells and T cells. Compared to CD45RA+ T cell fractions, only CD45RO+ memory T cells 
??????????????????????????????????????????????????????????????? ???????????? this way, naive primary 
immune responses can be excluded ?????????? ???? ????? (Schirrmacher et al., 2003; Sommerfeldt 
et al., 2006).
?????? ??? ?????? ?????????????? ???? ????????? ????? ????????? ???????, which were obtained 
through short-?????????????????????????????????????????????????????????, present memory T cell-
mediated secondary immune responses. However, since total CD3+ T cell populations were used 
for the investigations instead of purified CD45RO+ memory-like effector T cells, it might be possible 
that to some degree the presence of tumor-reactive T cells were underestimated. In general, total 
CD3+ T cell fractions were used, since the elimination of naive T cells was associated with a major 
general cell loss. In parallel, T cell responses against a large panel of various TAAs have been 
investigated. Therefore, a high T cell number was necessary to perform the above assays.            
In addition, the limited amount of cells that can be obtained from a maximum of 50 ml human 
patient-derived PB, led to the decision to use total CD3+ T cell populations instead of purified 
memory T cells.
???? ????? ??ISPOT assay is used for monitoring during clinical trials. The assay has an 
important advantage, since it does not require the expansion of specific T cells before investigation 
and therefore reflects the ex vivo ????????????????????????????????????????????, other cytokines and 
effector molecules ????????? ??? ?????????? ?? ?????? ?????????? ?????? ??-2 or perforin can be 
??????????? ????? ???? ??? ?????? ????? ?????????????? ??? ??? ??? ?? ????????? ?????? ????????? ?????????
molecule secreted by reactivated effector T cells that, e.g., can directly inhibit human tumor cell 
growth, while inducing apoptosis (Wall et al., 2003). Using this method, in the PB of non-
metastasized melanoma patients, pre-existing T cell responses were revealed against all tested 
TAAs, which showed a significant increase compared to the control IgG (Fig. 25). Importantly, the 
frequency of TAA-reactive T cells was significantly increased in the cohort of 36 non-metastasized 
melanoma patients compared to healthy donors, where TAA-reactive T cell responses were only 
rarely observed (Fig. 33). This comparable analysis indicated that the detected TAA responses are 
preferentially limited to the melanoma cohort.
The investigated TAAs represent 13 different antigens that belong to melanocyte 
linage/differentiation antigens, oncofetal/cancer-testis antigens, atypical antigens and antigens that 
are over-expressed in melanoma (for references see Tab. 8). In more than 75 % of all analyzed 
non-metastasized patients spontaneous T cell responses against at least one of the investigated 
antigens were detected. In contrast to colon carcinoma patients where on average 1.7 TAAs were 
recognized (Bonertz et al., 2009), interestingly, in the melanoma cohort preferentially responses 
Discussion
page | 169
against 4 or more antigens were observed, indicating polyvalent and patient-dependent individual 
T cell responses (Figs. 20 and 21). High T cell reactivities were obtained against all tested 
polypeptides, whereas the highest response rates - in more than 60 % of patients - were obtained
against the melanocyte linage/differentiation antigens Melan-A/MART-1 and Tyrosinase (Fig. 25A). 
Both antigens represent primary candidates that were and still are extensively studied for 
immunotherapy of cancer patients, especially for melanoma (Boon et al., 2006). In this context, 
multiple epitopes that are recognized by CTLs, but also CD4 effector T cells, have been described 
for Melan-A/MART-1 and Tyrosinase (cf., Cancer Immunity, peptide database, last update of 
January 2011; www.cancerimmunity.org; see also Valmori et al., 1999; Larrieu et al., 2007). 
Moreover, these antigens are partially involved in melanin production and therefore not exclusively 
expressed in melanoma but also in normal melanocytes. While the treatment in metastatic 
melanoma patients revealed promising results, which is indicated through reported regression of 
melanoma metastases (Rosenberg et al., 2008), side effects have been described using 
melanocyte differentiation antigens as targets for immune therapeutic interventions including 
adoptive immunotherapy. In this context, autoimmune melanocyte destruction was reported in 
several melanoma patients, as indicated by severe vitiligo in the skin and hair as well as uveitis of 
the eye (Robinson et al., 2004; Caspi, 2008; Rosenberg et al., 2008). These adverse events are 
due to the fact that the targeted antigens are not exclusively expressed by tumor cells. Tumor 
antigen-specific T cells home not only to the tumor to mediate tumor regression but also to 
melanocytes, which express melanin in healthy tissues including the skin, hair follicle and eye. This 
indicates that besides the promising results, obtained through known tumor antigens, there is still a 
central need in identifying new antigens that are more specific to the respective cancer or ideally 
only specifically expressed by cancer cells.
The antigen NA17-A, might be one candidate, as it represents an atypical protein that is 
encoded by an intron sequence of the human N-acetyl glucosaminyl-transferase V gene (GnT-V). 
Due to a cryptic activated promoter within the intron sequence this protein is translated. NA17-A is 
primarily expressed by melanoma but not in normal tissues and has therefore been described as a 
tumor-specific antigen (Guilloux et al., 1996). Interestingly, the data presented in this thesis 
revealed that pre-existing T cell responses against NA17-A were found in more than 40 % of non-
metastasized melanoma patients. Therefore, besides Melan-A/MART-1 and Tyrosinase, NA17-A
represents the third most common antigen which could be specifically recognized by spontaneous 
T cell responses (Fig. 25).
In general, during melanoma cohort analysis, high T cell reactivities were detected. Thereby, 
the response rates were distinctly higher than 20 % for all of the investigated antigens (Fig. 25), in 
comparison to colon carcinoma patients, where almost all peptide response rates were revealed to 
be clearly lower than 20 % using the same assay system (Bonertz et al., 2009).
An explanation for the different proportions of colon carcinoma and melanoma patients, that 
exerted significant T cell reactivities against polypeptides derived from the respective TAAs, can be 
due to the different medical backgrounds of the two cancer cohorts. The colon carcinoma patients 
were still tumor-bearing when the PB was taken for investigation of pre-existing tumor antigen-
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reactive T cells. In contrast, the melanoma cohort did not have a direct tumor stimulus at the 
moment of PB investigation for T cell responses, since the patients were non-metastasized and the 
primary tumor had already been resected.
In order to investigate, how the frequency of TAA-reactive T cells behave over time after primary 
tumor resection, in non-metastasized melanoma patients different time points after the resection of 
the primary tumor were analyzed. Surprisingly, the T cell frequencies increased significantly over 
time up to d60 after the removal of the tumor (cf., Figs. 26 and 27). This observation indicated that 
the presence of the tumor controlled pre-existing memory T cell responses in the PB. Furthermore, 
it showed that after tumor removal the cancer-suppressive control was lost, resulting in a strong 
increase of pre-existing T cell responses. In this context, based on the cancer immunoediting 
hypothesis (Schreiber et al., 2011; Vesely et al., 2011), the clinically apparent, non-metastasized 
primary melanoma may represent tumors that have escaped immune control.
The cancer immunoediting hypothesis highlights that the immune system directly interacts with 
the development of the tumor. Thereby, on the one hand the immune system protects the host 
against the formation of immunogenic tumors. On the other hand, it edits tumor immunogenicity 
and promotes tumor growth. In this context, cancer immunoediting represents a dynamic extrinsic 
process composed of 3 distinct phases: elimination, equilibrium and escape (Schreiber et al., 2011; 
Vesely et al., 2011). The elimination process is a modernized view of cancer immunosurveillance 
that has first been hypothesized in content by Burnet and Thomas in the 1950s (Burnet, 1957; 
Thomas, 1959). Thereby, the innate and adaptive immunity directly fight and protect the organism 
against unedited developing tumors that were finally destroyed long before they become clinically 
apparent. If all tumor cells were destructed, the elimination phase represents an endpoint of cancer 
immunoediting. However, tumor cell variants that may survive the elimination phase can enter the 
equilibrium, where the adaptive immune system prevents tumor outgrowth. In the equilibrium
phase, tumor cells can become functionally dormant and remain clinically unapparent. Since this 
phase can last for the entire life of the host, it can characterize a second stable endpoint of cancer 
immunoediting. Finally, due to changes resulting from an active immunoediting process, cancer-
induced immunosuppression or immune system failure, tumor cells can escape from immune 
control resulting in a clinically apparent tumor formation (Schreiber et al., 2011; Vesely et al., 
2011). In this line, since cancer immune-based approaches including vaccine therapies for 
melanoma have to deal with tumors that escaped immune control, it might be explainable why they 
often revealed limited overall success or even completely failed (Eggermont, 2009; Chi and Dudek, 
2011). Based on this condition, one might ask the question, if clinically apparent edited tumors, the 
targets of cancer therapy that grow in an immunologically unrestricted manner, are still feasible 
targets for immunotherapy. During the last years, many efforts of various research groups 
worldwide positively answered the question. For example, Galon et al. (2006) showed that the 
infiltration, the location and the density of T cells in tumors indicate a major prognostic factor of 
cancer patient outcome. Moreover, cancer-induced immunosuppressive mechanisms are now 
better understood (Eggermont, 2009).
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Nowadays, it is believed, that the immune system is capable of efficiently fighting the tumor 
growth when it receives help by powerful therapeutic intervention approaches. The checkpoint 
blockade of immunosuppressive molecules such as CTLA-4 or PD-1 on T cells represents an 
important possibility of such an intervention (Korman et al., 2006; Schreiber et al., 2011).            
For example, the therapy using CTLA-4 blocking Abs revealed a significant survival benefit in 
metastatic melanoma patients (Hodi et al., 2010; Wolchok et al., 2011). Thereby, the anti-tumor 
effect obtained through Ab blockade of, e.g., CTLA-4 resulted from increased T cell activation. The 
positive results of the checkpoint blockade showed also that antigens relevant for tumor targeting 
are still present in edited tumors and more important that it is still possible to fight cancer in an 
immunological fashion, even when the escape phase is already entered.
An effective immunotherapy is dependent on the quality and quantity of immune effector cells, 
including memory T cells (Kaech et al., 2002). In this thesis, it could be shown that high 
frequencies of pre-existing tumor antigen-reactive memory T cells are present in the PB of non-
metastasized melanoma patients while testing a broad variety of different melanoma TAA 
polypeptides in vitro (Figs. 25-27 and 33). After the resection of the tumor, the T cell responses 
strongly increased, which may implicate a protective relevance, meaning that TAA-reactive T cells 
are present in vivo. In order to provide their functional potential, they have to be reactivated. Based 
on the produced in vitro data, a potent peptide vaccine would result in an efficient memory T cell 
reactivation in vivo using for example long peptides for Melan-A/MART-1, Tyrosinase or NA17-A,
which revealed the highest response rates. At later time points above d60, the increased tumor 
antigen-reactive T cell frequencies declined to basal numbers in the PB. The decrease of 
TAA-reactive T cell frequencies could be explained by the hypothesis that cells might leave the 
blood and enter lymphoid immune organs including the bone marrow via circulation. It has been 
described that TAA-specific memory CD8+ T cells persist in high numbers in the bone marrow 
(Mahnke et al., 2005). In this context, the bone marrow microenvironment is suggested to have 
special features for the maintenance of immunological T cell memory. Furthermore, memory T cells 
have a self-renewal capacity and are characterized by their longevity (Schirrmacher et al., 2003). 
When they get specifically activated, at any later time point in life, memory T cells can mount 
efficient immune responses. Importantly, immune responses by memory T cells are faster and 
stronger than primary responses and their requirements for activation are less strict (Sallusto et al., 
2004). It has also been shown that they need lower antigen concentration and are less dependent 
on co-stimulation than naive T cells (Schirrmacher et al., 2003). For a durable prevention of tumor 
recurrence and metastasis formation, tumor-reactive memory T cell responses might therefore be 
required (Côté et al., 2008).
Although, non-metastasized melanoma is considered to be cured after the surgical removal of 
the primary tumor, still a moderate or intermediate risk remains for novel melanoma or metastases 
development, decades after apparently successful initial treatment (Cancer Research UK, 2010). 
Melanoma has a high metastatic potential and melanoma recurrence can occur very late and has 
been reported after a disease-free interval of 35 years (Tahery and Moy, 1993). Importantly, 
melanoma tumor dormancy through micrometastases or solitary dormant cells during a tumor 
Discussion
page | 172
equilibrium state might be, at least in part, responsible for the late cancer recurrence (Townson and 
Chambers, 2006; Strauss and Thomas, 2010). A high incidence of circulating tumor cells (CTC) in 
early melanoma, with 32 % in stage I and 42 % in stage II have been reported (Mocellin et al., 
2006; Strauss and Thomas, 2010). The early spread of CTCs is usually undetected by current 
high-resolution imaging techniques and therefore tremendous efforts are currently performed, to 
optimize sensitive immunocytochemical and molecular assays to detect CTCs at the single-cell 
stage (for reviews see Pantel et al., 2009; Pantel and Alix-Panabieres, 2010). Moreover, whether
CTC contain cancer stem cells is currently under debate, especially for melanoma (Panel et al., 
2009; Girouard and Murphy, 2011). Patients with melanoma micrometastases survive without 
metastatic relapse as long as solitary tumor cells or micrometastases are kept dormant in the 
immunocompetent host (Thomas, 2008; Strauss and Thomas, 2010). Nevertheless, considering 
the transmission of melanoma by apparent melanoma disease-free organ donors that had a 
previous history of melanoma, the presence of dormant tumor cells and in this context the role of a 
functional and effective immune control becomes obvious. Several case reports exist showing that 
dormant melanoma cells escaped in an immunosuppressed recipient after organ transplantation. In 
this line, melanoma is one of the most often reported and lethal donor-derived malignancies with a 
high tumor-transmission rate of 74 %, thereby showing 58 % mortality (Buell et al., 2004). Since 
even melanoma patients with early disease can harbor systemic dormant tumor cells that can 
survive unlimited, it has been advised that patients with early, apparently cured melanoma should 
not be considered as organ donors (Strauss and Thomas, 2010). The clinical relevance and the 
prognostic influence of CTCs in early melanoma in immunocompetent hosts are still unclear and 
therefore require further future investigations (Strauss and Thomas, 2010).
However, the presence of polyvalent spontaneously induced tumor antigen-reactive memory T 
cells, as detected in non-metastasized melanoma patients (Figs. 18-21, 24-27, 29 and 32-37) might 
be of importance in controlling potential tumor recurrence caused by CTC or micrometastases, 
based on the longevity of memory T cells. Furthermore, memory T cells can be boosted for 
therapeutic purposes at any time by the application of, e.g., peptide vaccines specific for TAAs.
The here presented investigation of spontaneous tumor-reactive memory T cell responses was 
performed with long synthetic polypeptides composed of 50 amino acids (aa). The strategy to use 
long polypeptide for T cell stimulation has several advantages, compared to short peptides with 
exact binding properties (for discussion see Melief and van der Burg, 2008). Thus, vaccination with 
exact short MHC-binding peptides, preferentially presented by MHC class I molecules (mainly HLA-
A2-restricted) reveals a popular approach that is widely used for cancer immunotherapy. But, apart 
from promising outcomes obtained in melanoma, so far this approach showed disappointing overall 
success, caused among other reasons, by an induction of only CD8+ T cell responses. Since long 
peptides are not able to bind directly to MHC molecules, they can induce more effective immune 
responses as they must be processed by dendritic cells before they can be presented to T cells 
(Melief and van der Burg, 2008). Therefore, the 50aa long polypeptides, used in this thesis, were 
constructed to cover at least one known MHC class I, HLA-A2-restricted epitope that has well been 
described in the literature (cf., Tab. 8). In addition, other putative MHC class I and II epitopes, 
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predicted by database analysis on the basis of computer algorithms were covered. In order to test, 
whether HLA-A2 negative patient-derived T cells recognized the polypeptides, patient samples 
were separated based on the expression of HLA-A2 by flow cytometry, into HLA-A2+ and HLA-A2-
patients. Importantly, TAA-derived polypeptides were recognized by both groups (Fig. 23). In line 
with this finding, CD8+ as well as CD4+ T cells of the same patient significantly recognized the 
tested synthetic melanoma polypeptides (Fig. 24). Thus, the designed polypeptides were proved to 
contain epitopes that can efficiently be recognized by HLA-A2+ and HLA-A2- T cells. Importantly, 
the investigation showed that the length of the polypeptides was sufficient to allow an efficient 
presentation on various HLA alleles.
The use of such polypeptides for cancer immunotherapy approaches has the mature advantage 
that patients not longer have to be selected according to the expression of defined HLA molecules. 
Moreover, an important implication might be that more patients and no longer only subsets of 
patients could benefit from the treatment. Through polyvalent induction of CD4+ and CD8+ T cells, 
both subsets can contribute together to the anti-tumor response. It has been shown that a synthetic 
peptide-mediated activation of CD4+ T cells is necessary for the induction and maintenance of 
efficient anti-tumor memory T cells over time (for discussion see Khazaie et al., 2009). 
Consequently, the lack of dependence on restricted HLA types might represent an important 
advantage to minimize the immune escape of cancer cells in a vaccination setting through 
downregulation of certain HLA alleles. For example, it has been described for melanoma, that HLA-
A2 is down-regulated with melanoma disease progression (Kageshita et al., 2001). 
The effectiveness of such peptide vaccination approaches can be confirmed by current 
vaccination studies. Exemplarily, a recent study of stage IV melanoma patients, that combined 
cancer vaccination with chemotherapy using a telomerase peptide vaccination together with the 
chemotherapeutic agent temozolomide, showed that the majority of patients (78 %) had 
telomerase-specific immune responses and developed long-term T cell memory (Kyte et al., 2011). 
Using this treatment, some patients developed partial tumor regression or showed a stable 
disease. Interestingly, in one patient a complete remission was reported. Thereby, the telomerase 
peptide sequence, used for this clinical trial, was selected on the basis of computer algorithms that 
predicted strong human HLA class I and class II binding motifs that can recruit CD4+ T helper cells 
and CD8+ CTLs.
Noteworthy, in the presented thesis, in addition to non-metastasized melanoma also T cells of 
metastasized melanoma patients showed polyvalent and HLA-type independent spontaneous 
tumor antigen-reactive T cell responses to the constructed synthetic 50aa polypeptides (Figs. 20, 
21 and 23). These observations indicate that the polypeptides can be efficiently used in order to 
induce pre-existing T cell responses in melanoma patients, independent of the disease stage and 
HLA-type. Importantly, since endogenous responses against human IgG were subtracted, the 
measured pre-existing T cell frequencies represented TAA-reactive frequencies. 
It is unlikely that the detected increased TAA-reactive T cell responses over time after resection 
of the primary tumor or lesion occurred as an unspecific response or side effect to the surgical 
intervention. The fact that in PB samples of the same patient before and after surgical resection 
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TAA-reactive T cell responses specifically increased over time, while TAA-unspecific responses 
against IgG did not alter in the same magnitude, support this statement (Fig. 29). Moreover, 
autoimmune markers investigated in the plasma of the patients, before and after resection, did not 
considerably increase, which also supports indirectly the previous interpretation (cf., Tab. 10).        
In addition, one would expect that if a T cell response had been induced by the surgical 
intervention, it would most likely be detectable soon after the resection. Since it is known that after 
antigen encounter it takes ~4-5 d until clonal expansion is completed and naive T cells have 
differentiated into effector cells (e.g., Murphy et al., 2008). Comparing the T cell responses in the 
??????????????????????????????????????? ???? ??????????? ???? ??????????????????????????????????????
elevated, as shown for both TAA-specific and -unspecific responses (Fig. 29A). But, in agreement 
with the cumulative data (Fig. 26), the TAA-specific T cell responses of the same patient increased 
strongly over time up to d 64 after resection, in a significant higher magnitude compared to control 
IgG (Fig. 29A). This indicates that at later time points after the resection, the cancer/lesion-induced 
suppression of specific immune responses is no longer taking place and therefore allows the 
increased manifestation of tumor specific pre-existing memory T cell responses. 
Even more interesting was the observation that using the synthetic polypeptides, significantly 
increased TAA-reactive memory T cell responses were detected in patients with dysplastic nevi 
lesions, compared to healthy donors (Figs. 22 and 37). Thereby, the frequencies of TAA-reactive T 
cells in dysplastic nevi patients were intermediate between healthy donors and melanoma patients. 
Moreover, the revealed T cell responses were higher after resection of the pre-malignant lesion 
compared to the responses measured before (Figs. 29A and 37). In this context, as already 
discussed for melanoma, the dysplastic nevi lesions, indicating benign neoplasms of melanocytes, 
seemed to control pre-existing memory T cell responses in the PB. This observation of a lesion-
dependent immune control also indicated that already pre-malignant dysplastic nevi lesions might 
be edited and escaped immune control. In agreement with other research observations, this data 
suggests that during melanoma genesis immune tolerance is early induced, in order to favor 
melanoma growth (Mourmouras et al., 2007). Importantly, in this context, it has been shown that 
already dysplastic nevi contain mutations that are reported for melanoma including BRAF and 
NRAS mutations (Poynter et al., 2006; Wu et al., 2007). Therefore, they are placed in a tumor 
progression lineage with melanoma, intermediate between common nevi and melanoma.
Moreover, they present a pre-malignant stage that indicates an increased risk of developing 
cutaneous melanoma (Edler, 2010). Depending on the study conducted about 25-50 % of 
melanoma tumors have been shown to derive from a histological associated nevus, thereby often 
from a dysplastic nevus (Edler, 2010; Ko et al., 2010). Because of their relative small size and
questionable malignant potential, melanocytic dysplastic nevi lesions have previously been studied 
less extensively (Hussein, 2005), but gained more attention during the last years. In this context, a 
recent study investigated the molecular profiling of dysplastic nevi and identified altered biological 
processes (Scatolini et al., 2010).
Despite the fact that CD3+ tumor-infiltrating lymphocytes (TILs) were detected in dysplastic nevi 
in contrast to benign nevi, where they are almost absent (e.g., Hussein et al., 2006; Mourmouras et 
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al., 2007), little is known about circulating pre-existing melanoma TAA-reactive memory T cells in 
dysplastic nevi patients. Summarized, this thesis for the first time reports the presence of these 
T cells in the PB of dysplastic nevi patients. In response to synthetic 50aa melanoma polypeptides 
the presented data indicated a cell population that could be specifically reactivated through peptide 
vaccination. Moreover, based on the fact that at least a proportion of melanoma develops from 
dysplastic nevi, these lesions and the underlying immune reactions through, e.g., pre-existing 
memory T cell responses may provide further important insights into mechanisms of melanoma 
progression and may disclose possible future treatment interventions.
In the course of my thesis it additionally could be shown that in the PB of non-metastasized 
melanoma patients after resection of the primary tumor on average 5 % of the CD4+ T cells were 
Foxp3+ Treg (Fig. 30). This number was comparable to the Treg percentage detected in the PB of 
healthy donors and is in accordance with data recently shown by other research groups (e.g., 
McCarter et al., 2007). In this reports, healthy donors and stage I melanoma patients had 
comparable amounts of circulating Treg of about 6 % whereas stage IV metastasized patients had 
a doubling of Treg compared to the other two cohorts. In the PB of the metastasized patients 
~12 % circulating Treg were detected, in accordance with a more immunosuppressive phenotype in 
????????? ?????????? ?????????? ??? ???? ????? ?????? ????? ????? ?????? ??????? ????? ??????????????
higher in stage I and stage IV melanoma patients compared to healthy donors (McCarter et al., 
????????????????????? ??????? ?n stage I patients were intermediate between normal controls and 
stage IV patients. It is known that Treg mediate their suppressive function preferentially through 
??????????? ?????????? ?????????????????????? ???????????????????????????????????????? ?????? ???ls in 
order to induce an immune suppressive state, while inhibiting immune cell functions (Vignali et al., 
2008; Wan and Flavell, 2008; Lohr et al., 2011; Vesely et al., 2011). Moreover, Treg have been 
described to affect both, innate and acquired immunity and are regarded as the primary mediators 
of peripheral self tolerance. They are involved in a variety of human disorders such as autoimmune 
diseases, infectious and inflammatory diseases, allergies, organ transplantation and cancer (for 
reviews see, e.g., Vignali et al., 2008; Sakaguchi, 2011). Importantly, in melanoma, Treg have 
been described to induce immune tolerance in order to favor melanoma growth and control 
immune responses through inhibition of T cell proliferation (Mourmouras et al., 2007; Niu et al., 
2011).
In agreement with reports on PB samples of breast and colon carcinoma patients (Bonertz et 
al., 2009; Ge, 2009), this thesis shows that the depletion of Treg in some investigated non-
metastasized melanoma patients after primary tumor resection led to increased recognition rates of 
TAA polypeptides by tumor antigen-reactive memory T cells (Fig. 32). The data revealed that in 
these patients pre-existing TAA-specific immune responses were suppressed by Treg. This was 
observed in ~16 % of all patients investigated. In this line, TAA-reactive T cell responses especially 
for Melan-A/MART-1, p53 and Tyrosinase were shown to be preferentially controlled by Treg. In 
contrast to the findings in the melanoma cohort, it has been reported for colon carcinoma that Treg-
mediated T cell inhibition was predominantly not observed for the p53 antigen, which was defined 
as a “Treg-independent antigen” for colon carcinoma (Bonertz et al., 2009). Although, p53-specific 
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T cells have been reported to be present in a majority of human cancers (e.g., Chikamatsu et al., 
1999; Hoffmann et al., 2000; Albers et al., 2005), the Treg-mediated control of those p53-reactive 
T cell responses seems to differ for the individual cancer cohorts. In agreement with the
observation made in this thesis that Melan-A/MART-1 T cell responses were suppressed by Treg, 
an in vivo depletion study of Treg in melanoma patients, that used recombinant IL-2-diphteria toxin 
fusion protein (ONTAK), led to enhanced immune functions. This was characterized exemplarily 
through induction of Melan-A/MART-1-specific CD8+ T cells (Mahnke et al., 2007).
Unexpectedly, however, the cumulative data of 36 non-metastasized patients showed that the 
Treg depletion did not lead to a further increase in the frequency of pre-existing TAA-reactive 
memory T cells in the investigated cohort in respect to the total patient group. This observation was 
independent of the time point that was investigated after resection of the primary tumor and was 
seen for all analyzed TAAs (Figs. 33-35). Furthermore, a reduction of T cell frequencies after Treg 
depletion was shown to be a result of a co-depletion of conventional T cells, indicated by 
investigating the depleted cell fraction for the marker proteins CD127 and Foxp3. As previously 
mentioned by other groups that used for Treg depletion, out of the CD4+ population, a protocol that 
focused on CD25 high cells, besides Treg conventional T cells were also depleted (Fig. 40; see 
also, Lahl et al., 2007). Since CD127 is present in the majority of mature T cells but absent on 
Treg, a flow cytometry staining using Abs against CD127 and Foxp3 allowed the distinction of Treg 
and conventional T cells. Moreover, the presence of CD127 has shown to be inversely correlated 
with Foxp3 expression (Liu et al., 2006; Seddiki et al., 2006). 
Based on the cumulative analysis no essential role of Treg in controlling spontaneous TAA-
reactive T cell responses was observed after surgical removal of the primary tumor. In view of this 
finding, the biological background of the melanoma patients might be of importance. The reason 
may be that the studied cohort represented a group of patients that were non-metastasized and the 
primary tumor was already resected at the time of PB examination. It can therefore be assumed 
that the analyzed patients were tumor free, with the restriction of a possible presence of undetected 
dormant CTCs or micrometastases that are most likely immune controlled (see, e.g., Barnhill, 
2001; Mocellin et al., 2006; Thomas, 2008; Strauss and Thomas, 2010). In this context, after 
resection a central tumor-mediated immune suppression mechanism that may include immuno
suppressive cellular mediators such as Treg might not longer be functionally active. This 
interpretation is supported on the one hand by the observation that the frequency of pre-existing 
memory TAA-reactive T cells significantly increased after tumor resection over time and on the 
other hand by the fact that Treg depleted T cell responses were not additionally increased. In 
contrast, as exemplarily shown for colon carcinoma in tumor-bearing patients, Treg depletion led to 
an increased recognition of most of the investigated TAAs by tumor antigen-specific memory         
T cells (Bonertz et al., 2009). This observation, however, allow the interpretation that in the tumor-
bearing patient cohort pre-existing TAA-specific immune responses were suppressed by Treg 
(Bonertz et al., 2009).
Besides circulating Treg, tumor-infiltrating Treg have also been reported for several cutaneous 
melanoma lesions, including dysplastic nevi as well as primary and metastatic lesions 
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(Mourmouras et al., 2007). Nevertheless, the performance of repeated analyses in some patients, 
before and after resection, revealed that a depletion of Treg did not result in significantly increased 
TAA-reactive T cell frequencies, independent if the lesion was present or not (Fig. 37). However, in 
the presence of the respective lesion, pre-existing Treg with TAA specificities for MDM2, p53, 
Tyrosinase and Melan-A/-MART-1 as well as for human IgG could be detected in the circulation of 
dysplastic nevi and melanoma patients (Fig. 39). In contrast, after tumor resection, the number of 
detected specific Treg strongly decreased, since only Treg with specificities for p53 and IgG could 
be observed. This observation implicated that functional specific Treg seemed to be reduced after 
removal of the lesions or that the detection method was not sensitive enough, which may be 
caused by low cells frequencies. Finally, the investigations showed that even TAA-specific Treg are 
present in the PB of non-metastasized melanoma and dysplastic nevi patients, while a central role 
of Treg in controlling pre-existing TAA-reactive memory T cell responses could not be observed. 
Consequently, the tumor or lesion-mediated suppression of TAA-reactive memory T cell responses 
might preferentially by facilitated via other effector mechanisms of immunosuppression. Thereby,
combinations of soluble and cellular mediators are most likely. Besides Treg, further potent 
???????????????????????????????????????????????????????-4, PD-1, MDSCs or M2 macrophages 
(for recent literature see, e.g., Sakuishi et al., 2010; Sica, 2010; Tarhini and Iqbal, 2010; 
Goedegebuure et al., 2011; Heitger, 2011; Schreiber et al., 2011; Solito et al., 2011).
Moreover, based on the findings that no specific Treg for NA17-A were detected, irregardless of 
the dysplastic nevi or melanoma cohort, this 50aa long peptide might be useful in terms of peptide 
vaccination. The generated synthetic polypeptide efficiently reactivated pre-existing NA17-A-
reactive memory T cell responses in dysplastic nevi and melanoma patients without inducing 
NA17-A-specific Treg (Figs. 22, 25, 29 and 39). In this line, the frequency of NA17-A-reactive 
T cells significantly increased over time after primary tumor resection (Fig. 27). Importantly, besides 
the known HLA-A2-restricted epitope that was shown to efficiently induce CD8+ T cell responses 
(Guilloux et al., 1996; Fonteneau et al., 1997), the long peptide sequence contained further 
predicted HLA-A2 independent epitopes, that were useful to additionally induce responses of CD4+
T cells (Fig. 24).
Derbinski et al. (2001) showed that tissue-specific antigens like gp100 and Tyrosinase are 
expressed in adulthood in the thymus by mTECs, in a process termed as “promiscuous gene 
expression”, that is important for the induction of T cell tolerance to self-antigens and induction of 
Treg (for review see also Kyewski and Klein, 2006). Nevertheless, promiscuous gene expression 
for NA17-A has so far not been reported. Moreover, as already discussed, the synthetic long 
peptide sequence for the atypical peptide NA17-A is partially coded through an intron-based 
nucleotide sequence and therefore is naturally not translated into a protein (cf., Fig. 16; Guilloux et 
al., 1996). Especially in melanoma cells, a cryptic promoter within the intron sequence is active and 
lead to the transcription of a known HLA-A2-restricted epitope (Guilloux et al., 1996) that is 
comprised by the generated 50aa peptide sequence. HLA-A2-restricted NA17-A peptide 
vaccination has already been used for clinical trials as part of combinational treatments for 
melanoma patients. For example, currently a randomized phase II clinical trial that used NA17-A
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short peptide vaccination was conducted in patients with metastatic melanoma 
(http://clinicaltrials.gov /NCT00064168, ID: CDR0000309519). The trial applied a vaccine therapy 
of peptide-pulsed autologous PBMC together with IL-12, with or without low-dose IL-2. In addition, 
a peptide mixture of MAGE-3, MART-1, gp100 and NA17-A was used. Furthermore, a multicenter 
randomized phase III clinical trial with HLA-A2+ primary ocular melanoma patients has been 
performed using vaccination with NA17-A, Tyrosinase, Melan-A and gp100 short peptides 
(http://clinicaltrials.gov/NCT00036816, ID: CDR0000069325). Finally, a third study currently started 
to recruit metastatic melanoma patients. This phase II clinical trial uses a vaccine therapy with 
MART-1, gp100, MAGE-3 and NA17-A short peptides together with or without IL-12 and the 
humanized mAb against CD25, daclizumab. Thereby, daclizumab is aimed to deplete CD4+CD25+
Treg (http://clinicaltrials.gov/NCT01307618, ID: CDR0000696233). However, the effectivity of the 
individual treatment interventions and a possible superior role of the NA17-A vaccination will be 
seen in the future.
9.2. In vivo tumor growth control by optimized TCR transgenic human T cells
Nowadays, adoptive immunotherapy is used for cancer treatment and especially for melanoma 
revealed promising results (cf., Dudley et al., 2005, 2008). In this context, T cell receptor (TCR) 
gene therapy gained increased importance for adoptive transfer treatment interventions. In mouse 
tumor models and initial studies in melanoma patients, the programming of T cells with genes 
encoding antigen-specific TCR were shown to be functional, although the efficacy in humans in 
terms of low response rates was limited so far (Xue et al., 2005; Morgan et al., 2006; Johnson et 
al., 2009). Nevertheless, this method represents a great advantage, since TCRs directed against 
any desired target antigen, including TAAs, can be generated and introduced into T cells. 
To provide self-tolerance under normal conditions in the host, high-avidity T cells are eliminated 
from the T cell repertoire during the negative selection process that occurs in the thymus            
(von Boehmer et al., 1989; Robey and Fowlkes, 1994). However, high-avidity T cells might be 
needed in order to facilitate effective anti-tumor reactions (Kieback and Uckert, 2010). On the one 
hand, since high-avidity T cells can be generated with this gene transfer method, adoptive transfer 
of TCR engineered T cells might help to overcome the limitation caused by the self tolerance 
mechanism. On the other hand, caution should be demanded in the generation of the constructs as 
long as the target antigen is not exclusively restricted to the tumor and might also be expressed on 
normal tissues. Under these circumstances, “on-target” toxicity on healthy tissue might be possible 
(for review see Kieback and Uckert, 2010). 
Moreover, the correct pairing of the introduced exogenous TCR chains is crucial in terms of 
safety aspects and represents currently an important field of research. When introduced into 
human T cells, the transfer of exogenous TCRs, which consist of two chains, can potentially lead to 
hybrid/mixed dimer formation with endogenous TCRs. The undesired pairing of the introduced TCR 
chains with the endogenous chains has two principle consequences. First, it reduces the correct 
pairing of the introduced engineered TCRs on the cell surface, resulting in a restricted 
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effectiveness of the treatment. Second, TCRs with unpredictable specificities can occur and may 
cause “off-target” reactivities, potentially leading to autoimmune reactions, since those transgenic 
T cells have not been negatively selected in the thymus (Schumacher, 2002; Kieback and Uckert, 
2010). Thereby, the general possibility of mispaired hybrid heterodimers could already be shown 
(Sommermeyer et al., 2006; Heemskerk et al., 2007). Currently, different strategies are 
investigated to avoid misspairing and promote preferential pairing, such as the modification of the 
?????????? ??????? ??? ???? ??????? ?????????? ??? ???? ??????????? ??? ???-like molecules (Voss et al., 
2008, 2010; see also Kieback and Uckert, 2010). In order to evaluate the advances made in the 
generation of TCR transgenic T cells, mouse studies have to be conducted to investigate the         
in vivo potential of those optimized constructs. 
Parts of the presented thesis, in a collaboration project, dealed with TCR transgenic T cells with 
specificities for the antigens MDM2 or gp100 that had been optimized in order to avoid the 
formation of hybrid TCRs. Thereby, the efficiency of the optimized MDM2 and gp100 TCR 
transgenic human T cells to control tumor growth was shown for the first time in an in vivo murine 
xenotransplantation model (Voss et al., 2010).
Therefore, as target cell line, cells of the human melanoma line MeWo, established from a 
lymph node metastasis of a nodular melanoma (Bean et al., 1975; Carey et al., 1976) were used. 
As melanocytes in the basal layer of the epidermis have been specifically stained with vimentin 
(Mahrle et al., 1983), the melanocyte-derived origin of the MeWo cells was controlled by analyzing 
the intermediate-sized filaments vimentin as well as keratins 8 and 18. Vimentin which primarily 
indicates cells of mesenchymal-derived origin (Franke et al., 1978) was positive in the MeWo 
cells, whereas keratins 8 and 18 which are used to differentiate cells of epithelial-derived origin 
were negative (cf., Fig. 41; for reviews see also Moll et al., 1982, 2008; Kurokawa et al., 2011). In 
addition, the melanocyte antigens gp100 and Melan-A/MART-1 were shown to be positive.
Moreover, MeWo cells were revealed to be HLA-A2+ and MDM2+ (Figs. 41, 42 and 45). These
observations agreed with the analyses of other groups that also showed positivity of MeWo for 
HLA-A2, MDM2 and gp100 (cf., Bakker et al., 1994; Schreurs et al., 1998; Pedeux et al., 2002). 
The presence of these three markers indicated a precondition to be used as target line for 
recognition by the MDM2 or gp100 TCR engineered T cells, since their TCRs only recognize the 
respective peptide epitopes in a HLA-A2-restricted manner. In addition, the MeWo cell line has 
widely been used for studies on the basis of human tumor xenograft mouse models (e.g., Cornil et 
al., 1989; Skobe et al., 2001; Petrangolini et al., 2003; Schoensiegel et al., 2004). Mouse 
xenotransplantation models using immunocompromised mice, are important instruments to 
investigate factors involved in malignant transformation, invasion and metastasis. Moreover, they 
are used to study responses to therapies including cancer therapeutic approaches in vivo
(Thallinger et al., 2003; Richmond and Su, 2008). The disadvantages of these models are that the 
stromal components of the developing tumors are rodent and the hosts are immunodeficient. 
Nevertheless, since human tumor xenograft models comprise human malignant cells and are 
reproducible, they present clinically relevant tumor models (Sausville and Newell, 2004; Teicher, 
2006). 
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During the course of the presented thesis, the cells of the line MeWo were injected i.d. onto the 
flank of NOD-SCID or NSG mice, resulting in a tumor formation in all treated mice. Since the cells 
were implanted into the tissue of their origin, the performed administration indicated an orthotopic 
model (Petrangolini et al., 2003). Besides the MeWo parental cells, firefly luciferase stable 
transfected MeWo cells were used as target line for the xenotransplantation model. The 
advantages of labeled tumor models are that the tumor growth can be visualized in vivo with 
imaging approaches and metastases can be detected (Teicher, 2006). 
The in vivo tumor growth control in response to MDM2 or gp100 TCR-redirected T cells was 
analyzed and showed that human T cells transduced with optimized TCR constructs, in order to 
avoid the formation of mixed TCR dimers, efficiently controlled the tumor growth. The highest 
reactivity and strongest control was revealed for the constructs, of a gp100 scTCR that co-
expressed a consta??? ????????????????????????????????????? ?????????? ????????????? ?????? ???????
dcTCR, that comprised a reciprocal Arg/Gly amino acid mutation in the core C-domain interface 
(Figs. 56 and 58). Correspondingly, the optimized TCR constructs were generated based on two 
different strategies to prevent the formation of mispaired heterodimers. First, to favor the specific 
pairing of the MDM2 TCR chains an approach was utilized to modify the molecular design of the 
???? ??? ?????????? ?????? ??? ????? ??????? ????????? ???? underlying concept was a reciprocal 
replacement of amino acid residues at the interface of the TCR ????????? ????????????????????????
configurational changes resulted in a selective assembly of the introduced TCR chains with 
preserved receptor functions including TCR specificity and avidity for antigen fragment ligands 
(Voss et al., 2008). Moreover, the analyzed high-avidity HLA-A2-restricted MDM2 TCR constructs 
indicated murine TCRs. Originally, the MDM2 TCR was generated in a partially humanized, HLA-
A2.1 transgenic mouse model while performing an immunization with the human MDM2 (81-88) 
peptide (Stanislawski et al., 2001). This short peptide indicates a tumor antigen that is presented by 
HLA-A2 and has shown to be recognized by MDM2-specific CTLs (Stanislawski et al., 2001). 
Moreover, this sequence is integrated in the 50aa long peptide for MDM2 that had successfully 
been used in order to reactivate pre-existing TAA-reactive memory T cells in the PB of melanoma 
and dysplastic nevi patients (cf., Figs. 18 and 22). The transforming potential of the ubiquitous self-
protein MDM2 resulting by over-expression, leads to the inactivation of the p53 tumor suppressor 
gene (Momand et al., 1992). In this line, high levels of MDM2 have shown to be present in a 
number of human tumors (Finlay, 1993; Leach et al., 1993; Freedman and Levine, 1999). In 
agreement, MDM2 positivity was revealed for a panel of melanoma cell lines as well as for the 
breast adenocarcinoma cell line MCF-7 (Fig. 41).
It has been further reported that murine TCRs can efficiently replace human TCRs on the 
human T cell surface, indicating the potential of mouse-derived TCRs in the course of human 
therapeutic interventions (Sommermeyer et al., 2006). As it might be possible that murine amino 
acids are immunogenic in humans and cause the elimination of the transferred engineered T cells, 
human trials have therefore been combined with non-myeloablative lymphodepletion (Kieback and 
Uckert, 2010). In this line, a clinical trial that used a complete murine TCR showed that the cells 
can persist in humans (Johnson et al., 2009). Interestingly, Voss et al. (2006) demonstrated that a 
Discussion
page | 181
humanized version of the MDM2-specific Wt murine TCR revealed diminished functions. Thus, in 
order to mount equivalent cytotoxicity, the transgenic T cells showed a higher demand for peptide 
than the murine TCR.
Nevertheless, a crucial requirement for an effective use of TCR gene therapy involving adoptive 
transfer of TCR gene-modified T cells is the sufficient expression of transferred TCRs. In this 
direction, it could be shown that murinization of constant regions of human TCRs led to improved 
chain pairing, elevated TCR expression and function (Cohen et al., 2006). Recently, Sommermeyer 
and Uckert (2010) identified nine critical amino acid residues that differ between mouse and human 
constant regions, allowing to generate minimal murinized human TCRs. Those chimeric TCRs 
show an enhanced expression compared to complete human TCRs. Most likely, minimal murinized 
therapeutic TCRs will not be immunogenic in humans while preserving the positive effects of 
murinization. 
The second TCR gene-modified T cell approach investigated during this thesis used gp100 
specific TCRs. As strategy to promote preferential pairing, Voss et al. (2010) developed a novel 
3-domain scTCR approach with murine constant regions that additionally co-expressed a constant 
??????? ?? ??????? ??? ?????? ??? ??????????? ?? ??????? ???? ??????????? ???? ???????????? ???? ???????????
original HLA-A2-restricted gp100 dcTCR that recognizes the gp100 peptide (280-288) has 
previously been generated (Schaft et al., 2003). The melanoma TAA gp100 is a melanocyte 
linage/differentiation antigen, from which various epitopes have been described, that can generate 
antitumor immune responses in melanoma patients. Moreover, it has also successfully been used 
in clinical trials (Rosenberg et al., 2003; Schwartzentruber et al., 2009). 
So far, affinity of scTCR constructs were shown to be reduced compared to full-length TCRs 
(Zhang et al., 2004). Therefore, of importance is the here presented observation that optimized 
chimeric gp100 scTCR constructs revealed the highest reactivity in terms of tumor growth control in 
NOD-SCID mice in vivo and were even superior compared to the Wt dcTCR (cf., Fig. 58). In this 
line, an optimized scTCR with an additional disulfide bond between the constant domains showed 
the best results. Naturally, the TCR ??????????????? ???? ??????????? ?????????? ?? ???????????????????
bond between the constant regions (Kieback and Uckert, 2010). Thereby, interestingly, the 
introduction of a secondary cysteine bridge enhanced the preferential pairing and improved the 
TCR expression and function (Kuball et al., 2007). In addition, the observation that the tumor 
growth was even significantly reduced after a secondary tumor challenge in the same animals 
indicated a persistent and memory T cell response of the transduced TCR engineered T cells        
in vivo. Since the TCR gene-modified T cells showed an effector memory-like phenotype with a 
CD27 expression in some cells (Fig. 54), the revealed phenotype supported this observation. It has 
been described that CD27 promote long-term survival and persistence of functional effector 
memory T cells in vivo (Ochsenbein et al., 2004). Therefore, it can be assumed that a fraction of 
the transferred T cells persisted in vivo as a less-differentiated, peripheral effector memory-like 
T cell subset or gave rise to central memory-like T cells that could home to secondary lymphoid 
organs (Sallusto et al., 2004; Schwendemann et al., 2005; Romero et al., 2007; Ahmed et al., 
2009). Moreover, using optimized scTCR modified T cells, the persistence of effector memory-like 
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T cells and their ability to exert immediate rapid effector functions might be responsible for the 
observed stronger tumor growth control of the secondary compared to the primary tumor.
Nevertheless, in none of the in vivo experiments the tumor was completely rejected by the 
therapeutic TCR gene-modified T cells and only a tumor growth control could be observed. This 
might be due to insufficient presentation of the specific peptide epitopes through the HLA-A2 
molecules of the melanoma cells. Additionally, using TCR gp100 transduced T cells, as effector
cells, a specific lysis of MeWo cells in vitro did not exceed 50 % and normally reclined between 20-
50 % (Fig. 77; see also Voss et al., 2010). 
The fact, that the here shown combination of a 2 Gy local low dose irradiation of the tumor and 
adoptive T cell transfer of scTCR gp100 transduced T cells further helped to control the tumor 
growth compared to the single approaches, indicated the efficiency of combinational treatments. 
It is well known that irradiation can efficiently kill tumor cells and release tumor antigens that can be 
presented to T cells (e.g., Watters, 1999; Larsson et al., 2001). The impact of a local low dose 
irradiation of the tumor for importance of T cell tumor targeting has been shown for the RIP1-Tag5 
mouse model of spontaneous insulinomas (Seibel, 2010). Here, a strong infiltration of T cells into 
the tumor could be detected when the tumor was irradiated locally, thereby irradiation with 2 Gy 
revealed consistent responses in terms of increased T cell infiltration. That irradiation affected the 
aberrant tumor vasculature, leading to a normalization of the capillaries accompanied by infiltration 
of TAA-specific effector T cells, has also previously been shown (Ganss et al., 2002). In 
agreement, here demonstrated, tumor-infiltrated human CD45+ cells were only detected in the 
combinational approach of 2 Gy tumor irradiation together with adoptive transfer of TCR 
engineered T cells (Figs. 69 and 70). However, the low CD45+ cell numbers that were detected 
inside the tumors might be due to the type of animal model used, since the effect of irradiation 
might be more pronounced in an immunocompetent environment. It has been shown that during 
the phase of vasculature normalization and tumor regression, caused by irradiation, besides TAA-
specific T cells, further immune cells including macrophages, are strongly involved in the process 
of tumor rejection (Ganss et al., 2002). Thereby, macrophages trigger the infiltration of T cells by 
production of nitric oxide (NO). In the absence of macrophages or NO the tumor growth was no 
longer controlled, independently if T cells were present or not (Seibel, 2010). Since 
immunodeficient mice including NOD-SCID and NSG have defects in function and activity of 
immune cells (Shultz et al., 1995, 2005; Zhou et al., 2003), the revealed low infiltration rate of 
human transgenic T cells into the tumor might be explainable. However, the here presented study 
was able to show that TCR transgenic T cells, generated in order to avoid hybrid TCR formation, 
were effective in terms of in vivo tumor growth control. Moreover, especially in a combinational 
setting with local low dose tumor irradiation they obtained promising results. Future studies have to 
show, whether the in vitro optimized TCR constructs that revealed to be functional in animal studies 
in vivo might have a clinical impact.
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9.3. Tumor-mediated immune suppression through cell adhesion molecules
Malignant tumors escape immune recognition through a panel of different strategies including the 
reduction of immune recognition, increased resistance to cytotoxic effects of immunity as well as 
cancer-induced immunosuppression (for recent references see, e.g., Khong and Restifo, 2002; 
Zitvogel et al., 2006; Schreiber et al., 2011; Vesely et al., 2011). Thereby, tumors suppress immune 
responses through immunosuppressive cytokines, the recruitment of regulatory immune cells or 
expression of molecules that are able to mediate inhibitory responses that control the activation 
status of T cells.
In this context, the cell adhesion molecule CEACAM1 has been discussed in order to facilitate 
immunosuppressive mechanisms of melanoma cells while developing a resistant phenotype upon 
recognition by specific T cells (Markel et al., 2006). Thus, homophilic interactions of CEACAM1 
molecules, expressed by melanoma cells and activated T cells were shown to be responsible for 
the inhibition of T cell properties including speci??????????????????????????????????????????????????? ???
could also be shown that melanoma cells are able to increase their surface CEACAM1 expression 
in an active process which resulted in enhanced resistance against autologous or allogenic TILs 
(Markel et al., 2008). CEACAM1 has the ability to recruit Src homology domain 2-containing 
tyrosine phosphatase-1 (SHP1) to its cytoplasmic tail (Nagaishi et al., 2006), that causes 
dephosphorylation of the protein tyrosine kinases Lck and ZAP-70, resulting in the inhibition of TCR 
signaling and thus interfere in T cell activation and cell proliferation (Smith-Garvin et al., 2009). 
Correspondingly, in T cells CEACAM1 has a predominantly inhibitory function.
Normally, in resting T cells CEACAM1 is stored in intracellular vesicles and only low levels are 
expressed on the surface of CD4+ cells (Gray-Owen and Blumberg, 2006). But, within minutes after 
cellular activation high levels of CEACAM1 can be detected on the cell surface of CD4+ and CD8+
T cells (Kammerer et al., 1998; Nakajima et al., 2002). Thereby, the kinetic of CEACAM1 
mobilization was shown to be comparable to the early activation molecule CD69. Consequently, 
CEACAM1 preceded the activation-induced expression of the inhibitory receptor CTLA-4, indicating 
that CEACAM1-mediated inhibition can function before CTLA-4-mediated inhibition occurs (Gray-
Owen and Blumberg, 2006). Furthermore, CEACAM1 has shown to be expressed on T cells also in 
vivo (Morales et al., 1999). However, the reason that only CEACAM1 and no other CEACAM-family 
members are expressed on T cells may indicate a unique role for CEACAM1 in terms of T cell 
function (Gray-Owen and Blumberg, 2006).
Accordingly, since with exception of melanoma, many other tumors do not express CEACAM1, 
during the presented study an immunosuppressive function of further CAMs was addressed. 
Interestingly, it could be shown that as a result of CEACAM6 and L1CAM expression on tumor 
cells, human autologous and allogenic TCR-engineered T cell responses against human tumor 
cells were functionally suppressed. CEACAM6 was detected on a panel of different human 
adenocarcinoma and multiple myeloma cell lines (Fig. 71). This observation has been confirmed by 
other groups who detected high levels of CEACAM6 on different cell lines that, e.g., derived       
from colon, breast, pancreatic or lung cancer (Scholzel et al., 2000; Blumenthal et al., 2007;           
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Singer et al., 2010). In accordance to the data presented as part of this thesis, a pronounced 
CEACAM6 presence has been revealed on various adenocarcinoma lines. Moreover, CEACAM6 
has shown to be associated with increased potential for metastases formation in vivo resulting in 
reduced survival (Duxbury et al., 2004). Through CEACAM6 inhibition, the ability of pancreatic 
adenocarcinoma cells to form liver metastases decreased (Duxbury et al., 2004). The present 
study clearly shows that an inhibition of CEACAM6 on tumor cells revealed increased functional 
T cell responses, mediated by ?????????? ????? ??????????? ?????? ????? ??????????? ???? ?? ?????? ?????
competent to accomplish intensified specific tumor cell killing (Figs. 72, 75 and 76). Thereby, the 
immunosuppressive role of CEACAM6 might be comparable to the verified role of tumor-expressed 
CEACAM1 in terms of T cell response inhibition and can be interpreted as a mechanism to escape 
recognition by effector T cells. Moreover, also heterophilic interactions of CEACAM molecules have 
been shown to occur (Oikawa et al., 1991). Therefore, it might be conceivable that CEACAM6 on 
the surface of tumor cells exerts T cell inhibition through binding to CEACAM1 molecules on the 
T cell surface. So far, however, heterophilic interactions between CEACAM1 and CEACAM6 have 
not been described. 
Besides CEACAM6, preliminary data revealed an immunosuppressive role of L1CAM. In 
accordance to previous studies, cells of the melanoma cell line MeWo showed high L1CAM levels 
(cf., Figs. 41 and 77; see also Thies et al., 2007). Furthermore, besides melanoma, L1CAM has 
also been reported for a number of further cancer types including ovarian and colorectal 
carcinomas and is correlated with an adverse prognosis for the cancer patients (Fogel et al., 2003; 
Kaifi et al., 2007). Moreover, especially shown for melanoma it has been revealed that L1CAM 
presence on tumor cells lead to increased proliferation, cell migration and invasive capacities 
(Meier et al., 2006). Finally, in contrast to Balaian et al. (2000) who reported a co-stimulatory 
function of L1CAM for T cell activation through homophilic binding of L1CAM molecules, in the 
present report the specific inhibition of L1CAM on tumor cells revealed a significant increase of 
cytolytic T cell function against melanoma cells (Fig. 77). This finding may indicate that melanoma 
cells take advantage not only of CEACAM1 but most likely in addition other CAMs including 
L1CAM in order to mediate their escape from immune control. To proof this hypothesis, further 
studies will have to be conducted in the future. 
9.4. Human tumor cell infection by T cell-transferred Newcastle disease virus 
In order to efficiently fight tumor growth, besides the direct use of the immune system through 
cellular components including TAA-specific T cells, oncolytic virotherapy can additionally be used 
for cancer intervention. So far, a combination of immune cell and viral therapy for the treatment of 
cancer demonstrated efficiency in a number of murine- and human-based studies (e.g., 
Schirrmacher, 2005; Thorne and Contag, 2007; Qiao et al., 2008; Schulze et al., 2009). Despite the 
knowledge about anti-tumor responses of viruses and viral-transfer vectors, the efficient viral 
targeting of the tumor tissue represents still a crucial problem. The reason is that, the virus has to 
transit through several distinct tissues in order to reach the tumor target in a tumor-bearing host. 
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Therefore, after systemic application the majority of the viral vectors may distribute in various 
normal tissues and in addition, a part of the virus might also become neutralized in the PB.
Consequently, to increase the efficiency of the viral treatments, different approaches have been 
addressed. For example, the targeting of Newcastle disease virus (NDV) could be shown to be 
improved using bispecific adapter proteins (Bian et al., 2006). Nevertheless, efficient tumor 
targeting of oncolytic viruses remains still a major problem. 
As part of the presented thesis, the loading of human T cells with NDV was described for the 
first time in an in vitro co-culture system (Pfirschke and Schirrmacher, 2009). In this context, the 
NDV-loaded T cells were able to transfer the virus in a “hitchhiking”-like process to tumor cells, 
leading to tumor cell infection and destruction, while affecting the tumor growth behavior. 
Interestingly, this observation is in agreement with studies of other groups that could show a 
transfer of retrovirus and vesicular stromatitis virus on blood circulating cells (Cole et al., 2005;
Rooney, 2005; Qiao et al., 2008). Based on the revealed transfer mechanism of virus particles, it 
can be assumed that circulating tumor-homing T cells indicate effective virus carriers in order to 
facilitate tumor targeting.
In general, oncolytic virotherapy is a strategy for cancer therapy implemented by viruses that 
feature tumor selective replication, cell lysis of tumor cells, viral spread and the induction of anti-
cancer immune responses. However, the effectiveness of the oncolytic cancer virotherapy is 
primarily based on the characteristic of the virus type used. In this line, for NDV anti-neoplastic and 
immune stimulatory properties have been reported (Csatary et al., 2004; Schirrmacher, 2005; 
Freeman et al., 2006; Schirrmacher and Fournier, 2008). Moreover, NDV shows a tumor selective 
replication, while normal cells induce a strong anti-viral gene expression in response to NDV 
infections that triggers a virus-resistant phenotype (Wilden et al., 2009). Thus, in response to 
doubled stranded viral RNA several cellular defense mechanisms are activated in normal cells 
including type I IFNs. In contrast, it has been shown that in tumor cells the IFN response is often 
inefficient due to mutations (Wilden et al., 2009). 
Furthermore, off importance for cancer treatment are immune stimulatory properties that are 
induced during virus infection. It has been reported that after efficient and selective replication of 
NDV in the cell cytoplasm of tumor cells, tumor antigens, immunostimulatory cytokines and danger 
signals including IFNs and dsRNA are released (Schirrmacher et al., 2003). However, since viruses 
as single agents might not be sufficient for an optimal use in cancer therapy they have often been 
used as vectors for cancer gene therapeutic approaches (e.g., Rein et al., 2006; Janke et al., 2007; 
Zhao et al., 2008). In this combination, they are attractive anti-cancer agents that allow the transfer 
of genetic material with a therapeutic targeting mechanism. Besides the advantages of viruses, the 
here presented hitchhiking approach utilizes T cells that are also able to directly fight cancer 
growth. T cells circulate through the body, can penetrate deep into multilayered tissues and have
even shown to cross the blood-brain barrier when they receive the appropriate homing signals 
(Butcher and Picker, 1996). Once TAA-specific T cells reach tumor cells, which they specifically 
recognize through antigen presentation, they get activated, gain effector functions followed by the 
recruitment and activation of additional T cells or further immune cells (Schreiber et al., 2011). 
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The data of the presented thesis report that T cells can be efficiently modified with different NDV 
strains (Figs. 78-84). While it has been shown that an amplification of viral M gene expression was 
detected in activated NDV-modified T cells, the virus could not form infections progeny in the 
lymphocytes (cf., Fig. 79; see also Pfirschke and Schirrmacher, 2009). In contrast, progeny 
infectious viral particles accumulated in the supernatant of MCF-7 breast tumor cells (Fig. 79). The 
effectiveness of the NDV hitchhiking process to tumor cells was shown to depend on the used viral 
amounts, the T cell to tumor cell ratio, the activation status of the carrier cells, the co-culture time 
and the virulence of the investigated NDV strain (Figs. 80-84). Even more interesting was the 
observation that monolayers of human tumor cells could be completely destroyed by the addition of 
polyclonally activated human T cells that were loaded with oncolytic NDV of strain MTH-68
(Fig. 84). Moreover, the tumor growth control through hitchhiking on activated T cells was superior 
to non-activated T cells. This finding indicated that the combination of the effectiveness of activated 
T cells together with the oncolytic viral potential resulted in the optimal tumor growth inhibition. In 
view of these findings, activated T cells were reported to undergo stronger contacts with tumor cells 
than non-activated T cells (Bromley et al., 2001). These contacts might help to facilitate a more 
efficient transfer of the virus to the tumor target, while NDV becomes focused in the contact zone of 
the stabilized immunological synapse. In addition, much of the cell bound virus might only be 
loosely attached to the glycocalyx. Therefore, it can be more easily transferred to tumor cells when 
the T cells undergo strong contacts. 
Finally, in a retroviral hitchhiking study, viral transfer to tumor cells was dependent on the 
enzyme heparanase (Cole et al., 2005). In contrast, T cell-mediated hitchhiking of NDV to tumor 
cells was proven to be heparanase-independent (Pfirschke and Schirrmacher, 2009). This 
observation indicated that the mechanisms of NDV transfer in the course of T cell-mediated 
hitchhiking differ to other viruses. Furthermore, the NDV hitchhiking kinetic was revealed to be 
faster than the retrovirus or vaccinia virus transfer (cf., Fig. 81, see also Cole et al., 2005; Thorne et 
al., 2005). The efficiency of NDV hitchhiking using further carrier cells besides human T cells as 
well as pilot in vivo experiments utilizing hitchhiking of NDV have been described (Pfirschke and 
Schirrmacher, 2009). Future in vivo studies will therefore have to show the effect of NDV 
hitchhiking on TAA-specific T cells and might reveal a positive impact in terms of improved human 
cancer treatments.
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9.5. Concluding remarks and future perspectives
Despite the fact that the clinical efficiency of present cancer immune therapeutic interventions is 
limited, the molecular and regulatory mechanisms that affect the cancer-directed properties of the 
immune system are currently of great scientific interest. However, detailed mechanisms that 
influence the potential of tumor immunotherapies still remain poorly understood. Accordingly, the 
findings revealed during the course of the presented thesis added new aspects to the optimization 
of cancer immune therapeutic approaches in the areas of peptide-based immunotherapy, adoptive 
cell transfer of TCR-transgenic T cells, oncolytic virotherapy and cancer-induced 
immunosuppressive mechanisms. 
Adapted from these observations, peptide-based immunotherapies might be appropriate to 
obtain clinically relevant future results, while using a potent combination of multiple polypeptides 
that reactivate pre-existing anti-tumor memory T cells. The used peptides should efficiently be able 
to activate CD4+ and CD8+ tumor-reactive T cell responses while avoiding the reactivation or 
induction of Treg or further immunosuppressive cells. Thereby, atypical or mutated tumor-specific 
peptides that are not expressed on normal tissues should preferentially be used. Moreover, a
vaccine that will be effective against cancer might not only focus on peptide-based immunotherapy 
as a monotherapy, rather a combination with mechanisms that block or destroy mediators of 
cancer-induced immunosuppression might be needed.
In order to obtain effective clinical tumor targeting results, in general, combinational treatments 
will probably be of central importance for the majority of immune-based approaches. Consequently, 
as demonstrated during the presented thesis, combinations with oncolytic viruses, low dose 
irradiation therapies or treatments that inhibit tumor cell-induced immunosuppression, mediated 
through CAMs could serve as useful treatment additions. To prove the functional relevance of 
these combinational approaches, further studies will be necessary. This, hopefully, will lead to a 
better understanding of the tumor disease nature and potentially contribute to the development of 
functional and effective clinical treatment strategies for improved future cancer immunotherapies. 
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13. Appendix
13.1. Plasmid map of pBullet_IRESpuro-[NcoI]
Appendix
page | 214
13.2. Plasmid map of pBullet_IRESneo-[NcoI]
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13.3. Plasmid map of pBullet_Mu Wta TCR MDM2_IRESpuro
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13.4. Plasmid map of pBullet_Mu Wtb TCR MDM2_IRESneo
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13.5. Plasmid map of pBullet_Mu Mta TCR MDM2 G85.1caR_IRESpuro
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13.6. Plasmid map of pBullet_Mu Mtb TCR MDM2 R88cbG_IRESneo
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13.7. Plasmid map of pBullet_Hu Wta TCR gp100_IRESpuro
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13.8. Plasmid map of pBullet_Hu Wtb TCR gp100_IRESneo
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13.9. Plasmid map of pBullet_Mu Ca T84caC_IRESpuro
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13.10. Plasmid map of pBullet_Hu Chim scTCR gp100 Mu Cb S79cbC_IRESneo
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13.11. Plasmid map of pBullet_eGFP_IRESneo
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13.12. Predicted HLA-A2-negative sequences (MHC class I- and II-restricted)
For all generated 50aa polypeptides possible HLA-A2-negative epitope sequences were predicted 
via Syfpeithi database (cf., Tab. 8).
GAGE-1:
MSWRGRSTYR  PRPRRYVEPP  EMIGPMRPEQ  FSDEVEPATP  EEGEPATQRQ (1-50)
HLA-A*01
1 M S W R G R S T Y
7 S T Y R P R P R R Y
6 R S T Y R P R P R R Y
HLA-A*03
1 M S W R G R S T Y
10 R P R P R R Y V E
22 M I G P M R P E Q F
HLA-A*1101
7 S T Y R P R P R R
6 R S T Y R P R P R
1 M S W R G R S T Y R
HLA-A*2402
15 R Y V E P P E M I
22 M I G P M R P E Q F
HLA-A*26
34 E V E P A T P E E
34 E V E P A T P E E G
HLA-A*6801
7 S T Y R P R P R R
1 M S W R G R S T Y R
HLA-B*0702
18 E P P E M I G P M
HLA-B*08
10 R P R P R R Y V
10 R P R P R R Y V E
HLA-B*1501
1 M S W R G R S T Y
HLA-B*18
33 D E V E P A T P E
33 D E V E P A T P
HLA-B*2705
14 R R Y V E P P E M
HLA-B*2709
14 R R Y V E P P E M
9 Y R P R P R R Y V
HLA-B*37
23 I G P M R P E Q F
HLA-B*3801
14 R R Y V E P P E M I
HLA-B*4001
17 V E P P E M I G P
HLA-B*4101
17 V E P P E M I G P
HLA-B*4402
17 V E P P E M I G P M
HLA-B*4501
17 V E P P E M I G P
HLA-B*5001
33 D E V E P A T P E
HLA-B*5101
27 R P E Q F S D E V
10 R P R P R R Y V
HLA-DRB1*0101
20 P E M I G P M R P E Q F S D E
HLA-DRB1*0401
28 P E Q F S D E V E P A T P E E
HLA-DRB1*1101
6 R S T Y R P R P R R Y V E P P
13 P R R Y V E P P E M I G P M R
HLA-DRB1*1501
14 R R Y V E P P E M I G P M R P
Appendix
page | 225
gp100/pmel17:
SITGSLGPLL  DGTATLRLVK  RQVPLDCVLY  RYGSFSVTLD  IVQGIESAEI (449-498)
HLA-A*01 
472 P L D C V L Y R
471 V P L D C V L Y R Y
469 R Q V P L D C V L Y
470 Q V P L D C V L Y R Y
468 K R Q V P L D C V L Y
HLA-A*1101 
460 G T A T L R L V K
460 G T A T L R L V K R
470 Q V P L D C V L Y R
456 P L L D G T A T L R
HLA-A*2402 
479 R Y G S F S V T L
485 V T L D I V Q G I
HLA-A*26
488 D I V Q G I E S A
448 E S I T G S L G P L
HLA-A*6801
461 T A T L R L V K R
457 L L D G T A T L R
484 S V T L D I V Q G
460 G T A T L R L V K R
456 P L L D G T A T L R
470 Q V P L D C V L Y R
460 G T A T L R L V K
HLA-B*0702
455 G P L L D G T A T L
HLA-B*08
466 L V K R Q V P L
465 R L V K R Q V P L
HLA-B*1402
464 L R L V K R Q V
468 K R Q V P L D C
459 D G T A T L R L
HLA-B*1501
472 P L D C V L Y R Y
470 Q V P L D C V L Y
475 C V L Y R Y G S F
469 R Q V P L D C V L Y
HLA-B*18
459 D G T A T L R L
HLA-B*2705
469 R Q V P L D C V L
465 R L V K R Q V P L
HLA-B*2709
468 K R Q V P L D C V
465 R L V K R Q V P L
469 R Q V P L D C V L
479 R Y G S F S V T L
HLA-B*37
458 L D G T A T L R L
475 C V L Y R Y G S F
465 R L V K R Q V P L
HLA-B*3801
478 Y R Y G S F S V T L
464 L R L V K R Q V P L
468 K R Q V P L D C V L
457 L L D G T A T L R L
450 I T G S L G P L L
HLA-B*3901
468 K R Q V P L D C V
479 R Y G S F S V T L
HLA-B*3902
469 R Q V P L D C V L
HLA-B*4001
465 R L V K R Q V P L
479 R Y G S F S V T L
HLA-B*4701
458 L D G T A T L R L
469 R Q V P L D C V L
HLA-B*4901
458 L D G T A T L R L
HLA-B*5001
488 D I V Q G I E S A
HLA-B*5101
459 D G T A T L R L V
HLA-DRB1*0101 
484 S V T L D I V Q G I E S A E I
HLA-DRB1*0301
453 S L G P L L D G T A T L R L V
482 S F S V T L D I V Q G I E S A
468 K R Q V P L D C V L Y R Y G S
HLA-DRB1*0701 
455 G P L L D G T A T L R L V K R
HLA-DRB1*1101
461 T A T L R L V K R Q V P L D C
HLA-DRB1*1501
474 D C V L Y R Y G S F S V T L D
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MAGE-A1:
PARYEFLWGP  RALAETSYVK  VLEYVIKVSA  RVRFFFPSLR  EAALREEEEG (259-308)
HLA-A*01
274 T S Y V K V L E Y
273 E T S Y V K V L E Y
272 A E T S Y V K V L E Y
HLA-A*03
270 A L A E T S Y V K
276 Y V K V L E Y V I K
289 R V R F F F P S L R
282 Y V I K V S A R V R
HLA-A*1101
295 P S L R E A A L R
276 Y V K V L E Y V I K
282 Y V I K V S A R V R
HLA-A*2402
263 E F L W G P R A L
275 S Y V K V L E Y V I
293 F F P S L R E A A L
HLA-A*26
273 E T S Y V K V L E Y
HLA-A*6801
276 Y V K V L E Y V I K
282 Y V I K V S A R V R
HLA-B*0702
294 F P S L R E A A L
HLA-B*08
287 S A R V R F F F
294 F P S L R E A A L
HLA-B*1402
290 V R F F F P S L
302 L R E E E E G V
HLA-B*1501
285 K V S A R V R F F F
HLA-B*1510
263 E F L W G P R A L
HLA-B*18
272 A E T S Y V K V L
298 R E A A L R E E E
275 S Y V K V L E Y
HLA-B*2705
290 V R F F F P S L R
268 P R A L A E T S Y
HLA-B*2709
289 R V R F F F P S L
HLA-B*37
272 A E T S Y V K V L
285 K V S A R V R F F
HLA-B*3801
288 A R V R F F F P S L
HLA-B*4001
272 A E T S Y V K V L
HLA-B*4101
262 Y E F L W G P R A
280 L E Y V I K V S A
HLA-B*4402
272 A E T S Y V K V L
262 Y E F L W G P R A L
HLA-B*4501
262 Y E F L W G P R A
280 L E Y V I K V S A
272 A E T S Y V K V L
292 F F F P S L R E A
HLA-B*4901
272 A E T S Y V K V L
HLA-B*5001
262 Y E F L W G P R A
280 L E Y V I K V S A
HLA-B*5101
271 L A E T S Y V K V
HLA-DRB1*0101
259 P A R Y E F L W G P R A L A E
HLA-DRB1*0301
281 E Y V I K V S A R V R F F F P
291 R F F F P S L R E A A L R E E
HLA-DRB1*0701
279 V L E Y V I K V S A R V R F F
HLA-DRB1*1101
277 V K V L E Y V I K V S A R V R
261 R Y E F L W G P R A L A E T S
290 V R F F F P S L R E A A L R E
259 P A R Y E F L W G P R A L A E
HLA-DRB1*1501
287 S A R V R F F F P S L R E A A
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MAGE-C2:
WGPRAHSESI  KKKVLEFLAK LNNTVPSSFP  SWYKDALKDV  EERVQATIDT (301-350)
HLA-A*01
323 N T V P S S F P S W Y
HLA-A*03
320 K L N N T V P S S F
HLA-A*1101
330 P S W Y K D A L K
326 P S S F P S W Y K
HLA-A*2402
313 K V L E F L A K L
328 S F P S W Y K D A L
HLA-A*26
308 E S I K K K V L E F
HLA-A*6801
335 D A L K D V E E R
339 D V E E R V Q A T I
HLA-B*0702
329 F P S W Y K D A L
HLA-B*08
309 S I K K K V L E
308 E S I K K K V L
311 K K K V L E F L
330 P S W Y K D A L
309 S I K K K V L E F
307 S E S I K K K V L
310 I K K K V L E F L
HLA-B*1501
320 K L N N T V P S S F
324 T V P S S F P S W Y
HLA-B*18
307 S E S I K K K V L
HLA-B*2705
303 P R A H S E S I K
304 R A H S E S I K K
313 K V L E F L A K L
HLA-B*2709
313 K V L E F L A K L
HLA-B*37
307 S E S I K K K V L
HLA-B*3902
310 I K K K V L E F L
HLA-B*4001
307 S E S I K K K V L
HLA-B*4402
307 S E S I K K K V L
HLA-B*4701
313 K V L E F L A K L
HLA-B*4901
340 V E E R V Q A T I
HLA-B*5001
338 K D V E E R V Q A
HLA-B*5101
302 G P R A H S E S I
318 L A K L N N T V
HLA-DRB1*0301
326 P S S F P S W Y K D A L K D V
HLA-DRB1*1501
311 K K K V L E F L A K L N N T V
MDM2:
KEVLFYLGQY  IMTKRLYDEK  QQHIVYCSND  LLGDLFGVPS  FSVKEHRKIY (51-100)
HLA-A*01
67 Y D E K Q Q H I V Y
66 L Y D E K Q Q H I V Y
91 F S V K E H R K I Y
HLA-A*1101
62 M T K R L Y D E K
89 P S F S V K E H R K
HLA-A*2402
66 L Y D E K Q Q H I
90 S F S V K E H R K I
HLA-A*26
52 E V L F Y L G Q Y
HLA-A*6801
52 E V L F Y L G Q Y
57 L G Q Y I M T K R
56 Y L G Q Y I M T K R
HLA-B*1501
92 S V K E H R K I Y
58 G Q Y I M T K R L Y
65 R L Y D E K Q Q H I
HLA-B*18
68 D E K Q Q H I V Y
84 D L F G V P S F
HLA-B*37
79 N D L L G D L F
83 G D L F G V P S F
HLA-B*3801
72 Q H I V Y C S N D L
HLA-B*3902
58 G Q Y I M T K R L
HLA-B*4402
68 D E K Q Q H I V Y
51 K E V L F Y L G Q Y
HLA-B*4701
83 G D L F G V P S F
HLA-B*4901
66 L Y D E K Q Q H I
HLA-DRB1*0101
79 N D L L G D L F G V P S F S V
HLA-DRB1*0301
71 Q Q H I V Y C S N D L L G D L
HLA-DRB1*0701
82 L G D L F G V P S F S V K E H
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Melan-A/MART-1:
GHGHSYTTAE  EAAGIGILTV  ILGVLLLIGC  WYCRRRNGYR  ALMDKSLHVG (16-65)
HLA-A*03
39 V L L L I G C W Y
38 G V L L L I G C W Y
HLA-A*1101
33 L T V I L G V L L L
HLA-A*2402 
35 V I L G V L L L I
34 T V I L G V L L L
53 G Y R A L M D K S L
HLA-A*26
34 T V I L G V L L L
33 L T V I L G V L L L
HLA-B*1402
34 T V I L G V L L L
54 Y R A L M D K S L
35 V I L G V L L L
50 R R N G Y R A L
HLA-B*1501
39 V L L L I G C W Y
38 G V L L L I G C W Y
HLA-B*18 
25 E E A A G I G I L
HLA-B*2705 
49 R R R N G Y R A L
50 R R N G Y R A L M
HLA-B*2709
49 R R R N G Y R A L
50 R R N G Y R A L M
HLA-B*37
33 L T V I L G V L
25 E E A A G I G I L
HLA-B*3801
48 C R R R N G Y R A L
32 I L T V I L G V L L
HLA-B*3901
54 Y R A L M D K S L
HLA-B*4001
25 E E A A G I G I L
34 T V I L G V L L L
HLA-B*4402
25 E E A A G I G I L
24 A E E A A G I G I
24 A E E A A G I G I L
HLA-B*4501
25 E E A A G I G I L
HLA-B*4701
49 R R R N G Y R A L
HLA-B*4901
24 A E E A A G I G I
HLA-B*5001
20 S Y T T A E E A A
HLA-B*5101
27 A A G I G I L T V
23 T A E E A A G I
26 E A A G I G I L
HLA-DRB1*0101 
30 I G I L T V I L G V L L L I G
HLA-DRB1*0401
51 R N G Y R A L M D K S L H V G
HLA-DRB1*0701 
51 R N G Y R A L M D K S L H V G
18 G H S Y T T A E E A A G I G I
HLA-DRB1*1501
30 I G I L T V I L G V L L L I G
MIF:
LMAFGGSSEP  CALCSLHSIG  KIGGAQNRSY  SKLLCGLLAE  RLRISPDRVY (47-96)
HLA-A*01
53 S S E P C A L C S
HLA-A*03
78 K L L C G L L A E
87 R L R I S P D R V Y
58 A L C S L H S I G K
HLA-A*1101
53 S S E P C A L C S
58 A L C S L H S I G K
HLA-A*2402
75 S Y S K L L C G L
75 S Y S K L L C G L L
HLA-A*6801
79 L L C G L L A E R
78 K L L C G L L A E R
58 A L C S L H S I G K
HLA-B*08
83 L L A E R L R I
76 Y S K L L C G L
76 Y S K L L C G L L
HLA-B*1402
73 N R S Y S K L L C
73 N R S Y S K L L
88 L R I S P D R V
HLA-B*1501
87 R L R I S P D R V Y
HLA-B*1510
51 G G S S E P C A L
HLA-B*18
54 S E P C A L C S L
HLA-B*2705
86 E R L R I S P D R
88 L R I S P D R V Y
HLA-B*2709
82 G L L A E R L R I
HLA-B*37
54 S E P C A L C S L
85 A E R L R I S P D
HLA-B*3901
62 L H S I G K I G G
HLA-B*3902
71 A Q N R S Y S K L
HLA-B*4001
54 S E P C A L C S L
HLA-B*4402
54 S E P C A L C S L
85 A E R L R I S P D
71 A Q N R S Y S K L L
HLA-B*4501
85 A E R L R I S P D
HLA-B*4701
80 L C G L L A E R L
HLA-B*4901
54 S E P C A L C S L
82 G L L A E R L R I
HLA-B*5101
57 C A L C S L H S I
HLA-DRB1*0101
77 S K L L C G L L A E R L R I S
HLA-DRB1*0301
65 I G K I G G A Q N R S Y S K L
HLA-DRB1*0701
47 L M A F G G S S E P C A L C S
HLA-DRB1*1101
59 L C S L H S I G K I G G A Q N
81 C G L L A E R L R I S P D R V
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NA17-A:
MVLPDVFIRC  VVFCLTVVCW  TWVPLRGPSS  PGSYRKWMCF  SESQVQPTQK (1-50)
HLA-A*01
26 R G P S S P G S Y
25 L R G P S S P G S Y
24 P L R G P S S P G S Y
HLA-A*03
5 D V F I R C V V F
10 C V V F C L T V V C
HLA-A*1101
42 E S Q V Q P T Q K
17 V V C W T W V P L R
HLA-A*2402
6 V F I R C V V F C L
HLA-A*26
5 D V F I R C V V F
5 D V F I R C V V F C
HLA-A*6801
1 M V L P D V F I R
17 V V C W T W V P L R
HLA-B*0702
30 S P G S Y R K W M
3 L P D V F I R C V V
HLA-B*08
7 F I R C V V F C L
HLA-B*1402
5 D V F I R C V V F
8 I R C V V F C L
HLA-B*1501
5 D V F I R C V V F
HLA-B*18
5 D V F I R C V V F
HLA-B*2705
28 P S S P G S Y R K
HLA-B*37
41 S E S Q V Q P T
HLA-B*3901
17 V V C W T W V P L
HLA-B*4001
17 V V C W T W V P L
HLA-B*4402
28 P S S P G S Y R K W
HLA-B*4701
4 P D V F I R C V V
HLA-B*5101
3 L P D V F I R C V
23 V P L R G P S S
HLA-DRB1*0101
19 C W T W V P L R G P S S P G S
HLA-DRB1*0301
14 C L T V V C W T W V P L R G P
HLA-DRB1*0401
19 C W T W V P L R G P S S P G S
HLA-DRB1*0701
34 Y R K W M C F S E S Q V Q P T
HLA-DRB1*1101
17 V V C W T W V P L R G P S S P
HLA-DRB1*1501
14 C L T V V C W T W V P L R G P
NY-ESO-1:
FTVSGNILTI  RLTAADHRQL  QLSISSCLQQ  LSLLMWITQC  FLPVFLAQPP (126-175)
HLA-A*01
139 A A D H R Q L Q L
139 A A D H R Q L Q L S
139 A A D H R Q L Q L S I
HLA-A*03
134 T I R L T A A D H
127 T V S G N I L T I
134 T I R L T A A D H R
HLA-A*1101
128 V S G N I L T I R
126 F T V S G N I L T
127 T V S G N I L T I R
HLA-A*26
162 I T Q C F L P V F
126 F T V S G N I L T I
147 L S I S S C L Q Q L
161 W I T Q C F L P V F
HLA-A*6801
128 V S G N I L T I R
127 T V S G N I L T I R
134 T I R L T A A D H R
HLA-B*08
139 A A D H R Q L Q L
HLA-B*1402
150 S S C L Q Q L S L
142 H R Q L Q L S I
151 S C L Q Q L S L
HLA-B*1501
158 L L M W I T Q C F
157 S L L M W I T Q C F
HLA-B*2705
135 I R L T A A D H R
HLA-B*37
140 A D H R Q L Q L
146 Q L S I S S C L
139 A A D H R Q L Q L
HLA-B*3801
138 T A A D H R Q L Q L
149 I S S C L Q Q L S L
141 D H R Q L Q L S I
139 A A D H R Q L Q L
HLA-B*3901
141 D H R Q L Q L S I
163 T Q C F L P V F L
HLA-B*3902
145 L Q L S I S S C L
163 T Q C F L P V F L
143 R Q L Q L S I S S
HLA-B*4001
163 T Q C F L P V F L
139 A A D H R Q L Q L
129 S G N I L T I R L
HLA-B*4101
131 N I L T I R L T A
HLA-B*4701
129 S G N I L T I R L
145 L Q L S I S S C L
HLA-B*4901
127 T V S G N I L T I
HLA-DRB1*0301
156 L S L L M W I T Q C F L P V F
155 Q L S L L M W I T Q C F L P V
HLA-DRB1*0401
134 T I R L T A A D H R Q L Q L S
156 L S L L M W I T Q C F L P V F
HLA-DRB1*0701
142 H R Q L Q L S I S S C L Q Q L
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p53:
TAKSVTCTYS  PALNKMFCQL  AKTCPVQLWV  DSTPPPGTRV RAMAIYKQSQ (118-167)
HLA-A*01
154 G T R V R A M A I Y
HLA-A*03
156 R V R A M A I Y K
136 Q L A K T C P V Q L
HLA-A*1101
124 C T Y S P A L N K
156 R V R A M A I Y K
149 S T P P P G T R V R
HLA-A*2402
125 T Y S P A L N K M
125 T Y S P A L N K M F
HLA-A*26
121 S V T C T Y S P A L
HLA-A*6801
148 D S T P P P G T R
149 S T P P P G T R V R
HLA-B*0702
151 P P P G T R V R A
HLA-B*08
130 L N K M F C Q L
137 L A K T C P V Q L
154 G T R V R A M A I
HLA-B*4001
137 L A K T C P V Q L
HLA-B*5101
137 L A K T C P V Q L
HLA-DRB1*0101
131 N K M F C Q L A K T C P V Q L
HLA-DRB1*0701
119 A K S V T C T Y S P A L N K M
123 T C T Y S P A L N K M F C Q L
HLA-DRB1*1101
131 N K M F C Q L A K T C P V Q L
HLA-DRB1*1501
134 F C Q L A K T C P V Q L W V D
140 T C P V Q L W V D S T P P P G
RAB38/NY-Mel-1:
ATIGVDFALK  VLHWDPETVV  RLQLWDIAGQ  ERFGNMTRVY  YREAM GAFIV (40-89)
HLA-A*01
71 R F G N M T R V Y
70 E R F G N M T R V Y
69 Q E R F G N M T R V Y
70 E R F G N M T R V Y Y
HLA-A*03
77 R V Y Y R E A M G
HLA-A*1101
40 A T I G V D F A L K
HLA-A*2402
79 Y Y R E A M G A F
53 W D P E T V V R L
78 V Y Y R E A M G A F
79 Y Y R E A M G A F I
HLA-A*26
56 E T V V R L Q L W
43 G V D F A L K V L
40 A T I G V D F A L
70 E R F G N M T R V Y
56 E T V V R L Q L W D
HLA-A*6801
40 A T I G V D F A L K
HLA-B*0702
54 D P E T V V R L Q L
HLA-B*1402
38 Y R A T I G V D F
70 E R F G N M T R V
59 V R L Q L W D I
44 V D F A L K V L
HLA-B*1501
50 V L H W D P E T V
62 Q L W D I A G Q E
71 R F G N M T R V Y
71 R F G N M T R V Y Y
HLA-B*1510
53 W D P E T V V R L
HLA-B*18
55 P E T V V R L Q L
54 D P E T V V R L
56 E T V V R L Q L
65 D I A G Q E R F
HLA-B*2705
70 E R F G N M T R V
76 T R V Y Y R E A M
HLA-B*2709
70 E R F G N M T R V
76 T R V Y Y R E A M
HLA-B*37
44 V D F A L K V L
53 W D P E T V V R L
HLA-B*3801
52 H W D P E T V V R L
HLA-B*4001
55 P E T V V R L Q L
53 W D P E T V V R L
HLA-B*4402
55 P E T V V R L Q L
40 A T I G V D F A L
55 P E T V V R L Q L W
HLA-B*4701
53 W D P E T V V R L
64 W D I A G Q E R F
HLA-B*4901
81 R E A M G A F I V
HLA-B*5101
42 I G V D F A L K V
54 D P E T V V R L
HLA-DRB1*0301
48 L K V L H W D P E T V V R L Q
69 Q E R F G N M T R V Y Y R E A
HLA-DRB1*1101
69 Q E R F G N M T R V Y Y R E A
72 F G N M T R V Y Y R E A M G A
HLA-DRB1*1501
47 A L K V L H W D P E T V V R L
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TRP2:
ALPHSAANDP  IFVVISNRLL  YNATTNILEH  VRKEKATKEL  PSLHVLVLHS (381-430) 
HLA-A*01 
393 V V I S N R L L Y
392 F V V I S N R L L Y
391 I F V V I S N R L L Y
HLA-A*03 
398 R L L Y N A T T N
410 H V R K E K A T K
407 I L E H V R K E K
393 V V I S N R L L Y
406 N I L E H V R K E K
HLA-A*1101 
410 H V R K E K A T K
404 T T N I L E H V R K
403 A T T N I L E H V R
HLA-A*2402 
400 L Y N A T T N I L
391 I F V V I S N R L
391 I F V V I S N R L L
HLA-A*26
393 V V I S N R L L Y
392 F V V I S N R L L Y
419 E L P S L H V L V L
414 E K A T K E L P S L
HLA-A*6801
390 P I F V V I S N R
404 T T N I L E H V R
404 T T N I L E H V R K
403 A T T N I L E H V R
409 E H V R K E K A T K
HLA-B*0702
420 L P S L H V L V L
382 L P H S A A N D P I
419 E L P S L H V L V L
HLA-B*08
411 V R K E K A T K
416 A T K E L P S L
413 K E K A T K E L
411 V R K E K A T K E
HLA-B*1402
420 L P S L H V L V L
421 P S L H V L V L
HLA-B*1501
393 V V I S N R L L Y
392 F V V I S N R L L Y
HLA-B*1510
391 I F V V I S N R L
HLA-B*18
418 K E L P S L H V L
413 K E K A T K E L
HLA-B*37
413 K E K A T K E L
418 K E L P S L H V L
420 L P S L H V L V L
HLA-B*3801
383 P H S A A N D P I F
411 V R K E K A T K E L
383 P H S A A N D P I
HLA-B*3902
412 R K E K A T K E L
418 K E L P S L H V L
HLA-B*4001
418 K E L P S L H V L
420 L P S L H V L V L
HLA-B*4101
408 L E H V R K E K A
413 K E K A T K E L P
418 K E L P S L H V L
HLA-B*4402
418 K E L P S L H V L
387 A N D P I F V V I
373 H S F L N G T N A L
HLA-B*4501
408 L E H V R K E K A
413 K E K A T K E L P
418 K E L P S L H V L
HLA-B*4901
418 K E L P S L H V L
403 A T T N I L E H V
417 T K E L P S L H V
HLA-B*5001
408 L E H V R K E K A
HLA-B*5101
420 L P S L H V L V L
386 A A N D P I F V V
385 S A A N D P I F V
420 L P S L H V L V
386 A A N D P I F V
HLA-DRB1*0101 
388 N D P I F V V I S N R L L Y N
HLA-DRB1*0301
390 P I F V V I S N R L L Y N A T
389 D P I F V V I S N R L L Y N A
HLA-DRB1*0401 
389 D P I F V V I S N R L L Y N A
388 N D P I F V V I S N R L L Y N
HLA-DRB1*0701
389 D P I F V V I S N R L L Y N A
397 N R L L Y N A T T N I L E H V
388 N D P I F V V I S N R L L Y N
HLA-DRB1*1101
405 T N I L E H V R K E K A T K E
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Tyrosinase:
MLLAVLYCLL  WSFQTSAGHF  PRACVSSKNL  MEKECCPPWS  GDRSPCGQLS (1-50)
HLA-A*03 
4 A V L Y C L L W S F
24 C V S S K N L M E K
HLA-A*1101 
25 V S S K N L M E K
24 C V S S K N L M E K
HLA-A*2402 
12 S F Q T S A G H F
HLA-A*26
4 A V L Y C L L W S F
HLA-A*6801
14 Q T S A G H F P R
24 C V S S K N L M E K
HLA-B*1402
1 M L L A V L Y C L
42 D R S P C G Q L
HLA-B*1501
5 V L Y C L L W S F
4 A V L Y C L L W S F
HLA-B*1510
18 G H F P R A C V S
HLA-B*18
31 M E K E C C P P W
HLA-B*2709
22 R A C V S S K N L
41 G D R S P C G Q L
HLA-B*37
41 G D R S P C G Q L
HLA-B*3801
21 P R A C V S S K N L
HLA-B*4402
31 M E K E C C P P W
HLA-B*4701
41 G D R S P C G Q L
HLA-B*5001
31 M E K E C C P P W
9 L L W S F Q T S A
15 T S A G H F P R A
33 K E C C P P W S G
HLA-B*5101
3 L A V L Y C L L
HLA-DRB1*0101 
10 L W S F Q T S A G H F P R A C
HLA-DRB1*0401
4 A V L Y C L L W S F Q T S A G
HLA-DRB1*1501 
7 Y C L L W S F Q T S A G H F P
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13.13. Predicted HLA-A2-restricted sequences
For all generated 50aa polypeptides, possible HLA-A2-restricted epitope sequences were predicted 
via Syfpeithi database (cf., Tab. 8).
GAGE-1:
MSWRGRSTYR  PRPRRYVEPP  EMIGPMRPEQ  FSDEVEPATP  EEGEPATQRQ (1-50)
HLA-A*0201
9 Y R P R P R R Y V
gp100/pmel17:
SITGSLGPLL  DGTATLRLVK  RQVPLDCVLY  RYGSFSVTLD  IVQGIESAEI (449-498)
HLA-A*0201
456 P L L D G T A T L
449 S I T G S L G P L
457 L L D G T A T L R L
MAGE-A1:
PARYEFLWGP  RALAETSYVK  VLEYVIKVSA  RVRFFFPSLR  EAALREEEEG (259-308)
HLA-A*0201
278 K V L E Y V I K V
270 A L A E T S Y V K V
MAGE-C2:
WGPRAHSESI  KKKVLEFLAK  LNNTVPSSFP  SWYKDALKDV  EERVQATIDT (301-350)
HLA-A*0201
313 K V L E F L A K L
317 F L A K L N N T V
309 S I K K K V L E F L
MDM2:
KEVLFYLGQY  IMTKRLYDEK  QQHIVYCSND  LLGDLFGVPS  FSVKEHRKIY (51-100)
HLA-A*0201
80 D L L G D L F G V
Melan-A/MART-1:
GHGHSYTTAE  EAAGIGILTV  ILGVLLLIGC  WYCRRRNGYR  ALMDKSLHVG (16-65)
HLA-A*0201
31 G I L T V I L G V
35 V I L G V L L L I
31 G I L T V I L G V L
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MIF:
LMAFGGSSEP  CALCSLHSIG  KIGGAQNRSY SKLLCGLLAE  RLRISPDRVY (47-96)
HLA-A*0201
79 L L C G L L A E R
79 L L C G L L A E R L
NA17-A:
MVLPDVFIRC  VVFCLTVVCW  TWVPLRGPSS  PGSYRKWMCF  SESQVQPTQK (1-50)
HLA-A*0201
7 F I R C V V F C L
2 V L P D V F I R C V
NY-ESO-1:
FTVSGNILTI  RLTAADHRQL  QLSISSCLQQ  LSLLMWITQC  FLPVFLAQPP (126-175)
HLA-A*0201
148 S I S S C L Q Q L
127 T V S G N I L T I
158 L L M W I T Q C F L
126 F T V S G N I L T I
p53:
TAKSVTCTYS  PALNKMFCQL  AKTCPVQLWV  DSTPPPGTRV RAMAIYKQSQ (118-167)
HLA-A*0201
129 A L N K M F C Q L
132 K M F C Q L A K T
136 Q L A K T C P V Q L
RAB38/NY-Mel-1:
ATIGVDFALK  VLHWDPETVV  RLQLWDIAGQ  ERFGNMTRVY  YREAM GAFIV (40-89)
HLA-A*0201
50 V L H W D P E T V
40 A T I G V D F A L
TRP2:
ALPHSAANDP  IFVVISNRLL  YNATTNILEH  VRKEKATKEL  PSLHVLVLHS (381-430)
HLA-A*0201
399 L L Y N A T T N I L
385 S A A N D P I F V V
Tyrosinase:
MLLAVLYCLL  WSFQTSAGHF  PRACVSSKNL  MEKECCPPWS  GDRSPCGQLS (1-50)
HLA-A*0201
1 M L L A V L Y C L
2 L L A V L Y C L L
1 M L L A V L Y C L L
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